**Scientific Programme**

**Sunday, 12. July 2020**

**Plenary Session**
07:30 - 08:30  
Virtual Meeting Room 1

**PL 01, Plenary Session**
Chair: Flora Peyvandi (Italy)  
Chair: Marco Cattaneo (Italy)

- ISTH 2020 Virtual Congress Welcome and Introduction  
  Speaker: Flora Peyvandi (Italy)  
  Speaker: Marco Cattaneo (Italy)  
  07:30

- Advances in Gene Therapy and Ethical Aspects  
  Speaker: Luigi Naldini (Italy)  
  08:00

**SSC Session**
08:00 - 09:30  
Main Foyer

**Test session**

- Test Presentation  
  08:00

**Virtual Exhibition**
08:00 - 14:00  
Virtual Meeting Room 7

**State-of-the-Art Session**
08:45 - 10:00  
Virtual Meeting Room 1

**SOA 01, State-of-the-Art on Hemophilia and Rare Bleeding Disorders**
Illustrated SOA Capsules: [https://www.isth.org/page/soair](https://www.isth.org/page/soair)

Chair: David Lillicrap (Canada)

- Progress and Obstacles to Hemophilia Gene Therapy  
  Speaker: Amit Nathwani (United Kingdom)  
  08:45

- Q&A  
  09:05

- Immunogenicity of Adeno-Associated Vectors  
  Speaker: Federico Mingozi (United States)  
  09:10

- Q&A  
  09:30

- Immune Responses to Factor VIII in Hemophilia  
  Speaker: Sebastien Lacroix-Desmazes (France)  
  09:35
**Scientific Programme**

**Q&A** 09:55

**State-of-the-Art Session**
08:45 - 10:00  
Virtual Meeting Room 2

**SOA 02, State-of-the-Art on Thrombotic Microangiopathies**
Illustrated SOA Capsules: [https://www.isth.org/page/soair](https://www.isth.org/page/soair)
Chair: Marina Noris (Italy)

- **Differential Diagnosis of Thrombotic Microangiopathies** 08:45  
  Speaker: Giuseppe Remuzzi (Italy)

- **Q&A** 09:05

- **First Guideline of ISTH on Diagnosis and Treatment of Thrombotic Thrombocytopenic Purpura** 09:10  
  Speaker: X. Long Zheng (United States)

- **Q&A** 09:30

- **Drug-Associated Thrombotic Microangiopathies: Emerging Toxicities of Novel Drugs** 09:35  
  Speaker: Marcel M. Levi (United Kingdom)

- **Q&A** 09:55

**State-of-the-Art Session**
08:45 - 10:00  
Virtual Meeting Room 3

**SOA 03, State-of-the-Art on Fibrinolysis and Proteolysis**
Illustrated SOA Capsules: [https://www.isth.org/page/soair](https://www.isth.org/page/soair)
Chair: José A. Páramo (Spain)

- **Visualizing Thrombosis to Improve Thrombolysis** 08:45  
  Speaker: John W. Weisel (United States)

- **Q&A** 09:05

- **PAI-1 and the Multi-Morbidity of Aging** 09:10  
  Speaker: Douglas E. Vaughan (United States)

- **Q&A** 09:30

- **Fibrinolysis and Bleeding of Unknown Cause** 09:35  
  Speaker: Ingrid Pabinger (Austria)

- **Q&A** 09:55
Scientific Programme

State-of-the-Art Session
08:45 - 10:00
Virtual Meeting Room 4

SOA 04, State-of-the-Art on Role of Hemostatic System in Cancer, Inflammation and Immunity
Illustrated SOA Capsules: https://www.isth.org/page/soair
Chair: Suzanne Cannegieter (the Netherlands)

The Role of Platelets in Sepsis 08:45
Speaker: Oonagh Shannon (Sweden)

Q&A 09:05

Fibrinolytic Factors in Cancer Progression 09:10
Speaker: Marie Ranson (Australia)

Q&A 09:30

Inflammatory Roles of Platelets 09:35
Speaker: John W. Semple (Sweden)

Q&A 09:55

State-of-the-Art Session
08:45 - 10:00
Virtual Meeting Room 5

SOA 05, State-of-the-Art on Arterial Thromboembolism
Illustrated SOA Capsules: https://www.isth.org/page/soair
Chair: Francesco Violi (Italy)

120 Years of Aspirin: Retiring, Recombining, or Repurposing? 08:45
Speaker: Carlo Patrono (Italy)

Q&A 09:05

Triple or Double Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention? With What Drugs? 09:30
Speaker: Renato D. Lopes (United States)

Q&A 09:50

State-of-the-Art Session
08:45 - 10:00
Virtual Meeting Room 6

SOA 06, State-of-the-Art on Platelets and Megakaryocytes
Illustrated SOA Capsules: https://www.isth.org/page/soair
Chair: Alessandra Balduini (Italy)
Scientific Programme

**Inherited Thrombocytopenias as a Model to Study the Mechanisms of Platelet Formation**
Speaker: Hana Raslova (France)  
08:45

**Q&A**  
09:05

**Small GTPases in Megakaryocyte and Platelet Biology**
Speaker: Wolfgang Bergmeier (United States)  
09:10

**Q&A**  
09:30

**Gpibα- Drive Force for Liver Thrombopoietin Generation**
Speaker: Heyu Ni (Canada)  
09:35

**Q&A**  
09:55

SSC Session  
10:00 - 12:00  
Main Foyer

**Test SSC**

**Oral Communication Session**  
10:15 - 11:30  
Virtual Meeting Room 1

**OC 01, Arterial Thromboembolism Oral Communication Session**
Chair: Filippo Crea (Italy)

**von Willebrand Factor as a Predictor of Mortality and its Target Concentration Dependent Inhibition by BT200 Aptamer in Patients Treated with Potent ADP Receptor Blockers**
Speaker: Katarina D. Kovacevic (Austria)  
10:15

**Low-grade Endotoxaemia Enhances Artery Thrombus Growth via Toll-like Receptor 4: Implication for Myocardial Infarction**
Speaker: Cristina Nocella (Italy)  
10:27

**Unraveling the Protective Effects of Factor Xa Inhibition by Rivaroxaban on Atherosclerosis by RNA Sequencing**
Speaker: Jens JN Posma (the Netherlands)  
10:39

**Reduction of Intracellular Sodium Protects from Inflammation and Atherosclerotic Plaque Progression**
Speaker: Philipp Hohensinner (Austria)  
10:51

**Impact of Platelet-Selective TGF-β1-Deficiency in Atherogenesis and CD4+ T Effector Responses Using a No-Germline Genetic Engineering Atherosclerosis Mouse Model**
Speaker: Shuai Tan (Sweden)  
11:03

**Q&A**  
11:15
Oral Communication Session
10:15 - 11:30
Virtual Meeting Room 2

OC 02, Fibrinolysis and Proteolysis Oral Communication Session

Chair: Ton Lisman (the Netherlands)

Fibrin γ-chain Crosslinking Plays an Important Role in Preventing Thrombus Breakdown and Embolisation in-vivo
Speaker: Cédric Duval (United Kingdom)
10:15

Chemical Modulation of Fibrinogen Production and its Impact on Venous Thrombosis
Speaker: Rui Vilar (Switzerland)
10:27

FXIII Catalyses Histone-Fibrin Crosslinking to Inhibit Fibrinolysis
Speaker: Matthew Locke (United Kingdom)
10:39

Fibrinogen Is Citrullinated in Venous Thrombi and Forms Fragile Clots with Increased Resistance to Lysis
Speaker: Imre Varju (Hungary)
10:51

Low α2-plasmin Inhibitor Antigen Levels on Admission Predict Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis
Speaker: Zsuzsa Bagoly (Hungary)
11:03

Q&A
11:15

Oral Communication Session
10:15 - 11:30
Virtual Meeting Room 3

OC 03, Hemophilia and Rare Bleeding Disorders Oral Communication Session 1

Chair: Sebastien Lacroix-Desmazes (France)

Immune Profiling of Previously Untreated Patients with Severe Haemophilia A by High-throughput Mimotope Variation Analysis
Speaker: Guido Baselli (Italy)
10:15

Final Results of PUPs A-LONG Study: Evaluating Safety and Efficacy of rFVIIIFc in Previously Untreated Patients with Haemophilia A
Speaker: Christoph Königs (Germany)
10:27

Deciphering the Ets-1/2-mediated Transcriptional Regulation of F8 Gene Identifies a Minimal F8 Promoter for Hemophilia A Gene Therapy
Speaker: Ester Borroni (Italy)
10:39

First In Human Liver Biopsy Study Following Gene Therapy for Hemophilia A
Speaker: Sylvia Fong (United States)
10:51

Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for >2 Years with Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A
Speaker: Lindsey A George (United States)
11:03

Q&A
11:15
OC 04, Platelets and Megakaryocytes Oral Communication Session

Chair: Mauro Torti (Italy)

Moderate Platelet Defects but Efficiently Restored Thrombopoietin Production Early after Partial Hepatectomy via JAK2-STAT3 Signaling in Mice  
Speaker: Friedrich Reusswig (Germany)  
10:15

GPR56 is a Platelet Collagen-Responsive GPCR and Hemostatic Sensor of Shear Force  
Speaker: Gregory Tall (United States)  
10:27

CD84 Links T Cell and Platelet Activity in Cerebral Thrombo-inflammation in Acute Stroke  
Speaker: David Stegner (Germany)  
10:39

Hemostasis vs. Homeostasis: Platelets Are Essential for Preserving Vascular Barrier Function in the Absence of Injury  
Speaker: Shuchi Gupta (United States)  
10:51

BIN2 Orchestrates Platelet Calcium Signaling in Thrombosis and Thrombo-inflammation  
Speaker: Sarah Beck (Germany)  
11:03

Q&A  
11:15

OC 05, Coagulation and Natural Anticoagulants Oral Communication Session

Chair: Alberto Tosetto (Italy)

The Fibronectin Type II Domain of Factor XII Prevents Inappropriate Zymogen Activation  
Speaker: Chantal C. Clark (the Netherlands)  
11:45

A Novel Contact Pathway Inhibitor Improves Hemostasis and Maintains Circuit Patency in a Piglet Model of Pediatric ECMO  
Speaker: Christopher Reed (United States)  
11:57

Neutrophil Extracellular Traps and Inflammasomes Form an Inflammatory Circuit Promoting Venous Thrombosis  
Speaker: Joana Campos (United Kingdom)  
12:09

Exogenous Microparticles Bearing Tissue Factor Improve Outcome After Collagenase-Induced Intracranial Hemorrhage  
Speaker: Fanny Potzeha (France)  
12:21

Complement Regulator Factor H is a Cofactor for Thrombin in both Pro- and Anticoagulant Roles  
Speaker: Genevieve McCluskey (United Kingdom)  
12:33

Q&A  
12:45
Scientific Programme

Oral Communication Session
11:45 - 13:00
Virtual Meeting Room 2

OC 06, Role of Hemostatic System in Cancer, Inflammation and Immunity Oral Communication Session
Chair: Pierre Mangin (France)

11:45
OvCa-Chip: A New Organ-on-a-Chip Experimental Model to Dissect Platelet & Vascular (dys)Function in Ovarian Cancer
Speaker: Abhishek Jain (United States)

11:57
Preclinical in Vivo Characterization of a First-In-Class, Fully Humanized Antibody Targeting Alternatively Spliced Tissue Factor
Speaker: Clayton Lewis (United States)

Clotting Promotes Glioblastoma Progression

12:09
Activated Protein C Reverses the p21-Mediated Hyperglycemic Memory in Diabetic Nephropathy
Speaker: Ahmed Elwakiel (Germany)

12:21
Platelets Expressing FcγRIIA/CD32A Determine the Severity of Immunological Transfusion-Related Acute Lung Injury in Mice
Speaker: Beatrice Hechler (France)

Q&A

Oral Communication Session
11:45 - 13:00
Virtual Meeting Room 3

OC 07, Thrombotic Microangiopathies Oral Communication Session
Chair: Ilaria Mancini (Italy)

11:45
How to Open ADAMTS13: An Integrative Approach to Build ADAMTS13 in Closed Conformation
Speaker: Bogac Ercig (the Netherlands)

ADAMTS13 Conformation Is Closed in Acquired Thrombotic Thrombocytopenic Purpura in the Absence of Anti-ADAMTS13 Autoantibodies
Speaker: Elien Roose (Belgium)

Severity of Acute Events in Patients with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) with or without Regular Plasma Prophylaxis: Results from the International Hereditary TTP Registry
Speaker: Erika Tarasco (Switzerland)

Longitudinal Assessment of ADAMTS13-activity Helps Predict Recurrence of Immune Thrombotic Thrombocytopenic Purpura (iTTP): Results from the German TTP-registry
Speaker: Charis von Auer-Wegener (Germany)

The Relative Impact of Treatment Approaches on the Outcome of Catastrophic Antiphospholipid Syndrome (CAPS): Analysis of an Updated Database
Speaker: Philip A Haddad (United States)
Scientific Programme

Q&A  
12:45

Plenary Session
13:15 - 13:45  
Virtual Meeting Room 1

PL 02, Plenary Session

Chair: Raimondo De Cristofaro (Italy)
Chair: Armando Tripodi (Italy)

VWF in Hemostasis: From Basic Science to Clinic  
Speaker: Peter J. Lenting (France)

On-Demand Poster Session
14:00 - 15:00  
Virtual Meeting Room 6

Arterial Thromboembolism Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Acute Coronary Syndromes

Clopidogrel Resistance and P2y12 Receptor Gene Polymorphisms in Patients with Non-ST Elevated Acute Coronary Syndrome
Speaker: Dina Shorikova (Ukraine)

Improved Antithrombotic Activity and Diminished Bleeding Side Effect of a PEGylated αIIbβ3 Antagonist, Disintegrin
Speaker: Tur-Fu Huang (Taiwan, Republic of China)

Correlation of D-Dimer Levels with Troponin I in Patients with Acute Myocardial Infarction
Speaker: Muhammad Ismail (Pakistan)

How Much Evidence Is Needed to Conclude against the Use of Oxygen Therapy in Acute Myocardial Infarction?
Speaker: Ambrish Singh (India)

White Clot is More Permeable and Stronger than the Red Clot
Speaker: Dongjune Kim (United States)

Thrombophilia and Myocardial Infarction with Non-Obstructive Coronary Arteries
Speaker: Tatyana Kondrateva (Russian Federation)

Contribution of Fibrin and von Willebrand Factor to Platelet Adhesion on Ruptured Atherosclerotic Plaque in Acute Myocardial Infarction
Speaker: Atsushi Yamashita (Japan)

A Case Report of a Patient with Hereditary Angioedema and Samter’s Syndrome Treated with Anticoagulant of Direct Action Anti Xa (Rivaroxaban), Secondary to Angioplasty due to Ischemic Heart Disease
Speaker: Fernando Vidal Martinez (Mexico)
Differential Effects of Clopidogrel with or without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Placebo-Controlled Trial in Healthy Volunteers
Speaker: Ludwig Traby (Austria)

Hydrodynamic Activation of von Willebrand Factor under Flow Conditions May Contribute to Thrombotic Complications in Coronary Heart Disease
Speaker: Zufar Gabbasov (Russian Federation)

Antiphospholipid Antibodies in Acute Myocardial Infarction
Speaker: Yang Zhang (China)

BDNFVal66Met Polymorphism Affects Cardiac Remodeling and Modulates Macrophage Polarization After Myocardial Infarction
Speaker: Leonardo Sandrini (Italy)

Plasma Exosomes in Patients with ST-Elevation Acute Myocardial Infarction (STEMI) and in Patients with Stable Coronary Artery Disease (CAD)
Speaker: Marta Zarà (Italy)

Interventions Needed in Antithrombotic Therapy in a Real Life Hospitalized Population; Evaluation of Interventions Initiated by a Multidisciplinary Antithrombotic Team Regarding Antithrombotic Agent Combinations in In-Patient Care
Speaker: Marlotte van der Veer (the Netherlands)

Changes of Soluble Fibrin-Monomer Complex Concentration in Different Types of Coronary Artery Disease
Speaker: Yuliya Tyravska (Ukraine)

In-Vivo Biomarkers of Platelet Function in Women with Ischemic Heart Disease: What We Learned from the EVA Study
Speaker: Lucia Stefanini (Italy)

Clot Formation, Ultrastructure and Lysis in Patients with Acute Phase Myocardial Infarction
Speaker: Stephen R Baker (United States)

Myocardial Infarction as a First Symptom of Activated Protein C Resistance Associated to Hyperhomocysteinemia
Speaker: Melek Kechida (Tunisia)

Postoperative Dual Antiplatelet Therapy is Influenced by Platelet Regeneration
Speaker: Till Hoffmann (Germany)

New Rat Model of Ferric Chloride-Induced Acute Coronary Artery Thrombosis for Pharmaceutical Treatment of Myocardial Infarction
Speaker: Charles-Edouard Laurent (Canada)

Smoking Status as Risk Factor and Risk Factors in Young and Elderly Patients Suffered from Myocardial Infarction
Speaker: Nebojsa Antonijevic (Serbia)

Atherosclerosis

High-Dose Atorvastatin - Loaded Microbubbles-Mediated Sonoporation Therapy using B-Mode Ultrasound - Guided Focused Electrohydraulic Shock Waves Decreases Inflammation and Restenosis after Laser Angioplasty of Advanced Atherosclerotic Severe Stenosis
Speaker: Hossein Mehrad (Iran, Islamic Republic of)
Scientific Programme

**Synthetic Antisense Oligodeoxynucleotides - Loaded Microbubbles - Mediated Transfection Therapy using B-Mode Ultrasound - Guided Focused Shock Waves Decreases Neointimal Hyperplasia Restenosis after Laser Angioplasty of Advanced Atherosclerotic Severe Stenosis**

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

**Effect of Phosphomimetic Endothelial Nitric Oxide Synthase - Loaded Microbubbles-Mediated Transfection Therapy using B-Mode Ultrasound-Guided Focused Low Level Confocal Dual-Pulse Electrohydraulic Shock Waves on Early Stage Atherosclerosis**

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

**Intravenous Lipid-Based Encapsulated Paclitaxel Nanoparticles Administration Enhances 5-Aminolevulinic Acid-Mediated B- Mode Ultrasound-Guided Electrohydraulic Shock Wave Sonodynamic Therapy of Intermediated Stage Atherosclerosis**

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

**Immuno-Radio-Metric TSH in TRH Test of Optimal Substitutive Thyroid Hormones**

Speaker: Pierre-Jean Guillausseau (France)

**Association of MMP-12 and SDF1 with Symptomatic and Asymptomatic Atherosclerosis**

Speaker: María Marcos Jubilar (Spain)

**Antioxidant Defense Gene Polymorphism in the Nenets Population**

Speaker: Nadezda Vorobyeva (Russian Federation)

**Diabetes Mellitus and Risk of Intracranial Atherosclerosis: A Meta-Analysis Using Real-World Evidence**

Speaker: Salman Hussain (India)

**In vitro Occlusive Clot Growth and Retraction**

Speaker: Britt Johanna Maria van Rooij (the Netherlands)

**Selective Targeting of Shear Gradient Activated Von Willebrand Factor by the Novel Single-Chain Antibody Scfv-A1 Reduces Occlusive Thrombus Formation**

Speaker: Akshita Rana (Australia)

**Trash Feet: Is Anticoagulation Therapy Useful?**

Speaker: Veerendra Chadachan (Singapore)

**Impact of Gut Microbiota on Late Atherosclerosis and Atherothrombosis: A Study with Germ-Free Mice**

Speaker: Giulia Pontarollo (Germany)

**In vitro Investigation of the Impact of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells**

Speaker: Helene Haguet (Belgium)

**In vitro Evaluation of the Impact of BCR-ABL Tyrosine Kinase Inhibitors on Atherosclerosis Plaque Rupture**

Speaker: Helene Haguet (Belgium)

**Evaluation of the Selectivity of BCR-ABL Tyrosine Kinase Inhibitors (TKIs): A Systematic Review**

Speaker: Helene Haguet (Belgium)

**The Role of ERp44 in the Atherosclerosis**

Speaker: Qiuya Lu (China)
Importance of Arginase-1 in Erythrocytes for Smooth Muscle Cell Calcification and Atherosclerosis  
Speaker: Rajinikanth Gogiraju (Germany)

Absence of Protein Tyrosine Phosphatase-1B in Smooth Muscle Cells Promotes Perivascular Fibrosis: Role of Receptor Tyrosine Kinase Signaling  
Speaker: Sogol Gachkar (Germany)

Relationship between Distal Venous Thrombosis and Asymptomatic Atherosclerotic Disease  
Speaker: Luca Spiezia (Italy)

Un Untargeted Lipidomic Analysis Reveals Lactosylceramide as Mediator of Monocyte Migration in Coronary Artery Disease Patients  
Speaker: Susanna Fiorelli (Italy)

Effect of BTK Inhibition on Platelet-mediated Inflammation in an Obese Rhesus Macaque Model of Early Atherosclerosis  
Speaker: Tia Kohs (United States)

Effect of Photobiomodulation Therapy on Arterial Biomechanical Parameters in a Rabbit Carotid Artery Model of Early Stage Atherosclerosis  
Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Effect of Photodynamic Therapy on Arterial Biomechanical Parameters in a Rabbit Carotid Artery Model of Neointimal Hyperplasia  
Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Cardiovascular Risk Factors

The Level of SPECAM-1 and von Willebrand Factor during the Supraventricular Arrythmia Episodes in Patients with Arterial Hypertension  
Speaker: Eugene Shorikov (Ukraine)

The State of Carotids and the von Willebrand Factor Levels in Patients with Arterial Hypertension  
Speaker: Eugene Shorikov (Ukraine)

Assessing the Impact of Switching to the Tobacco Heating System on Cardiovascular Disease: Translating Basic Science into Clinical Benefit  
Speaker: Calin Pater (Switzerland)

Comparison and Association of Fibrinogen, von Willibrand Factor and Factor VIII Levels with Risk of Cardiovascular Disease in Cigarette Smokers Residing in Calabar Metropolis, Nigeria  
Speaker: Dorothy Chioma Okpokam (Nigeria)

A Study on Pressure Overload-Induced Cardiac Hypertrophy Model in Mice by Applying Transverse Aortic Constriction and O-Ring Ascending Aortic Banding Technique: A Comparative Analysis  
Speaker: Anas Rashid (Italy)

Factor V Leiden but Not Factor II 20210G>A Is a Risk Factor in a Large Cohort of Iranian Patients with Premature Coronary Artery Disease  
Speaker: Ilaria Mancini (Italy)

Thrombin-Induced Platelet Fibrin Clot Strength Identified by Thromboelastography: A Potential Marker of Increased Thrombotic Risk in Older Adults with Coronary Artery Disease  
Speaker: Rahul Chaudhary (United States)
Tissue Factor Cytoplasmic Tail Promotes Inflammatory Myeloid Cell Derived Superoxide Formation and TGF-β1 Driven Cardiac Remodeling in Myocardial Infarction
Speaker: Venkata Garlapati (Germany)

Crosstalk between Platelet and Endothelial Dysfunction in Survivors of Allogeneic Hematopoietic Cell Transplantation Independently of Traditional Cardiovascular Risk Assessment
Speaker: Eleni Gavriilaki (Greece)

Study of Fluctuations in the Endothelin Concentration of the Crew Trans-Latitude Journey Transarctica-2019
Speaker: Nadezda Vorobyeva (Russian Federation)

Study of Thrombine Generation Assay Parameters of the Crew Trans-Latitude Journey Transartika-2019
Speaker: Nadezda Vorobyeva (Russian Federation)

Monitoring the Safety and Effectiveness of Antiplatelet Therapy
Speaker: Nadezda Vorobyeva (Russian Federation)

Aspirin Antiplatelet Effects Are Associated with Body Weight
Speaker: Lisa Dannenberg (Germany)

Overexpression of FXII as a Risk of Thrombosis in Patients with SAMTER Syndrome, Angioneurotic Edema, and its Association with Smoking Rate and Hematological Parameters
Speaker: Brenda Sarai Ascencio (Mexico)

Folate Exchange in Athletes of North-West Russia
Speaker: Nadezda Vorobyeva (Russian Federation)

Changes in the Hemostasis System in Athletes
Speaker: Nadezda Vorobyeva (Russian Federation)

The Antidepressant Drug Desipramine Prevents Arterial Thrombosis in a Mouse Model Carrying the Human BDNFVal66Met Polymorphism
Speaker: Silvia Stella Barbieri (Italy)

Gender-Associated Cardiometabolic Biomarkers in Young Adults
Speaker: Vasilii Chulkov (Russian Federation)

MiR-146a Mediates Neutrophil Extracellular Traps Formation in Acute Myocardial Infarction (AMI) in Young Patients
Speaker: Ascensión María de los Reyes-García Pastor (Spain)

Study of the Endothelial Dysfunction in Patients with Cancer: Preliminary Results
Speaker: Elisabetta Borella (Italy)

Platelet Glycoprotein IIIa Leu 33 Pro Polymorphism and Susceptibility to ST-segmented and Non-ST-segmented Myocardial Infraction
Speaker: Elshazali Mohamed Ahmed (Sudan)

Cardiovascular Risk in Systemic Lupus Erythematosus
Speaker: Melek Kechida (Tunisia)

Apolipoprotein A-IV Is an Endogenous Inhibitor of Thrombosis: The Roles of Polymorphisms in the Risk of Cardiovascular Disease
Speaker: Daniel *MacKeigan (Canada)
Scientific Programme

Von Willebrand Factor in Stroke and Non-valvular Atrial Fibrillation Patients
Speaker: Martha Eva Viveros-Sandoval (Mexico)

PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation
Speaker: Vittoria Cammisotto (Italy)

Systemic Aspirin Esterification in Subjects with Cardiovascular Disease: Impact of Body Size
Speaker: Benedetta Porro (Italy)

Endogenous PCSK9 Is Related to Circulating CD34bright/CD146- Cells in Patients with Type 2 Diabetes Mellitus
Speaker: Romina Tripaldi (Italy)

Clinical Implications of White Blood Cell Count and Platelet Indices in Individuals with Risk Factor of Coronary Artery Disease
Speaker: Supakanya Lasom (Thailand)

Proteases from Pathogenic and Non-pathogenic Bacteria Activate Prothrombin (ProT) in Human Plasma: Implications in Thrombotic Diseases
Speaker: Vincenzo De Filippis (Italy)

Evaluation of Biological Effects of Airborne / Urban Pollution Particles
Speaker: Cornelis Kluft (the Netherlands)

The Clinical Predictors of Coronary Artery Disease: A Population-based Study from Developing Country
Speaker: Muhamad Fajri Addai (Indonesia)

African American Women with Diabetes Undergoing Catheterization Represent Most Prothrombotic Subgroup: An Explanation for the Platinum Diversity Study Results?
Speaker: Paul Gurbel (United States)

Pulmonary Thromboembolism in General Practice
Speaker: Tamar Saralidze (Georgia)

Cerebrovascular Disorders

Thromboembolism in Thalassemia Patients: Is Aspirin Protective against Brain Ischemia over Three Years Follow Up in Beta Thalassemia Patients?
Speaker: Mehran Karimi (Iran, Islamic Republic of)

Silent Brain Ischemia in Thalassemia Patients: Breaking the Silence
Speaker: Mehran Karimi (Iran, Islamic Republic of)

Hereditary Thrombophilia in Arterial Ischemic Stroke: A Study from the South of Tunisia
Speaker: Fatma Megdich (Tunisia)

Histological Analysis of a Thrombectomy-Resistant Thrombus in Acute Ischemic Stroke
Speaker: Senna Staessens (Belgium)

Impact of Protease Nexin-1 in Cerebral Ischemia
Speaker: Marie-Christine Bouton (France)

Hemorrhagic and Ischemic Stroke in Patients after Allogeneic Stem Cell Transplantation
Speaker: Xuan Cai (China)
Scientific Programme

A Recurrent Ischaemic Stroke Case with Type 1 von Willebrand Disease
Speaker: Handan Haydaroğlu Şahin (Turkey)

Plasma Calprotectin as a Novel Independent Predictor of Mortality in Acute Ischemic Stroke
Speaker: Manuel Navarro-Oviedo (Spain)

Effect of Pulsatility on Thrombosis Modelling in Cerebral Aneurysms
Speaker: Struan Hume (South Africa)

Temporary Hypofibrinogenemia in Reversible Cerebral Vasoconstriction Syndrome (SRVC) Associated a Cannabis Overdose
Speaker: Sonia Herrero (Spain)

Secondary Brain Damage in Mouse Models of Focal and Global Ischaemia and Haemorrhagic Stroke: A Comparative Study
Speaker: Maithili Sashindranath (Australia)

Characterization and Antithrombotic Treatment of Patients with Acute Ischemic Stroke and No Atrial Fibrillation: A Real-world Study
Speaker: Lu Wang (United States)

Plasma Concentration of Apolipoprotein C-III is Associated with Ischemic Cerebrovascular Events in High-Risk Cardiovascular Patients Taking Anticoagulant Therapy with Warfarin
Speaker: Filippo Stefanoni (Italy)

PI3KC2β Deficiency Stabilizes Adherens Junctions and Preserves Vascular Integrity in Stroke Models
Speaker: Marie-Pierre Gratacap (France)

Antiaggregation Evaluation of Aspirin and Clopidogrel in Endovascular Treatment of Intracranial Aneurysms with Flow Diverter Stents
Speaker: Antonio Moscardo (Spain)

Thrombin Generation in Patients with Non-traumatic Intracerebral Hemorrhage
Speaker: Linda Lóczi (Hungary)

Characteristics and Recurrence of Acute Ischemic Stroke in Children: An Examination Using Real World Data
Speaker: Jill Hardin (United States)

The Use of in Vitro Clot Lysis Assay for Predicting Outcomes in Non-traumatic Intracerebral Hemorrhage Stroke Patients
Speaker: Rita Orbán-Kálmándi (Hungary)

The Epinephrine-induced Platelet Aggregation Changes in Arterial Hypertension of Very High Risk
Speaker: Eugene Shorikov (Ukraine)

The Optimal Treatment of Atrial Fibrillation in Patients with Cancer
Speaker: Inna Tzoran (Israel)

Incidence of Recurrent Ischemic Stroke in Patients without Atrial Fibrillation: A Real-world Study
Speaker: James Weaver (United States)

Peripheral Artery Disease
Scientific Programme

Acute Leriche Syndrome in a 55-Year-Old Woman with Recurrent Central Pulmonary Embolism: A Case Report
Speaker: Viktoria Muster (Austria)

Elevated Levels of Activated Factor XII Are Associated with an Increased Risk of Atherothrombotic Events in Peripheral Artery Disease
Speaker: Bram Kremers (the Netherlands)

The Prevalence of Peripheral Artery Disease in Hospitalized Patients with Heart Failure
Speaker: Chiara Fantoni (Italy)

Poorly Compressible Lower Extremity Arteries Are Associated with Venous Thromboembolism
Speaker: Fadi Shamoun (United States)

Development of a Clinical Cohort of HIV-infected Patients with Peripheral Vascular Disease
Speaker: Elizabeth Mayne (South Africa)

Rationale and Design for the Study Apixaban versus ClopidoGRel on a Background of Aspirin in Patients Undergoing InfraPoPliteal Angioplasty for Critical Limb Ischemia - AGRIPPA Trial
Speaker: Rodrigo Biagioni (Brazil)

On-Demand Poster Session
14:00 - 15:00 Virtual Meeting Room 6

Coagulation and Natural Anticoagulants Abstracts

Animal Models in Thrombosis and Hemostasis

Small-Molecule Factor XIa Inhibitor, BMS-986177/JNJ-70033093, Prevents and Treats Arterial Thrombosis in Rabbits at Doses that Preserve Hemostasis
Speaker: Pancras Wong (United States)

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Liquorice and Sumac Attenuate Brain Damage Caused by Ischemic Stroke in Rat
Speaker: Mohammad Babaian (Iran, Islamic Republic of)

Anti-Aggregant Effect of Butanolic Extract of Rubia Tinctorum on Platelets in vitro and ex vivo
Speaker: Fatima Zahra Marhoume (Morocco)

Hemolysis Triggers Platelet-Dependent Pulmonary Arteriole Thrombosis
Speaker: Tomasz Brzoska (United States)

Increased Levels of von Willebrand Factor Associated with Acute Inflammation Contribute to Enhanced Venous Thrombosis
Speaker: Seon Jae Choi (Canada)
Non-Invasive Optical in vivo Imaging Reveals Tumor-Derived Prothrombin with a Functional Role in Hemostasis and Tumor Progression
Speaker: Lina Katharina Schott (Germany)

Heart Failure, Induced by Excess Neurohormonal Activation, Results in Significant but Non-Critical Telomere Shortening in Cardiomyocytes and Peripheral Blood Mononuclear Cells
Speaker: Hendrik Dörschmann (Germany)

The Initial Formation of a Transient Sub-Occlusive Mural Thrombus Appears to Protect Coagulation to Leave a Thin Platelet- and Fibrin-Rich Patch Covering the Site of Injury
Speaker: Alexandra Yakusheva (France)

High Salt Intake Increases Platelet Counts and Plasma Fibrinogen Levels but Has No Effect on Thrombus Formation or Resolution in a Murine Model of Venous Thrombosis
Speaker: Johannes Wild (Germany)

Platelet Analysis of Diet-Induced Obesity Rat Model: Elucidating Platelet Dysfunction in Obesity
Speaker: Maria N. Barrachina (Spain)

Fibrin Deposits on Peritoneal Carcinomatosis Serves as a Niche for Cancer Cell Implantation and Dissemination. A Scanning Electron Microscopy Analysis
Speaker: Iman Aldybiat (France)

Novel Mouse Model for Studying Hemostatic Function of Human Platelets
Speaker: David S. Paul (United States)

Cardiac Myosin Promotes Thrombin Generation and Coagulation in vitro and in vivo
Speaker: Meenal Shukla (United States)

Thrombin Generation Following Vipera berus Envenomation: A Canine Model
Speaker: Hannah Jayne Harjen (Norway)

Multiple Gene Knockdowns Simultaneously to Study Hemostasis in Zebrafish
Speaker: Pudur Jagadeeswaran (United States)

Sex Bias in Animal Models of Thrombosis Research
Speaker: Paul Thuan Tieu (Canada)

CRISPR/Cas9-Mediated Generation of a RUNX1 Knock-In Mice Model and Platelet Characterization
Speaker: Ana Marín-Quílez (Spain)

Maternal Deficiency of Endothelial Protein C Receptor Causes Severe Pregnancy Complications Prevented by Inactivation of Protease Activated Receptor 4, but not Clotting Factor VIII
Speaker: Michelle Castillo (United States)

Immunization with Recombinant Atherogenic Antigen (AHC) Does Not Increase Susceptibility to Venous Thrombosis
Speaker: Xinjie Lu (United Kingdom)

Antithrombotic Properties of Carvedilol Shown in Two Independent Intravital Real Time Models of Thrombosis
Speaker: Przemyslaw Czajkowski (Poland)
Reported Values and Methodologies for Detecting Plasma D-dimer in Rat Models: A Systematic Review and Meta-analysis
Speaker: Jason Chung (Canada)

Von Willebrand Factor (VWF) Deficiency Leads to Altered Angiogenesis in the Gastrointestinal Tract
Speaker: Mario von Depka (Germany)

Real-time in vivo Visualization of Infused FVIIa in Hemophilia A Mice Following Injury
Speaker: Juliana C Small (United States)

Novel Oral Anticoagulants Do Not Expand Haematoma Volume in an Intracerebral Hemorrhage Model in Rats
Speaker: Juliana Ferreira (Brazil)

Effects of Hibernation on the Platelet Proteome of 13-lined Ground Squirrels
Speaker: Joseph Aslan (United States)

Identification of Thrombosis Predictors in an ex vivo Shunt Model through Retrospective Analysis
Speaker: Hari Hara Sudhan Lakshmanan (United States)

Early Indicators of Thromboembolic Events Caused by Prolonged Tourniquet Application: A Rat Model
Speaker: Jason Chung (Canada)

Coagulation Factors and Inhibitors

Inhibitor against Congenital Coagulation Factor XIII Deficiency: A Case Report
Speaker: Mehran Karimi (Iran, Islamic Republic of)

Activated recombinant Factor VII (rFVIIa) Inhibitor in Iran: Immunogenicity is a Major Challenge through Treated Bleeds Covered with rFVIIa
Speaker: Mehran Karimi (Iran, Islamic Republic of)

Efficacy and Safety of Prothrombin Complex Concentrate in Obstetric Hemorrhage
Speaker: Alexandr Ronenson (Russian Federation)

Protein C Activity and Fibrinogen Levels in Nigerians Receiving Renal Replacement Therapy for Chronic Kidney Disease
Speaker: Omolade Awodu (Nigeria)

von Willebrand Factor Levels and Expression Pattern Are Altered in Response to Aging
Speaker: Parnian Alavi (Canada)

A Novel Rare C. - 39C>T Mutation in the PROS1 5'UTR Causes Protein S Deficiency by Creating a New Upstream Translation Initiation Codon and an Overlapping Open Reading frame
Speaker: David-Alexandre Trégouët (France)

G-Quadruplex Related Aptamers to Thrombin Exosite I with Additional Duplex Region. Relationships between their Structure, Stability and Antihtrombin Activity
Speaker: Alexey Mazurov (Russian Federation)

Prophylaxis in Adult Population. Experience and Results in a 5-Year Follow-up Cohort
Speaker: Claudia Casas (Colombia)
Operational Feasibility of a Pharmacist-Guided Personalized Medicine Consult Service for Warfarin in Mandatory and Optional Testing Settings  
Speaker: Ashwini Zolekar (United States)

Acquired Haemophilia Spanish Registry, First Five Years of Activity  
Speaker: María Eva Mingot-Castellano (Spain)

Impact of DOACs on Hemostasis Diagnostic Tests. Practical Recommendations and Guidance for the Laboratory  
Speaker: Romain Siriez (Belgium)

Drug Interactions in Edoxaban Treated Patients: A Pilot Study Revealing the Changes of the Metabolite to Parent Ratio and its Potential Clinical Importance  
Speaker: Romain Siriez (Belgium)

Comparison of a Validated UHPLC-MS/MS Method and Chromogenic Anti-Xa Assays from Different Manufacturer for the Assessment of Edoxaban and its M4 Metabolite Levels in Plasma  
Speaker: Romain Siriez (Belgium)

Anticoagulation with the Novel, Small-molecule Factor Xla (fXla) Antagonist, EP-7041, Prevents Oxygenator Clotting but Conserves Hemostasis in a Canine Extracorporeal Circulation (ECMO) Model  
Speaker: Michael Andrew Kurz (United States)

Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1  
Speaker: Lisa Dannenberg (Germany)

Validation of a Non-Sensitive aPTT Reagent for the Presence of Anti-Phospholipid Abs (Lupus Anti-Coagulant)  
Speaker: Sigal Nakav (Israel)

A Novel Prediction Platform to Enhance the Design of Therapeutic SERPINs  
Speaker: Wariya Sanrattana (the Netherlands)

Natural Compounds as Anticoagulant Drug: A New Avenue for Improving Thrombosis Outcome  
Speaker: Swati Sharma (India)

Factor Xa Stimulates PAR-Independent Pro-Inflammatory Responses in Primary Adult Rat Cardiac Fibroblasts  
Speaker: Elisa D’Alessandro (the Netherlands)

Evaluation of the CEPHEN™ Reagent for the Determination of Activated Partial Thromboplastin Time in Current Practice  
Speaker: Corinne Frere (France)

Natural Anticoagulant from Peony  
Speaker: Margarita Lyapina (Russian Federation)

Identification of Novel Proteins Binding to Coagulation Factor XIII Free B-Subunit  
Speaker: Bojun Li (Switzerland)

Higher Protection against Inhibitors with pdFVIII/VWF Complex Concentrate Compared to Complex Formed in the Circulation between Isolated FVIII and VWF of HA Patients: An ex vivo Study  
Speaker: Maria Isabel Bravo (Spain)
Rare Coagulation Disorders in Children - Is it Like to Buy a Pig in a Poke or Nothing Special? Experience of Saint Petersburg, Russia
Speaker: Natalia Sokolova (Russian Federation)

Transplacental Delivery of Maternal Factor VIII for Induction of Immune Tolerance to Therapeutic Factor VIII
Speaker: Angelina Mimoun (France)

Endocytosis of Factor VIII by Human Dendritic Cells in the Presence of Anti-Factor VIII Antibodies from Patients with Hemophilia A
Speaker: Mélissa Bou Jaoudeh (France)

Antithrombotic Effects of a Novel Small Molecular Fxia Inhibitor BMS-986177/JNJ-70033093 in a Rabbit AV-Shunt Model of Thrombosis
Speaker: Xinkang Wang (United States)

Effects of Anticoagulants on Fibrin Clot Structure: A Comparison between Vitamin K Antagonists and FXa inhibitors
Speaker: Julia S. Gauer (United Kingdom)

Anticoagulant Effects of Parenteral Sulodexide as Measured by Activated Clotting Time. Relevance to Dosing in Various Indications
Speaker: Bharathi Daravath (United States)

Structures in the Presence and Absence of an Anti-Factor VIII C1 Domain Antibody Bound to a Bioengineered Factor VIII Construct Indicates Multiple C2 Domain Conformations
Speaker: P. Clint Spiegel (United States)

Pharmacopeial Potency Equated Sulodexide Produces Comparable Anticoagulation as Studied in Whole Blood
Speaker: Bharathi Daravath (United States)

Factor XII Deficiency - A Very Rare Coagulation Disorder: Case Report
Speaker: Deniza Stambolieva (Macedonia, the Former Yugoslav Republic of)

Suppression of Factor VIII-Specific Memory B Cells by Murine and Human BAR-Tregs
Speaker: David Scott (United States)

Preclinical Pharmacology of BAY 2433334, a Small Molecule Inhibitor of Coagulation Factor Xa
Speaker: Stefan Heitmeier (Germany)

Role of Kunitz Domain 3 of Tissue Factor Pathway Inhibitor in Zebrafish
Speaker: Revathi Raman (United States)

A Double Heterozygous Factor VII (FVII) Deficiency: Exon 9 Missense Mutation (Arg364Gln - FVII Padua) and a Novel Exon 3 Missense Mutation (Ala87Gly)
Speaker: Christian Aledia Gallardo (Singapore)

Congenital Factor X Deficiency with Isolated Prothrombin Time Prolongation
Speaker: Dilek Gurlek Gokcebay (Turkey)

Molecular Analysis in 12 factor XI Deficiency Patients from China: Identification of Three Novel Splicing Mutations
Speaker: Donglei Zhang (China)
**Scientific Programme**

**Point-of-Care and Storage-Stable, Single-Use 8-Channel Microfluidic Chip for Rapid Testing of DOACs and DOAC Reversal Agents under Whole Blood Flow**
Speaker: Jason Rossi (United States)

**Transplacental Delivery of Fc-fused Factor VIII (rFVIIIIFc) in FVIII-Deficient Mice**
Speaker: Sandrine Delignat (France)

**Identification of Key Residues in Protein Z Dependent Protease Inhibitor (ZPI) for Efficient Protease Inhibitor**
Speaker: Chellam Gayathri Subash (India)

**Protein S Deficiency, Inflammation and Sickle Cell Anemia**
Speaker: Awa Oumar Touré (Senegal)

**First-in-Human Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of ONO-7684, an Oral Small Molecule Factor Xa Inhibitor in Healthy Subjects**
Speaker: Dominic Beale (United Kingdom)

**Library Screening and Combinatorial Approaches Identify an Alpha-1 Proteinase Inhibitor Variant with Enhanced Specificity for Factor Xa**
Speaker: William Sheffield (Canada)

**The Antiplasmin Activity of the Kunitz Protease Inhibitor Domain of Protease Nexin 2 Affects Thrombolysis and Thrombosis in Mouse Models**
Speaker: William Sheffield (Canada)

**Nontoxic Polyphosphate Inhibitor that Reduces Thrombosis without Increased Bleeding**
Speaker: Stephanie A. Smith (United States)

**A Comparison of Mass and Potency Equated Bovine and Porcine Heparins**
Speaker: Sharan Krishnappan (United States)

**Optimisation of Assays for Laboratory Monitoring of Emicizumab in Treated Patients**
Speaker: Aine N McCormick (United Kingdom)

**Comparison of Medication Adherence Between Different Oral Anticoagulants: A Propensity Weighted Nationwide Cohort Study**
Speaker: Arnar B. Ingason (Iceland)

**The FibWave, a New Sensitive and Relevant Tool for Analysing the fibrin Clot Formation: Comparison with the Calibrated Automated Thrombogram to Assess Direct Oral Anticoagulants**
Speaker: Jonathan Evrard (Belgium)

**Hypofibrinogenemia with a New Heterozygous Mutation in Fibrinogen in a Patient with Thrombotic Complications**
Speaker: Soraya Hadjali-Saichi (Algeria)

**Characterisation and Evaluation of a Candidate Bethesda Assay Reference Reagent Developed from Recombinant, Patient-Derived FVIII Inhibitors**
Speaker: Carmen Coxon (United Kingdom)

**Rare Bleeding Disorders in North India - Study from a Tertiary Care Centre**
Speaker: Sabina Langer (India)

**Discordance Between the Neutralization Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban in the Clotting Assays and Anti-Xa Measurements**
Speaker: Fakiha Siddiqui (United States)
Circulating T Helper 17 Cells (Th17) Increase at a Higher Rate than Tregs in Previously Untreated Patients with Severe Hemophilia A Who Develop Inhibitors During the First 50 Exposure Days to rFVIII
Speaker: Deborah Brown (United States)

New Peptide Inhibitors of Serine Proteases of the Blood Coagulation System
Speaker: Liliya Mukhametova (Russian Federation)

HIPS Qualification Testing (HQT): Qualification of Hemophilia Treatment Centers to Perform PBMC Re-Stimulation for the Hemophilia Inhibitor in Previously Untreated Patients (HIPS) Study
Speaker: Deborah Brown (United States)

Anticoagulant Effect of Novel Nanoparticles Functionalized with Synthetic Piperazinone Derivatives as FXa Inhibitors
Speaker: Flavia Zacconi (Chile)

Bisecting the Role of the C-terminal End of Antithrombin: Natural Variants due to a Frameshift at Different Secondary Structures May Exacerbate or Ameliorate a New Dominant-negative Effect
Speaker: Carlos Bravo-Perez (Spain)

Deep Vein Thrombosis and Coagulation Factor Deficiency: A Paradoxical Association
Speaker: Yosra Cherif (Tunisia)

Clinical Significance of T-cell Subsets for the Inhibitor Development in Pediatric Hemophilia A Patients
Speaker: Zhenping Chen (China)

Effect of Mg(II) Ion on the Interaction of Coagulation Factors with Phospholipid Membranes
Speaker: Yasuo Shikamoto (Japan)

Warfarin and Vitamin K Epoxide Reductase: A Mechanism for Inhibition Using Molecular Dynamics Simulation
Speaker: Sangwook Wu (Korea, Republic of)

Are the Plasma Levels Thresholds of DOAC Rationale and Appropriate for Clinical Decision-making? A Reappraisal Using Thrombin Generation Testing
Speaker: Jonathan Evrard (Belgium)

Combined Analysis of Dendritic Cell (DC) HLA-class-II (HLAclII) Peptidomic Profiling Data Derived from Different Therapeutic Factor VIII Proteins (tFVIIIs) in Independent Experiments/Laboratories
Speaker: Tom E Howard (United States)

Perioperative Management of Acquired Factor XI Deficiency: A Case Report and Review of Literature
Speaker: Corentin Achard (France)

Probing Interaction of TOS with ATIII Using MD Simulation and Biophysical Studies; Its Effect on Clot Formation and FXa Inhibition
Speaker: Irshad Ahmad (India)

A Novel Coagulation Factor VIII with Reduced Immunogenicity
Speaker: Steffen Kistner (Germany)
A Sensitive and Specific Assay to Measure TF Activity in Cell-derived Extracellular Vesicles Based on Thrombin Generation
Speaker: Bjarne Østerud (Norway)

Measurement of Polyphosphate in Biologic Samples
Speaker: Stephanie A. Smith (United States)

Anti-factor V Inhibitor after Liver Transplantation
Speaker: Alessandro Ciavarella (Italy)

Addition of Histone Deacetylase Inhibitors Increases Recombinant Factor V Expression in BHK Cells
Speaker: Teodolinda Petrillo (United States)

The Distribution of Hemophilia A-causing Genetic Variants by Race/Ethnicity and Association with Inhibitors among Enrollees in the Hemophilia Inhibitor Research Study (HIRS)
Speaker: Amanda B. Payne (United States)

The Anticoagulant Effect of Protamine - A Stabilizer of the Factor V Procofactor State
Speaker: Teodolinda Petrillo (United States)

To Determine the Effect on Gender and Age of Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT) Levels and International Normalized Ratio (INR)
Speaker: Aysha Sultana (Pakistan)

Lysine Residues Impair the Efficacy of N-glycosylation: Pathological and Physiological Relevance in Antithrombin
Speaker: Maria Eugenia de la Morena-Barrio (Spain)

Whole Genome Sequencing Study of Coagulation Factor VIII and von Willebrand Factor Reveals New Genetic Associations
Speaker: Paul S de Vries (United States)

Baseline VWF Antigen Level Is Associated with the Outcome of Immune Tolerance Induction Using pdFVIII/VWF Concentrate in Hemophilia A with Inhibitor
Speaker: Zekun Li (China)

Assessment of Four Factor Prothrombin Complex Concentrate (4F-PCC) Usage in Emergency Department Patients: A Single Center Experience
Speaker: Hannah McRae (United States)

Sequence Mismatch Between Therapeutic (t) and Endogenous (e) Factor VIII Proteins (FVIIIs), and HLA-class-II (HLAII)-binding in the Development of Neutralizing Anti-tFVIII-Antibodies in Hemophilia A (HA): Evidence from the PATH Study
Speaker: Vincent P. Diego (United States)

Inactivation of Tissue Factor Pathway Inhibitor through Specific Citrullination by Peptide Arginine Deiminase 4
Speaker: Rory Koenen (the Netherlands)

Always Ask Relevant Questions to Patients Might Be They Tell You the Diagnosis
Speaker: Arshi Naz (Pakistan)

X-ray Crystallography and Hemostatic Activities of a Neutralizing Anti-TFPI Antibody, Marstacimab
Speaker: Debra Pittman (United States)

Contact Pathway
Allosteric Modulation of Exosite 1 Attenuates the Enhancing Effect of Polyphosphate on FXI Activation by Thrombin  
Speaker: Ruiqi Yin (Canada)

Histidine-Rich Glycoprotein Attenuates the Prothrombotic Activity of Polyphosphate in a FXII-Dependent Manner  
Speaker: Rida Malik (Canada)

First Evaluation of the Safety, Pharmacokinetics and Pharmacodynamics of BAY 2433334 a Small Molecule Targeting Coagulation Factor XIa in Healthy Young Male Participants  
Speaker: Dirk Thomas (Germany)

Are Therapeutic Immunoglobulins Free from Factor XIa?  
Speaker: Helen Wilmot (United Kingdom)

ONO-1600586, an Oral Direct Factor XIa Inhibitor, Suppresses Thrombus Formation in Rabbit Jugular Vein without Bleeding Tendency  
Speaker: Nobuyuki Oguri (Japan)

Detecting Oral Kallikrein-Targeting Therapy through Triggered Contact Activation: A Phase I Study  
Speaker: Chantal C. Clark (the Netherlands)

A Critical Role of Carboxyl-Terminal Alpha-Helix in the Secretion of Coagulation Factor XI  
Speaker: Yuri Hayakawa (Japan)

Activation of Coagulation by 5.8S RNA  
Speaker: Pudur Jagadeeswaran (United States)

Coagulation Assays Based on Surface-Mimicking Antibodies against Factor XII  
Speaker: Marco Heestermans (Germany)

Factor XII and Kininogen Complex with gC1qR/C1QBP/P32 Is Governed by Zinc Ions  
Speaker: Jonas Emsley (United Kingdom)

Importance of the Non-Catalytic Heavy Chains of the Homologs Factor XII and HGFA in Protease Function  
Speaker: Aleksandr Shamanaev (United States)

Structure-Function Relationships in Factor XII Studied with Factor XII-HGFA Chimeras  
Speaker: Aleksandr Shamanaev (United States)

Effects of Plasmin on Factor XII Structure and Activation  
Speaker: Ivan Ivanov (United States)

Evolutionary History of the Kallikrein-Kinin System and Factor XI  
Speaker: Michal Ponczek (Poland)

Neutralization of Osocimab-Induced Anticoagulation with Prothrombin Complex Concentrate, Activated Prothrombin Complex Concentrate and Recombinant Activated FVII in vitro  
Speaker: Anja Buchmueller (Germany)

Identification of the Histidine-rich Glycoprotein Domain Responsible for Contact Pathway Inhibition  
Speaker: Tammy Truong (Canada)
Design of Polyphosphate Inhibitors that Reduce Thrombosis without Increased Bleeding
Speaker: Chanel Carmen La (Canada)

Plasma Contact Activation through T Cell-Derived Polyphosphate
Speaker: Reiner K. Mailer (Germany)

Quantification of Free FXIa by an Innovative “Catch and Release” Assay
Speaker: Stan van der Beelen (the Netherlands)

The Misfolded Protein Glycated Albumin Activates the Contact System Leading to Plasma Kallikrein Activity But Not Intrinsic Coagulation
Speaker: Lewis Hardy (United Kingdom)

In-vivo Evidence for Contact Activation after Implantation of a Left Ventricular Assist Device in Patients with End-stage Heart Failure
Speaker: Omayra Liesdek (the Netherlands)

Relevance of Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 p.Thr309Lys Variant
Speaker: Maria Eugenia de la Morena-Barrio (Spain)

Corn Trypsin Inhibitor in the Preanalytical Phase of Contact Activation Assays
Speaker: Matthias M. Engelen (Belgium)

Critical Care and Perioperative
„Plasma Free” Perioperative Approach during Lung Transplantation Does Not Seem to Impair Secondary Hemostasis Measured by ROTEM
Speaker: Miroslav Durila (Czech Republic)

„Plasma Free” Perioperative Approach during Lung Transplantation Seems to Decrease FXIII Level which is Not Clinically Significant
Speaker: Miroslav Durila (Czech Republic)

Hemostasis Critical Values in a Laboratory without Hospitalization from CABA, Argentine
Speaker: María Luisa Iglesias Varela (Argentina)

Indiscriminate Coagulation Testing for Bleeding Risk Assessment Prior to Orthopedic Surgery. Is it a Rational Approach?
Speaker: María Ali (Pakistan)

Hematologic Laboratory Parameters and Hemostatic Thresholds for the Safe Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders: A Scoping Review
Speaker: Wynn Peterson (Canada)

External Quality Assurance (EQA) for the Thromboelastometry Devices: UK NEQAS BC Programme Update
Speaker: Dianne Patricia Kitchen (United Kingdom)

Thrombohemorrhagic Events and Management of Haemostasis in Adult Patients under Berlin Heart Excor Devices
Speaker: Miguel Argüello (Spain)

The Association of Prothrombin Complex Concentrates with Transfusion Requirement and Postoperative Outcomes in Cardiac Surgery: A Post-Hoc Analysis of the FIBRES Randomized Controlled Trial
Speaker: Justyna Bartoszko (Canada)
Delay in Time to Hip Fracture Repair Surgery among Elderly Patients Treated with Anti Platelet Therapy  
Speaker: Aaron Lubetsky (Israel)

Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal with 4F-PCC (KVAD Study)  
Speaker: Jessica Rimsans (United States)

Low Preoperative Antithrombin Activity Is Associated with Increased Red Cell and Plasma Transfusion during Neonatal and Infant Cardiac Surgery  
Speaker: Zhe Amy Fang (Canada)

ROTEM Parameters As Bleeding Predictors In Pediatric Cardiac Surgery With Cardiopulmonary Bypass  
Speaker: Diem Truong-Pham (Viet Nam)

Implementation of the Management of Anticoagulation in the Periprocedural Period (MAPPP) App into an Electronic Health Record (EHR): A Prospective Cohort Study  
Speaker: Dimitrios Giannis (United States)

Coagulation Research in Paediatric ECMO: Delayed Consent to Improve Enrolment  
Speaker: Suelyn Van Den Helm (Australia)

The Comparison of Critical Care Instrument CoaguChek® Pro II with Coagulation Analyzers Sysmex CS-5100 and Cobas t 511  
Speaker: Martin Pulcer (Czech Republic)

Coagulation Research in Paediatric ECMO: The Need for a Common Language  
Speaker: Joppe Geert Frederik Drop (the Netherlands)

Presentation of Three Patients Treated with Dabigatran that Strongly Confirm the Importance of Quantitative Measurement of Dabigatran Concentration in Selected Clinical Situations: Case Reports  
Speaker: Ivana Ćelap (Croatia)

Clinical Outcome of Using Three-Factor Prothrombin Complex Concentrate in Patients with Major Bleeding Associated with Factor Xa Inhibitor  
Speaker: Thipsumon Raksintham (Thailand)

Comparison of a New Point-of-Care Hemostasis Analyzer with Laboratory Parameters in Patients with Veno-venous Extracorporeal Membrane Oxygenation  
Speaker: Corinne Frere (France)

Haemostatic Markers in Cardiopulmonary Bypass Surgery  
Speaker: Amita Ranger (United Kingdom)

Use of Recombinant von Willebrand Factor Alone during Surgeries in Type 2 von Willebrand Patients: Case Reports  
Speaker: Sara Boukhial (France)

Pharmacodynamic Approach to Manage Patients on Direct Oral Anticoagulants Undergoing Elective Major Surgery and Operative Endoscopy  
Speaker: Sophie Testa (Italy)
Scientific Programme

Prospective Study of Haemostatic Activation Markers and Correlation with Bleeding and Thrombotic Complications in Patients Receiving Veno-Venous Extra-Corporeal Membrane Oxygenation (VV-ECMO) - HAE Study
Speaker: Deepa Jayakody Arachchillage (United Kingdom)

PTT a Surrogate for Quantification of Factor VIII Inhibitor
Speaker: Kimberly Klein (United States)

A Multicenter Experience with Idarucizumab “In Real World” as Reversal Anticoagulation of Dabigatran
Speaker: Irene Amarilla Lanzas (Spain)

Whole Blood Coagulation Profiles at the Time of Emergency Unit Admission in Patients with Major Trauma
Speaker: Luca Spiezia (Italy)

Postoperative Heparin Monitoring by Anti-Xa Is More Accurate Than by aPTT After Pulmonary Endarterectomy - Role of Increased Systemic and Endothelial Production of Factor VIII
Speaker: Antti Nykanen (Canada)

Predictors of Residual Preprocedural DOAC Levels
Speaker: Joseph Shaw (Canada)

Microstructural Characterisation of in vivo Paediatric ECMO Circuit Binding and Blood Clot Structure
Speaker: Tengyi Cai (Australia)

Investigation of the Coagulation Potential of PAS-E Resuspended Platelets
Speaker: Anaïs Lotens (Belgium)

Use of Prothrombin Complex Concentrate for Reversal of Oral Anticoagulants in the Clinical Practice of a Portuguese Tertiary Hospital
Speaker: Diana Cibele (Portugal)

Efficacy and Safety of Ciraparantag in Reversing Apixaban and Rivaroxaban as Measured by Whole Blood Clotting Time in Healthy Adults
Speaker: Jack Ansell (United States)

Assessment of the Difference Between EXTEM and FIBTEM Amplitudes (PLTEM) and Their Correlation with Platelet Count (PLT), and the Effect of Fibrinogen and Hematocrit (HTC) in Cardiovascular Surgery (CVS)
Speaker: Marina Sol Lopez (Argentina)

Outcomes of Patients with Anti-Xa versus APTTr Monitoring for Unfractionated Heparin Infusions during Extracorporeal Membrane Oxygenation
Speaker: Andrew Doyle (United Kingdom)

Profile of Effect of Sugammadex on Coagulation and Fibrinolysis
Speaker: Cornelis Kluft (the Netherlands)

Reversal of Heparin Anticoagulation by Andexanet Alfa (Andexanet) in Human Plasma and Whole Blood: Differential Effect of Andexanet on Antithrombin-Dependent Anticoagulants and Direct Thrombin Inhibitors (DTIs)
Speaker: Genmin Lu (United States)
Scientific Programme

Rapid Thaw Plasma Units Thaw Significantly Faster than Standard Plasma Units while Retaining Similar Coagulation Profile over 5 Days of Cold Storage  
Speaker: Kathleen M. Madden (United States)

Investigation of Several Four Factor PCCs to Restore Thrombin Generation Following Anticoagulation with Rivaroxaban: Ex vivo Study  
Speaker: Oliver Grottke (Germany)

Clinical Study of Children's Intracranial Hemorrhage in Single Hemophilia Center in China  
Speaker: Xiaoqin Feng (China)

Bleeding and Thrombotic Complications in Patients Undergoing Major Cardiac Surgery on Single, Dual Antiplatelet Treatment Compared to Controls  
Speaker: Christopher Little (United Kingdom)

Thrombocytopenia in adult ICU patients with sepsis  
Speaker: Lene Russell (Denmark)

A Strategy of Continued Antiplatelet Agents, Vitamin K Antagonists, and Direct Oral Anticoagulants throughout the Perioperative Period of Diabetic Foot Surgery in Patients Receiving Chronic Antithrombotic Therapy  
Speaker: Dmytro Dmytriiev (Ukraine)

VMX-C001 Is a Reversal Agent for FXa-inhibiting DOACs and Displays a Favorable Pharmacokinetic and Pharmacodynamic Profile  
Speaker: Daniël Verhoef (the Netherlands)

Management of Intracranial Hemorrhage in Patients under Non-vitamin K Antagonist Oral Anticoagulants  
Speaker: Lúcia Vieira (Portugal)

Routine Coagulation Assays for the Detection of Residual NOAC Levels in Patients Undergoing Elective Invasive Procedures  
Speaker: Thomas Vanassche (Belgium)

Haemostatic Changes in Patients Undergoing Renal Transplantation  
Speaker: Ruchika Kohli (United Kingdom)

Reversal of Dabigatran by Idarucizumab in Heart Transplantation Surgery: A Case Report  
Speaker: Filipe Robles de Vasconcelos (Portugal)

Prevention of Thromboembolism Complications in Preoperative Patients  
Speaker: Tamari Svanidze (Georgia)

FVIII/IX

Comparative Pharmacokinetics of Two Recombinant FVIII Concentrates in Chinese Pediatric Patients with Severe Hemophilia A: A Single-Center Study  
Speaker: Kun Huang (China)

Monitoring and Pharmacodynamic Effect of Eftrenonacog-Alfa (Alprolix®) in Severe Hemophilia B Patients: A Real-Life Study  
Speaker: Georges Jourdi (France)

Identification of a Novel “Laminin G” Domain Mutant of Protein S Defective in Binding and Inhibiting FXa and Unaffected in APC/TFPI Cofactor Activities  
Speaker: Rinku Majumder (United States)
Bleeds and Imaging Scores in Relation to Pharmacokinetics of Coagulation Factor VIII in Chinese Pediatric Patients with Severe Hemophilia A
Speaker: Huang Kun (China)

Emicizumab Treatment in Pediatric Patients with Hemophilia A without Inhibitors: A Single-Institution Study
Speaker: Mika Mori (Japan)

Comparative Analysis of the Coagulometric and Chromogenic Methods for the Determination of Factor VIII Activity in the Plasma of Patients Suspected with Blood Coagulation Disorders
Speaker: Ewelina Wojtasinska (Poland)

Inhibitor Risks Estimation Associated with F9 Genotype Types in Patients with Severe Haemophilia B: Argentine vs EAHAD Database
Speaker: Pamela Radic (Argentina)

A New Test Set up to Dose Factor VIII Ability to Bind Exogenous VWF
Speaker: Aurélie Juif (France)

Use of Thromboelastography to Monitor Emicizumab in a Patient with Severe Haemophilia A without Inhibitor
Speaker: Elvira Grandone (Italy)

FVIII Gene Mutation Analysis and Evaluation of Clinical Data: One Center Result
Speaker: Birol Baytan (Turkey)

Identification of Zebrafish Orthologue to Human Factor IX Gene and its Age Dependent Regulation
Speaker: Neha Iyer (United States)

Difference Molecular Profiles of Type 1 and 2 Inhibitor Developed in Mild/Moderate Hemophilia A
Speaker: Shoko Furukawa (Japan)

Treatment and Joint Health in Nordic Moderate Haemophilia Patients - the Mohem Study
Speaker: Ragnhild Måseide (Norway)

Screening of Hematuria in Children with Hemophilia: A Preliminary Report
Speaker: Dilek Gurlek Gokcebay (Turkey)

Evaluation of Structurally Altered Protein in Factor VIII Therapeutic Products Using Chromatography on Immobilized von Willebrand Factor
Speaker: Andrey Sarafanov (United States)

New Hyperactive Factor IX Variants Identified with a Novel Computational Analysis
Speaker: Ben Samelson-Jones (United States)

Potential Role for Regulatory B-cells in the Control of Immune Tolerance to Factor VIII Treatment in Haemophilia A: Evaluation of Involvement of Regulatory Cell Types and Markers in Immune Tolerance Induction (ITI) in Haemophilia A
Speaker: Sarah Schep (the Netherlands)

Protease Domain Determinants of the Distribution, Clearance and in vivo Activity of Human Factor IX(a) in Hemophilic Mice
Speaker: John Sheehan (United States)
Scientific Programme

aPTT Reaction Curves Provide Important Additional Information in Hemophilia Patients
Speaker: Josipa Pavic (Bosnia and Herzegovina)

Real-world Analysis of Hemophilia Patients in China: A Single Center’s Experience
Speaker: Xuewen Song (China)

Evaluation of Coagulation FIX Binding to Collagen IV and the Impact on Thrombin Generation
Speaker: Gael Beverley Morrow (United Kingdom)

Evaluation of the Effect Emicizumab Neutralizing Antibodies on aPTT Clotting-based Tests Results in Patients Treated with Emicizumab
Speaker: Cristina Novembrino (Italy)

An Overview of Patients with Hemophilia A in China: Epidemiology, Disease Severity, and Treatment Strategies
Speaker: Xuewen Song (China)

Detection and Quantification of F8 Inv1 and Inv22 Inversions Using Digital Droplet PCR and Mile-post Assays
Speaker: Eric Manderstedt (Sweden)

Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia - A Systematic Review and Meta-analysis
Speaker: A. Abdi (the Netherlands)

Pleiotropic Effects of PCSK9-inhibition on Hemostasis: Anti-PCSK9 Reduce FVIII Levels by Enhancing LRP1 Expression
Speaker: Francesco Paciullo (Italy)

B Cell Cytokines in Italian Hemophilia A Patients with Inhibitors
Speaker: Bhavya Doshi (United States)

Analytical Variability (CV) of One Stage Factor VIII Assay: A Quality Control (QC) Experience. Argentinian Group of Biochemists in Hemophilia
Speaker: Mirta Arias (Argentina)

Real-life Inter-individual Variability of Pharmacokinetics - Reason for Individualization of Replacement Therapy in Haemophilia
Speaker: Adina Traila (Romania)

Development and Performance Characterization of an Automated Chromogenic Assay for Human Factor IX Activity
Speaker: Narayanan Ramamurthy (United States)

Hemostasis and Organ Dysfunction

Effect of Warfarin Addition in Diabetic Foot Ulcer Patients Receiving Cilostazol In Mohammad Hoesin Hospital, South Sumatera, Indonesia
Speaker: Erty Sundarita Maksudin (Indonesia)

Haemostatic Profile of Nigerian Children with Nephrotic Syndrome (NS)
Speaker: Theresa Nwagha (Nigeria)

Role of Serpine2 (PN-1) in Diabetic Nephropathy
Speaker: Véronique Arocas (France)
Liver Dysfunction Biomarkers Correlate with a Prothrombotic and Not with a Prohemorrhagic Hemostatic Profile in Cirrhotic Patients  
Speaker: Maxime G. Zermatten (Switzerland)

Utility of Prophylactic Fresh Frozen Plasma Transfusion for Correction of Coagulopathy Prior to Image-Guided Drainage for Infected Collections  
Speaker: Pradakshna Porchezhian (India)

Mechanisms of Blood Clotting Activation by Amniotic Fluid  
Speaker: Kirill Butov (Russian Federation)

Predictive Role of Natural Anticoagulants in Prognosis of Chronic Liver Disease in Pediatric Age Group  
Speaker: Sana Ajmal (Pakistan)

Simvastatin Prevents Liver and Kidney Microthrombosis After Exposure to Lipopolysaccharide by Preserving the Antithrombotic Properties of the Endothelium  
Speaker: Vincenzo La Mura (Italy)

ADAMTS-13/VWF as Biomarker for Portal Vein Thrombosis Development in Cirrhotic Patients: A Prospective Study  
Speaker: Monica Sacco (Italy)

APML: 2 Cases of Discordant Coagulation Results and ROTEM Testing  
Speaker: Ashlyn Chee (Australia)

Diagnosis and Treatment of Obstetrics Disseminated Intravascular Coagulation in Resource Limited Settings  
Speaker: Helen C. Okoye (Nigeria)

State of the Hemostatic System in Diffuse Congenital Arteriovenous Malformations of the Extremities  
Speaker: Larisa Chernukha (Ukraine)

Microparticles

Micropartical-Associated Thrombin Generation in Patients with Philadelphia-Negative Myeloproliferative Neoplasms  
Speaker: Olesya Matvienko (Russian Federation)

Microparticles Contribute to Hypercoagulation, but Not to Coagulation in Healthy Controls  
Speaker: Muriel Meiring (South Africa)

miRNAs 126 and 223 in Microparticles from Patients with Coronary Ischemic Disease  
Speaker: Aurora De la Peña Díaz (Mexico)

Influence of Specific Therapy on Microparticle-Associated Thrombin Generation in Patients with Primary Myelofibrosis  
Speaker: Olesya Matvienko (Russian Federation)

Adhesive Properties of Plasma-Circulating and Platelet-Derived Microvesicles  
Speaker: Elena Artemenko (Russian Federation)

Granulocyte Microvesicles with a High Plasmin Generation Capacity Promote Clot Lysis and Improve Outcome in Septic Shock  
Speaker: Sylvie Cointe (France)
Scientific Programme

Plasma Platelets Microparticles as a Biomarker of Thrombotic Event in Thrombotic Thrombocytopenic Purpura Patients
Speaker: Leila Tahmasbi (Iran, Islamic Republic of)

Effects of Chemotherapy on Extracellular Vesicles and Coagulation Activation in Advanced Colorectal Cancer Patients
Speaker: Ludwig Traby (Austria)

Plasma Levels of Platelet-derived Microvesicles Are Associated with Future Risk of Venous Thromboembolism
Speaker: Omri Snir (Norway)

Expression of Circulating Microparticles Procoagulant Activity in Cirrhotic Patients
Speaker: Belakremi Mejda (Tunisia)

Characterisation of Plasma Microvesicles in Type 2 Diabetes mellitus Patients with and without Microalbuminuria
Speaker: Aishwarya Vaidya (United Kingdom)

Procoagulant Microparticles Improve Hemostasis in Mice with Haemophilia A
Speaker: Yanan Zong (Sweden)

Protein C Pathway

The Diagnostic and Prognostic Role of Protein C and Padua Scale for Prediction of Lung Vessel Thrombosis in Patients with Community-Acquired Pneumonia
Speaker: Mariia Krykhtina (Ukraine)

The Effect of Protein C on Various Links of Hemostasis
Speaker: Aziza Makhmudova (Uzbekistan)

Activated Protein-C up Regulates Microparticles Release from Ovarian Cancer Cell Line
Speaker: Massoud Mirshahi (France)

A Single-Domain Antibody that Exerts an Anticoagulant Effect Dependent on Protein S
Speaker: Josepha-Clara Sedzro (France)

Role of Endothelial Protein C Receptor Gene Polymorphisms (4678G>C and 6936A>G) in Young Indian DVT Patients
Speaker: Amit Sharma (India)

Correlation between Protein C and CCL18 Levels in Multiple Sclerosis
Speaker: Nicole Ziliotto (Italy)

Inter-Laboratory Variability of the Standardized ETP-Based APC Resistance Assay
Speaker: Laure Morimont (Belgium)

Paradoxical Platelet Inhibitory Effect of Protein C Deficiency in Shear-dependent Thrombus and Fibrin Formation
Speaker: Sanne L.N. Brouns (the Netherlands)

Clinical Presentation and Management of Homozygous Protein C Deficiency: Cukurova Experience
Speaker: Nihal Boz (Turkey)

Regulation of Coagulation
Thr90Ser Mutation in Antithrombin Causes Recurrent Thrombosis in a Heterozygous Carrier
Speaker: Yeling Lu (China)

The Effects of Acids on Whole Blood Coagulation is Depended on the Type of Acid and Concentration as Assessed by Thromboelastography (TEG)
Speaker: Gordon Ogweno (Kenya)

Neutrophil Extracellular Trap in Patients with Peritoneal Carcinomatosis of Several Origins
Speaker: Shahsoltan Mirshahi (France)

A Hereditary Bleeding Disorder Caused by a Novel Homozygous Mutation of Thrombomodulin Gene
Speaker: Makoto Osada (Japan)

Acute Deep Vein Thrombosis Is Associated with Increased Platelet Thrombin Generation and Increased Procoagulant Oxidised Phosphatidylethanolamine
Speaker: Samya G Obaji (United Kingdom)

Heparin Affects the Induction of Regulatory T Cells Independent of Anticoagulant Activity and Suppresses the Allogeneic Immune Responses
Speaker: Yuji Kashiwakura (Japan)

Red Blood Cells Support Factor X Activation via Intrinsic Tenase
Speaker: Ivan A Chabin (Russian Federation)

Inhibition of Protein Disulfide Isomerase (PDI) with PACMA-31 Amplifies LPS-Induced Expression of Tissue Factor (TF) in Monocytes
Speaker: Lennart Beckmann (Germany)

Correlation between ADAMTS13 and VAP1 Levels in Multiple Sclerosis with Cerebral Microbleeds
Speaker: Nicole Ziliotto (Italy)

Praxbind for Reversal of Dabigatran: Experience in a Tertiary Hospital
Speaker: Aaron Lubetsky (Israel)

Platelet Activation via GPVI Initiates FXII- and TF-independent Thrombin Generation
Speaker: Li Li (the Netherlands)

Exploring the Effectiveness of DNA and Glycosaminoglycans as Inhibitors of Histones
Speaker: Neha Sharma (Canada)

The Role of the Protein C Pathway in Hemostasis: The Importance of Physiological Context
Speaker: Tanya T. Marar (United States)

Inhibition of Factor Xa by Specific Reversible Inhibitors Is Selective for Factor Xa Generated by Factor IXa
Speaker: Cornelis Kluft (the Netherlands)

System Wide Investigation into Coagulation Profile of Premature Myocardial Infarction Subjects
Speaker: Joanne Dunster (United Kingdom)

A novel Interaction between Coagulation Factor XI and its Activated Form, FXIa, with the Complement Protein Properdin
Speaker: Samantha Louise Heal (United Kingdom)
Plasma Levels of DNase I Activity and Circulating-free DNA Are Associated to an Increased Risk of Venous Thromboembolism  
Speaker: Julia Oto (Spain)

Study of a New Synthetic Thrombin Inhibitor IEM-2280  
Speaker: Daria Grigorieva (Belarus)

Coagulation Factor Xa [(Recombinant) Andexxa®] for Reversal of Apixaban and Rivaroxaban in Patients Diagnosed with Intracranial Hemorrhage  
Speaker: Mark Vestal (United States)

Tissue Factor Pathway  
A Membrane-Adjacent Region in Tissue Factor Provides Substrate Selectivity  
Speaker: Fabienne Birkle (United States)

Coagulation Factor IIa (f3a) Knockdown in Zebrafish Leads to Defective Angiogenesis and Bleeding Phenotype  
Speaker: Saravanan Subramaniam (United States)

Plasma Tissue Factor Pathway Inhibitor (TFPI) in Pediatric End Stage Liver Disease  
Speaker: Amir H Navaei (United States)

Tissue Factor Pathway Inhibitor Is Increased in Plasma of Patients with a mild to Moderate Bleeding Tendency Independent of Known Genetic Variations in the factor V Encoding Gene  
Speaker: Dino Mehic (Austria)

Simulation of TF-dependent Factor X Activation on Phospholipid Vesicles: The Role and Importance of Individual Reaction Stages  
Speaker: Tatiana Kovalenko (Russian Federation)

Anticoagulant Activity in Unclassified Bleeding Disorders  
Speaker: Danielle White (United Kingdom)

On-Demand Poster Session  
14:00 - 15:00

Diagnostics and OMICs Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Biomarkers of Thrombosis and Hemostasis

Gene-Gene Interactions of Folate Cyclein as a Potential Factor of the Risk of Thromboses in Patients with Breast Cancer  
Speaker: Alexander Markovsky (Russian Federation)

The Diagnostic Significance of Platelet-Derived Microparticles Quantification by Flow Cytometry in Egyptian Patients with Ischemic Heart Disease  
Speaker: Nermeen Farouqe (Egypt)

High TAFI Level as a Predictor of VTE Recurrences during Long-Term Warfarin Therapy  
Speaker: Natalya Vorobyeva (Russian Federation)
Soluble Glycoprotein VI is an Independent Predictor of Major Bleeding in Patients with Suspected Heparin-Induced Thrombocytopenia
Speaker: Allyson Pishko (United States)

Global Coagulation Assays in Patients with Chronic Kidney Disease
Speaker: Hui Yin Lim (Australia)

Evaluation of Global Coagulation Assays in Pregnancy
Speaker: Hui Yin Lim (Australia)

Laboratory Accuracy Assessment of a Novel INR Point-of-Care Test Compared with Laboratory Reference Methods Used Across Four Independent Clinical Sites
Speaker: Jayne Ellis (United Kingdom)

Platelet Procoagulant Membrane Dynamics in Cardiac Surgery with Cardiopulmonary Bypass: Outcomes of a Pilot Study
Speaker: Ejaife Ono Agbani (Canada)

Plasma Levels of von Willebrand Factor and Future Risk of Incident Venous Thromboembolism
Speaker: Magnus Sandvik Edvardsen (Norway)

Circulating MicroRNAs and Platelet Extracellular Vesicles as Novel Biomarkers in Acute Ischaemic Stroke
Speaker: Ceren Eyileten (Poland)

The Presence of Anti-Phosphatidylserine/Prothrombin Antibodies Enhance Differences in the Thrombin Generation Phenotype among Subjects with Lupus Anticoagulant Not Meeting Antiphospholipid Syndrome Criteria
Speaker: Diego Velasco-Rodríguez (Spain)

Canonical Signaling Pathways Dysfunctions in the Development of Major Cardiovascular Complications, Circulating Micrornas as Novel Biomarkers and their Link to Inflammation in Diabetic Patients
Speaker: Ceren Eyileten (Poland)

The Importance of Altered Symmetric Dimethylarginine Levels with Platelet Hyperreactivity in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Speaker: Ceren Eyileten (Poland)

Standardization of a Flow Cytometry Platelet Sialylation Assay, and reference Values for Beta-Galactose Exposure in Healthy Subjects
Speaker: Alexandre Kauskot (France)

Upregulation of Inflammatory Biomarkers in Pulmonary Embolism as Studied by a Biochip-Array Profiling Approach
Speaker: Emily Bontekoe (United States)

Preanalytical Considerations for Evaluation of NETosis Biomarkers
Speaker: Chloé James (France)

Cell-free DNA Is Elevated in Chronic Myeloproliferative Neoplasms: Correlation with Thrombosis and Disease Progression
Speaker: Geraldine De Luca (Argentina)

Influence of Antiphospholipid Antibodies on Arterial Thrombosis in Myeloproliferative Neoplasia Patients: One Centre Experience
Speaker: Rūta Dambrauskiene (Lithuania)
Evaluation of Plasma Level of Soluble CLEC2, a Novel Platelet Activation Marker, in Patients with Sepsis Induced Coagulopathy - A Pilot Study
Speaker: Hiroyasu Ishikura (Japan)

Quantification of Neutrophil Extracellular Trap by Flow Cytometry: Technical Development
Speaker: Pierre-Elian Chaghouri (France)

Evaluation of the Accuracy of INR Values Measured by a POCT System in a German Clinic with Patients Taking Phenprocoumon as VKA Therapy
Speaker: Jayne Ellis (United Kingdom)

Comprehensive Platelet Phenotyping Supports the Role of Platelets in the Pathogenesis of Acute Venous Thromboembolism - Results from Clinical Observational Studies
Speaker: Marina Panova-Noeva (Germany)

Neutrophils Extracellular Traps (NETs) Contribute to Thrombin Generation (TG) Potential in Patients with Essential Thrombocythemia (ET)
Speaker: Sara Gamba (Italy)

Extensive Characterization of the Hemostatic Changes during Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Peritoneal Carcinomatosis
Speaker: Patricia Gomez Rosas (Italy)

The Role of Phosphatidylserine-Exposing Microparticles and Glycophorin-Exposing Microparticles in Hemostasis System in Children with Hemolytic Anemia
Speaker: Elena Seregina (Russian Federation)

Usefulness of D-dimers Levels Determination in the Prediction of Thromboembolic and Cardiovascular Events in Patients with Atrial Fibrillation during Anticoagulant Therapy
Speaker: Sarra Bounaas (Algeria)

Analysis of Biomarkers of Hemostatic Dysregulation and Inflammation in Lymphoma Patients
Speaker: Darko Antic (Serbia)

Clot Contraction Drives Structural Redistribution of Platelets, Fibrin and Red Blood Cells through Active Cell Sorting
Speaker: Valerie Tutwiler (United States)

Histidine-rich Glycoprotein Levels Contribute to Prolonged Clot Lysis Time in Acute Pulmonary Embolism
Speaker: Patrick Bladek (Poland)

Platelet-Associated Tissue Factor Predicts 5-Years Mortality in Coronary Artery Disease Patients
Speaker: Marta Brambilla (Italy)

Dyslipidaemia Associated with Increase of Thrombin Generation in Renal Transplant Recipients
Speaker: Suellen Martins (Brazil)

Active Thrombin and its Value: New Approach to Diagnosis of Thrombosis?
Speaker: Jan Dyr (Czech Republic)

FM and D-di in Preeclampsia and in vitro Fertilization
Speaker: Tatiana Vavilova (Russian Federation)
Identification of a Circulating Lipid Profile Associated with Venous Thromboembolism  
Speaker: Alvaro Fernandez-Pardo (Spain)

Circulating MicroRNA Levels Indicate Platelet Activation in Endotoxemia Despite Platelet P2Y12 Inhibition  
Speaker: Clemens Gutmann (United Kingdom)

Profiling of Inflammatory Biomarkers and Coagulation Factors in End-stage Renal Disease  
Speaker: Emily Bontekoe (United States)

LBP as a Novel Plasma Protein Associated to Venous Thromboembolism  
Speaker: Alvaro Fernandez-Pardo (Spain)

Development of a Microfluidic Pillar Device to Study Hemostasis in vitro  
Speaker: Hari Hara Sudhan Lakshmanan (United States)

Familial Thrombophilia of Unknown Origin (TUO) Is Associated with Low Activated Protein C (APC) Response to in vivo Thrombin Formation in Stimulated Hemostasis Activity Pattern Evaluation (SHAPE)  
Speaker: Heiko Rühl (Germany)

Cross-sectional Study of Thrombin Generation and Overall Hemostatic Potential in a Cohort Clinically Investigated for Thrombophilia  
Speaker: Maria Farm (Sweden)

Molecular Pathogenesis of Bone Degenerative Disease and Associated Inflammatory and Thrombotic Processes  
Speaker: Priya Joshi (United States)

Defining Acetylsalicylic Acid Responsiveness: Understanding the Relation between Thromboxane B2 Inhibition and Aggregation Induced by Arachidonic Acid  
Speaker: Paul Gurbel (United States)

The Prognostic Role of Red Cell Distribution Width in Venous Thromboembolism and Related Mortality  
Speaker: Muhamad Fajri Adda'i (Indonesia)

Acquired Antithrombin III Deficiency Is a Risk Factor for Venous Thromboembolism after Severe Injury  
Speaker: Jessica Cardenas (United States)

Evaluation of Thrombomodulin Levels in Women with Breast Cancer Undergoing Doxorubicin Treatment  
Speaker: Michelle Teodoro Alves Vieira (Brazil)

RMean Platelet Volume to Lymphocyte Ratio and VTE Recurrence  
Speaker: Ana Carina Pizzarossa (Uruguay)

Panel of Prothrombotic-inflammation Genetic Markers and Thrombin Generation Assay for Evaluation of Thromboprophylaxis and Thrombosis Risk in Thrombophilia Patients  
Speaker: Ana-Rebeca Jaloma-Cruz (Mexico)

Blood Components and Management  
Administration of Fibrinogen vs. Cryoprecipitate Stored out to 10 Days in Microfluidic Models of Coagulopathies in Hemorrhage  
Speaker: Susan M. Shea (United States)
Scientific Programme

Improved Functional and Biochemical Characteristics of Buffy-Coat Platelet Concentrates Stored in Citrate-Free PAS-III Additive Solution for 7 Days
Speaker: Catherine Ravanat (France)

An Audit of Fresh Frozen Plasma Transfusions: Justified or Not?
Speaker: Ayesha Memon (Pakistan)

Thromboelastometry Identifies Coagulopathy Associated with Liver Failure and DIC Caused by Yellow Fever, Guiding Specific Hemostatic Therapy: A Case Report
Speaker: Tomaz Crochemore (Brazil)

Apoptosis Inhibition during Cold Storage of Apheresis Platelet Concentrates Improves Cell Vitality without Affecting the Functionality
Speaker: Irene Marini (Germany)

Study of the Stability of the Main Parameters of Hemostasis Over Six Hours
Speaker: Soraya Hadjali - Saichi (Algeria)

The Use of Platelet Transfusions during Extracorporeal Membrane Oxygenation in a Large Tertiary Centre
Speaker: Andrew Doyle (United Kingdom)

The Functional Profiles of Platelets Collected from Blood Diversion Pouches and Apheresis Concentrates Are Comparable to the Ones from Platelets Isolated through Standard Methods
Speaker: Pavel Davizon-Castillo (United States)

Deciphering the Protein Secretome of Leukocyte-platelet Rich Fibrin
Speaker: Lidia Hermida Nogueira (Spain)

Six Years of Experience with Plasma Fractionation Industries at a Private Super Speciality Hospital in South India: Renaissance in Usage of Excess Plasma in Blood Banks
Speaker: Bala Bhasker (India)

Overdosing of Protamine during Cardiopulmonary Bypass May Increase Use of Unnecessary Blood Product Administration when Monitoring with ROTEM
Speaker: Christopher Webb (United States)

Cellular Therapies

Enhancing Transfusable Platelets Using mRNA Therapy to Produce Exogenous Proteins
Speaker: Jerry Leung (Canada)

Gene Therapy Model by Modification of F9 Gene through CRISPR/Cas9 for Functional Factor IX Production in Mesenchymal Stem Cells: Preliminary Results
Speaker: Irving Jair Lara Navarro (Mexico)

Epigenetics, OMICs and Bioinformatics

Quantitative Mass-Spectrometry-Based Targeted Proteomics of Plasma from Colorectal Cancer Patients with Venous Thromboembolism
Speaker: Jeroen T Buijs (the Netherlands)

Interest of Improved Z-Score Bivariate Analysis: Application to a ECAT DDimer Survey
Speaker: Frederic Sobas (France)

Physicochemical Changes by Missense Mutations Influences in Hemophilia A Determination
Speaker: Mariana Meireles (Brazil)
**Scientific Programme**

Protein Expression Profiling Suggests Relevance of Non-Canonical Pathways in Isolated Pulmonary Embolism  
Speaker: Vincent Ten Cate (Germany)

Development of an Accessible Open Source Code in Python for High-Resolution Melting Data Analysis from Patients Diagnosed with Hemophilia A in Bogotá, Colombia  
Speaker: Juliana Lago (Colombia)

Exome-array Analysis of Plasma Hemostatic Factors D-dimer, tPA and PAI-1 Identifies Novel Genes  
Speaker: Florian Thibord (France)

The CDC Hemophilia A Mutation Project (CHAMP) F8 Mutation List: 2020 Update  
Speaker: Amanda B. Payne (United States)

Von Willebrand Disease Type 1 Is Associated with Number of Rare Nonsynonymous Variants in the VWF Gene  
Speaker: Brooke Sadler (United States)

Laboratory Diagnostics

Severe Haemophilia A Plasma Artificially Spiked with Emicizumab and Recombinant Factor VIII Concentrates: Measurement by One-Stage and Chromogenic Factor VIII Assays  
Speaker: Annette Bowyer (United Kingdom)

The use of an Automated Thrombin Generation Assay for the Measurement of Emicizumab and Recombinant Factor VIII in Spiked Plasma  
Speaker: Annette Bowyer (United Kingdom)

Diagnosing and Categorizing Acquired Fibrinolysis Activity with Global Hemostatic Assays  
Speaker: Ganesh Mohan (India)

Negative Effect of Pre Pre-Analytical Error Sources on the APTT Test  
Speaker: Carmen Delianu (Romania)

Rotational Thromboelastometry - A Point of Care Tool to Assess Bleeding Risks in Hemophilia A and B  
Speaker: Andaleb Kholmukhamedov (United States)

Effect of Dabigatran versus Enoxaparin on Blood Coagulation using the Viscoelastic Coagulation Test  
Speaker: Vanessa M. Silva (Brazil)

Low-Angle Light Scattering for the Analysis of the Platelet Functions: Preanalytical Variables and Evaluation in Pediatric Patients  
Speaker: Galina Svidelskaya (Russian Federation)

Lidocaine Effects on Coagulation Assessed by Whole Blood Rotational Thromboelastometry  
Speaker: Ecaterina Scarlatescu (Romania)

The Sensitivity of Two New APTT Reagents to Factors VIII, IX and XI  
Speaker: Annette Bowyer (United Kingdom)

Establishment of a Novel Mixing Test Using Activated Partial Thromboplastin Time (aPTT)-Based Clot Waveform Analysis  
Speaker: Naruto Shimonishi (Japan)
Influence of Anticoagulants on the Biomechanical Phenotype of Platelets  
Speaker: Raghavendra Palankar (Germany)

Evaluation of the Newly-developed Collagen Induced Platelet Aggregation Level (CPAL) System in Aggregometer on Automated Coagulation Analyzer  
Speaker: Keisuke Kitano (Japan)

Heparin-Insensitive Chromogenic Measurement of Activated Factor XI  
Speaker: Alfred Weber (Austria)

UK NEQAS for Blood Coagulation D-Dimer Point of Care Testing Programme: A Review of Data  
Speaker: Dianne Patricia Kitchen (United Kingdom)

Laboratory Test Ordering Practices for Suspected Heparin-Induced Thrombocytopenia  
Speaker: Paul Lindholm (United States)

Comparison of the Biophen® Heparin LRT with the HemosIL® Liquid Anti-Xa Assay for the Measurement of Apixaban, Edoxaban and Rivaroxaban  
Speaker: Christian Bundschuh (Austria)

Estimation and Analysis of Measurement Uncertainty Acceptability: The Interest of Bayesian Inference  
Speaker: Frederic Sobas (France)

Long-Term Internal Quality Control Management: The Interest of Bayesian Inference  
Speaker: Frederic Sobas (France)

The Effect of RBCs on Different Platelet Count Enumeration Methods in Patients with Hemoglobinopathies  
Speaker: Roshini Shekhar (India)

Inter-Centre and Inter-Observer Agreement of Determination of DOACs in Urine Samples of Patients by Means of DOAC Dipstick Test  
Speaker: Job Harenberg (Germany)

Discrimination between Acquired Hemophilia A and Lupus Anticoagulant Using Rotational Thromboelastometry (ROTEM)  
Speaker: Yushi Chikasawa (Japan)

Development of a Logistic Regression Model for Prediction of Conversion Risk from Mild Cognitive Impairment (MCI) to Alzheimer’s Disease (AD)  
Speaker: Gisele Santos Gonçalves (Brazil)

XIIa-Dependent Fibrinolysis in Patients with Ph-Negative Myeloproliferative Neoplasms (MPN)  
Speaker: Natalya Silina (Russian Federation)

Multicentre Performance Evaluation of the Protein C Chromogenic Assay on the Cobas t 711 Analyser  
Speaker: Moniek P.M. de Maat (the Netherlands)

Performance Evaluation of Anysis-200 Platelet Function Analyzer in Cardiology Patients  
Speaker: Sehyun Shin (Korea, Republic of)

The Basic Evaluation of the Newly Developing Modified Diluted Prothrombin Time Reagent for Direct Oral Anticoagulants Measurements  
Speaker: Osamu Kumano (Japan)
New Formula of “Ratio of Inhibited Thrombin Generation” Based on Modified Diluted Prothrombin Time Reagent Predicts Bleeding Risk of Patients with Low Coagulation Activity in Direct Oral Anticoagulants Therapy  
Speaker: Osamu Kumano (Japan)

Extensive Experiments in (Un)Diagnosed Bleeding Patients with Prolonged Platelet Function Analyser Closure Times  
Speaker: Floor Heubel-Moenen (the Netherlands)

Assessing the Quality of Interpretative Comments for Prolonged Activated Partial Thromboplastin Time and Mixing Tests  
Speaker: Josep Miquel Bauça (Spain)

APTT Clot Waveform Analysis: A Tool in Prediction of Pre-Analytical Errors in Short APTT-Retrospective Analysis  
Speaker: Rajesh Phatale (India)

Paediatric APTT, PT and Fibrinogen Reference Intervals Using STA® - CK Prest, STA® - NeoPTimal and STA® - Liquid Fib  
Speaker: Natasha Letunica (Australia)

Impact of Combination of Factor VIII-Deficient Plasma and Activator in One-Stage Clotting Assay on Potency Testing of Factor VIII Products  
Speaker: Atsuo Suzuki (Japan)

Establishing an External Quality Assessment Scheme (EQAS) for D-Dimer Assay in India: Results from a Pilot  
Speaker: Sukesh Nair (India)

Multicentre Performance Evaluation and Reference Range Determination for a New Assay for the Quantitative Evaluation of Factor VIII in Citrated Plasma  
Speaker: Anna Lowe (United Kingdom)

Correlation between the VerifyNow P2Y12 Assay and the Newly-Developed APAL System in Neuroendovascular Patients  
Speaker: Tasuku Sakayori (Japan)

FIBTEM Parameters Correlate Well with the Fibrinogen Concentration Measured by the Clauss Assay in Patients and Healthy Subjects  
Speaker: Judith Juliana de Vries (the Netherlands)

Performance of Thrombophilia Markers Assays Evaluated from Results of an External Quality Assessment Program  
Speaker: Chantal Bon (France)

Comparison of New Scoring System of Platelet Aggregation on Automated Coagulation Analyzer CN-6000 with CS-5100  
Speaker: Tasuku Sakayori (Japan)

Basic Evaluation of Novel Automated Coagulation Analyzer CN-6000  
Speaker: Ryosuke Narisada (Japan)

Sample Stability for a Broad Panel of Coagulation Assays on the Cobas t 711 Analyser Using Plasma Stored under Different Conditions  
Speaker: Michael Hoffmann (Germany)
Scientific Programme

Comparison of a Novel Viscoelastic Device with Standard Laboratory Tests for its Clinical Validation in Peri-Operative Cardiac Patients
Speaker: Bethany Brannan (United Kingdom)

The PFA Results Are Affected by Low Number of Platelets, Low Hematocrit and High Proportion of Immature Platelets
Speaker: Petr Kessler (Czech Republic)

Hemostatic and Inflammatory Markers in Patients with Alzheimer’s Disease or Fronto-Temporal Dementia
Speaker: Cristina De Mello Loures (Brazil)

Effect of Antiepileptic Therapy on Platelet Aggregation
Speaker: Ivana Čelap (Croatia)

Analysis of Megathrombocytes as a New, Fast, and Low Cost Tool to Indicate Thrombosis and Predict Prognosis in Sickle Cell Disease
Speaker: Luciana Wermelinger Serrao (Brazil)

Does Normal Diluted Russell Viper Venom Time Test Result Can Exclude Concentrations of Direct Oral Anticoagulants below 30 ng/mL?
Speaker: Sandra Margetić (Croatia)

Method Comparison of Eight Coagulation Assays on the Cobas t 411 versus Cobas t 511/t 711 Analysers
Speaker: Jürgen Oberstraß (Germany)

Effect of Activated Charcoal in Removing Interference in Thrombophilia Assays: Resistance to Activated Protein C, Activity of Coagulation Factor VIII and Antithrombin Activity
Speaker: Sandra Margetić (Croatia)

Modified Anti-Xa Assay for Measuring Betrixaban (Bevyxxa®) Activity in Plasma on STA-R Max
Speaker: Matthieu Bourdin (France)

An Improved Algorithm for the Detection of Lipemia as Interfering Substances on a Fully Automated Coagulation Analyzer
Speaker: Silke Echternacht (Germany)

Fibrinogen Prothrombin Time Derived Method Is Not Useful in Anticoagulated Patients with Apixaban
Speaker: Cristina Duboscq (Argentina)

Platelet Aggregation Testing by Light Transmission Aggregometry with Drug Specific Agonists in Patients on Mono and Dual Antiplatelet Therapy
Speaker: Sandra Margetić (Croatia)

Multicentre Performance Evaluation and Reference Ranges for a New Assay for Quantitative Determination of von Willebrand Factor (vWF) Activity
Speaker: Steve Kitchen (United Kingdom)

Comparison of Two Quantitative Methods for Determination of Dabigatran Concentration: Diluted Thrombin Time Test and Innovance Dabigatran Test in Real Life Patients Treated with Dabigatran
Speaker: Sandra Šupraha-Goreta (Croatia)
Pre - Analytical Variables in Haemostasis: Results of the UK National External Quality Assessment Scheme for Blood Coagulation Haemolysis Supplementary Exercise
Speaker: Lilia Brown (United Kingdom)

Loop-Mediated Isothermal Amplification without DNA Extraction for Simultaneous Detection of Factor V Leiden and Prothrombin-G20210A Genetic Variants
Speaker: Giovanni, Luca Tiscia (Italy)

Comparative Evaluation of the Aggregation Studies in a Sysmex CS2500 Coagulometer with a Standard Turbidimetric Technique
Speaker: Ana Belen Moreno Castaño (Spain)

Comparative Evaluation of the Aggregation Studies in a Sysmex CS2500 Coagulometer with a Standard Turbidimetric Technique
Speaker: Ana Belen Moreno Castaño (Spain)

Comparative Evaluation of the Aggregation Studies in a Sysmex CS2500 Coagulometer with a Standard Turbidimetric Technique
Speaker: Ana Belen Moreno Castaño (Spain)

Comparative Evaluation of the Aggregation Studies in a Sysmex CS2500 Coagulometer with a Standard Turbidimetric Technique
Speaker: Ana Belen Moreno Castaño (Spain)

Low Molecular Weight Heparin Calibrated Anti-Xa Assays can Identify Patients with Low Apixaban or Rivaroxaban Drug Levels
Speaker: Siraj Mithoowani (Canada)

Bethesda Assay for the Detection and Titration of an Anti-VIII Inhibitor: Interest of the Chromogenic Assay
Speaker: Christophe Nougier (France)

Thrombin Generation Analysis in Patients with Venous Thromboembolism and Atrial Fibrillation on Anticoagulant Therapy: Comparison between Direct Oral Anticoagulants and Antivitamin K Antagonists
Speaker: Claudia Dellanoce (Italy)

Validation of a Warfarin Dose Prediction Model: A Single Center Retrospective Study
Speaker: Aaron Lubetsky (Israel)

Biosimilar Enoxaparin Sodium Inhixa® Compared with Clexane®: An in vitro Study
Speaker: Claudia Dellanoce (Italy)

Discrepant Interpretation of HIT Screening Results on the Same Sample - Data from a UK NEQAS for Blood Coagulation Exercise
Speaker: Ian Jennings (United Kingdom)

Antifactor Xa Levels vs. Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin
Speaker: Vanessa M. Silva (Brazil)

Effects of Rivaroxaban on Thrombophilia Screening Tests - Results from a UK NEQAS (Blood Coagulation) Exercise
Speaker: Ian Jennings (United Kingdom)

Analytical Performance Validation of the T-TAS 01 PL Assay
Speaker: Jeffrey Dahlen (United States)

Clinical Validation of the T-TAS 01 PL Assay in Patients with von Willebrand Disease and Glanzmann’s Thrombasthenia
Speaker: Jeffrey Dahlen (United States)

Clinical Validation of the T-TAS 01 PL Assay in Patients Taking Antiplatelet Therapy
Speaker: Jeffrey Dahlen (United States)
Comparison of the T-TAS 01 PL Assay with PFA-100 for Assessment of Primary Hemostatic Function
Speaker: Jeffrey Dahlen (United States)

Evaluation of a New Benzylsulfonyl-D-Arg-Pro-4-Amidinobenzylamide (BAPA) Blood Collection Tube for Platelet Function Studies
Speaker: Jeffrey Dahlen (United States)

Correlation between Thrombin Generation and Prothrombin Fragment F1+2 Plasma Levels
Speaker: Marco Capecchi (Italy)

Global Thromboelastometry in Patients with Acute Bleedings on Direct Oral Anticoagulant (DOA) Treatment: The RO-DOA Bleed Study
Speaker: Maria Cristina Vedovati (Italy)

Laboratory Assessment of Efficacy and Safety of Direct Oral Anticoagulants in Real Clinical Practice
Speaker: Nadezda Vorobyeva (Russian Federation)

Effect of Vitamin K Antagonist Therapy on the Dynamics of Hypercoagulation Syndrome in Patients with Deep Vein Thrombosis
Speaker: Nadezda Vorobyeva (Russian Federation)

An International Study on the Interpretation of Test Results of the APTT Mixing Test
Speaker: Piet Meijer (the Netherlands)

Challenges in Anticoagulation Management at an Academic Medical Center, 20 Years of Clinical Observations
Speaker: Scott Kogan (United States)

Influence of Phospholipids on the Measurement of Extended Half-Life Factor VIII Activity in One-Stage Clotting Assay
Speaker: Yuta Fujimori (Japan)

Application of EP15A3 and EP15A2 Protocols to Verify the Performance of a Coagulometer in the Coagulation Laboratory of the National Institute of Respiratory Diseases in Mexico City
Speaker: Brenda Sarai Zuñiga Ascencio (Mexico)

Accuracy of Commercial Universal Calibrators for Measurement of Heparin and Low Molecular Weight Heparin
Speaker: John Hogwood (United Kingdom)

The Effect of trough Dabigatran Plasma Concentration on Thrombin Generation
Speaker: Marija Milic (Croatia)

Sigma Metrics Scores for Routine Haemostasis Assays in a Small Laboratory
Speaker: Halimatus Radziah Binti Othman (Malaysia)

Laboratory Analysis of Half-Life-Prolonged Coagulation Factors VIII Rupiocog Alfa Pegol and IX, Nonacog Beta Pegol and of rVWF - Vonicog Alpha in Spiked Human Plasma Samples - First Results of a Multicentre Study by the Austrian Laboratory Societies ÖGLMKC and ÖQUASTA
Speaker: Alexander C. Haushofer (Austria)

Comparison of Visual versus Reader Results of the Point of Care Test of Direct Oral Anticoagulants from Urine Samples
Speaker: Job Harenberg (Germany)
Monitorig of Direct Oral Anticoagulants in Routine Practice  
Speaker: Lidija Lokar (Slovenia)

Performance of Thrombin Generation Test (TGT) versus Conventional Coagulometric Methods in Snakebites: Preliminary Results  
Speaker: Rita Carolina Figueiredo Duarte (Brazil)

The Basic Evaluation of Light Transmission Platelet Aggregation Method on an Automated Coagulation Analyzer CN-6000  
Speaker: Mai Egashira (Japan)

Comparison of the One-Stage Clot-Based and Chromogenic Factor VIII Activity Measurement  
Speaker: Radhiya Al Buraidi (Oman)

A Strategy for the Prenatal Diagnosis for Fetus with Hemophilia A without Genetic Defects  
Speaker: Yihong Li (China)

The Effects of EDTA as an Anticoagulant and Delayed Processing on the Measurement of Plasma VWF Antigen  
Speaker: Matthew Christopher Sims (United Kingdom)

Evaluation of EQA Material on Lumira Dx Point of Care Platform: UK NEQAS for Blood Coagulation Study  
Speaker: Lilia Brown (United Kingdom)

The Novel Prothrombin Time (MRX PT DOAC) Assay - Can Be Used to Detect Interfering DOACs in Thrombophilia Investigation  
Speaker: Liselotte Onelöv (Sweden)

Assessment of ExpertCor, a New Set of Frozen Plasmas for Assay Comparability Studies  
Speaker: Audrey Carlo (France)

Clinical Performance of the Tina-Quant D-Dimer Gen 2 Assay on the Cobas t 711 Analyser for Evaluation of Patients with Suspected Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE)  
Speaker: Thomas Bertsch (Germany)

Reference Values of 117 Healthy Donors on the ST Genesia with the STG-BleedScreen, STG-DrugScreen and STG-ThromboScreen Reagents  
Speaker: Marisa Ninivaggi (the Netherlands)

The Severity of Hemophilia A Patients Varies among Different Types of Factor VIII Gene Mutation  
Speaker: Yihong Li (China)

Measuring Thrombin Generation in the Presence of Haemoglobin on the ST Genesia  
Speaker: Marisa Ninivaggi (the Netherlands)

Variable Findings in One-Stage Clotting Assays in a Patient with Waldenstrom’s Macroglobulinaemia  
Speaker: Sean Platton (United Kingdom)

Assessing the Effect of Freezing and Thawing of Samples for Anti-Factor Xa Testing for the Determination of Enoxaparin Activity  
Speaker: Susan Louw (South Africa)
Apixaban Plasma Concentration Estimation by Anti Xa Activity Assay Calibrated with Heparin Calibrators with 2 Different Reagent/Systems
Speaker: Marta M Martinuzzo (Argentina)

A Performance Evaluation of Chemiluminescent-Enzyme Immunoassays on a Routine Coagulation Analyser
Speaker: Chris Gardiner (United Kingdom)

Assessment of the CN-6000; a Novel, High-Speed Coagulation Analyser, Utilising Coagulation, Chromogenic, Immuno-Turbidimetric and Light Transmission Aggregation Technologies
Speaker: Anita Woolley (United Kingdom)

Can Bone Marrow Cells Be Differentiated and Counted Using a Novel Hematology Analyzer?
Speaker: Zühre Kaya (Turkey)

Excluding Anticoagulants and Antiplatelet Drugs with Rotational Thromboelastometry
Speaker: Anne-Marije Hulshof (the Netherlands)

Rivaroxaban Plasma Concentration Values and Risk Factors for Adverse Events in Patients Experiencing Bleeding: Results from a Prospective Study
Speaker: Jüri Arjakse (Estonia)

Clinical Exomes for the Diagnosis of Inherited Bleeding, Thrombotic and Platelet Disorders: The Belgian Experience
Speaker: Christine Van Laer (Belgium)

An Evaluation of the Assay Performance of the Antifactor Xa Assay for Rivaroxaban
Speaker: Vishnu Prasad (Singapore)

ISTH SSC Plasma Standard Lot #5 - Results in a UK National External Quality Assessment Scheme for Blood Coagulation (NEQAS BC) Exercise
Speaker: Ian Jennings (United Kingdom)

Analytical Verification of Automated Latex-Enhanced Particle Immunoturbidimetric D-Dimer Assays on Different Analytical Platforms and Comparability of Test Results
Speaker: Ivana Lapić (Croatia)

Correlation between INR Pocket Test and Standard Coagulation Test
Speaker: Alicia B Vilaseca (Argentina)

The SSC Working Party on Thrombin Generation: Inventory of Thrombin Generation Methods
Speaker: Marisa Ninivaggi (the Netherlands)

DOAC Intra-individual Variability in Patients with Non Valvular Atrial Fibrillation
Speaker: Sophie Testa (Italy)

Evaluation of INR and APTTs Using the Q Family of Analysers in Comparison to ACL TOP
Speaker: Anita Woolley (United Kingdom)

Genetic Analysis for Investigation of Heritable Bleeding and Thrombotic Disorders - Variable Interpretation of Data Identified by the UK National External Quality Assessment Scheme (UK NEQAS) Blood Coagulation Programme
Speaker: Ian Jennings (United Kingdom)

Variability in Dabigatran and Apixaban trough Concentrations
Speaker: Patrizia Della Valle (Italy)
Scientific Programme

A Universal Quality Control Plasma for Anti-Xa and Anti-IIa Drugs
Speaker: Loris Pozzi (Italy)

Hemostatic Profile: Is There Any Difference between Alzheimer’s Disease and Frontotemporal Dementia?
Speaker: Cristina De Mello Loures (Brazil)

How Does Changing the Reagent/Instrument Affect the INR?
Speaker: Mohamed Amine Hmida (Tunisia)

An Evaluation of Treatment Monitoring in Patients with VWD Using a Chemiluminescent (VWF:GP1bR) Assay Compared to a Lyophilised Platelet Assay with Ristocetin (VWF:RCo)
Speaker: Anne Riddell (United Kingdom)

Evaluation of the Succeeder SF-8200 Fully Automated Coagulation Analyzer
Speaker: Oguzhan Zengi (Turkey)

Evaluation of Hemostatic Markers in Patients with Sickle Cell Disease Using or Not Hydroxyurea
Speaker: Melina Pinheiro (Brazil)

The Effect of Haemolysis in Patient Samples on Coagulation Tests Performed on ACL TOP 550
Speaker: Kieron Hickey (United Kingdom)

Analysis of Platelet Functional Activity by Flow Cytometry: Reference Intervals and Cut-off Value for Evaluating the Efficiency of Antiplatelet Therapy
Speaker: Aleksei Ermakov (Russian Federation)

Evaluation of IgG4 ELISA for the Screening of Factor VIII Inhibitors in Hemophilia A
Speaker: Namrata Awasthi (India)

Speaker: Diego Velasco-Rodríguez (Spain)

Influence of DOAC Remove on Coagulation Assays During Thrombophilia Testing in Patients Treated with Rivaroxaban or Dabigatran
Speaker: Mirjana Kovac (Serbia)

Impact of Centrifugation on Thrombin Generation Analysis Evaluated in Healthy Subjects and Patients Treated with Direct Oral Anticoagulants
Speaker: Michaël Hardy (Belgium)

Performance Evaluation of Automated Thrombin Generation Measurement on Ceveron® t100 with Normalized TGA Parameters
Speaker: Lieselotte Wagner (Austria)

Quantification of Emicizumab in a Modified APTT and with Clot Growth Analysis
Speaker: Cornelis Kluit (the Netherlands)

Comparison of Different Stago Instruments for Fibrinogen Level Assessment with STA-liquid Fib
Speaker: Audrey Carlo (France)

Analytical Validation of a Novel Whole Blood Coagulometer for NOAC Testing
Speaker: Sasha Bakhru (United States)
Rivaroxaban 20 mg Oce Daily Decreases Thrombin Generation in Patients with Venous Thromboembolism for up to 24 Hours  
Speaker: Jan Kvasnicka (Czech Republic)

Evaluation of Thrombogenicity of Apheresis-collected Platelet Concentrates under Blood Flow Condition  
Speaker: Tomoka Nagasato (Japan)

A Novel Point-of-Care Whole Blood Coagulation Assay to Screen for Hemostatic Defects  
Speaker: Sanjay Ahuja (United States)

Artificial Intelligence to Identify Neutrophil Extracellular Traps in Periphereral Blood Smears  
Speaker: Morayma Reyes Gil (United States)

Monitoring of Different FVIII Replacement Drugs Using the FVIII One-stage Clotting Assay on Cobas t 511/711 Analyzers  
Speaker: Carolin Ketteler (Germany)

Distinguishing Patients Presenting Prolonged Activated Partial Thromboplastin Time with and without Bleeding Diathesis by Comparison of Immediate and post Incubation Mixing Test  
Speaker: Yu Liu (China)

Multimer Analysis in von Willebrand Disease Diagnosis: the Experiency of Use  
Speaker: Alexander Poletaev (Russian Federation)

Establishing Reference Range and Validating Precision Performance of the TES-6s System  
Speaker: Min Young Lee (Korea, Republic of)

Who May Benefit from Direct Oral Anticoagulant Level Monitoring? A Systematic Literature Review  
Speaker: Rebecca Vicente-Steijn (the Netherlands)

Performance of the DP-Filter to Remove DOACs from Plasma. An Analytical Validation Demonstrating its Efficiency and Innocuity  
Speaker: Julien Favresse (Belgium)

Validation of a New Point-of-Care Platelet Counter  
Speaker: Magdolna Nagy (the Netherlands)

DP-Filter, a Medical Device to Remove Edoxaban and Edoxaban-M4 from Plasma of Patients Taking Edoxaban  
Speaker: Julien Favresse (Belgium)

The Effect of DOAC-Stop® on Several Oral and Parenteral Anticoagulants  
Speaker: Nicoletta Riva (Malta)

Results of Anti-Xa Activities for Monitoring Therapeutic and Prophylactic Doses of Low Molecular Weight Heparin in Children  
Speaker: Jasna Obuljen (Croatia)

Fibrinolysis Detection by TEG and ROTEM Viscoelastic Analysers: An in vitro Comparison  
Speaker: Joao. D Dias (Switzerland)

Real-time Intra-site and Multi-site Correlations and Evaluation of Time Stability with the Same Frozen Plasmas Kits which Cover the Full Measuring Range for Routine Tests and Anticoagulant Monitoring Tests  
Speaker: Claire Flaujac (France)
Evaluation of the Atellica® COAG 360 (Siemens Healthineers) at Caen-Normandy University Hospital (FRANCE)
Speaker: Yohann Repessé (France)

Identifying and Reducing the Cause of Haemolysis in Coagulation Blood Samples due to Sample Transport in a Pneumatic Tube System
Speaker: Steve Kitchen (United Kingdom)

Calibrated Automated Thrombogram II: A New Thrombin Generation Test
Speaker: Magdolna Nagy (the Netherlands)

A Novel Quantitative Chromogenic Fibrinogen Assay Adaptable to Centralized Laboratory Analyzers
Speaker: San Pun (Switzerland)

Possibilities of Thromboelastography in Patients with Severe Burns
Speaker: Marina Presnyakova (Russian Federation)

Feasibility of a Universal Calibrator for Direct FXa Inhibitor DOACs
Speaker: Nikolaus B. Binder (Austria)

Comparison of Thromboelastography with T2MR Data
Speaker: Michael Stolz (Germany)

Evaluation of a New Device to Remove Direct Oral Anticoagulants (DOACs) from Plasma Samples
Speaker: Pierre Olivier Sevenet (France)

Performance Evaluation of a New Fibrinogen Assay Reagent Using Recombinant batroxobin
Speaker: Rojin Park (Korea, Republic of)

Improving Comparability of Optical Aggregometry Results from Automated Coagulation Analyzer Systems Compared with a Manual Aggregometer
Speaker: Florian Prüller (Austria)

Altered FIBTEM/Fibrinogen Correlation in Liver Transplant Patients Relative to Cardiac Surgery Patients
Speaker: Eric Salazar (United States)

Effects of Anticoagulants and Common Interfering Substances on Four Commercially Available dRVVT Assays
Speaker: Ali Sadeghi-Khomami (Canada)

A Correlation of Thrombin Generation Assay and Clot Waveform Analysis in Patients on Warfarin
Speaker: May Anne Cheong (Singapore)

Diagnostic Performances Evaluation of LIAPHEN Free Protein S on CS-2500
Speaker: Claire Dunois (France)

Top 50 Cited Papers in Developmental Hemostasis: A Scoping Review
Speaker: Paul Thuan Tieu (Canada)

Health Outcomes after the Implementation of POCT Rotational Thromboelastometry in Patients Undergoing Cardiac Surgery
Speaker: Isabel Rodríguez Martín (Spain)
Scientific Programme

How Does the Availability of Thromboelastography Influence Clinical Reasoning in a Paediatric Intensive Care Unit? A Narrative View  
Speaker: Amy Knott (United Kingdom)  

Laboratory Validation of a Novel Hexagonal Phase Phospholipid Neutralization Assay for Lupus Anticoagulant Detection  
Speaker: Colin Douglas (Canada)  

Determination of Serotonin Concentration in Single Human Platelets by Single-entity Electrochemistry  
Speaker: Jaewoo Song (Korea, Republic of)  

Point-of-Care Method in Determining the Activated Partial Thromboplastin Time  
Speaker: Marinez Farana Matos (Brazil)  

Development of a Flow Cytometry-based Assay for the Detection of ITP Autoantibodies  
Speaker: Miguel Neves (Canada)  

New Ready-to-Use Liquid Multiplatform Global Screening Assays with Extended Stabilities to Facilitate Laboratory Practice  
Speaker: Claire Dunois (France)  

Updated CLOTSref: A Mobile Application for Standardized Reference Ranges in Developmental Hemostasis  
Speaker: Paul Thuan Tieu (Canada)  

Unique Ready to Use, Highly Stable Multiplatform Chromogenic Assays to Facilitate Laboratory Practice  
Speaker: Marie Peyrafitte (France)  

Establishment of Reference Intervals for Automated Light Transmission Aggregometry  
Speaker: Desiree Coen Herak (Croatia)  

HFLC and IPF, Can these Two Parameters Reliably Distinguish between Dengue and ITP?  
Speaker: Jawad Hassan (Pakistan)  

Institutional Review of Reflex Factor Coagulation Testing in Patients with an Unexplained Prolonged aPTT  
Speaker: Eman M. Mansory (Canada)  

Validation of the Atellica COAG 360 Coagulation Analyzer  
Speaker: Emilija Krstova Krajnc (Slovenia)  

Rapid Latex Enhanced Immunoassay (LIA) for Heparin Induced Thrombocytopenia and False Positivity  
Speaker: Daniel Welder (United States)  

Advancing the Understanding and Significance of Genetic Testing Results in Hemostasis/Thrombosis  
Speaker: Kristy Lee (United States)  

Factor V inhibitor in a patient with Strongyloides Stercolaris and antibiotic therapy  
Speaker: Mirta Arias (Argentina)  

Clinically Significant Disagreement between Point-of-Care INR and Central Laboratory-assessed INR in Acute Stroke Patients  
Speaker: Eric Salazar (United States)
Scientific Programme

Inherited Coagulopathies Study by Massive Sequencing (NGS) Experience of a Diagnostic Portuguese Center
Speaker: Patrícia Martinho (Portugal)

Identifying DOACs in Mixing Study Samples
Speaker: Eric Salazar (United States)

Validation of the ROTEM PLATELET® Module as an Impedance Platelet Aggregation Test Compared to the Gold Standard Test: Conventional Platelet Aggregation
Speaker: João Guerra (Brazil)

Two Cases in which Measuring Dabigatran Plasma Levels Is Indicated and Recommended
Speaker: Franco Piovella (Italy)

Quantra Reported Stiffness Values Have a Strong Linear Relationship with Clot Max Stiffness
Speaker: Francesco Viola (United States)

Interference of C - Reactive Protein Level in Activated Partial Thromboplastin Time
Speaker: Marinez Farana Matos (Brazil)

Clinical Utilization of Lupus Anticoagulant Testing in a Large Hospital System
Speaker: Anjanaa Vijayanarayanan (United States)

Prevalence and Pattern of Pseudo-thrombocytopenia in a Nigerian Tertiary Hospital
Speaker: Abiola Bolarinwa (Nigeria)

Comparison of Thromboelastometry by ROTEM® Delta and ROTEM® Sigma in Obese Patients
Speaker: Cristiana Bulato (Italy)

On the Measurement of Direct Anti-Xa-Inhibitors
Speaker: Thomas Siegemund (Germany)

Use of Liquid Low Molecular Weight Heparin Anti-Xa Assay for Detection of Apixaban
Speaker: Nicole De Simone (United States)

Impact of Anticoagulant and of Time Elapsed Since Blood Collection on Platelet Function Assessed by Multiple Electrode Impedance Aggregometry
Speaker: Michaël Hardy (Belgium)

APTT Mixing Studies in the Preoperative Setting
Speaker: Meritxell Nomdedeu (Spain)

Algorithm for Detection of Procoagulant Samples with Elevated Prothrombin and Reduced Antithrombin by their Ability to Deplete Fluorogenic Thrombin Substrate
Speaker: Mikhail Ovanesov (United States)

Batroxobin Based Method to Measure Fibrinogen to Overcome Interfering Effects of New Anticoagulant Agents Targeting Thrombin
Speaker: Jaewoo Song (Korea, Republic of)

Thrombus Formation Study of Upstream Activation and Downstream Adhesion of Platelets in a Highly Integrated Microfluidic System
Speaker: Sehyun Shin (Korea, Republic of)

Nanotechnology and Novel Biomolecules
Scientific Programme

In vitro Studies of the Blood Compatibility of Water-Soluble Pristine C60 Fullerenes
Speaker: Tetiana Halenova (Ukraine)

Effects of Squalene-Adenosine Nanoparticles on Platelet Aggregation, Thrombin Generation and Endothelial Cells
Speaker: Julie Laloy (Belgium)

Blood Compatibility of Injectables Liposomes Encapsulating Estrogen Estetrol to Prevent Cerebral Ischemia of Prematurity
Speaker: Julie Laloy (Belgium)

Thermostable Inhibitor of Contact Activation (TICA) Fully Blocks Contact Activation when Added to Blood Withdrawal Tubes
Speaker: Tom van de Berg (the Netherlands)

Fibrinolysis and Proteolysis Abstracts

Fibrinogen and Factor XIII
A Case Report of Spontaneous and Recurrent Arterial and Venous Thrombotic Events in a Child with FGA c.1372C>T Mutation
Speaker: He Yixuan (China)

Assessment of in vitro Effects of Direct Thrombin Inhibitors on Activation of Coagulation Factor XIII through Enzyme Kinetics in the Synthetic Substrate-Based Assay
Speaker: Yuta Fujimori (Japan)

Fibrinogen Concentrate Replacement Guided by Thromboelastometry Can Improve Clot Strenght in Adult Dengue with Severe Thrombocytopenia
Speaker: Tomaz Crochemore (Brazil)

Factor XIIa-Mediated Red Blood Cell Retention in the Contracting Clot Is Impaired in Hereditary Dysfibrinogenemia
Speaker: Rita Marchi (Venezuela)

Effects of Lysine-Containing Peptides Treatment on FXIII Activity and Fibrinogen Level of Metabolic Disorders
Speaker: Tatyana Shubina (Russian Federation)

High Individual Variation of Thrombin Generation by Genesia and Correlation of Fibrin-Associated ROTEM with Fibrinogen Activity in Patients with Congenital Fibrinogen Defects
Speaker: Timea Szanto (Finland)

The Glycan Structure Associated to Factor XIII Subunit B and its Functional Importance
Speaker: László Muszbek (Hungary)

Congenital Qualitative Fibrinogen Disorders: Case Series from Argentina; Multicentric Collaborative Study
Speaker: Claudio Martin Rosa (Argentina)
Fibrin Deposition in Mouse Transfusion-Related Acute Lung Injury Via Coagulation or Fibrinolysis Dysfunction  
Speaker: Yunhong Yu (China)

Cellular Factor XIII Externalization in Platelets and Platelet Microparticles Induced by Receptor Mediated and Non-Receptor Mediated Platelet Activation  
Speaker: Laura Somodi (Hungary)

Fibrinogen Supplementation in Patients with Acquired Hypofibrinogenaemia: Meta-Analysis and Systematic Review  
Speaker: Niels Rahe-Meyer (Germany)

Transcriptome Profiling of Coagulation Factor XIII Genes: Implications for Pleiotropic Pathways and Inter-Subunit Regulation  
Speaker: Muhammad Ahmer Jamil (Germany)

Comparison Natural History and Genotype of 31 Patients with Inherited Dysfibrinogenemia  
Speaker: Tomas Simurda (Slovakia)

Factor XIII Cross-Links Fibrinogen Independent of Fibrin Polymerization in Experimental Acute Liver Injury  
Speaker: Lauren G. Poole (United States)

The Effects of (Patho)Physiological Fibrinogen γ Levels on Static and Dynamic Clot Formation  
Speaker: Fraser Macrae (United Kingdom)

Performance of a New Automated FXIII Activity Assay  
Speaker: Martina Leitner (Austria)

Plasma Fibrin Clots of Acute Pulmonary Embolism Patients Present Reduced Amounts of Coagulation Factor XIII and α2-antiplasmin Compared to Clots Generated after 3-Month Anticoagulation  
Speaker: Michal Zabczyk (Poland)

Eight Successful Pregnancies in Patients with Congenital Fibrinogen Disorders - Single Centre Study  
Speaker: Viera Pohlreichová (Czech Republic)

Factor XIII-A Is Present within Organelles Known to Mediate Unconventional Protein Secretion  
Speaker: Richard Pease (United Kingdom)

A Genetic Modifier of Venous Thrombosis in Zebrafish Reveals a Functional Role for Fibrinogen AαE in Early Hemostasis  
Speaker: Richard Fish (Switzerland)

Multi-ethnic Whole Genome Sequence Analysis of Plasma Fibrinogen in over 150,000 Samples  
Speaker: Jennifer Huffman (United States)

The Fibrinogen αC Region Is a Major Contributor to the Mechanical Strength of Fibrin Fibers  
Speaker: Martin Guthold (United States)

A New Genetic Alteration in Fibrinogen Gene with a Direful Phenotype: A Tie-in in a Newborn  
Speaker: Tehmina Nafees (Pakistan)
Fibrinolytic Factors and Inhibitors

Fibrinolytic Response Plays a Central Role in Trauma Induced Coagulopathy
Speaker: Hau Kwaan (United States)

Carboxypeptidase U (CPU, TAFIa, CPB2) Generation in Acute Ischemic Stroke Patients Undergoing Thrombolysis and Endovascular Thrombectomy
Speaker: Joachim Mertens (Belgium)

Dipicolinic Acid Produced by Fermentation (Bacillus subtilis natto)
Speaker: Hiroyuki Sumi (Japan)

Nattokinase - Inhibition of Melanin Synthesis (Whitening Effect)
Speaker: Hiroyuki Sumi (Japan)

Transition Patterns in the Fibrinolytic Response are Superior to Admission ROTEM Values in Stratifying Risk for Late Clinical Outcomes after Major Trauma
Speaker: Andrea Rossetto (United Kingdom)

Modulation of Thrombin Generation or Thrombin Activity on Activated Platelets Surface Largely Affected TAFI-Dependent Regulation of Fibrinolysis
Speaker: Yuko Suzuki (Japan)

HISTORY, an International Retrospective and Prospective Registry of Patients with Plasminogen Deficiency
Speaker: Amy Shapiro (United States)

Polyphosphate Nanoparticles Are More Potent Stabilizers of Fibrin than Linear Polyphosphates and Histones Enhance their Effect
Speaker: Miklos Lovas (Hungary)

Hypercoagulability State in Iranian Patients with β-Thalassemia
Speaker: Samin Mohsenian (Iran, Islamic Republic of)

Downregulation of the Procarboxypeptidase U (proCPU, TAFI, proCPB2) System in ApoE-/-/Fbn1C1039G+/- Mice Is a Non-Lipid Related Pleiotropic Effect of Statin Therapy
Speaker: Karen Claesen (Belgium)

To Evaluate the Effect of Hydroxyurea on Blood Coagulation and Endothelial Activation in Sickle Cell Disease
Speaker: Munira Borhany (Pakistan)

Online Apps Improve Haemostasis Assay Reproducibility and Facilitate Open Data and Code Sharing
Speaker: Colin Longstaff (United Kingdom)

Deep Mutational Scanning and High-Throughput Kinetics to Quantitatively Assess Plasminogen Activator Inhibitor-1 Variants
Speaker: Laura M. Haynes (United States)

Changes in Fibrinolytic Factors in a Simulated Extracorporeal Membrane Oxygenator Circuit
Speaker: Andrew Doyle (United Kingdom)

Down-regulation of Plasminogen Activator Inhibitor-1 (PAI-1) by in vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC) in Carriers of the Factor V Leiden (FVL) and Prothrombin 20210G>A Mutation (PTM)
Speaker: Heiko Rühl (Germany)
Total and C-terminally Truncated Alpha2-plasmin Inhibitor Levels in Venous Thrombosis  
Speaker: Éva Katona (Hungary)

Different Incorporation of Apha2-plasmin Inhibitor C-terminal Forms into the Fibrin Clot  
Speaker: Barbara Baráth (Hungary)

Production of Nanobodies Targeting Plasminogen and Plasmin  
Speaker: Eva Maria Klein (Germany)

Targeted Measurement of Plasmin Kinetics on the Activated Platelet Membrane  
Speaker: Megan Simpson (United Kingdom)

The Influence of Prothrombin Complex Concentrates on Clot Stability  
Speaker: Cecilia Diaz Garcia (United Kingdom)

Low Fibrinolytic Activity Following Ischemia Reperfusion Is Not a Single Etiology: Fibrinolysis Shutdown versus Hypofibrinolysis  
Speaker: Hunter Moore (United States)

Thrombolytic Therapy  

B- Mode Ultrasound-Guided Photomechanic-Shock Wave Combination Thrombolytic Therapy of Embolic Artery Accompanied by Simultaneously Streptokinase-Loaded Microbubbles Administration  
Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Effect of B-Mode Ultrasound-Guided Pulsed - High Intensity Focused Ultrasound-Mediated Inertial Cavitation Thrombolytic Therapy Accompanied by Air-Contained Sonicated Dextrose Albumin Microbubbles Administration on Embolic Artery Occlusion  
Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Effect of Streptokinase-Loaded Microbubbles-Mediated B-Mode Ultrasound-Guided Sono-Photomechanic Combination Thrombolytic Therapy on Atherothrombotic Stenosis  
Speaker: Hossein Mehrad (Iran, Islamic Republic of)

The Effect of the Fibrino(gen)lytic Enzymes from Tissues of Antarctic Hydrobionts on Hemostasis  
Speaker: Nataliia Raksha (Ukraine)

Microlyse: A VWF-Targeting Thrombolytic Agent for Thrombotic Thrombocytopenic Purpura  
Speaker: Steven de Maat (the Netherlands)

The Mechanism of Antifibrinolytic Action of Anionic Polyamidoamine Dendrimers  
Speaker: Roza Aisina (Russian Federation)

Covalent Prourokinase-dendrimer Complexes with Increased Plasma Stability and High Thrombolytic Activity in vitro  
Speaker: Elizaveta Ivanova (Russian Federation)

Elevated Levels of Circulating Markers of Neutrophil Extracellular Traps (NETs) Are Associated with Unfavorable Outcomes in Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis  
Speaker: Rita Orbán-Kálmándi (Hungary)
Hemophilia and Rare Bleeding Disorders Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Acquired Hemorrhagic Coagulation Disorders

**The VWF/ADAMTS13 Unbalance, but Not Global Coagulation or Fibrinolytic Status, Is Associated with Outcome and Bleeding in Patients with Acute Liver Failure**
Speaker: Ellen Driever (the Netherlands)

**Acquired Deficiency of Dependent Coagulation Factors of Vitamin K, at the Teaching Center: Experience In 10 Years**
Speaker: Claudia Casas (Colombia)

**A Rare Case of Acquired Haemophilia A with Platelet Dysfunction Associated with Non Hodgkin Indolent Lymphoma**
Speaker: Raffaella Rossio (Italy)

**In vitro Correction of Thrombin Generation by Recombinant Porcine Factor VIII (rpFVIII) in Plasma Containing Anti-Factor VIII Inhibitory Antibodies**
Speaker: Shannon L. Meeks (United States)

**The FARES Study: A Multicenter, Randomized, Active-Control, Pragmatic, Phase 2 Pilot Study Comparing Prothrombin Complex Concentrate versus Frozen Plasma in Bleeding Adult Cardiac Surgical Patients**
Speaker: Keyvan Karkouti (Canada)

**Postpartum Acquired Hemophilia A Persists as a Diagnostic Challenge**
Speaker: Irtis O F Junior (Brazil)

**Analysis of Patients with Diagnosis of Acquired Haemophilia in a Third Level Hospital**
Speaker: Ana Gómez Martínez (Spain)

Speaker: Wolfgang Miesbach (Germany)

**Acquired Hemophilia in Argentina: A Multicentric Study**
Speaker: Fernando Chuliber (Argentina)

**Autoimmune Acquired Factor XIII Deficiency: A Case Report**
Speaker: Ana Marco (Spain)

**Global Coagulation Analysis for Acquired Hemophilia A Patients with the Marked Elevation of Factor VIII Activity during Remission Phase**
Speaker: Masahiro Takeyama (Japan)

**Emicizumab for the Treatment of Acquired Hemophilia A**
Speaker: Paul Knoebl (Austria)

**Real Life Experience on 61 Acquired Haemophilia A (AHA) Patients from a Single Center**
Speaker: Marika Porrazzo (Italy)

**Diagnosis and Management of Acquired Von Willebrand Disease in Two Italian Centers**
Speaker: Antonietta Ferretti (Italy)
Advanced Principles of Prevention and Treatment of Preeclampsia in Women with Antiphospholipid Syndrome (APS) and MTHFR C677T Mutation  
Speaker: Marina Jangidze (Georgia)

Major Bleeding after a Gynecological Operation in Patient with Thrombocytosis and Anemia: Acquired von Willebrand Syndrome?  
Speaker: Karmen Bilic (Croatia)

Coagulation and Inflammation Genes Are Differently Expressed during the Acquired Coagulation Disorder Induced by Snake Envenomation  
Speaker: Ana Teresa Azevedo Sachetto (Brazil)

Experience with Recombinant Porcine FVIII in Patients with Acquired Factor VIII Deficiency Undergoing Major Surgery  
Speaker: Miguel Escobar (United States)

Prophylactic Potential of Standard and Modified Emicizumab Prophylaxis in 2 Patients with Acquired Hemophilia: A Case Report  
Speaker: Miguel Escobar (United States)

Rutin and Rutin Succinate Improve Murine Survival in an Experimental Model of Acute Hemostatic Disturbances  
Speaker: Ana Teresa Azevedo Sachetto (Brazil)

A Novel Therapeutic Approach for Acute Thrombo-hemorrhagic Disorders Evoked by Snake Venom: Potential of Rutin and Rutin Succinate  
Speaker: Ana Teresa Azevedo Sachetto (Brazil)

Successful Treatment of a Rare Acquired Thrombin Inhibitor in a Patient with Hemodialysis-dependent End-stage Renal Disease  
Speaker: Chatphatai Moonla (Thailand)

Acquired Hemophilia A in Young Nulliparous Woman: A Case Report  
Speaker: Eunkyoung You (Korea, Republic of)

Real World Experience on Use of Susoctocog-alfa (rpFVIII) in the Treatment of a Population of Italian Elderly Patients with Acquired Haemophilia A  
Speaker: Ezio Zanon (Italy)

Disseminated Intravascular Coagulation  
The ISTH DIC Score Predicts Outcome in Non-Septic Patients Admitted to a Cardiovascular Intensive Care Unit  
Speaker: Jürgen Grafenden (Austria)

A New Classification of Sepsis-Associated Disseminated Intravascular Coagulation (DIC) Based on Comprehensive Evaluation of Coagulation and Fibrinolysis  
Speaker: Tomoko Onishi (Japan)

Coagulopathy in Pediatric Patients with Hemophagocytic Lymphohistiocytosis  
Speaker: Mark Shamoun (United States)

A Multicenter Prospective Validation Study on Disseminated Intravascular Coagulation in Trauma-Induced Coagulopathy  
Speaker: Satoshi Gando (Japan)
Scientific Programme

Hypofibrinogenemia Is a High Risk for Infectious Type of Disseminated Intravascular Coagulation
Speaker: Hideo Wada (Japan)

Hemophilia - Basic

Exploring the Relationship between Condition Severity and Health-Related Quality of Life in Haemophilia A
Speaker: Charlotte Camp (United Kingdom)

The Role of Genetic and Environmental Factors in Development of Inhibitor in Hemophilia A
Speaker: Narges Beigom Mirbehbahani (Iran, Islamic Republic of)

Effect of the First Factor VIII Infusions on Immunological Biomarkers in Children with Hemophilia A: Results from the HEMFIL Study
Speaker: Leticia Lemos Jardim (Brazil)

Small RNAs Influence the Pathophysiology of Hemophilic Synovitis and Arthropathy
Speaker: Giridhara R. Jayandharan (India)

Self-Adjustment of Prescribed Dosing Regimens and Physical Activity by Persons with Hemophilia (PwH): Findings from the HemACTIVE Patient Survey
Speaker: Diane Nugent (United States)

Seeking New Approaches: Aberrant Clots, Fibrin Degradation Products and their Effects on Clot Stability
Speaker: Catherine Rea (United Kingdom)

X Chromosome Inactivation: A Modifier of Factor VIII and IX Plasma Levels in Haemophilia Carriers
Speaker: Isabella Garagiola (Italy)

Impact of APTT Reagents on Factor VIII Assay in Plasma Spiked with a Pegylated Recombinant FVIII: A French Multicentre Study
Speaker: Claire Pouplard (France)

Exploring the Relationship between Common Complications of Haemophilia and Anxiety and Depression in People with Haemophilia A
Speaker: Charlotte Camp (United Kingdom)

Contributions of the Individual Components of an Activated Prothrombin Complex Concentrate to Thrombin Generation in the Presence of Emicizumab
Speaker: Maureane Hoffman (United States)

Next Generation Sequencing Antibody Repertoire Analysis of Inhibitory Immune Response in Hemophilia A
Speaker: William D Lees (United Kingdom)

Examining the Hemophilia Disability Paradox
Speaker: Diane Nugent (United States)

Concizumab Does Not Affect Activated Partial Thromboplastin Time, Prothrombin Time or Factor VIII/IX Activity Measured Using One-Stage Clotting or Chromogenic Substrate Assays
Speaker: Marianne Kjalke (Denmark)

Unexpected Phenotypic Characteristics Associated with Severe Haemophilia B in Two Paediatric Patients with Deletions Involving the Whole F9 and Contiguous Genes
Speaker: Pamela Radic (Argentina)
In vitro Effect of Concizumab on Protein C Activation and Antithrombin Activity
Speaker: Marianne Kjalke (Denmark)

Emicizumab Prophylactic Therapy in Patients with Hemophilia A Is Better Measured by Thrombin Generation Assay Than Thromboelastography
Speaker: Erika J. Martin (United States)

Fibrin Polymerization Ability Is Variable in Patients with Severe Haemophilia and Might Influence their Joint Condition
Speaker: Paula Acuña-Butta (Spain)

Diagnosis and Management of Acute Hemarthrosis and Haemophilic Arthropathy in Spain Using Unified Clinical and Ultrasound Criteria: Preliminary Results
Speaker: Ana Chimeno Hernandez (Spain)

Association of Adherence and Bleeding Frequency among Severe Hemophilia A Patients on Prophylactic Factor VIII
Speaker: Fadzlin Mohd Mokhtar (Malaysia)

Testing the Impact of Recombinant von Willebrand Factor and Recombinant Factor VIII on Osteoclastogenesis
Speaker: Axel Schlagenhauf (Austria)

Prediction of the Response to FVIII Treatment in Haemophilia A
Speaker: Marisa Ninivaggi (the Netherlands)

Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations
Speaker: Maria Francesca Testa (Italy)

Increased Plasmin Generation in People with Severe Haemophilia
Speaker: Aisling M. Rehill (Ireland)

Identification of Novel Genetic Risk Factors in the Conserved Haplotype Region Surrounding the LCT Locus on Chromosome 2q21
Speaker: Andrea Cairo (Italy)

Uptake of MyABDR in Australia
Speaker: Sumit Parikh (Australia)

Bone Remodeling Alterations in Haemophilia: A Cell Biology Approach
Speaker: Stefano Lancellotti (Italy)

Reduced Splenic T Cells Count in an Untreated Mouse Model of Severe Hemophilia A
Speaker: Chiara Borsotti (Italy)

Discrepancies between FVIII Assays in Routine Diagnosis and Treatment Monitoring of Haemophilia A
Speaker: Charlotte Fauconnier (Belgium)

Factor VIII Does Not Elicit Danger Signals to Innate Immune Cells in Vivo
Speaker: Matthew Christopher Cormier (Canada)

Two-year Update on the WFH World Bleeding Disorders Registry
Speaker: Emily Ayoub (Canada)
In vitro and in sillico Analysis of F9 Gene Missense Mutations at Exons 2 and 3 Causative of Severe Hemophilia B  
Speaker: Lennon Melendez Aranda (Mexico)

Animal Model Construction for Hemophilic Arthritis: Evaluation of Hemophilia Joint by Ultrasound Detection  
Speaker: Cong Xu (China)

Feasibility of Using Hospital Episode Statistics in England to Assess the Resource Use and Outcomes in Haemophilia  
Speaker: George Morgan (United Kingdom)

Evaluation of Intron 22 and Intron 1 Inversions of Factor VIII Gene in Haemophilia A Patients  
Speaker: Irsa Khuwaja (Pakistan)

Methodological Validation of the Measurement of Ultra-low Levels of Factor VIII Activity by Chronometric APTT-based Assay  
Speaker: Clémentine Wahl (France)

Platelet Activation in Patients with Severe Haemophilia A  
Speaker: Joachim Potgieter (South Africa)

Inflammation in Hemophilia Is Marked by Up-regulation of LPS-binding Protein  
Speaker: Lynn M. Knowles (Germany)

Differences in the Prediction of the Time above Target in Hemophilia A Patients Using a Chromogenic Assay and a One-stage Assay in Model-informed Precision Dosing  
Speaker: David William Uster (Germany)

Decreased Platelet Surface Phosphatidylserine Predicts Increased Bleeding in Patients with Severe Factor VIII Deficiency  
Speaker: Andrew L. Frelinger III (United States)

ELISA-based Quantification of intracellular FVIII Protein in IPS Derived Vascular Endothelial Cells from HA-patients with Nonsense Mutations  
Speaker: Heike Singer (Germany)

The Relationship between Societal Costs Associated with Haemophilia and Disease Severity: A Regression Analysis Using CHESS II Data  
Speaker: Tom Burke (United Kingdom)

Modelling the Cost of Equivalent trough Level across Gene Therapy and Factor IX Replacement Therapy in Haemophilia B  
Speaker: Tom Burke (United Kingdom)

Intracellular Visualization of FVIII Protein in Selected Knockouts in the Conventional and Alternative Secretion Pathways  
Speaker: Salima Hazzouri (Germany)

Proteomic Profile of Blood Outgrowth Endothelial Cells (BOEC) from a Severe HA Patient with the Reintroduction of FVIII  
Speaker: Gillian E. Walker (Italy)

The Synergistic Effect of Emicizumab and Factor VIIa on Thrombin Generation Is Dependent on Factor VIIa Activation of Factor IX  
Speaker: Maureane Hoffman (United States)
Scientific Programme

APC: A New Suspect in the Hunt for a Mechanism of Bone Disease in Hemophilia
Speaker: Galen Goldscheitter (United States)

The Annual Global Survey Continues to Close the Gap in Data Collection of Bleeding Disorders
Speaker: Jeffrey Stonebraker (United States)

Non-Human Glycans Regulate FVIII Inhibitor Formation in Mice
Speaker: Connie Arthur (United States)

A Comparative Analysis of the Immune Response to Homologous Coagulation Factors V and VIII
Speaker: Monica L. Sauer (United States)

Differential Systemic Transcriptional Responses to Induced Joint Bleeding in Wild-type and Factor VIII-deficient Mice
Speaker: Esther Cooke (United States)

Molecular Analysis of Factor VIII Genes in Patients with Hemophilia A; Identification of Specific Mutation in Colombian Patients with Inhibitors
Speaker: Samuel Sarmiento Doncel (Colombia)

A Generic Recombinant Factor VIIa Is Comparable to the Branded Novoseven in In-vitro and Pharmacokinetic Studies in Primates
Speaker: Massimo Iacobelli (United States)

Hemophilia - Clinical

Long Term Joint Outcomes through Ultrasound for Hemophilia: First Interim Results from Prospective J-DaUPHIN Study
Speaker: Azusa Nagao (Japan)

Healthcare Resource Utilization and Cost Burden of Hemophilia B in the US
Speaker: Tyler W Buckner (United States)

Hemophilia A with Spontaneous Left Frontotemporal Epidural Hematoma (EDH) and Left Frontotemporoparietal Subdural Hematoma (SDH)
Speaker: Ellyana Perwitasari (Indonesia)

Use of Thromboelastography and Thrombin Generation Assay in a Patient Treated with Emicizumab
Speaker: Dominique Desprez (France)

Finding the Efficacy of Low Dose Prophylactic Regimen in Children Diagnosed with Severe Hemophilia
Speaker: Arooj Fatima (Pakistan)

Endothelial Specific Isoform of Type XVIII Collagen (COL-18N): A Marker of Vascular Integrity in Hemophilic Arthropathy
Speaker: Nayera Abdelhafetz (Egypt)

Incidence, Presentation and Management of Pseudotumors in Hemophilics: A Systemic Review
Speaker: Romana Akbar (Pakistan)

Limited Port-A-Cath Need for Hemophilia Patients in the Past: Experience in a Single Center
Speaker: Kaan Kavakli (Turkey)
BAY 81-8973 prophylaxis in Patients with Hemophilia A: Interim Usage and Safety Results from the TAURUS Real-World Study
Speaker: Cristina Santoro (Italy)

Prophylaxis Outcome in Patients with Severe Hemophilia in Southern Iran: Near Five-Year Experience from a Single-Center Study
Speaker: Mehran Karimi (Iran, Islamic Republic of)

Clinical Review of Patients with Haemophilia (PwH) in a Malaysian Tertiary Center
Speaker: Yang Liang Boo (Malaysia)

Real-World Cost of Emicizumab
Speaker: Amy L. Dunn (United States)

The Role of Ultrasonography versus MRI in the Diagnosis of Joint Problems in Hemophilic Children
Speaker: Osama El Safi (Egypt)

A Real-World Qualitative Analysis of the Burden of Hemophilia B and Patient Experiences with Prophylactic Nonacog Beta Pegol
Speaker: Chai Phua (Canada)

Efficacy and Safety of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients with Severe or Moderately Severe Hemophilia A: Results from a Phase 4 Study
Speaker: Yongqiang Zhao (China)

Real Life Use of Emicizumab in Pediatric Patients without Inhibitors
Speaker: Sabine Irene Heine (Germany)

Longitudinal Analysis of rFVIIIIFc Use and Efficacy in the UK: A Report from the National Haemophilia Database
Speaker: Caroline Wall (United Kingdom)

Real-World Effectiveness Evaluation of the Recombinant Factor VIII Fc Fusion Protein in Adolescents and Children with Hemophilia A in Japan: “Fc Adolescent and Children Treatment” Study (FACTs) Part 1 Interim Analysis
Speaker: Mutsumi Shiraishi (Japan)

Incidence of Neutralizing Antibody (Inhibitor) in Previously Untreated Patients (PUPs) with Severe Hemophilia A
Speaker: Shashikant Apte (India)

Successful Multiple Surgeries in Adult Patients with Haemophilia A (HA) Treated With Turoctocog Alfa Pegol (N8-GP) in the Pathfinder 3 trial
Speaker: Kingsley Hampton (United Kingdom)

Resolution of Target Joints (TJs) in Children with Severe Haemophilia A (HA) Treated with Turoctocog Alfa Pegol (N8-GP) Prophylaxis: Results from the Pathfinder 5 Trial
Speaker: Sonata Saulyte Trakymienė (Lithuania)

FⅨa-Triggered Thrombin Generation Assay for Monitoring Very Low Levels of FⅧ Activity in Hemophilia A
Speaker: Mei Juan Huang (China)

Total Elbow Replacement: Financial Burden Impact
Speaker: Jorge H Ramirez-Varela (Colombia)
Major Surgery in Emicizumab Haven 1 Trial Patients: The New Zealand Experience
Speaker: Paul A. Ockelford (New Zealand)

Prophylaxis with Turoctocog Alfa Pegol (N8-GP) Maintains Improvements in Health-Related Quality of Life (HRQoL) and Treatment Satisfaction (TS) over ≥4.5 Years in Patients with Haemophilia A (HA)
Speaker: Nicola J Curry (United Kingdom)

Treatment of Hemophilic Arthropathy with Hyaluron
Speaker: Aziza Makhmudova (Uzbekistan)

A French Multicentre Prospective, Non-Interventional Study (B-SURE) Evaluating Real-World Usage and Effectiveness of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in People with Haemophilia B: Baseline Data
Speaker: Caroline Martinez (France)

Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Previous Treated Hemophilia A Patients
Speaker: Feng Xue (China)

The Current State of Biochemical Marker Research in Hemophilic Arthropathy: A Review
Speaker: E.D.P. van Bergen (the Netherlands)

Promising Prospective Data on the Effect of Ankle Joint Distraction in Hemophilic Arthropathy
Speaker: E.D.P. van Bergen (the Netherlands)

Detectability and Clinical Significance of Calcium Exchange and 25 (OH) D in the Development of Osteoporosis in Patients with Hemophilia
Speaker: Naima Akhrarova (Uzbekistan)

A Randomized Controlled Trial: Pharmacokinetic-Guided Dosing of Factor VIII Concentrate Versus Standard Replacement Therapy in Perioperative Hemophilia A Patients (OPTI-CLOT Trial)
Speaker: Iris van Moort (the Netherlands)

Assessing the Bleeding Phenotype in Non-Severe hemophilia by use of the ISTH Bleeding Assessment Tool (BAT)
Speaker: Fabienne Roelfien Kloosterman (the Netherlands)

Comparison of FVIII Prophylaxis Treatment Regimen and Associated Clinical Outcomes between rVIII-SingleChain and Other rFVIII Products Commonly Used in Italian Hemophilia A Patients
Speaker: Cristina Santoro (Italy)

Prophylactic Factor VIII Consumption and Clinical Outcomes in Italian Hemophilia A Patients who Switched to Extended Dosing Intervals with Long-Acting rVIII-SingleChain: A Retrospective Patient Chart Review
Speaker: Maria Elisa Mancuso (Italy)

Joint Health Outcomes in Patients with Hemophilia A Receiving Antihemophilic Factor (Recombinant) in a Real-World Setting: Results of a 6-Year Interim Analysis of the AHEAD International Study
Speaker: Margareth Ozelo (Brazil)

Pharmacokinetic Profile of Southeastern Brazilian Hemophilia A Patients on Prophylaxis with Octocog Alfa
Speaker: Ricardo Camelo (Brazil)
Plasma Factor VIII Activity Measured by Coagulation One-Stage and Chromogenic Assays in Patients with Hemophilia A Treated with Emicizumab
Speaker: Teruhisa Fujii (Japan)

Thrombin Generation is a Better Predictor for Factor VIII Replacement Therapy Effect Than Factor VIII Activity Levels
Speaker: Lars L.F.G. Valke (the Netherlands)

A Canadian, Multi-Center, Retrospective, Non-Interventional Study of Clinical Outcomes from Early Use of N9-GP Compared with Previous Treatment in Patients with Hemophilia B in a Real-World Setting
Speaker: Man-Chiu Poon (Canada)

Baropodometric Barefoot Analysis for Musculoskeletal Health Assessment in Congenital Hemophilia
Speaker: Roberta Gualtierotti (Italy)

Favourable Outcomes in Two Young Patients with Severe Haemophilia B After Switching to rIX-FP
Speaker: Gianluca Sottilotta (Italy)

Evaluation of Factors Associated with Extended Half-Life Product Utilization for Men with Hemophilia B Participating in the Community Counts Registry from 2014-2018
Speaker: Fiona Bethea (United States)

Hip Bleeds in Boys with Mild Haemophilia A: A Single Centre Experience
Speaker: Deepan Gosrani (United Kingdom)

Rationale and Study Design for a Prospective, Low-Interventional Study to Investigate whether Systematic Joint Examination Impacts Haemophilia Treatment Management Decisions in Patients with Haemophilia A in France: The A-MOVE Study
Speaker: Yohann Repessé (France)

Evaluation of Bleeding in Haemophilia Carriers by ISTH-BAT: A Single Center Experience
Speaker: Mimosa Mortarino (Italy)

Current Challenges in Diagnosis and Management of Hemophilia Afghanistan
Speaker: Sayed Hamid Mousavi (Afghanistan)

Inhibitors in Hemophilia: Treatment Challenges in Afghanistan
Speaker: Sayed Hamid Mousavi (Afghanistan)

Elbow Embolization for Recurrent Massive Hemarthrosis: A Case Series with Successful Outcome
Speaker: Simona Maria Siboni (Italy)

Emicizumab Concentration in Children: A Single Centre Real World Experience
Speaker: Deepan Gosrani (United Kingdom)

Efficacy and Safety of BAY 94-9027 Prophylaxis for ≥5 Years: Outcomes in 36 Patients from the PROTECT VIII Extension Study
Speaker: Maria Elisa Mancuso (Italy)

Joint Bleeding Outcomes in Patients with Hemophilia A Receiving Long-Term Prophylaxis with BAY 94-9027 in the PROTECT VIII Extension Study
Speaker: Mark Reding (United States)
Final Safety Outcomes Following ≥5 Years’ Observation of BAY 94-9027 Treatment in Patients with Hemophilia A in the PROTECT VIII Extension
Speaker: Johannes Oldenburg (Germany)

Real-World Outcomes before and after Switching from Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in the United States
Speaker: Shawn X. Sun (United States)

Personalizing Prophylaxis with Rurioctocog Alfa Pegol in Previously Treated Patients with Severe Hemophilia A: Outcomes from the Phase 3b CONTINUATION and Phase 3 PROPEL Studies
Speaker: Carmen Escuriola-Etttingshausen (Germany)

Efficacy and Target Joint Resolution with Pharmacokinetic-Guided Rurioctocog Alfa Pegol Prophylaxis Targeting Two Factor VIII trough Levels in Patients with Severe Hemophilia A: Post-Hoc Analysis of the Phase 3 PROPEL Trial
Speaker: Peter Collins (United Kingdom)

Safety and Efficacy of Albutrepenonacog Alfa ih Haemophilia Patients: The Greek Experience
Speaker: Marina Economou (Greece)

Screening of Inhibitor Development among Haemophilia a Patients Being Treated with Recombinant Factor VIII Concentrates in South-East Nigeria
Speaker: Eyiuche Ezigbo (Nigeria)

Prediction Markers for Development of Persistent Inhibitors in Previously Untreated Patients with Severe Hemophilia A
Speaker: Sayna Miri (Italy)

The Experience of Orthopedic Surgeries in Ukrainian Hemophilia Patients with Inhibitor
Speaker: Yuliia Kashpurenko (Ukraine)

Real-World Experience with Emicizumab in Persons with Hemophilia A (HA) with or without Inhibitors
Speaker: Magdalena Lewandowska (United States)

Hemlibra Treatment in Pediatric Hemophilia A Patients - Real World Data of Safety and Uptake in the PedNet Cohorts
Speaker: Gili Kenet (Israel)

Efficacy and Safety of a 21-Day Individualized Dosing Interval in Patients with Hemophilia B Treated with rIX-FP
Speaker: Ingrid Pabinger (Austria)

Total Hip Arthroplasty In Avascular Necrosis of the Femoral Head in a Patient with Hemophilia A
Speaker: Joana Cabral (Portugal)

Prospective, Non-Interventional Study to Assess the Burden in Adolescents and Adults with Haemophilia A (HA) without Inhibitors and their Caregivers in Spain - Hemolife Study
Speaker: María Eva Mingot-Castellano (Spain)

Dynamic Changes in Peripheral Blood Transcriptome Profiles May Predict Inhibitor Formation in Previously Untreated Patients with Severe Hemophilia A
Speaker: Paul Batty (Canada)
Cardiovascular Risk Factor Profile among North-Eastern Brazilian Adults with Haemophilia
Speaker: Ricardo Camelo (Brazil)

Real World Efficacy of Emicizumab in Haemophilia A with Inhibitors: A Report from the UK National Haemophilia Database
Speaker: Caroline Wall (United Kingdom)

No Relapse in Patients with Previous Inhibitors Switched to rFVIIIFc in Ongoing Observational Phase 4 Studies
Speaker: Stefan Lethagen (Sweden)

Improved Prophylaxis Adherence After Switching to Emicizumab: Real-World Data from a Single Center
Speaker: Tyler W Buckner (United States)

Does Variation between Label and Actual Potency of Factor VIII Concentrate Vials Affect Results of Pharmacokinetic (PK)-Guided Dosing of Replacement Therapy in Hemophilia A?
Speaker: Mariechristine Henriëtte Jeanine Goedhart (the Netherlands)

Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with FVIII Inhibitors: Data from the Second Interim Analysis
Speaker: Giancarlo Castaman (Italy)

Primary Prophylaxis Assessment in Patients with Severe Haemophilia A without Inhibitors Based on Genetic Load and Thrombin Generation Test
Speaker: Ana Marco (Spain)

Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Ascending Doses of Subcutaneous Marzeptacog Alfa (Activated) in Adult Subjects with Hemophilia
Speaker: Linda Neuman (United States)

Pharmacokinetics and Coagulation Biomarkers in Persons with Hemophilia A (PwHA) and FVIII Inhibitors Receiving Emicizumab in the Phase IIIb STASEY Study
Speaker: Anna Kiialainen (Switzerland)

Associations between Physical Activity Levels and Bleeding Frequency in People with Mild, Moderate, and Severe Hemophilia A (HA): A Preliminary Analysis of the CHESS II Study
Speaker: Francis Nissen (Switzerland)

Coinfection by Hepatitis B, C and HIV in Patients with Haemophilia
Speaker: Thais S Esposito (Brazil)

Haemostatic Efficacy of rVIII-SingleChain in a Case of Surgical Prophylaxis for Hip Replacement
Speaker: Cristina Dainese (Italy)

UK EHL Registry: Patient Reported Outcomes Measured by Haemoprefer Patient Treatment Preference and Perception Tool
Speaker: Pratima Chowdary (United Kingdom)

Real-World Data of First-Time and Rescue Immune Tolerance Induction with Recombinant Factor VIII Fc Fusion Protein in Patients with Hemophilia A with Inhibitors in Japan: “Fc Adolescent and Children Treatment” Study (FACTs) Part 2 Interim Analysis
Speaker: Mutsumi Shiraishi (Japan)
Population Pharmacokinetic (PK) Analysis of BIVV001 (Rfviiifc-VWF-XTEN), a New Class of Factor VIII (FVIII) Replacement
Speaker: Suresh Katragadda (United States)

Long-Term Safety and Efficacy of Emicizumab for up to >5 Years in a Phase 1/2 Study in Patients with Severe Hemophilia A
Speaker: Midori Shima (Japan)

Females with Haemophilia in Nordic Countries Have a Higher Risk of Developing Pain, Anxiety and Depression Based on Treatment Patterns as Compared to Matched Controls: Data from a Registry Study over a Period of 11 Years
Speaker: Bent Winding (Sweden)

First Interim Analysis of a 24-Month, Prospective, Non-Interventional, Multicentre Study in Germany Evaluating the Real-World Usage and Effectiveness of rFVIIIFc and rFIXFc in Patients with Haemophilia A or B (PREVENT)
Speaker: Christoph Bidlingmaier (Germany)

A Single Center Data on Extended Half-Life Recombinant Factor VIII (FVIII:Fc) in Patients with Hemophilia A
Speaker: Simon Braham (Italy)

Abdominal Catastrophe in Hemophilic Patients: Towards Wise Decision Making
Speaker: Mohamed Abdelkader Morad (Egypt)

Treatment-Based Risk Assessment of Developing Pain, Anxiety, and Depression as Compared to Matched Controls in People with Haemophilia. A Nordic Registry Study Over a Period of 11 Years
Speaker: Bent Winding (Sweden)

Final Results of PUPs B-LONG Study: Evaluating Safety and Efficacy of rFIXFc in Previously Untreated Patients with Haemophilia B
Speaker: Beatrice Nolan (Ireland)

A Randomized, Multicenter, Open-label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Persons with Hemophilia A in the Asia-Pacific region (HAVEN 5)
Speaker: Renchi Yang (China)

Second Interim Analysis Results from the STASEY Trial: A Single-Arm, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Safety and Tolerability of Emicizumab Prophylaxis in People with Hemophilia A (PwHA) with FVIII Inhibitors
Speaker: Victor Jimenez-Yuste (Spain)

Safety and Efficacy of FVIII Replacement with Turoctocog Alfa in the UK
Speaker: Ben Palmer (United Kingdom)

Implication of Weight Excess in Hemophilic Arthropathy. The Results of a Colombian Reference Center
Speaker: Jose Lopez-Lopez (Colombia)

Adverse Event Reporting in Haemophilia A Patients with and without Inhibitors Treated with Emicizumab: A Report from the Co-morbidity Working Party of the UK Haemophilia Centres Doctors’ Organisation (UKHCDO)
Speaker: Caroline Wall (United Kingdom)

One-Stage versus Chromogenic Factor IX Activity in Haemophilia B
Speaker: Maria Bruzelius (Sweden)
Use of Emicizumab Prophylaxis in Adult and Pediatric Hemophilia A Patients with and without Inhibitors: Single Center Experience  
Speaker: Natalie Montanez (United States)

Evaluation of Factors Associated with Prophylaxis Treatment Regimen among Men with Hemophilia B Participating in the Community Counts Registry from 2014-2018  
Speaker: Fiona Bethea (United States)

Comorbidities in Patients with Severe Haemophilia: Birth Cohort Analysis of Taiwan Society of Thrombosis and Hemostasis Database  
Speaker: Jiaan-Der Wang (Taiwan, Republic of China)

The Feasibility of Teaching Handheld Ultrasound (HHUS) for Home Use to Identify Bleeding in Hemophilia  
Speaker: Bruno Steiner (United States)

Comparison of Bleeding Pattern and Inhibitor Development among Hemophilia Patients: Prophylactic versus On-Demand Treatment  
Speaker: Gilbert Wilfred (Malaysia)

The Impact of Switching Previously Treated Patients (PTPs) to Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Reducing the Annualized Bleeding Rate (ABR): A Single Center Experience  
Speaker: Olga Benitez (Spain)

"Best of Both Worlds": Combination Treatment of Desmopressin and FVIII Concentrates in Hemophilia Patients Optimizes Therapy and Reduces Costs  
Speaker: Lorenzo Gaetano Renata Romano (the Netherlands)

Monitoring of Hemlibra Prophylaxis in Children - Real World Data  
Speaker: Ilia Tamarin (Israel)

The Clinical Picture in Romanian Patients with Severe Forms of Hemophilia A: What Role did the Intron 22 Inversion and Age Play?  
Speaker: Mihnea-Alexandru Gaman (Romania)

Impact of a New Drug in the Real Child’s Life  
Speaker: Gabriela Sliba (Argentina)

Emicizumab and Surgery in Severe Haemophilia A with Inhibitor: Our First Experience  
Speaker: Veena Selvaratnam (Malaysia)

Real-World Experience of rVIII-SingleChain Treatment in a French Single Center  
Speaker: Abel Alain Hassoun (France)

Impact of Switching to Prophylaxis with Recombinant Factor IX Fc Fusion Protein Concentrate on Patient Reported Outcomes in People with Haemophilia B Using the PROBE Questionnaire  
Speaker: Mairead O’Donovan (Ireland)

The CHiC Study: The Canadian Hemophilia Carriers Study - Preliminary Results  
Speaker: Kalandra de Repentigny (Canada)

Perioperative Management with Recombinant Factor IX Fc Fusion (rFIXFc): Irish and UK Experience  
Speaker: Mairead O’Donovan (Ireland)
Successful Parotid Tumor Surgery in Hemophilia a Patient after Immune Tolerance Induction (ITI) with High-Purity Human FVIII/ von Willebrand Factor (vWF)
Speaker: Merlyna Savitri (Indonesia)

The 2-Years Successful Experience of Immune Tolerance Induction (ITI) with High-Purity Human FVIII/ von Willebrand Factor (vWF) in Hemophilia A Patients
Speaker: Merlyna Savitri (Indonesia)

Surrogate FVIII Activity in Patient and Constructed Plasma Samples Containing Emicizumab: A National External Quality Assurance Scheme for Blood Coagulation (UK NEQAS BC) Exercise
Speaker: Anna Lowe (United Kingdom)

FVIII Assay and APTT Results on Obizur in-vitro Spiked Plasma Samples: Analysis from the First UK National External Quality Assurance Scheme for Blood Coagulation (UK NEQAS BC) Obizur Exercise
Speaker: Anna Lowe (United Kingdom)

The Role of Clinical Psychologist in Mothers of Children with Hemophilia
Speaker: Aya Nakao (Japan)

Physical Activity, Sport and Haemophilia: An Observational Study on Risk Assessment
Speaker: Antonio Coppola (Italy)

Low-Dose Prophylaxis versus On-Demand Treatment in Pakistan with Severe Hemophilia A: Updated
Speaker: Munira Borhany (Pakistan)

How to Treat Hemophilia A and B Patients Prophylactically on Standard and Extended Half-Life Factor Concentrates under Pharmacokinetic (PK) Guidance? First Experiences of a Prospective Cohort Study (OPTI-CLOT TARGET)
Speaker: Mariechristine Henriëtte Jeanine Goedhart (the Netherlands)

Data Mining: An Innovative Approach to Optimise Post-Hoc Analyses of Large Trial Data Sets into Clinically Relevant Results
Speaker: Pratima Chowdary (United Kingdom)

First Episode of Macroscopic Hematuria in Hemophilia: Causes and Treatment
Speaker: Lorenzo Gaetano Renata Romano (the Netherlands)

Clinical Validation of Population Pharmacokinetic Model for Plasma-Derived Factor VIII/VWF Comparing 3 Years Follow-up
Speaker: Juan Eduardo Megías-Vericat (Spain)

Third Time’s the Charm? Tachyphylaxis of Desmopressin Response in Non-Severe Hemophilia A Patients and Comparison to Earlier Response: The DAVID Study
Speaker: Lorenzo Gaetano Renata Romano (the Netherlands)

Incidence of Factor VIII and IX Inhibitors in Hemophilia A and B in China
Speaker: Xueqing Dou (China)

Long-Term Immunogenicity, Efficacy and Safety of Simoctocog Alfa in Patients with Severe Haemophilia A who Had Completed the NuProtect PUP Study
Speaker: Ri Liesner (United Kingdom)
The Haemophilia A Patients whose FVIII: C by Chromogenic Substrate Assay were Higher than by One-Stage Substrate Assay Showed Risk of Development of Haemophiliac Arthropathy Silently
Speaker: Nobuaki Suzuki (Japan)

Immune Tolerance Induction (ITI) with a Single Factor VIII/von Willebrand Factor Concentrate in Haemophilia A Patients with Inhibitors - Update from the ObsITI Study
Speaker: Carmen Escuriola-Ettingshausen (Germany)

Dissecting the Paradox of “Severe” Hemophilia A (Clotting Factor VIII &LT; 1%) with a Mild Clinical Phenotype in the Era of Prophylaxis
Speaker: Ohad S. Bentur (United States)

Differences in Pharmacokinetic Evaluated by Clotting and Chromogenic Factor VIII Assays in Twelve Persons with Severe Hemophilia A on Prophylaxis with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc)
Speaker: Eugenia Cruz (Portugal)

Haemophilia B Patients Switched to Recombinant Factor IX-Albumin Fusion Protein (rIX-FP): Ultrasound and Clinical Joint Assessment
Speaker: Gianna Franca Rivolta (Italy)

Non-Sever Hemophilia Is Not Benign? - Insights from the PROBE Study
Speaker: Chatree Chai-Adisaksopha (Canada)

Prospective Comparative Analysis of Joint Structure and Function in Chinese Children with Severe Hemophilia A under Different Doses Factor VIII
Speaker: Lei Meng (China)

Pain Status in Patients with Hemophilia: Evaluation of Routine Pain Assessment in an Unselected Cohort of Patients with Hemophilia A and B
Speaker: Katharina Holstein (Germany)

The Impact of Physical Activity on the Pharmacokinetics of Factor VIII / IX in a Cohort of Pediatric Patients with Hemophilia A / B in Pharmacological Prophylaxis
Speaker: Carmela Pastore (Italy)

Validation of an Algorithm to Identify Hemophilia A Patients in Administrative Database
Speaker: Arafat Ul Alam (Canada)

Association Between Aging and Health Status in Persons Leaving with Hemophilia and Controls Without a Bleeding Disorder - Insights from the PROBE Study
Speaker: Federico Germini (Canada)

Inhibitor Development in Hemophilia A - Refining the Risk Assessment
Speaker: Ana Duraes (Portugal)

Subclinical deep venous thrombosis identified in 7,5% of people with hemophilia undergoing major orthopedic surgery in the absence of pharmacological thromboprophylaxis
Speaker: Cedric Hermans (Belgium)

Joint Damage in Non-severe Hemophilia A - Preliminary Results from an Explorative Study
Speaker: Anne-Fleur Zwagemaker (the Netherlands)

Haemophilia Breakthrough in Developing Countries. Is it Possible?
Speaker: A. Patricia Nally (Argentina)
Measuring the Impact of Hemophilia on Families  
Speaker: Victoria Price (Canada)

ATHN 7: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Hemophilia—Demographics and Preliminary Results  
Speaker: Tyler W Buckner (United States)

Management of Hemostatic Balance in Elective Joint Replacement Surgery in Patients with Haemophilia  
Speaker: Oana Viola Badulescu (Romania)

Treatment Patterns and Bleeding Outcomes in Persons with Severe Hemophilia A and B in a Real-World Setting  
Speaker: Leonard Perschy (Austria)

Comorbidities of Hemophilia & Factor XIII Deficiency Patients  
Speaker: Majid Naderi (Iran, Islamic Republic of)

The Clinical Phenotype of Patients with Non-severe Hemophilia A and B  
Speaker: Anne-Fleur Zwagemaker (the Netherlands)

Efficacy of Platelet-rich Plasma in the Treatment of Hemophilic Arthropathy  
Speaker: Peyman Eshghi (Iran, Islamic Republic of)

Quality of Life in Children with Congenital Bleeding Disorders: A Scoping Review of Current Research State and Knowledge Gaps  
Speaker: Elise J. Huisman (the Netherlands)

Immune Tolerance Induction (ITI) with a Plasma-derived Factor VIII for Patients with Hemophilia A and Inhibitors: A Retrospective Study  
Speaker: Novinyo Amega (United States)

Use of Desmopressin in the Treatment of Bleeding in Non-severe Haemophilia A  
Speaker: Fabienne Roelfien Kloosterman (the Netherlands)

The Parameters of Modified Clot Waveform Analysis Using the Plasmas of Hemophilia A Patients Treated with Emicizumab  
Speaker: Naoya Yamasaki (Japan)

Distribution of Hemophilia A and B within the INSIGHT Consortium  
Speaker: Anne-Fleur Zwagemaker (the Netherlands)

Prophylaxis with Emicizumab in Children and Adults with Hemophilia A and Inhibitors: Real-World Data of 17 Patients from 4 Portuguese Hemophilia Treatment Centers  
Speaker: Cristina Catarino (Portugal)

Thrombin Generation Assay to Tailored Treatment in Hemophilia a Patients  
Speaker: María De Lourdes Herrera (Argentina)

Reference Ranges of HJHS Scores in Healthy Adult Males without Hemophilia  
Speaker: Jean St-Louis (Canada)

Value of Super Microvascular Imaging and Contrast-enhanced Ultrasound in Evaluating the Neovascularization of Synovial Hypertrophy in Hemophilia Joints  
Speaker: Yingjia Li (China)
A Multicenter Open-label Single Arm Trial to Evaluate Safety and Efficacy and Pharmacokinetics of Recombinant Human Coagulation Factor VIII (SCT800) in Previously Treated Patients with Severe Hemophilia A under Prophylaxis Therapy
Speaker: Wei Liu (China)

Pharmacokinetic and Clinical Improvements after PK-guided Switch from Standard Half-life to Extended Half-life Factor VIII Products
Speaker: Juan Eduardo Megías-Vericat (Spain)

Molecular Mechanisms Underlying Haemophilia A and B Expression in 7 Females
Speaker: Qiulan Ding (China)

Prophylactic Treatment with Low or Medium Dose Factor VIII for Children with Severe Hemophilia A in China: Evaluation of Joint Progression by Conventional Ultrasound and Hemophilia Joint Health Score
Speaker: Cong Xu (China)

Impact of Prophylactic Treatment Incorporation in Hemophilia A and B Hospitalization Rates of the State of São Paulo Patients - Brazil - from 2008 to 2018
Speaker: Ana Guersoni (Brazil)

Is intracranial haemorrhage in haemophilia patients still a present risk in the third millennium? The final results of the EMO.REC Registry: a 10-year Italian study on intracranial haemorrhage in haemophilia patients
Speaker: Ezio Zanon (Italy)

3D Gait Analysis, Hemophilia Joint Health Score, Leg Muscle Laterality, and Biomarkers of Joint Damage: A Cross-sectional Comparative Assessment of Hemophilic Arthropathy
Speaker: Peter Putz (Austria)

Pilot Study on Low-Dose Immune Tolerance Induction (ITI) Therapy in Severe Hemophilia A Children with High-Titer Inhibitors
Speaker: Mohsen Elalfy (Egypt)

Immune Tolerance Induction with Octanate® in Patients with Haemophilia A and Inhibitors: An Ongoing Case Series from a Malaysian Centre
Speaker: Zulaia Muda (Malaysia)

MOdern Treatment of Inhibitor-PositiVe PATIEnts with Haemophilia A - MOTIVATE
Speaker: Carmen Escuriola-Ettingshausen (Germany)

The Health Status of Older Patients with Hemophilia in the Netherlands
Speaker: Shermarke Hassan (the Netherlands)

Immune Tolerance Induction with Simoctocog Alfa in Patients with Haemophilia A: An Ongoing Multicentre Case Series from the UK
Speaker: Georgina W. Hall (United Kingdom)

Correlations of Von Willebrand Factor Levels, Factor VIII (FVIII) Pharmacokinetics and Prophylaxis Dose in Severe Haemophilia A Patients Switching to rFVIII-Fc Studied by Individual and Population Tool-assisted PK Assessments
Speaker: Gabriele Quintavalle (Italy)

Lack of Inhibitor Development after Switching to Rurioctocog Alfa Pegol in the American Thrombosis and Hemostasis Network (ATHN) 2: Factor Switching Study
Speaker: Janna Journeycake (United States)
Scientific Programme

Treatment of Hemophilia A with rVIII-SingleChain in Italy: Physician and Patient Survey
Speaker: Cristina Santoro (Italy)

Real-world Evidence on the Use of rIX-FP in Patients with Hemophilia B: Interim Results from Three Multinational Prospective, Non-interventional, Post-market Surveillance Studies
Speaker: Giancarlo Castaman (Italy)

A Simplified Health Education Program Improves Knowledge and Practices of Home Treatment in Hemophilia A Adolescents in a Developing Country
Speaker: Tamer Hassan (Egypt)

Vitamin D Status and Risk of Osteoporosis in Hemophilia Patients
Speaker: Marwa Zakaria (Egypt)

ASCVD Risk Score among Haemophilia Patients: Time to Formally Evaluate Cardiovascular Risk in People with Haemophilia
Speaker: Ricardo Camelo (Brazil)

Association between Platelet Glycoprotein Common SNVs and Bleeding Severity in Haemophilia Patients
Speaker: Loredana Bury (Italy)

Satisfaction and Preference of Hemophilia A Patients and Parents for the Treatments in Korea; Results from a Multicentered, Cross-sectional, Observational Study
Speaker: Kiyoung Yoo (Korea, Republic of)

Case report: Inhibitor Improvement with Low Dose Immune Tolerance Induction (ITI) with rFVIIIFc and Emicizumab after Failed First Line Therapy with High Dose ITI
Speaker: Ivonne Wieland (Germany)

Impact of Extended Half-life Product versus Conventional Factor Product in Children with Hemophilia A - Findings from a Tertiary Care Centre
Speaker: Mahasen Saleh (Saudi Arabia)

Successful Use of Immunotherapy in the Management of Cancer in Patients with Hemophilia B
Speaker: David Hedrick (United States)

rFVIIIFc at Lower Doses Can Achieve Clinically Meaningful Reduction of Annualized Bleed Rates in Children with Severe Haemophilia A
Speaker: Aby Abraham (India)

A Snapshot of a Prospective, Non-interventional Study to Evaluate Routine Practice Prophylactic Treatment Schedules - NIS-Previq
Speaker: Susan Halimeh (Germany)

Bleeding Outcomes, Factor Utilization and Cost Comparisons after Switching to an Extended Half-life Product for Prophylaxis in Haemophilia A in Austria
Speaker: Cihan Ay (Austria)

Rapid Desensitization and Subsequent Immune Tolerance Induction in a Patient with Hypersensitivity and Inhibitor to Factor VIII
Speaker: William Mitchell (United States)

Population Pharmacokinetic Simulation Analysis for Extended Dosing Regimens of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Adult and Pediatric Patients with Hemophilia B
Speaker: William McKeand (United States)
Evaluation of Inhibitor Risk Prediction Tools Based on Genetic Risk Factors in Persons with Hemophilia A
Speaker: Amanda B. Payne (United States)

Lower Incidence of Cardiovascular Disease in Patients with Haemophilia
Speaker: Paul van der Valk (the Netherlands)

Utilizing Continuous Factor Infusion Replacement in a Hemophilia B Patient Undergoing Cardiac Surgery
Speaker: Sarah Sewaralthahab (United States)

rFIXFc at Lower Doses Can Achieve Very Significant Reduction of Annualized Bleed Rates in Children with Severe Haemophilia B
Speaker: Aby Abraham (India)

Hemostatic Management of Severe Hemophilia A (SHA) Patient with Dilated Myocardioathy through Extracorporeal Membrane Oxygenation (ECMO), Ventricular Assist Device (VAD) and Heart Transplant (HT)
Speaker: Maria Florencia Tisi Bana (Argentina)

No Peak of New-onset Inhibitors in the Aging Hemophilia Population: An International, Retrospective, Observational, Cohort Study of New Inhibitors in People with Hemophilia Aged 40 Years and Older (the NIAP Study)
Speaker: Jan Astermark (Sweden)

Real World Experience with Rurioctocog Alfa Pegol in Vall d’Hebron University Hospital
Speaker: Gustavo Robayo Buitrago (Spain)

Switch to Extended Half-life Recombinant Single Chain Factor VIII in Haemophilia A Patients. Experience in One Centre
Speaker: Reyes Jimenez-Barcenas (Spain)

Feasibility of Implementation of Point-of-Care Musculoskeletal Ultrasound in Joint Status Assessment in Children with Hemophilia
Speaker: Osman Khan (United States)

A Descriptive Study of Physical Activity and Fitness Level Profiles of Nigerians with Haemophilia
Speaker: Helen C. Okoye (Nigeria)

Factor VIII trough Levels in Patients with Hemophilia A on Secondary Prophylaxis in Relation to Clinical and Radiological Outcomes
Speaker: Azza Tantawy (Egypt)

Successful Inhibitor Eradication for Hemophilia A Children with Poor-risk High-titer Inhibitor Using Low-dose Immune Tolerance Induction Strategy
Speaker: Zekun Li (China)

Total Knee Arthroplasty in Patients with Hemophilia A and B: Impact on Quality of Life
Speaker: Alessandra Nunes Loureiro Prezotti (Brazil)

Inhibitor Formation and Immune Tolerance Induction with Fc-fusion-Protein Recombinant Factor IX in Severe Hemophilia B
Speaker: Ali Amid (Canada)

Clinical Improvement of Haemophilic Arthropathy in a Female Pediatric Patient with Severe Hemophilia A Following Treatment with Emicizumab
Speaker: Frederico Xavier (United States)
**Scientific Programme**

- **Emicizumab Prophylaxis in a Racially Diverse Pediatric Population with Hemophilia A with and without Inhibitors**  
  Speaker: Jessica Garcia (United States)

- **Mode of Delivery in Haemophilia: Vaginal Delivery and Cesarean Section Carry Similar Risk for Inhibitor Development in Severe Haemophilia A**  
  Speaker: Julie Tarrant (Canada)

- **Inhibitor Epidemiology among People Living with Haemophilia A in South West Nigeria**  
  Speaker: Abiola Bolarinwa (Nigeria)

- **Is Radiosynovectomy a Tool in Advanced Hemophilic Arthropathy?**  
  Speaker: Guilherme Ocampos (Brazil)

- **Surgery in People with Haemophilia and Inhibitors: 10 Years of Experience in a Portuguese Comprehensive Care Centre**  
  Speaker: Cláudia Vaz (Portugal)

- **Immune Tolerance Induction in Children with Hemophilia A, in Times of Emicizumab: A Real Life Experience**  
  Speaker: Jesúa Ardila (Colombia)

- **Hemophilia Gene Therapy**
  - **Long-Term Vector Genome Outcomes and Immunogenicity of AAV FVIII Gene Transfer in the Hemophilia A Dog Model**  
    Speaker: Paul Batty (Canada)
  - **Frequency, Location and Nature of AAV Vector Insertions After Long-Term Follow up of FVIII Transgene Delivery in a Hemophilia A Dog Model**  
    Speaker: Paul Batty (Canada)
  - **In the Future, Will ADSCs Become the Target Cells for Hemophilia A Gene Therapy?**  
    Speaker: Zhen Yu Yan (China)
  - **Increase in the Treatment Efficacy of Genome Editing for Hemophilia B by Codon-Optimization of SaCas9 in Mice**  
    Speaker: Tsukasa Ohmori (Japan)
  - **Multi-Centre Field Study of One-Stage and Chromogenic Factor IX Assays in Samples Containing the Factor IX Padua Variant**  
    Speaker: Jonathan Foley (United Kingdom)

- **Consistent Structural Kinetics of Valoctocogene Roxaparvovec DNA in Human Blood Samples**  
  Speaker: Chris Russell (United States)

- **Adenovirus Mediates Expression of Human Coagulation Factor IX Gene in Adipose-Derived Mesenchymal Stem Cells**  
  Speaker: Zhen Yu Yan (China)

- **Clinical Immunogenicity of Valoctocogene Roxaparvovec in GENEr8-1, a Phase 3 Study of AAV5-Mediated Gene Therapy Encoding Human FVIII for the Treatment of Hemophilia A**  
  Speaker: Brian Long (United States)

- **Mechanistic Evaluation of Factor IX-Padua Activity in Chromogenic FIX and Thrombin Generation Assays**  
  Speaker: Erald Shehu (United Kingdom)
<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical Experience with Fidanacogene Elaparvovec</td>
<td>Lindsey A George (United States)</td>
<td></td>
</tr>
<tr>
<td>A Novel Human Factor VIII Variant Exhibits Increased Factor VIII Expression after AAV Gene Therapy in a Unique Hemophilia A Dog Model that is Tolerant to Human Factor VIII</td>
<td>Giang Nguyen (United States)</td>
<td></td>
</tr>
<tr>
<td>The World Federation of Hemophilia Gene Therapy Registry</td>
<td>Mayss Naccache (Canada)</td>
<td></td>
</tr>
<tr>
<td>Expectations and Concerns of Patients with Haemophilia towards Gene Therapy - Results of Patients and Expert Focus Groups</td>
<td>Sylvia von Mackensen (Germany)</td>
<td></td>
</tr>
<tr>
<td>Ultrasound Mediated Gene Delivery Targets Liver Sinusoidal Endothelial Cells to Achieve Endothelial-specific Factor VIII Expression</td>
<td>Megan Manson (United States)</td>
<td></td>
</tr>
<tr>
<td>Prevalence and Affinity/Avidity Assessment of Pre-Existing Neutralizing Antibodies (NABs) against Adeno-Associated Virus (AAV) Vector Serotypes 2, 5 and 8 Analyzed in the Serum of 300 Healthy Donors</td>
<td>Anna Majowicz (the Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Investigating the Stability of Lentiviral Vector Targeted Liver Cells during Post-Natal Growth for in Vivo Gene Therapy of Hemophilia</td>
<td>Michela Milani (Italy)</td>
<td></td>
</tr>
<tr>
<td>Activity Measurement of Factor IX Padua against the 4th International Standard for FIX, Plasma</td>
<td>Elaine Gray (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>Surgical Management of a Hemophilia B Gene Transfer Clinical Trial Participant: A Case Report Following Etranacogene Dezaparvovec (AMT-061) Gene Therapy</td>
<td>Adam Giermasz (United States)</td>
<td></td>
</tr>
<tr>
<td>Exploring RNA Editing System as Innovative Correction Strategy for Hemophilia A</td>
<td>Silvia Pignani (Italy)</td>
<td></td>
</tr>
<tr>
<td>Combined Gene and Cell Therapy for the Treatment of Hemophilia A within an Implantable Therapeutic Device</td>
<td>Cristina Oligasi (Italy)</td>
<td></td>
</tr>
<tr>
<td>Platelet-targeted Hyperactive Factor IX (FIX) Gene Therapy for Hemophilia B Mice with Pre-existing Anti-FIX Immunity</td>
<td>Qizhen Shi (United States)</td>
<td></td>
</tr>
<tr>
<td>Influence of N-linked Glycosylation in the A and C Domains on the Immunogenicity of Factor VIII</td>
<td>Amber Vander Kooi (United States)</td>
<td></td>
</tr>
<tr>
<td>Assessment of Vector Integration of AAV5-hF1X in Mice and Non-human Primates Indicates No Association with Tumorigenic Risk</td>
<td>Lisa Spronck (the Netherlands)</td>
<td></td>
</tr>
<tr>
<td>Management of Bleeding and Trauma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Activated Prothrombin Complex Concentrates for the Management of Direct Oral Anticoagulant-Associated Bleeding Events and Pre-Operative Administration for Urgent Surgery: Hemostatic and Thrombotic Outcomes  
Speaker: Joseph Shaw (Canada)

Reversal of Direct Oral Anticoagulants with Three-Factor Prothrombin Complex Concentrate: Real World Experience from a Tertiary Centre in Hong Kong  
Speaker: Shun Yin Kong (Hong Kong)

Effect of Oral Anticoagulant Use on Surgical Delay and Outcomes in Hip Fracture Patients: A Systematic Review and Meta-Analysis  
Speaker: Yan Xu (Canada)

Low-Factor Consumption and Cost Effectiveness for Surgeries in Hemophilia B Patients with N9-GP  
Speaker: Shuichi Okamoto (Japan)

Effect of rFVIIa on Thromboelastogram Parameters in Haemophilia A Patients with Inhibitor  
Speaker: Valeria Kravivska (Ukraine)

Continuous Infusion with Kovaltry (Octocog Alfa) during Cardiac Surgery for Tetralogy of Fallot in an Hemophilic Child  
Speaker: Anna Amoruso (Italy)

Comparison of Coagulation Parameters Associated with Fibrinogen Concentrate and Cryoprecipitate for Treatment of Bleeding in Patients Undergoing Cytoreductive Surgery for Pseudomyxoma Peritonei: Results from the FORMA-05 Study  
Speaker: Cristina Solomon (Switzerland)

Andexanet and Prothrombin Complex Concentrate Give Comparable Haemostatic Efficacy for Major Bleeding in Patients on Factor Xa Inhibitors  
Speaker: Tessa C.C. Jaspers (the Netherlands)

Treatment Options in Severe Hemophilia A Patients from Romania: What Role did the Intron 22 Inversion and Age Play?  
Speaker: Miheia-Alexandru Gaman (Romania)

Idarucizumab to Neutralize Dabigatran in a University Hospital: The Relevance of Renal Function  
Speaker: Annalisa Fattorini (Italy)

Methodological and Reporting Quality in Case Series of Four-Factor Prothrombin Complex Concentrate in the Management of Oral Factor Xa Inhibitor-Associated Bleeding  
Speaker: Olivia S. Costa (United States)

The Obstetric Experience of Carriers of Haemophilia  
Speaker: Ozlem Turan (United Kingdom)

The Need for Red Cell Support during Surgery in a Tertiary Care Hospital Is Associated to Pretransfusion Levels of FXIII and the Platelet Count  
Speaker: Wolfgang Korte (Switzerland)

Endovascular Abdominal Aortic Aneurysm Repair in a Mild Haemophilia A Patient: A Case Report  
Speaker: Elsa Lopez Ansoar (Spain)
Direct Oral Anticoagulants Bleeding Events in Patients with Atrial Fibrillation Vs Venous Thromboembolism Admitted to an Emergency Department: Real-Life Study  
Speaker: Farès Moustafa (France)

The Age Dependent Effects of Female Sex on Platelet Behavior after Injury  
Speaker: Zachary Matthay (United States)

Improved Sensitivity of Global Hemostasis Assays Using Different Combinations of Phospholipid Reagent and Tissue Factor  
Speaker: Puja Soni (India)

Extended Half-life FIX and Disruptive Therapies in Carriers with FVIII and FIX Deficiencies: Preliminary Experience  
Speaker: Cedric Hermans (Belgium)

Desmopressin Response and Clinical Outcome in Bleeding Disorders: A 30 Year Retrospective Analysis  
Speaker: Maria Rita Peralta (United Kingdom)

Glycocalyx Shedding as a Potential Driver of Trauma-induced Coagulopathy in Severe Trauma Patients: Insights from the TRAUCC Trial  
Speaker: Maximilien Desvages (France)

Biomarkers of Fibrinolysis Predict the Need for Massive Transfusion in Trauma  
Speaker: Anton Ilich (United States)

The Effect of Bypassing Agents in Combination with Emicizumab-treatment  
Speaker: Nina Haagenrud Schultz (Norway)

Intravenous Synthetic Platelet Nanotechnology for the Treatment of Bleeding Complications  
Speaker: Anirban Sen Gupta (United States)

The 2020 World Federation of Hemophilia Guidelines for the Management of Hemophilia  
Speaker: Alok Srivastava (India)

Novel Biotherapeutics in Hemophilia

Emicizumab in the Management of Hemophilia A: Real World Experience in East Malaysia  
Speaker: Andy Sing Ong Tang (Malaysia)

Perioperative Management of Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia  
Speaker: K. John Pasi (United Kingdom)

Correction of Human Hemophilia B Gene in iPSCs by Base-Editing Approach Based on Engineered Cas9 with Broad PAM Flexibility  
Speaker: Takafumi Hiramoto (Japan)

A Next Generation Recombinant Factor VIII for Subcutaneous Hemophilia A Prophylaxis  
Speaker: Peter Herbener (Germany)

New Factor VIII Function-Mimetic Bispecific Antibodies Engineered from Emicizumab for Further Improving the Treatment of Hemophilia A  
Speaker: Yuri Teranishi (Singapore)

Thrombin Generation Potential of Modified FIX: Dalcinonacog Alfa  
Speaker: Stella Williams (United Kingdom)
A Novel FVIIIa-Mimetic Bispecific Antibody, Mim8, Enhances FIXa Proteolytic Activity While Allowing for Efficient, Lipid-Dependent Assembly with FX

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays
Speaker: Hande Kizilocak (United States)

Determining the Approximate Factor VIII Level Equivalency of Patients with Severe Hemophilia A on Emicizumab Using Global Hemostasis Assays
Speaker: Hande Kizilocak (United States)

Assay of Emicizumab Using the Modified One-Stage Clotting Assay
Speaker: Helen Wilmot (United Kingdom)

Optimization of Measurement of Emicizumab, FVIII and Anti-FVIII Activity in Patients Treated with Emicizumab
Speaker: Laura Heireman (Belgium)

Determining the Optimal Method for FVIII:C and Anti-FVIII Quantification in a Patient Treated with Adynovi® who Developed Anti-FVIII during Treatment
Speaker: Laura Heireman (Belgium)

SIG-001 for Hemophilia A: Preclinical Safety and Efficacy Studies Conducted in Mice and Non-Human Primates
Speaker: Guillaume Carmona (United States)

Surgical Experience with Emicizumab: A Single Centre Experience with Central Venous Access Device Removal
Speaker: Saket Badle (United Kingdom)

Characterization of Factor IX-FIAV: A Factor IX Variant that Displays Cofactor-Independent Activity
Speaker: Viola J.F. Strijbis (the Netherlands)

Rescue of the Endogenous FVIII Expression in Hemophilia A Mice Using CRISPR/Cas9 Gene Editing
Speaker: Chun-Yu Chen (United States)

Design of a Novel Factor IX Albumin Fusion Protein with Enhanced Coagulant Activity and Pharmacokinetic Profile
Speaker: Silvia Lombardi (Italy)

Optimizing Outcomes in Hemophilia A Prophylaxis Using Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc): Results from Three Portuguese Haemophilia Centers
Speaker: Sara Morais (Portugal)

Characterization of Neutralizing Anti-emicizumab Antibody Developed in a Hemophilia A Patient
Speaker: Flora Peyvandi (Italy)

Raising Factor VIII’s Half-life to the Next Level
Speaker: Steffen Kistner (Germany)

Emicizumab, beyond Annualized Bleeding Rates: Real World Joint Health and Physical Activity Data
Speaker: Beth Boulden Warren (United States)
Scientific Programme

Marzeptacog Alfa (Activated) Population PK: Simulations for Dose Selection in Phase 3 Trials
Speaker: Tom Knudsen (United States)

Emicizumab beyond Annualized Bleeding Rate: Do Laboratory Assays Help Predict Emicizumab Effects?
Speaker: Genevieve Moyer (United States)

Emicizumab beyond Annualized Bleeding Rate: How Does Emicizumab Affect Bone Biomarkers?
Speaker: Marilyn J. Manco-Johnson (United States)

A Simple Algorithm to Identify Emicizumab Interference in Samples Received in the Clinical Coagulation Laboratory
Speaker: Brian Poirier (United States)

Rare Bleeding Disorders

Rare Bleeding Disorders in Southern Iran: Revisited and Updated Data
Speaker: Mohammadreza Bordbar (Iran, Islamic Republic of)

Isolated Factor VII Deficiency
Speaker: Amireche Amira (Algeria)

Results from a Phase 4, Real-World Study Confirm the Safety and Effectiveness of rFXIII-A2 for the Treatment of Congenital FXIII A-Subunit Deficiency
Speaker: Lone Hvitfeldt Poulsen (Denmark)

Economic Burden Associated with Vaso-Occlusive Crisis Management in Patients with Sickle Cell Disease
Speaker: Abiola Oladapo (United States)

Clinical Characteristics of Patients with Rare Bleeding Disorders: Real-Life Data from the Netherlands (RBiN Study)
Speaker: Joline L. Saes (the Netherlands)

Usefulness of Tissue Factor-Independent Coagulation Parameters for Monitoring FXI-Concentrate Replacement in Patients with FXI-Deficiency
Speaker: Debora Bertaggia Calderara (Switzerland)

Fibrin Clot Properties in Patients with Qualitative Fibrinogen Disorders: Data from the PRO-RBDD Cohort
Speaker: Alessandro Casini (Switzerland)

Inherited Rare Bleeding Disorders in Non-Consanguinity
Speaker: Ampaiwan Chuansumrit (Thailand)

Evaluation of the Potential Utility of the Total Thrombus-Formation Analysis System (T-TAS) in Comparison to the Platelet Function Analyzer (PFA) in Subjects with Primary Hemostatic Defects
Speaker: Mathieu Fiore (France)

Efficacy and Safety of Fibrinogen Concentrate for On-Demand Treatment of Acute Bleeding and Surgical Prophylaxis in Pediatric Patients with Congenital Fibrinogen Deficiency: Results from the FORMA-04 Study
Speaker: Bruce Schwartz (United States)
Achenbach Syndrome in a 19 Year-Old Girl: A Clinical Case  
Speaker: Nathalia N S Magalhaes (Brazil)

Long-Term Anticoagulant Treatment in Patients with Factor VII Deficiency: A Single Centre’s Experience  
Speaker: Baldomero Moriano (Spain)

Blocking Tissue Factor Pathway Inhibitor (TFPI) Function Has a Therapeutic Benefit in Murine Models of Factor Deficiencies  
Speaker: Lacramioara Ivanciu (United States)

Collagen Turnover and Plasma Ascorbic Acid Levels in Patients Suspected of Inherited Bleeding Disorders Harboring Variants in Collagen-related Genes  
Speaker: Marcus Fager Ferrari (Sweden)

Uncharacterised bleeding Disorders Are Associated with Reduced Platelet and Microparticle Thrombin Generation and Decreased Procoagulant Oxidised Phosphatidylcholine  
Speaker: Samya G Obaji (United Kingdom)

Single Centre Experience of Rare Bleeding Disorders  
Speaker: Monica Martinez (Argentina)

FXI Gene Mations in Northern Region of Turkey  
Speaker: Canan Albayrak (Turkey)

A Bypass Surgery with Congenital Factor 5 and Factor 8 Deficiency  
Speaker: Vahap Okan (Turkey)

Molecular Diagnosis of Quantitative and Qualitative Fibrinogen Deficiencies: A Portuguese Centre Experience  
Speaker: Catarina Silva Pinto (Portugal)

The F7 p.Val22Ile Missense Mutation Affects Splicing and Can Be Counteracted by a Compensatory U1snRNA  
Speaker: Paolo Ferraresi (Italy)

Modulation of Alternative Splicing of the F5 Gene Using Morpholino Antisense Oligonucleotides  
Speaker: Alice Todaro (the Netherlands)

Congenital Combined Bleeding Disorders, a Study on a Large Number of Iranian Patients  
Speaker: Shadi Tabibian (Iran, Islamic Republic of)

Combined Factor Deficiencies Rare among the Rare Bleeding Disorders among Pediatric Population, Seven Years Experience in a Tertiary Care Center of Lahore, Pakistan  
Speaker: Tooba Fateen (Pakistan)

Inhibitor Development in a Patient with Severe Congenital Factor V Deficiency  
Speaker: Natasha Pardy (Canada)

Perioperative Management of Patients with Rare Bleeding Disorders in a Hemophilia Comprehensive Care Centre  
Speaker: Carlos Francisco Hernandez Mata (Spain)

Use of the ISTH Bleeding Assessment Tool in Diagnosis of Bleeding Disorders in West Algeria  
Speaker: Driss Benlaldj (Algeria)
Characterization and Management of Patients with Mild or Moderate Hereditary Factor X Deficiency: A Retrospective Chart Review  
Speaker: Suchitra Acharya (United States)

A Digestive Hemorrhage Like No Other  
Speaker: Yosra Cherif (Tunisia)

Inherited Factor VII Deficiency in Women: Low Rate of Bleeding in Non-severe Disease  
Speaker: Fernando Chuliber (Argentina)

Congenital Afibrinogenemia. Report of a Case in the Children’s Hospital of Mexico Federico Gomez  
Speaker: José Francisco Mariano González (Mexico)

Afibrinogenemia: Identification of a New Mutation in FGB  
Speaker: Elena Chinni (Italy)

Menorrhagia in Egyptian Adolescents with Inherited Bleeding Disorders: A Single Centre Study  
Speaker: Magy Abdelwahab (Egypt)

Important Sex Differences in Patients with Autosomal Inherited Bleeding Disorders  
Speaker: Ferdows Atiq (the Netherlands)

Fibrinolytic Alterations in a Thrombomodulin-associated Coagulopathy Are Diminished by Coinheritance of a TAFI Mutation  
Speaker: Claire S Whyte (United Kingdom)

Missense Mutations and Predicted Effects on Splicing in Factor XI Deficiency  
Speaker: Federica Riccardi (Italy)

Genotype and Phenotype Characterization in RBDs: A Spanish Pilot Study  
Speaker: Beatriz Rey Búa (Spain)

An Italian Survey on the Real-world Use of rFXIII (Catridecagog) in Patients with Factor XIII Deficiency  
Speaker: Samantha Pasca (Italy)

Severe Factor V Deficiency Caused by Two Novel Pathological F5 Variants - First Insights into their Effect on Factor V Function  
Speaker: Justine Brodard (Switzerland)

Comparative Analysis of Three Custom Gene Panels Based on Next Generation Sequencing for Diagnostic of Inherited Coagulation Bleeding Disorders  
Speaker: Nina Borràs (Spain)

Unclassified Bleeding Disorder (UBD)-Bleeding Phenotype and Management  
Speaker: Susan Halimeh (Germany)

Whole Exome Sequencing Approach to Address the Genetic Heterogeneity of Inherited Platelet Disorders  
Speaker: Laura Martin-Fernandez (Spain)

Safety of Antithrombotic Therapy in Subjects with Hereditary Hemorrhagic Telangiectasia  
Speaker: Fabiana Agostini (Italy)
Scientific Programme

Inherited Factor VII Deficiency Associated with Thrombo-hemorrhagic Phenotype: A Case Report
Speaker: Alena Stryckova (Slovakia)

Evaluation of the Skeletal Lesions in the Lebanese Patients with Afibrinogenemia
Speaker: Claudia Djambas Khayat (Lebanon)

Thrombotic Events in the Patients with Haemorrhagic Disorders of Haemostasis
Speaker: Lucia Stanciakova (Slovakia)

On-Demand Poster Session
14:00 - 15:00
Virtual Meeting Room 6

Nurses Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Nurses and Allied Health

Warfarin - A Real Threat in Evaluation of Acute Poisoning in the Emergency Department (ED) of a Tertiary Care Hospital - A Base Line Study to Make a Strategy for Better Patient Outcome
Speaker: Feroza Perveen (Pakistan)

Implementation of Prefilled Doses- A Novel Approach to Decrease Medication Time to Administration and Errors In Critically Ill Pediatric Patients of Emergency Department (ED)
Speaker: Feroza Perveen (Pakistan)

Socio-Demographic Data and some Haematological Parameters of Nigerian Children Living on the Street: A Comparative Study
Speaker: Patience Akpan (Nigeria)

Knowledge and Attitude towards Safe use of Direct Oral Anticoagulants (DOACs) among Doctors, Nurses and Pharmacist in a Developing Country, Karachi, Pakistan
Speaker: Sumaira Khan (Pakistan)

A Nurse Led Service Providing Safe and Effective Peri-Operative Anticoagulation
Speaker: Paul Priest (United Kingdom)

Effect of Foot Bath on the Plasma Concentration of Plasminogen Activator Inhibitor-1 Produced by Endothelial Cells in Healthy Subjects
Speaker: Tatsuya Hayashi (Japan)

Elderly Patients with Atrial Fibrillation Have Higher Risk of Geriatric Syndromes: Results of the Nursing Study
Speaker: Irina Tsareva (Russian Federation)

Monitoring of Adverse Event of INR>6 Using IHI Global Trigger Tool in Cardiology Hospital, Pakistan
Speaker: Sumaira Khan (Pakistan)

Recommendation on the Treatment of Venous Thromboembolism in Cancer Patients at a Brazilian Public Oncological Institution: Educational Plan
Speaker: Cynthia Rothschild (Brazil)
Scientific Programme

The Role of the Nurse in the Therapeutic Education of Hemophiliac Patients in Preparation for Physiotherapy
Speaker: Mhamed Djaafri (Algeria)

Effectiveness of a Self-management Program in the Treatment Control of Oral Anticoagulants Antivitamin K
Speaker: Mireia Constans (Spain)

Successful Development and Implementation of Pharmacist-led VTE Stewardship. An Australian Tertiary Hospital Perspective
Speaker: Julianne Chong (Australia)

Psychosocial Burden of Hemophilia in a Canadian Cohort
Speaker: Julia Hews-Girard (Canada)

A Multi Centre Non-randomised Clinical Trial to Establish the Efficacy of Peer Reviewed Physiotherapy Treatment Protocols among PWH in India
Speaker: Pamela Narayan (India)

Patient Compliance with Aspirin and Rivaroxaban Post Elective Joint Replacement Surgery: A Quality Assurance Initiative
Speaker: Laurie Sardo (Canada)

Canadian Guidelines Regarding Safe Blood-draw Volumes for Research in Pediatric Participants
Speaker: Korinne Hamilton (Canada)

On-Demand Poster Session
14:00 - 15:00
Virtual Meeting Room 6

Pediatrics Abstracts

Bleeding in Neonates and Children

Single Center Analysis of the Phenotype of Children Immune Thrombocytopenia with Mutation Related to Common Variable Immunodeficiency
Speaker: Jingyao Ma (China)

High-throughput Sequencing in the Diagnosis of Inherited Immune-Thrombocytopenia from among Children with Apparent Chronic/Refractory ITP
Speaker: Jingyao Ma (China)

Chronic Refractory Immune Thrombocytopenia is Associated with a High Frequency of Potentially Damaging Variants in Immune Genes
Speaker: Shasha Zhao (China)

Retrospective Analysis of Characteristics and Outcomes of 340 Pediatric ITP Patients in One Center
Speaker: Rongwei Li (China)

Variability in Diagnosis and Management of Immune Thrombocytopenia in Children: Real Life According to Spanish Pediatricians and Hematologists
Speaker: Rubén Berrueco (Spain)
Secondary Immune Thrombocytopenia in Children: Characteristics and Outcome of a Large Cohort from Two Spanish Centers  
Speaker: Rubén Berrueco Moreno (Spain)

Impact of a Standardized, Moderate-Intensity Aerobic Exercise Regimen on Hemostasis in Adolescent Hemophilia A Carriers: A Pilot Investigation  
Speaker: Riten Kumar (United States)

Moderate Intensity Aerobic Exercise and Intranasal Desmopressin Additively Increase Factor VIII and von Willebrand Factor (VWF) Levels in Adolescent Males with Mild Hemophilia A - Principal Findings from a Randomized Trial  
Speaker: Riten Kumar (United States)

Haemostatic Disorders and their Correlation with Hepatic Fibrosis Markers in Case of Hepatic Cirrhosis in Children  
Speaker: Ekaterina Konovalova (Russian Federation)

The Relationship between Platelet Phenotype and Function with Clinical Outcomes in 57 Paediatric Veno-Arterial ECMO Patients  
Speaker: Suelyn Van Den Helm (Australia)

Isolated Thrombocytopenia in Children Is Not Always an Immune-Associated Disorder  
Speaker: Alkistis Adramerina (Greece)

Thrombin Generation Measurement Using ST-Genesia System in a Cohort of Healthy Children Including Neonates: Normal Values and Variability  
Speaker: Philippe Nguyen (France)

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPS Matter Study) Interim Analysis of the 2010-2019 Birth Cohort  
Speaker: Shannon Carpenter (United States)

Inflammation Associated Cell-Free microRNA Levels in Cerebrospinal Fluid of Premature Infants Upon Intraventricular Hemorrhage  
Speaker: Zsolt Fejes (Hungary)

Challenges in Diagnosing and Treating Polycythemia Vera with Acquired von Willebrand Disease in a Pediatric Patient  
Speaker: Juhi Jain (United States)

Predictive Factors for Disseminated Intravascular Coagulation in Childhood Acute Lymphoblastic Leukemia  
Speaker: Natsaruth Songthawee (Thailand)

Validity and Reliability of Self-Administered Thai Pediatric Bleeding Questionnaire (TPBQ) Application to Predict Risk of Bleeding in Pediatric Bleeding Disorders  
Speaker: Darintr Sosothikul (Thailand)

Comparison between Bleeding Time and PFA-200 to Evaluate Platelet Function Disorder in Children  
Speaker: Darintr Sosothikul (Thailand)

Hemostasis in Parenteral Nutrition Associated Cholestasis in Preterm Infants: An Observational Study  
Speaker: Erica Scalambro (Italy)
Scientific Programme

Assessment of Vitamin K Level in Newborn Presenting with Bleeding in Population of Rural Sindh, Pakistan
Speaker: Nazia Hafeez (Pakistan)

Application of the First Russian Biosimilar of Recombinant Clotting Factor VII in an Infant with Antenatal Cryptogenic Hepatitis and Bleeding Developed After Laparoscopic Liver Biopsy
Speaker: Karina Papayan (Russian Federation)

Features of Epistaxis Predictive of a Mucocutaneous Bleeding Disorder (MBD) in Children
Speaker: Margaret Rand (Canada)

Quantitation of Bivalirudin Effect Using Microliter Scale Sample Microfluidic Assay in a Pediatric ECMO Population
Speaker: Galit Frydman (United States)

Assessing Anticipatory Guidance Needs in Adolescents with Bleeding Disorders
Speaker: Daisy Cortes (United States)

Impact of Intravenous Iron Therapy in Post-menarchal Adolescents Hospitalized with Acute Heavy Menstrual Bleeding
Speaker: Hyojeong Han (United States)

Use of ‘Virtual Clinics’ Telehealth Model in Pediatric Patients with Hemophilia and Inherited Bleeding Disorders: Experience from a Tertiary Care Center
Speaker: Mahasen Saleh (Saudi Arabia)

Prevalence and Management Approach to the Newborn with Classical and Late Vitamin K Deficiency Bleeding (VKDB) in LMIC
Speaker: Gul Ambreen (Pakistan)

Pediatric Heart Transplantation and Mechanical Circulatory Assistance: A Challenge for Hemostasis
Speaker: Caroline Gomes (Brazil)

Use of Prolong Parenteral Lipid Emulsions in NICU and Hematologic Disorders
Speaker: Gul Ambreen (Pakistan)

Thrombosis in Neonates and Children

Asymptomatic Catheter Related Thrombosis in Neonates: The Role of Thrombophilia Testing
Speaker: Bader Allahyani (Canada)

Pediatric Hospital-Acquired Venous Thromboembolism: Mayo Eugenio Litta Children’s Hospital Experience
Speaker: Melissa Azul (United States)

Self-Management of Oral Anticoagulation with Vitamin K Antagonist Programs Progressively Improves Time in Therapeutic Range in Pediatric Population
Speaker: Rubén Berrueco (Spain)

Pharmacokinetic Modelling and Simulation Support the Age and Body-Weight-Adjusted Dosing of Dabigatran Etxelatate in Paediatric Patients with Venous Thromboembolism
Speaker: Daniel Roeshammar (Sweden)
Pharmacokinetic-Pharmacodynamic Relationship between Dabigatran Plasma Concentrations and Coagulation Laboratory Parameters in Paediatric Patients with Venous Thromboembolism
Speaker: Lesley Mitchell (Canada)

Improve the Quality of Life in Children with Thrombosis and Need for Oral Anticoagulation: The “Coagulin Project”
Speaker: Rafael Martos Martínez (Spain)

Heparin Induced Thrombocytopenia in a 9 Years Old Child: A Case Report
Speaker: Katerina Zdrahalova (Czech Republic)

The Role of Hereditary Elevated Lipoprotein (a) as a Thrombophilic Risk Factor in Two Siblings with Cerebral Vein Thrombosis
Speaker: Sarah Schober (Germany)

Right Atrial Thrombosis in Children: Patient Characteristics, Outcomes, and Interrater Reliability of Echocardiographic Characterization
Speaker: Benjamin T. Barnes (United States)

Management and Outcomes of Newborns at Risk for Inherited Antithrombin Deficiency at the Karolinska University Hospital, Stockholm, Sweden
Speaker: Susanna Ranta (Sweden)

Polygenic Risk Score-Analysis of Thromboembolism in Patients with Acute Lymphoblastic Leukemia
Speaker: Kirsten Brunsvig Jarvis (Norway)

Ischemic Strokes in Children
Speaker: Karina Papayan (Russian Federation)

Impact of a Perioperative Venous Thromboembolism Prophylaxis Screening Tool for Pediatric Orthopedic Surgical Patients
Speaker: Ketan Kulkarni (Canada)

Prevalence, Characteristics and Risk Factors of Peripherally Inserted Central Catheter-Related Venous Thromboembolism in a Pediatric Intensive Care Unit: A Cross-Sectional Retrospective Study
Speaker: Samantha Theraar (United States)

Homocystinuria in the Etiology of Sinüs Vein Thrombosis Presented with Focal Seizure: A Case Report
Speaker: Elif Güler Kazancı (Turkey)

Pediatric Thrombosis: A Retrospective Analysis of the Incidence, Characteristics and Risk Factors in a Spanish Center
Speaker: Irene Sánchez Bazán (Spain)

Coagulation Activation Via Extrinsic Pathway Is the Major Cause of Hypercoagulation in Newborns during First Days of Life
Speaker: Ekaterina Koltsova (Russian Federation)

Impact of Inherited Thrombophilia on Risk of a First Perinatal Arterial Stroke and Further Course or Recurrence Rates: A Systematic Review and Meta-Analysis of Observational Studies
Speaker: Tido Bajorat (Germany)
The Frequencies of Thrombophilic DNA Polymorphisms in Children with Hemolytic Uremic Syndrome from the North-Western Region of Russia  
Speaker: Eugene Pankov (Russian Federation)

The Throm-PED Registry: The Cornerstone of the International Pediatric Thrombosis Network  
Speaker: C. Heleen van Ommen (the Netherlands)

Thrombosis and Anticoagulant Therapy among Pediatric Patients with Active Cancer: Real Life Data  
Speaker: Momen Zeineddin (Jordan)

Thrombosis and Laboratory Monitoring in Children with Acute Lymphoblastic Leukemia  
Speaker: Elena Seregina (Russian Federation)

Bivalirudin as the Primary Anticoagulant for Pediatric Patients with a Berlin EXCOR Ventricular Assist Device (VAD)  
Speaker: Michael Silvey (United States)

Expanding the Spectrum of Heterozygous Antithrombin Deficiency Type II HBS? Unusual Presentation of Thromboembolic Events in Two Children  
Speaker: Karin Beutel (Germany)

Venous Thromboembolism (VTE) in Children with Community-acquired Staphylococcus Aureus Bacteremia (CA-SAB) in Children: Risk Factors and Prevalence Study from a Single Pediatric Tertiary Care Center in Argentina  
Speaker: Carolina Cervio (Argentina)

Pulmonary Embolism in Pediatric Age: Retrospective Analysis of 10 Year Period in a Tertiary Hospital  
Speaker: Diana Cibele (Portugal)

Arterial Ischemic Stroke in Greek Infants, Children and Adolescents: a Single-Centre Experience  
Speaker: Athina Dettoraki (Greece)

Pulmonary Embolism in Pediatric Patients: A Ten-year Experience from a Tertiary Center in Brazil  
Speaker: Liana Lira (Brazil)

Hospital Acquired Thrombosis in Pediatric Population  
Speaker: Bushra Moiz (Pakistan)

Heparin Resistance in Pediatric Patient with Homozygous Antithrombin Deficiency, Treated with Dabigatran: A Case Report  
Speaker: Evalina Doncheva (Bulgaria)

Qualitative and Quantitative Characterization of Plasma Exosomes from Neonates and Adults  
Speaker: Julia Peñás Martínez (Spain)

A Rare Case of Phlebothrombosis; An Unusual Underlying Reason for Portal Venous Thrombosis  
Speaker: Selin Aytac (Turkey)

The Prevalence of Lupus Anticoagulant in Children and Adolescences Referred to the Reference Coagulation Laboratory of Iranian Blood Transfusion Organization  
Speaker: Minoo Ahmadinejad (Iran, Islamic Republic of)
Clinical and Radiological Outcome in a Single Center Cohort of Pediatric Patients with Focal Cerebral Arteriopathy (FCA). Safety of Antithrombotic Prophylaxis and Therapy  
Speaker: Andrea Beccaria (Italy)

A Child with Ischemia of the Glans Penis after Circumcision  
Speaker: Ludi Dhyani Rahmartani (Indonesia)

Global Hemostasis, Procoagulation and Anticoagulation Proteins Derangements in Children and Adolescents with Hemoglobin H and Beta-Thalassemia/Hemoglobin E Diseases  
Speaker: Rungrote Natesirinilkul (Thailand)

Risk Factors for the Development of Hospital-acquired Pediatric Thromboembolism - Dealing with Potentially Causal and Confounding Risk Factors Using Direct Acyclic Graph (DAG) Analysis  
Speaker: Leonardo R. Campos (Brazil)

Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents with Lymphomas  
Speaker: Dmitrii Evstratov (Russian Federation)

Moyamoya Disease - A European Clinical Case Report  
Speaker: Lúcia Vieira (Portugal)

Effectiveness and Safety of Primary Thromboprophylaxis in Pediatric Renal Transplant: a Systematic Review of the Literature and Meta-Analysis  
Speaker: Ahmad Al-Huniti (Canada)

A Rise in Plasma Coagulability During the First 3 Months Following Provoked Venous Thromboembolism is Associated with the Development of Post-Thrombotic Syndrome in Children and Young Adults: Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank  
Speaker: Marisol Betensky (United States)

Antithrombin Activity Level below 60% in Children Has Implications for Heparin (LMWH) Dosing  
Speaker: Irene Regan (Ireland)

Impact of Blood Group on the Incidence of Thrombosis in Neonates  
Speaker: Kulsajan Bhatia (Canada)

Bivalirudin Administration in Pediatric Ventricular Assist Devices and in Pediatric ECMO  
Speaker: Chiara Giorni (Italy)

On-Demand Poster Session  
14:00 - 15:00  
Virtual Meeting Room 6

Platelet Disorders and von Willebrand Disease Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Acquired Thrombocytopenias

Can we Predict the Clinical Course of Children with ITP by MPV? A Preliminary Study  
Speaker: Yoonkyung Lee (Korea, Republic of)
Megakaryocytic Hyperplasia in Bone Marrow Biopsy as a Novel Predictor of Response in Patients with Immune Thrombocytopenia
Speaker: Jacopo Agnelli Giacchello (Italy)

Phase I/II, Open-Label, Ongoing Study of PRN1008 (Rilzabrutinib), an Oral Bruton Tyrosine Kinase Inhibitor, in Patients with Heavily Pretreated Immune Thrombocytopenia (ITP)
Speaker: David J. Kuter (United States)

Characteristics of Patients with Cyclic Thrombocytopenia: An Observational Cohort Study
Speaker: Oskar Steinbrecher (Austria)

Pathogenic Mechanisms Contributing to Thrombocytopenia in Patients with Systemic Lupus Erythematosus
Speaker: Maria Constanza Baroni Pietto (Argentina)

Elevated BAFF Promote B Cell Survival and Autoantibody Production through Upregulating Let-7b in Immune thrombocytopenia
Speaker: Yang He (China)

Role of Bone Marrow-Derived Mesenchymal Stem Cell Defects in CD8+ CD28- Suppressor T-Lymphocyte Induction in Patients with Immune Thrombocytopenia and Associated Mechanisms
Speaker: Huiyuan Li (China)

Platelet Surface GPIbα, Platelet Surface Activated GPIIb-IIIa and Platelet Surface P-Selectin in Veno-Arterial Extracorporeal Membrane Oxygenation Patients
Speaker: Yifeng Wu (United States)

Predictive Factors of Chronicity in Adult Idiopathic Thrombocytopenic Purpura
Speaker: Nadia Sari Hassoun (Algeria)

Antithyroid Treatment Improves Thrombocytopenia in a Young Patient with Graves´ Disease: A Case Report
Speaker: Viviana Valeria Palmieri (Italy)

Apoptotic Markers May Help in Predicting the Disease Course of Pediatric Immune Thrombocytopenic Patients
Speaker: Sarina Levy Mendelovich (Israel)

Glucocorticoid Receptor Modulates the Mitochondria Function of Myeloid-Derived Suppressor Cells in Immune Thrombocytopenia
Speaker: Shuwen Wang (China)

Desmopressin for Procedures or Radiological Interventions (DRIVE): Participant Characteristics in a Placebo-Controlled Double-Blind, Randomised Feasibility Trial of Desmopressin in Thrombocytopenic Critically Ill Patients Prior to Procedures
Speaker: Michael Desborough (United Kingdom)

Atorvastatin Restores the Imbalance of CD4+ T cells in Immune Thrombocytopenia via Ras/MEK/ERK and mTOR/PI3K/AKT Pathways
Speaker: Pengcheng Xu (China)

Use of Eltrombopag in Children with Chronic Immune Thrombocytopenia (ITP): A Real Life Retrospective Multicenter Experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)
Speaker: Giuseppe Lassandro (Italy)
Scientific Programme

Relationship between Platelet Function and Glycome Composition in Immune Thrombocytopenia
Speaker: Nora Butta (Spain)

Can we Predict the Outcome of Splenectomy for Primary Immune Thrombocytopenia? Conclusion Based on Systematic Review and Meta-Analysis
Speaker: Mirjana Mitrovic (Serbia)

Achieving Clinically Relevant Platelet Count Response Thresholds with Avatrombopag (AVA) in Immune Thrombocytopenia (ITP)
Speaker: Michael Vredenburg (United States)

Efficacy and Safety of Romiplostim in Children with Chronic and Persistent Immune Thrombocytopenic Purpura
Speaker: Mohamadreza Bordbar (Iran, Islamic Republic of)

Outcome of Splenectomy in Adult Refractory Immune Thrombocytopenic Purpura - A Descriptive Analysis
Speaker: Gilbert Wilfred (Malaysia)

Romiplostim Treatment in Patients with Refractory Inmune Thrombocytopenia Purpura: Experience in a Single Center
Speaker: Bianca Díaz Roldán (Spain)

Treatment of Immune Thrombocytopenia with Eltrombopag in Children: Single Center Experience
Speaker: Aylin Ayhan (Turkey)

Clinical and Laboratory Factors Affecting Chronicity in Children Diagnosed with Immune Thrombocytopenia
Speaker: Yılmaz Ay (Turkey)

Eltrombopag Suppresses Excessive Inflammation in Hepatitis B-Related Immunologic Thrombocytopenia through Inhibition of Toll-Like Receptor 4 Signaling Pathway
Speaker: Cheng Zhang (China)

Sustained Remission after Withdrawal of Thrombopoietin Receptor-Agonists in Immune Thrombocytopenia
Speaker: Jun Yamanouchi (Japan)

Risk Stratification for Intracranial Hemorrhage in Adults with Immune Thrombocytopenia: A Retrospective Multicenter Study
Speaker: Peng Zhao (China)

Factors Influencing Bleeding Severity in Adult Patients with Primary Immune Thrombocytopenia
Speaker: Johanna Gebhart (Austria)

CD4+ T Cell Expression of IL-10 Compared to IL-17 is Lower in Patients with Immune Thrombocytopenia (ITP) Who Do Not Respond Clinically to High Dose Corticosteroid
Speaker: Charlotte Bradbury (United Kingdom)

Clinical Practise of SMOG System for Assessing Severity of Hemorrhagic Manifestations of Immune Thrombocytopenia (ITP) in Children
Speaker: Daria Sigunova (Russian Federation)
Platelet Count Variation in a Cohort of Patients with Chronic HCV-Related Liver Disease Treated with Direct-Acting Antivirals  
Speaker: Gianmarco Podda (Italy)

Response to Avatrombopag (AVA) in Chronic Immune Thrombocytopenia: Alternative Efficacy Measures  
Speaker: Michael Vredenburg (United States)

Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling Providing Guidance for Selecting Avatrombopag (AVA) Dose when Switching from Eltrombopag in Chronic Immune Thrombocytopenia (ITP)  
Speaker: Michael Vredenburg (United States)

The Prevalence, Risk Factors, and Bleeding Tendency of Thrombocytopenia in Patients with Hepatitis C Virus and Hepatitis B Virus Infection  
Speaker: Cih-En Huang (Taiwan, Republic of China)

Pooled Safety Analysis of Avatrombopag (AVA) from Clinical Trials  
Speaker: Michael Vredenburg (United States)

Stability of Crushed Avatrombopag Tablets Demonstrated in Multiple Food Vehicles  
Speaker: Michael Vredenburg (United States)

The Significance of Platelet Factor 4 (Pf4 Antibody) in Diabetic and Non-Diabetic Population during Heparin Therapy In Pakistan  
Speaker: Razia Asif Abbasi (Pakistan)

Eltrombopag Therapy in Pediatric Acute and Chronic Immune Thrombocytopenia  
Speaker: Emine Zengin (Turkey)

Immune Thrombocytopenia Treatment with Fostamatinib, a Spleen Tyrosine Kinase Inhibitor: Reducing the Risk of Thrombosis  
Speaker: Nichola Cooper (United Kingdom)

Long Term Complications after Splenectomy in Chronic pITP Patients: A Retrospective Case Control Study  
Speaker: Marilena Marcosano (Italy)

Fostamatinib as Second-Line Therapy for ITP and in Earlier Stage ITP Patients  
Speaker: Waleed Ghanima (Norway)

Glibenclamide-Induced Thrombocytopenia: A Case Reort  
Speaker: Yosra Cherif (Tunisia)

Randomized Study for the Treatment of Primary Immune Thrombocytopenic Purpura (pITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone versus High-dose Dexamethasone. Preliminary Results. GIMEMA Protocol ITP0207  
Speaker: Maria Gabriella Mazzucconi (Italy)

Outcomes of Patients with Worsening Acquired Thrombotic Thrombocytopenic Purpura (TTP) Despite Daily Therapeutic Plasma Exchange (TPE) in the Phase 3 HERCULES Trial  
Speaker: Marie Scully (United Kingdom)

Response Rate and Response Duration after Discontinuation of Treatment with Thrombopoietin Receptor Agonists (TPO-RAS) in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study. Preliminary Results. GIMEMA Protocol ITP0714  
Speaker: Maria Gabriella Mazzucconi (Italy)
Comparison of Various Diagnostic Methods in Assessing Platelet Count in Patients with Immunotrombocytopenia
Speaker: Michal Witkowski (Poland)

A Long Term Survival Chronic DIC with ITP Treated with Low Dose Steroid
Speaker: Yoshinobu Seki (Japan)

Artificial Neural Network for Prediction of Hemorrhagic Severity in Patients with Immune Thrombocytopenia Purpura
Speaker: Tiago Dias Martins (Brazil)

Possible Impact of Polymorphism of GSTM1 and GSTT1 Genes on Bleeding Tendency in Immune Thrombocytopenia
Speaker: Samina Naz Mukry (Pakistan)

A Subpopulation of ITP Patients Resembling Glanzmann Thrombasthenia Phenotype Revealed by Flow Cytometry Analysis of Platelet Intracellular Signalling
Speaker: Alexey Martyanov (Russian Federation)

First Report of Rituximab Dependent Anti-platelet Antibodies as Cause of Acute Thrombocytopenia
Speaker: Yvonne Kong (Australia)

Pattern of Central Nervous System Involvement an Emerging Allied Complications of Dengue Hemorrhagic Fever. A literature Review
Speaker: Tanzeel Imran (Pakistan)

Characteristics and Outcome of Patients with Thrombocytopenia Secondary to Acute Cytomegalovirus Infection: Case Series and Literature Review
Speaker: Tamir Shragai (Israel)

Evaluation of Thrombocytopenia and Fetomaternal Outcome in Pregnancy at a Tertiary Care Hospital
Speaker: Kiran Aamir (Pakistan)

Investigations of the Impact of Sialidase-mediated Changes on the Life Span of Human Platelets Using a Humanized in vivo Mouse Model
Speaker: Lisann Pelzl (Germany)

Antimicrobial Prophylaxis in Patients with Immune Thrombocytopenia Treated with Rituximab: A Retrospective Multicenter Analysis
Speaker: Mariasanta Napolitano (Italy)

Corticosteroid Reduction or Discontinuation after Initiation of Avatrombopag Treatment in Patients with Chronic Immune Thrombocytopenia (ITP)
Speaker: Michael Vredenburg (United States)

Monoclonal Antibody Immobilization of Megakaryocyte Antigens (MAIMA) Assay: A Novel Tool for Detecting Human Platelet Antigens
Speaker: Josip Lucic (Germany)

Prevalence and Clinical Significance of Abnormal T-cell Large Granular Lymphocytes in Patients with Immune Thrombocytopenia
Speaker: Caroline Gabe (Canada)

Management of Steroid Refractory Acute Immune Thrombocytopenia Purpura - A Single Center Experience from India
Speaker: Nitin Gupta (India)
Antiplatelet Therapy

Platelet Function Assay PFA-200 for Monitoring of Antiplatelet Drug Effect
Speaker: Tatjana Makarovska Bojadjieva (Macedonia, the Former Yugoslav Republic of)

Long-term Variation of Platelet Reactivity in High-Risk Patients on Antiplatelet Therapy after Percutaneous Coronary Intervention
Speaker: Renske Olie (the Netherlands)

Synthesis of Antiplatelet Ortho-Carbonyl Hydroquinones: A Spiro Derivative is Selective against Collagen-Stimulated Platelets
Speaker: Diego Mendez (Chile)

The Effect of Aspirin in Tumor Growth of Obese Mice Involving Inhibition of Metabolism
Speaker: Jiaan-Der Wang (Taiwan, Republic of China)

Desmopressin for Reversal of Antiplatelet Drugs in Stroke due to Haemorrhage (DASH): Interim Report on Recruitment from a Phase II Double Blind Randomised Controlled Trial
Speaker: Michael Desborough (United Kingdom)

Lysine-Containing Peptides as Promising Antiplatelet Drugs
Speaker: Marina Grigorjeva (Russian Federation)

Efficacy of Antiplatelet Therapy in Patients with Acute Ischemic Stroke Treated with Acetylsalicylic Acid
Speaker: Lenka Bultasova (Czech Republic)

Detection of Clopidogrel Resistance: Comparison of Light Transmission Aggregometry and INNOVANCE® PFA P2Y Cartridge and Correlation with CYP2C19 Variants
Speaker: Laura Heireman (Belgium)

Potent platelet inhibition results in improved long-term clinical outcome independent from clinical variables
Speaker: Gloria Gager (Austria)

Comparison of Platelet Function Testing in Patients Undergoing Neuroradiological Flow Diversion Stents
Speaker: Mansour Gergi (United States)

Ticagrelor Mechanism of Action on Gram-Positive Bacteria
Speaker: Lucia Musumeci (Belgium)

Evaluation of Dual Antiplatelet Therapy Combining Aspirin and Clopidogrel for Intracranial Stenting Procedures: A Retrospective Single Center Study
Speaker: Luciana Goncalves (Portugal)

The Effect of Plasma Fibrinogen Level on Predictive Value of VerifyNow P2Y12 Assay Results in Patients Undergoing Percutaneous Coronary Interventions
Speaker: Anatoly Dobrovolsky (Russian Federation)

Discontinuation of Chronic Low Dose Acetylsalicylic Acid Therapy Upon Intensive Care Medicine Department Admission Appears to Increase Mortality
Speaker: Filipa Martins Pereira (Portugal)

Evaluation of Platelet Reactivity in Pediatric Patient on Dual Antiplatelet Therapy after Stent Implantation of Ductus Arteriosus: A Case Report
Speaker: Dobrinka Dineva (Bulgaria)
Circulating Myeloid-related Protein (MRP)-8/14 May Contribute to Suboptimal Response to Low Dose Aspirin in Patients with Type 2 Diabetes mellitus
Speaker: Paola Giustina Maria Simeone (Italy)

Correlation of VASP Phosphorylation Assay with Light Transmission Aggregometry for Patients Treated with Clopidogrel or Ticagrelor
Speaker: Maxime Moulard (France)

Intra-individual Residual Platelet Reactivity upon Antiplatelet Therapy in the Perioperative Period Significantly Differs over Time - What Is the Ideal Moment to Monitor Efficacy of Antiplatelet Therapy in Vascular Patients?
Speaker: Suzanne Korporaal (the Netherlands)

Assessment of the Hemostatic System by Total Thrombus-formation Analysis System (T-TAS) in Patients with Chronic Coronary Syndromes
Speaker: Olga Sirotkina (Russian Federation)

HIT
Evaluation of Fondaparinux (Arixtra®) at a Large Academic Medical Center
Speaker: Kassandra Marsh (United States)

Prospective Comparison of Two Specific IgG Immunoassays (HemosIL® AcuStar HIT IgG and HAT 45-G®) for the Biological Diagnosis of Heparin-Induced Thrombocytopenia: A Bayesian Approach
Speaker: Eve Anne Guery (France)

Characterization of Murine Monoclonal Anti-PF4/Polyanion Antibodies, as Potential Useful Tools for Studies on Typical and Autoimmune HIT
Speaker: Caroline Vayne (France)

Autoimmune Heparin-Induced Thrombocytopenia Successfully Treated using Direct Oral Anticoagulant and Intra-Venous Immunoglobulin
Speaker: Valérie Prouille (France)

Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies as Investigated in Platelet Aggregation Assays
Speaker: Ambar Farooqui (United States)

Insights into Autoimmune Heparin-Induced Thrombocytopenia
Speaker: Nora Krause (Germany)

Comparison of Clinical Adverse Events during Empiric Therapy for Patients with Suspected HIT
Speaker: Kaitlyn Dykes (United States)

Therapeutic Plasma Exchange in the Pre-Operative Management of Acute HIT
Speaker: Candice Cavalié (France)

Heparin-induced Thrombocytopenia in Intensive Care Patients with Extracorporeal Circulation
Speaker: Karina Althaus (Germany)

The Utility of a Platelet Count-Based Electronic Medical Record Alert to Facilitate Diagnosis of Heparin-Induced Thrombocytopenia
Speaker: Jori May (United States)
Detection of Pathogenic Anti-platelet Factor 4 Antibodies by Impedance Spectroscopy  
Speaker: Nida Zaman Khan (Germany)

Evaluation of 4T Probability Scores, Heparin PF4 Antibody, and Serotonin Release Values in End Stage Renal Disease Patients in the Assessment of Heparin Induced Thrombocytopenia  
Speaker: Julie Kelly (United States)

Inhibition of 12-LOX with VLX-1005 Has Clinical Utility for Prevention and Intervention of HIT  
Speaker: Michael Holinstat (United States)

Underlying Causes Greatly Influence the Development of HIT Antibodies and Clinical Outcomes in Patients with Heparin-induced Thrombocytopenia  
Speaker: Shigeki Miyata (Japan)

Platelet Flow Cytometry in the Diagnosis of Heparin-induced Thrombocytopenia  
Speaker: Polina Lavrova (Russian Federation)

First Performance Data of a New Latex Enhanced Immunoassay to Detect HIT Antibodies in Plasma Samples *  
Speaker: Matthias Ehm (Germany)

Addition of Exogenous Platelet Factor 4 in the Heparin Induced Platelet Activation (HIPA) Assay for the Detection of Pathogenic Heparin-induced Thrombocytopenia Antibodies  
Speaker: Dorothée Faille (France)

Effect of Synthetic Inhibitors on HIT Antigenic Complex - Therapeutic Approach Alternative to Anticoagulation  
Speaker: Lubica Rauova (United States)

Anaphylactic Shock to Apixaban in a Patient Treated for Heparin-induced Thrombocytopenia (HIT)  
Speaker: Mariana Afonso (Portugal)

A Challenging Case of Delayed-onset Refractory Heparin-induced Thrombocytopenia Complicated with Arterial Thrombosis  
Speaker: Saartje Van de Vondel (Belgium)

HIT Antibody-induced Aggregation of Breast Cancer Cells  
Speaker: Thi Nguyen (Germany)

Inherited Thrombocytopenias  

A Novel Missense Mutations of the WASp Gene Cause a Familial X-linked Thrombocytopenia  
Speaker: Huiqing Liu (China)

Diagnostic Approach to Inherited Thrombocytopenias in a Low-Income Setting  
Speaker: Ana C. Glembotsky (Argentina)

Highly Disturbed Platelet Ultrastructure in Two Families with Novel IKZF5 Variants and Inherited Thrombocytopenia  
Speaker: Eva Leinoe (Denmark)

Diagnosis of Inherited Platelet Disorders on a Blood Smear: The One-Year Experience of a Reference Laboratory  
Speaker: Carlo Zaninetti (Italy)
Clinical, Morphological and Functional Platelet Tests in Inherited Thrombocytopenia  
Speaker: Filipe Gonçalves (Portugal)

Genotypic Analysis at Transition from Idiopathic Thrombocytopenic Purpura to Inherited Thrombocytopenia  
Speaker: Canan Albayrak (Turkey)

Clinical Use of Carica Papaya Leaf Extract in Thrombocytopenia in Bernard-Soulier Syndrome  
Speaker: Osama El Safi (Egypt)

MYH9-Related Inherited Thrombocytopenia: 14 Newly Diagnosed Chinese Pedigree  
Speaker: Xueqing Dou (China)

Refractory Thrombocytopenia with TUBB1 Variants: Clinical Features and Responses to Eltrombopag Treatment  
Speaker: Miao Jiang (China)

Phenotype and Characteristics of a Cohort of Macrothrombocytopenic Patients Related to the AlphaIIbβ3a Variants  
Speaker: Anne Vincenot (France)

Flow Cytometry of Platelets: A Way for Distinguishing Patients with MYH9-related Disease from Patients with Other Inherited Thrombocytopenias and Immune Thrombocytopenia  
Speaker: Daria Fedorova (Russian Federation)

Determination of the Genotype of von Willebrand Disease Type 3  
Speaker: Dana Provaznikova (Czech Republic)

Variants of GFI1B: Phenotype/Genotype of a Series of 9 New Cases  
Speaker: Anne Vincenot (France)

New Clues to GNE Gene Role in the Pathogenesis of Inherited Thrombocytopenias  
Speaker: Ilaria Persico (Italy)

Platelets Function and Cytoskeletal Organization in a Patient with a Novel Variant in ACTB Causing Macrothrombocytopenia  
Speaker: Claudia Maria Radu (Italy)

Bernard-Soulier Syndrome (BSS): From Identification of the Variants to their Functional Studies  
Speaker: Giorgia Fontana (Italy)

Inherited Thrombocytopenia Associated with Haematological Malignancies  
Speaker: Michela Faleschini (Italy)

First Autosomal Recessive Variant in TUBB1 Impairs Proplatelet Formation and Results in Inherited Macrothrombocytopenia  
Speaker: Veronica Palma-Barqueros (Spain)

Identification and Functional Study of a New Germline Variant in Mecom Gene  
Speaker: Nicole Papa (Italy)

Ex vivo Observation of Platelet-granulocytes Interactions in Pediatric Patients with Congenital Platelet Defects  
Speaker: Daria Morozova (Russian Federation)

Platelet Antagonists and Novel Therapeutics
High-Dose Dexamethasone Effectively Replaces Traditional Full-Dose Prednisone as the First-Line Treatment of Children Immune Thrombocytopenia: A Prospective Randomized Single-Center Study
Speaker: Lingling Fu (China)

Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Organization and Inhibit Platelet Function
Speaker: Tony Zheng (United States)

Identification of the Sequence Specificity in C-Src SH3 Required for Binding to Integrin B3 as a Novel Anti-Thrombotic Target without Compromising Primary Hemostasis
Speaker: Xiaodong Xi (China)

Inhibition of Platelet Adhesion, Thrombus Formation and Fibrin Formation by a Potent αIIbβ3 Integrin Inhibitor
Speaker: D.L. van den Kerkhof (the Netherlands)

Selatogrel, a Potent P2Y12 Receptor Antagonist, Dissolves Pre-Formed Platelet-thrombi in vivo
Speaker: Markus A. Riederer (Switzerland)

Method of Anticoagulation Influences Potency of Reversible P2Y12 Receptor Antagonists
Speaker: Martine Baumann (Switzerland)

Idelalisib Selectively Inhibits GPVI-mediated Platelet Activation and Shows Anti-Atherothrombotic Activity
Speaker: Maria Nuñez Barrachina (Spain)

Role of Multidrug Resistance Protein 4 on Both Platelet Nitric Oxide Resistance and ADP Induced Platelet Aggregation
Speaker: Maria Luisa Guarino (Italy)

Antithrombotic Therapy by Charged Nanoparticles
Speaker: David N. Ku (United States)

Platelet Function Disorders, Acquired

Complex Changes in Plasma Associated with Platelet Dysfunction in Trauma Patients
Speaker: Alexander St. John (United States)

Platelet Dysfunction and Coagulation Activation in Intracerebral Hemorrhage
Speaker: Hau Kwaan (United States)

Platelet Purinergic Signaling Regulates Pulmonary Thrombosis in Sickle Cell Disease
Speaker: Tomasz Brzoska (United States)

«Aspirin-Like» Platelet Defect Induced by Gabapentin: A Case-Report
Speaker: Tatiana Baglo (France)

Uremia Induced Pre-Activation Results in Platelet Function Impairment in Chronic Kidney Disease
Speaker: Constance Baaten (Germany)

Bleeding Symptoms Associated with Platelet Function Abnormalities on Ibrutinib Therapy
Speaker: Anastasia Ignatova (Russian Federation)
Severe Platelet Dysfunction in Patient with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) after Tyrosine Kinase Inhibitor (TKI) Therapy
Speaker: Maria Rita Cozzi (Italy)

Dual Antiplatelet Therapy in One Patient with a Immune GPVI Deficiency
Speaker: Martine Jandrot-Perrus (France)

Quality of Life Today in Patients with Chronic Immune Thrombocytopenic Purpura
Speaker: Claudia Cristina Tarniceriu (Romania)

Dysregulation of Platelet Serotonin and Platelet 14-3-3-Related Biomarkers in Sudden Infant Death Syndrome
Speaker: Andrew L. Frelinger III (United States)

Assessment of Platelet Function after Shear Stress Simulation Using an ex vivo Model for Extracorporeal Circulation
Speaker: Oleg Hidiatov (Germany)

First Evidence: Rivaroxaban, Apixaban and Edoxaban Reduce Thrombin-Dependent Platelet Aggregation
Speaker: Juraj Sokol (Slovakia)

First Evidence: Edoxaban Affects TRAP-dependent Platelet Aggregation
Speaker: Lubica Vadelova (Slovakia)

Platelet Function Disorders, Hereditary

Successful Perioperative Hemostasis for Glyoblastoma Surgery in a Patient with Glanzmann Thrombasthenia
Speaker: Dario Schiavo (Italy)

A Whole Blood Flow Cytometric Method for Diagnosis of Platelet Function Disorders
Speaker: Rutvi Gautam Dave (India)

Platelet Activation Markers and Impaired Procoagulant Response in Pediatric Patients with Inherited Platelet Function Disorders
Speaker: Dmitri Polokhov (Russian Federation)

Hemarthrosis and Chronic Synovitis in Glanzmann Thrombasthenia
Speaker: Raghad Tarawah (Saudi Arabia)

Defective Endocytosis of Albumin, Fibrinogen and IgG in Platelets with RUNX1 Haplodeficiency
Speaker: A Koneti Rao (United States)

Usefulness of ISTH-BAT in Clinical Assessment of Inherited Platelet Disorders: Experience of the Spanish National Project
Speaker: José Maria Bastida (Spain)

Periodic rFVIIa Prophylaxis due to Recurrent Haemarthroses into the Right Ankle Joint in a Patient with Glanzmann’s Thrombasthenia
Speaker: Pawel Laguna (Poland)

The contribution of flow cytometry in the diagnosis of inherited thrombocytopenias
Speaker: Hacene Brouk (Algeria)
Scientific Programme

Glanzmann Thrombasthenia in Pakistani Patients: Biochemical Analyses & Identification of Novel Pathogenic Variants in the Fibrinogen Receptor \( \alpha IIb \beta 3 \)
Speaker: Muhammad Younus Jamal Siddiqi (Pakistan)

Inherited Platelet Disorders: Identification of Novel Disease Causing Variants Using Next Generation Sequencing
Speaker: Doris Böeckelmann (Germany)

Clinical and Molecular Characterization of Chinese Patients with Wiskott-Aldrich Syndrome
Speaker: Xian Zhang (China)

Genetic Characterization of Inherited Platelet Disorders in a Single Portuguese Center for Coagulopathies
Speaker: Sara Morais (Portugal)

Utility of the ISTH Bleeding Assessment Tool and the Pediatric Bleeding Questionnaire in predicting platelet function defects in pediatric patients with excessive bleeding
Speaker: Daria Fedorova (Russian Federation)

Correlation GLATIT Scores and the Number of Bleeding Episodes in the Assessment of the Prognosis of Inherited Platelet Disorder
Speaker: Reda Messaoudi (Algeria)

Utility of the ISTH Bleeding Assessment Tool (BATs) in Diagnosis of Glanzmann Thrombasthenia Patients - Experience from Pakistan
Speaker: Nazish Saqlain (Pakistan)

Efficacy of Novoseven in the Treatment of Bleeding Episodes During Glanzmann’s Thrombasthenia
Speaker: Reda Messaoudi (Algeria)

Use of a Whole Exome “Slice” for Evaluation of Inherited Platelet Disorders
Speaker: Kevin Todd Jr. (United States)

Defective RAB31-mediated Endosomal Trafficking in RUNX1 Haplodeficiency
Speaker: A Koneti Rao (United States)

Clinico-pathological Spectrum of GlanzmannThrombasthenia
Speaker: Dinesh Chandra (India)

Global Tests of Primary Hemostasis for the Diagnosis of Mild/Moderate Bleeding Disorders (MMBD): Rehabilitating the Skin Bleeding Time
Speaker: Andrea Baccolo (Italy)

Strategies for Analysis of Novel Molecular Variants in the RUNX1 Gene as a Cause of Familial Platelet Disorder with Predisposition to Acute Myeloid Leukemia (FPD/AML)
Speaker: Veronica Palma-Barqueros (Spain)

Identification of a Novel Molecular Variant in the PTGS1 Gene that Causes a Loss of a Glycan in the Catalytic Domain, Defects in Platelet Thromboxane A2 Synthesis, and Bleeding
Speaker: Veronica Palma-Barqueros (Spain)

Variants in the LLR5 Domain Confer to GPIb\(\alpha\) Increased Affinity for VWF: A Novel Case of Platelet-type von Willebrand Disease
Speaker: Loredana Bury (Italy)
Molecular Insights into Glanzmann’s Thrombasthenia through Family Forums for Gene Sequencing and Discovery
Speaker: Diane Nugent (United States)

Glanzmann Thrombasthenia-like Syndrome: Report of 2 Cases
Speaker: Khalida Mendi (Algeria)

LAD III, Platelet Pathology Related to GT: A Case Report
Speaker: Khalida Mendi (Algeria)

Platelet Reactivity, Independent of Platelet Count, Is Associated with Bleeding Severity in Patients with Gaucher Disease
Speaker: Shoshana Revel-Vilk (Israel)

Current Data About Arterial Thrombotic Events in Cerebrovascular Circulation Caused by Sticky Platelet Syndrome in the National Registry of Thrombophilic States in Slovak Republic
Speaker: Monika Brunclikova (Slovakia)

Targeted High-throughput Sequencing for Genetic Classification of Patients with Inherited Platelet Disorders
Speaker: Harald Schulze (Germany)

Association of Genetic Variability in Selected Genes in Patients with Deep Vein Thrombosis and Platelet Hyperaggregability
Speaker: Lenka Lisá (Slovakia)

Gynaecological Outcomes in Women with Inherited Platelet Function Disorders: Preliminary Data from the ISTH REDCap Registry
Speaker: Deborah Obeng-Tuudah (United Kingdom)

von Willebrand Factor Biology

The Method of Purification of von Willebrand Factor
Speaker: Nataliya Shurko (Ukraine)

Golgi SNARE STX5 Regulates Golgi Morphology and WPB Biogenesis
Speaker: Ellie Karampini (the Netherlands)

Inertial Forces Generated by a Vortex System Promote Cleavage of von Willebrand Factor
Speaker: Katrina Ashworth (United States)

Diagnosis of von Willebrand Disease in Algeria Laboratory and Clinical phenotype: Single Center Experience
Speaker: Driss Benlaldj (Algeria)

Structural Analysis of the VWF molecule with Compound in Cis Heterozygous p.R924Q and p.A2178S Mutations Causing a Type 2B-Like von Willebrand Disease
Speaker: Raimondo De Cristofaro (Italy)

The Scavenger Receptor Scara5 Mediates Clearance of the von Willebrand Factor Propeptide
Speaker: Orla Rawley (Canada)

Monitoring Recombinant and Plasma-Derived VWF Concentrates: An in vitro Study
Speaker: Melanie Daniel (France)
Scientific Programme

Excessive Angiogenesis in von Willebrand Factor Knockout Mice is Accompanied by Increased Perivascular Coverage of Neovessels
Speaker: Maureane Hoffman (United States)

Explanations for Rise of Levels of Factor VIII and von Willebrand Factor Antigen with Age
Speaker: Eugenia Biguzzi (Italy)

Comparison of an Automated von Willebrand Factor Activity Assay by HemosIL Werfen® with Ristocetin Cofactor Assay by Aggregometry in Thrombocytic Patients with Myeloproliferative Neoplasms or Secondary Thrombocytosis
Speaker: Chloé James (France)

The Super Glue of Ultra-Large Multimers - Characterisation of Recombinant and Platelet Derived von Willebrand Factor
Speaker: Thorsten Kragh (Germany)

Investigating Pathomolecular Mechanisms of Type 2A VWD Variants Located in D1 and A Domains of the VWF
Speaker: Hamideh Yadegari (Germany)

Reduced Cleavage of Circulating Ultra-large von Willebrand Factor by ADAMTS13 Exacerbates Microvascular Disease Following Traumatic Injury
Speaker: William Plautz (United States)

Lyophilized Human Platelets Show Hemostatic Function Independent of von Willebrand Factor
Speaker: Braden Ishler (United States)

Type 2B Mutations Differentially Alter Conformational Dynamics of VWF A1 Domain
Speaker: Emily R. Legan (United States)

Extracellular Role of the Von Willebrand Factor Propeptide (VWFpp) in Symptomatic Low VWF (SLVWF) in Flowing Blood
Speaker: Eric F. Grabowski (United States)

VWF and von Willebrand Factor Disorders - Clinical Conditions

Clinical Presentation of Von Willebrand Disease in a Developing Country-A Cross Sectional Study
Speaker: Arooj Fatima (Pakistan)

Population Pharmacokinetics and Pharmacodynamics of Recombinant von Willebrand Factor
Speaker: Martin Wolfsegger (Austria)

Symptomatic Venous Aneurysm of the Internal Jugular Vein Presenting with Small Thrombotic Inclusions in von Willebrand Disease Type I
Speaker: Katharina Guetl (Austria)

The Utility of ISTH-BAT in Iranian Patients with von Willebrand Disease
Speaker: Omid Seidi Zadeh (Iran, Islamic Republic of)

Investigating the Relationship between VWF Multimeric Pattern and VWF: RCo Activity through Population PK Modeling in Patients with Severe VWD Treated with Recombinant VWF
Speaker: Alexander Bauer (Austria)
Recombinant Human von Willebrand Factor (rVWF) Differs in Structure and Function from Plasma Derived Concentrates  
Speaker: Peter L Turecek (Austria)

von Willebrand Disease Combined with Other Coagulation Defects: Experience at a Single Reference Coagulation Laboratory in Iran  
Speaker: Omid Seidi Zadeh (Iran, Islamic Republic of)

Harnessing Social Media to Improve Awareness of Bleeding Disorders  
Speaker: Fatimah Alaya (Ireland)

Characterization of Type 2B VWD in the US Zimmerman Program  
Speaker: Pamela Christopherson (United States)

Response to Treatment for Gastro-Intestinal Bleeding in von Willebrand Disease  
Speaker: Eugenia Biguzzi (Italy)

Real-life Management of Digestive Endoscopies: Is There a Bleeding Risk for Patients with von Willebrand Disease?  
Speaker: Valerie Horvais (France)

A Retrospective Study to Evaluate the Efficacy and Safety of a Plasma-Derived, von Willebrand Factor-Containing FVIII Concentrate, in Patients with Von Willebrand Disease (VWD) in Spain: Interim Analysis Results  
Speaker: Roser Mir (Spain)

von Willebrand Factor Propeptide: Useful Diagnostic Add-On to Differentiate von Willebrand Disease Based upon Increased von Willebrand Factor Clearance  
Speaker: Oliver Tiebel (Germany)

WISH-QoL Study: Assessment of Health-Related Quality of Life and Health-Economic Aspects in Patients with von Willebrand Disease in France: Results from the 2nd Interim Analysis on the 355 Enrolled Patients  
Speaker: Annie Borel Derlon (France)

The Role of the von Willebrand Factor Propeptide (VWFpp) in the Evaluation of Desmopressin Response in a Patient with Acquired von Willebrand Syndrome (AVWS)  
Speaker: Paola Colpani (Italy)

Retrospective Chart Review of Gastrointestinal Bleeding in Patients with von Willebrand Disease: Study Design and Initial Demographic Results  
Speaker: Peter Kouides (United States)

Treatment with Emicizumab Leads to Clinical Improvement in a Type 3 von Willebrand Disease Patient with Inhibitor Suffering from a Left Ankle Arthropathy  
Speaker: Marianne Sigaud (France)

Clinically Relevant Differences between Two New Generation VWF: GPIbR Assays in a Patient with Acquired von Willebrand Syndrome - Case Report  
Speaker: Katarzyna Mayger (United Kingdom)

Recombinant von Willebrand Factor (rVWF) in Patients with von Willebrand Disease (VWD) Undergoing Elective or Emergency Surgery in Real World Setting - The Dijon University Hospital Experience from March 2019 to January 2020  
Speaker: Fabienne Genre Volot (France)
Scientific Programme

**Inhibition of ADAMTS13 Rescues Acquired von Willebrand Syndrome in a Preclinical Mechanical Circulatory Support Animal Model**  
Speaker: Shannen Deconinck (Belgium)

**Quality of Peri-Procedural Care in Patients with von Willebrand Disease**  
Speaker: Craig Seaman (United States)

**Clinical and Phenotypic Evaluation of Patients with Low von Willebrand Factor**  
Speaker: Omid Seidi Zadeh (Iran, Islamic Republic of)

**The Compound Heterozygosity with Two in Cis Mutations p.R924Q and p.A2178S in the D’D3 and D4 Domain Causes a Type 2B-Like von Willebrand Disease**  
Speaker: Stefano Lancellotti (Italy)

**Increased von Willebrand Factor Levels in Polycythemia Vera and Phenotypic Differences with Essential Thrombocytopenia**  
Speaker: Monica Sacco (Italy)

**Prevalence and Diagnostic Rate of von Willebrand Disease in an Argentine Medical Care Program**  
Speaker: Fernando Chuliber (Argentina)

**Evaluation of Carriers of Type 3 von Willebrand Disease with PFA200**  
Speaker: Tulasi Geevar (India)

**Prophylaxis with Recombinant von Willebrand Factor in a Case of Concomitant von Willebrand’s Disease and CREST Syndrome**  
Speaker: Claudia Binder (Germany)

**Pelvic Haematoma in Women with Bleeding Disorders: A Single Center Experience**  
Speaker: Veena Selvaratnam (Malaysia)

**The Impacts of Genetic Polymorphisms on the Von Willebrand Factor Level in Type 1 Von Willebrand Disease**  
Speaker: Yeu-Chin Chen (Taiwan, Republic of China)

**Adolescent Menorrhagia and Von Willebrand Disease**  
Speaker: Yamina Ouarhlent (Algeria)

**Response to Desmopressin Acetate in Von Willebrand Disease Type 2**  
Speaker: Guilherme Almeida Maia (Brazil)

**Gastrointestinal Bleeding from Angiodysplasia in Constitutional von Willebrand Disease: Improved Diagnosis Yield and Risk Stratification when Using Video Capsule on Top of Conventional Endoscopy**  
Speaker: Antoine Rauch (France)

**Successful Surgical Interventions In Children with von Willebrand Disease Type 3**  
Speaker: Karina Papayan (Russian Federation)

**Establishing Reference Intervals for von Willebrand Factor Multimers**  
Speaker: Marika Pikta (Estonia)

**Inhibitor Development in Patients with Type 3 von Willebrand Disease, a Comprehensive Study on a Large Number of Iranian Patients**  
Speaker: Shadi Tabibian (Iran, Islamic Republic of)
The Homozygous Variant p.Gln1311* in Exon 28 of VWF Is Causing Type 3 von Willebrand Disease and Is at High Risk of Allo-Immunisation
Speaker: Fanny Lassalle (France)

High Variability of Laboratory Phenotype in Genetically Proven von Willebrand Disease Type 2B
Speaker: Ralf Knöfler (Germany)

Increasing Levels of von Willebrand Factor (VWF) and Factor VIII (FVIII:C) with Age in Patients Affected by von Willebrand Disease (VWD)
Speaker: Eugenia Biguzzi (Italy)

Desmopressin in Patients with Type 2B von Willebrand Disease: Differential Impact on VWF and Platelet Function
Speaker: Annabelle Dupont (France)

Comparison of von Willebrand Factor (VWF) Multimeric Profile Obtained by a Commercial Electrophoretic Test (Hydragel 5 von Willebrand Multimers) and Classical Home-made with a Discontinuous 1% Agarose Gel Electrophoresis
Speaker: Marina Sol Lopez (Argentina)

Gynaecological Problems, Management and Outcomes in Women with Moderate and Severe von Willebrand Disease (VWD)
Speaker: Ozlem Turan (United Kingdom)

Degradation of High Molecular Weight von Willebrand Factor Multimers during Extracorporeal Membrane Oxygenation-Treatment
Speaker: Min-Sun Kim (Korea, Republic of)

Acquired von-Willebrand-Disease (aVWD) in ECMO Patients: a 3-Year Cohort Study
Speaker: Tido Bajorat (Germany)

Prothrombotic Gain-of-Function Variants of von Willebrand Factor
Speaker: Maria A. Brehm (Germany)

Type 2N von Willebrand Disease (VWD2N): Is it Always a Recessive Trait?
Speaker: Adriana Ines Woods (Argentina)

Severe Thrombocytopenia after DDAVP Test (DDAVPt) in a Girl with a p.Cys1272Gly Variant of the VWF Gen
Speaker: Juan Pablo Frontroth (Argentina)

Measurement of VWF:FVIII Binding (VWF:FVIIIB) in a Cohort of Patients with Suspected Type 2N VWD and Correlation with Genetic Analysis of the VWF Gene
Speaker: Mairead Doyle (Ireland)

Uncommon Types of von Willebrand Disease
Speaker: Petr Birke (Czech Republic)

Diagnostic Performances Evaluation of LIAPHEN vWF: Ag on CS-2500
Speaker: Claire Dunois (France)

Diagnosis and Management of von Willebrand Disease in a Portuguese Reference Center of Congenital Coagulopathies
Speaker: Teresa Fidalgo (Portugal)

Real World Experience of Major Surgery and Delivery in Von Willebrand Disease
Speaker: Brian Craven (United Kingdom)
Scientific Programme

Von Willebrand’s Disease: A Diagnostic Evaluation Using Current Guidelines
Speaker: Emily Bar (United Kingdom)

Laboratory Monitoring of Perioperative von Willebrand Factor Replacement
Speaker: Cynthia Rothschild (Brazil)

The VWF Variant D1472H Affects VWF Binding to Ristocetin in vitro in the Platelet Agglutination Assay but Not with Latex Particles (HemosIL® Acustar VWF:GpIbR): The Usefulness to Change Practices to Avoid VWD Genotyping
Speaker: Fanny Lassalle (France)

Gum Bleeding in Low Von Willebrand Factor- What’s the Score?
Speaker: Alison Dougall (Ireland)

On-Demand Poster Session
14:00 - 15:00
Virtual Meeting Room 6

Platelets and Megakaryocytes Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Megakaryocytes and Thrombopoiesis

Megakaryocytes Possess a Functional Necroptosis Pathway
Speaker: Diane Moujalled (Australia)

Combined α4a- and β1-Tubulin Deficiencies Profoundly Affect Platelet Biogenesis and Haemostasis
Speaker: Quentin Kimmerlin (France)

Systemic Study of Biological Properties and Functions of Bone Marrow Mesenchymal Stem Cells from Patients with Essential Thrombocythemia and Explore the Effects of Interferonα-2b on Them
Speaker: Ting Sun (China)

A Novel Image-Based Chemical-Genetics Screen Identifies Inducers of Platelet Release from Immortalized Megakaryocytic Cell Lines, Enabling Clinical-Scale Production of Functional Platelets
Speaker: Arunoday Bhan (United States)

Mesenchymal Stromal Cells Display Metabolic Alterations in JAK2-Mutant Myeloproliferative Neoplasms
Speaker: Ting Sun (China)

Dysfunctional RBM8A/Y14 Does Not Impair Megakaryopoiesis but Terminal Thrombopoiesis in Thrombocytopenia Absent Radii (TAR) Syndrome
Speaker: Georgi Manukjan (Germany)

Essential Thrombocythemia (ET): A Study of Clinical Features and Treatment Outcome in Pediatric Patients at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Speaker: Muhammad Ameen (Saudi Arabia)
Autoantibody Mediated Changes in Megakaryocytes Glycan Pattern: Potential Impact on Thrombopoiesis in Immune Thrombocytopenia  
Speaker: Irene Marini (Germany)

Megakaryocyte Mitochondrial Dynamics and Oxidative Metabolism Are Essential to Initiate Platelet Biogenesis  
Speaker: Dominique Baruch (France)

The Ablation of Collagen VI Leads to the Release of Platelets with Altered Functions  
Speaker: Vittorio Abbonante (Italy)

Generation of Megakaryocytes from Human Bone Marrow Aspirates as a Simple Diagnostic and Research Tool: Assay Development and Validation  
Speaker: Kirill Butov (Russian Federation)

A Close Relationship between Adipocytes and Megakaryocytes  
Speaker: Sonia Severin (France)

Thrombopoiesis in Bone Marrow Culture in Norm and in Some Pathological States  
Speaker: Tamar Saralidze (Georgia)

Short-term Application of Caffeic Acid Specifically Promotes Expansion of Hematopoietic Stem Cells  
Speaker: Ruting Wang (China)

TREM-like Transcript-1 Is a Positive Regulator of Platelet Production and Thrombosis  
Speaker: Alexandra Mazharian (France)

Accelerated Death of Wiskott-Aldrich Syndrome Megakaryocytes  
Speaker: Sergei Obydennyi (Russian Federation)

Impact of Irradiation on the Bone Marrow Matrix and Megakaryopoiesis  
Speaker: Kristina Faber (Germany)

Hyperactive SRC Kinase Results in Inherited Thrombocytopenia: Transcriptomics and Proteomics to Delineate the Defect in Megakaryopoiesis  
Speaker: Lore De Kock (Belgium)

Role of Platelet Production/Destruction Imbalance on the Interindividual Variability in Aspirin Response in Diabetic and Non-diabetic Patients  
Speaker: Rossella Liani (Italy)

Rap1a/b Isoforms Differentially Regulate Megakaryocyte Biology  
Speaker: Dorsaf Ghalloussi (United States)

Ikaros/AhR Interaction Favors Expansion of Megakaryocytic Precursors with a High Potential to Produce Proplatelets  
Speaker: Valentin Do Sacramento (France)

Platelet Function and Interactions

Association of Platelet Derived - Microparticles and Endothelia Dysfunction in NVAF Patients Undertaking PCI  
Speaker: Bing Ding (China)

Thrombotic Disease Caused by Hypothermia-Induced Activation of the Splenic Platelet Pool in a Mouse Model  
Speaker: Kie Horioka (Sweden)
Kupffer Cells Clear Aged Platelets through Macrophage Galactose Lectin  
Speaker: Carsten Deppermann (Germany)

Cold over Room Temperature Storage of Apheresis Platelets Better Preserves Hemostatic Function out to 21 Days  
Speaker: Susan M. Shea (United States)

Video Rate, High Contrast Morphological Imaging of Blood Thrombus using Label - Free Coherent Optical Scattering and Interferometry (COSI) Microscopy  
Speaker: Yujie Zheng (Australia)

Exercise Training Enhances Mitochondrial Bioenergetics of Platelets in Patients with Peripheral Arterial Disease  
Speaker: Jong-Shyan Wang (Taiwan, Republic of China)

Evaluation of Platelet Count and Platelet Indices of Male Cannabis Sativa ( Marijuana) Consumers in Calabar South, Cross River State, Nigeria  
Speaker: Dorathy Chioma Okpokam (Nigeria)

Epinephrine Enhances Platelet Aggregation at the Expense of Procoagulant Activity  
Speaker: Alessandro Aliotta (Switzerland)

MiR-204-5p Regulates Platelet Adhesion to Fibrinogen  
Speaker: Alix Garcia (Switzerland)

Platelet Aggregation is Suppressed in the Quinonoid Dihydropteridine Reductase Knockout Mice  
Speaker: Yui Suganuma (Japan)

Platelets form Fibrillar Adhesions: Implications for Force-Regulated Thrombus Remodeling  
Speaker: Sebastian Lickert (Switzerland)

An Elevated Platelet Count Increases the Rate of Prothrombin Activation, but Not the Total Amount of Thrombin Formed  
Speaker: Qiuting Yan (the Netherlands)

Effect of Three Types of Mixed Anesthesia ( MMB) for Platelet Function  
Speaker: Taiki Kano (Japan)

Antibodies Protect Platelets against Streptococcus Pneumoniae Toxin Pneumolysin  
Speaker: Stefan Handtke (Germany)

Modified Plasma Recalcification Assay for Evaluation of Platelet Procoagulant Activity  
Speaker: Alexey Mazurov (Russian Federation)

Importance of Platelet Contractility at Different Stages of Thrombus Formation  
Speaker: Martin Kenny (Ireland)

The Effect of IL-6-Primed Platelets on ADAMTS13-Mediated Clearance of Platelet-Bearing ULVWF and its Mechanism  
Speaker: Hyun-jeong Kim (Korea, Republic of)

Reduced GPVI Signalling in Genetic and Disease Models of Thrombocytopenia  
Speaker: Stephanie R. Hyslop (Australia)

Microparticles Released from Stored Platelet Increase Coagulation Ability  
Speaker: Ippei Noboruo (Japan)
Characterization of the Hypercoagulable State and NETosis in Systemic Lupus Erythematosus  
Speaker: Elena Monzón Manzano (Spain)

The Active Recruitment of Red Blood Cells to Activated Platelets via CD36 and FasR Is Crucial for Arterial Thrombus Formation  
Speaker: Kim Krott (Germany)

Interaction between Platelets and Streptococcus pneumoniae  
Speaker: Axel Florian Aschenbrenner (Germany)

Streptococcus pneumoniae Toxin Pneumolysin Renders Platelets Non-Functional  
Speaker: Sven Hammerschmidt (Germany)

Septins Contribute to Platelet Shape and Functionality  
Speaker: Oleg Kim (United States)

LV-AO Angle Is Associated with Platelet Reactivity in Patients with Aortic Stenosis  
Speaker: Lisa Dannenberg (Germany)

Collagen-Induced Thrombocyte Aggregation in Essential Arterial Hypertension with Subclinical Organ Damage  
Speaker: Dina Shorikova (Ukraine)

The Effects of E.coli Lipopolysaccharides on Platelet Function Are Limited to Re-Sensitization  
Speaker: Alexey Martyanov (Russian Federation)

Emerging Roles of CLEC-2 during Development of Monocrotaline-Induced Liver Injury in Mice  
Speaker: Shimon Otake (Japan)

Assessment of Thrombus Formation under Flow-Conditions in Essential Thrombocythemia/Polycythemia Vera  
Speaker: Yuichi Ikeda (Japan)

Healthy Pediatric Platelets are Moderately Hyporeactive But Hyper-Coagulant within a Wide Age Range  
Speaker: Evgeniya Ponomarenko (Russian Federation)

Bcl-Xl Deamidation State Tells Platelets Age  
Speaker: Chloé James (France)

Platelet Functions Defects in Calreticulin and JAK2V617F MPN Patients  
Speaker: Mathieu Fiore (France)

Characterizing Platelet Granules of von Willebrand Disease Patients Using Super-Resolution Structured Illumination Microscopy  
Speaker: Maurice Swinkels (the Netherlands)

Effects of GPVI on Clot Structure: Reduction in Procoagulant Platelets in GPVI-Deficient Clots  
Speaker: Julia S. Gauer (United Kingdom)

Targeting the Chemokine Receptor CXCR7 Favours an Anti-thrombotic Platelet Lipidome and Regulates Thromboinflammatory Functions  
Speaker: Madhumita Chatterjee (Germany)
Platelets and Aortic Valve Calcification: Insights from a Rabbit Model and from Patients with Severe Aortic Stenosis  
Speaker: Nathalie Donis (Belgium)

Dietary Intake of Zinc Modulates Platelet Intracellular Levels and Haemostatic Parameters  
Speaker: Ummay Sumya (United Kingdom)

Platelet Ageing Is Associated with Cytoskeletal Degradation and a Reduction in Cytoskeletal Dynamics  
Speaker: Harriet E. Allan (United Kingdom)

Direct Temporal Labelling of Platelets in vivo Allows Monitoring and Examination of Newly Formed and Aged Platelets to Reveal Changes in Receptor Expression Levels and Loss of Functional Ability  
Speaker: Paul Armstrong (United Kingdom)

Omega-3 Fatty Acids Significantly Improve the Antiplatelet Profile of Triflusal  
Speaker: Aikaterini N. Tsouka (Greece)

Platelet-Derived Extracellular Vesicles Actively Process Proteins and Present Antigen via MHC Class I  
Speaker: Genevieve Marcoux (Canada)

A Novel Reporter Mouse Line Enables in vivo Imaging of Intracellular Calcium Fluxes in Platelets  
Speaker: Vanessa Klaus (Germany)

Hyperglycemia Primes Procoagulant Platelet Formation and Exacerbates Ischemic Stroke Independent of Platelet Glucose Uptake  
Speaker: Frederik Denorme (Belgium)

C-type Lectin-like Proteins D and E, but Not Botrocetin, Cause Thrombocytopenia during Bothrops jararaca Snakebite Envenomation  
Speaker: Marcelo L. Santoro (Brazil)

Variability in Platelet Function among Patients with von Willebrand Disease Type 2B (VWD2B): Focus on Patients Historically Diagnosed with Montreal Platelet Syndrome (Historic-MPS)  
Speaker: Margaret Rand (Canada)

Mepacrine Uptake & Release Assay in Thrombocytopenic Patients  
Speaker: Macarena Asensio (Argentina)

Liver Diseases Contribute to Functional Platelet Aggregation Defects  
Speaker: Cassandra Bacher (United States)

Large and Small Platelets Differently Contribute to Whole-Blood Thrombus Formation  
Speaker: Stefan Handtke (Germany)

A Novel Methodology to Study αIIbβ3 Interactions with Polymerizing Cross-linked Fibrin  
Speaker: Claudia Bultrago (United States)

The Role of Coagulation-generated Components on GPVI-mediated Platelet Activation  
Speaker: Ilaria De Simone (the Netherlands)

Evaluation of a New Agonist (ADP-HS®) for Platelet Function Testing with Light Transmittance Aggregometry: A Bi-Center Study  
Speaker: Alain Stepanian (France)
Scientific Programme

Glycans on the Surface of Platelet Microparticles Mediate Binding by Hepatocytes
Speaker: Dianne E. van der Wal (Australia)

The Role of Platelets in the Adhesion of Normal Freshly Isolated Lymphocytes to Fibrin
Speaker: Alexey Solpov (Russian Federation)

Platelet Activation and Aggregation Induced by NS1 Dengue Protein
Speaker: Nallely Itandehui Garcia-Larragoiti (Mexico)

Platelet PN-1 Regulates Clot Structure and Retraction
Speaker: Stephane Loyau (France)

Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-induced Coagulation: Additive Effects of Aspirin
Speaker: Marijke J E Kuijpers (the Netherlands)

Implication of Platelet Adhesiveness in the Risk of Venous Thromboembolic Disease
Speaker: Maribel Diaz-Ricart (Spain)

Assessing Platelet Function in Large Cohorts, a Means to Donor Stratification
Speaker: Joanne Dunster (United Kingdom)

PCSK9 in Human Platelets: Characterization and Mechanism of Platelet Activation
Speaker: Marta Brambilla (Italy)

The Effects of Platelet Agonists and Priming on Platelet Populations
Speaker: Alicia Veninga (the Netherlands)

Platelet Interactions with von Willebrand Factor under Dynamic Shear Stress
Speaker: Tatiana Salikhova (Russian Federation)

Novel Role for Intracellular Lipases in Platelets
Speaker: Madeleine Goeritzer (Austria)

Platelet Procoagulant Potential Is Reduced in Platelet Concentrates ex vivo But Appears to Be Restored in vivo Following Transfusion
Speaker: Ibrahim Tohidi-Esfahani (Australia)

Mean Platelet Volume, and Not Platelet Aggregation, Is Associated with Diabetes: Population Studies from 3,000 to 463,000 Individuals
Speaker: Melissa Victoria Chan (United States)

Physiological extracellular calcium levels impairs platelet aggregation as a result of iPLA2 inhibition due to lack of calcium stores’ depletion
Speaker: Aleksandra Filkova (Russian Federation)

Characterization of Thrombus Heterogeneity and Dynamics of Formation on Collagen Spots in a Parallel-plate Flow Chamber
Speaker: Alexander Ryabykh (Russian Federation)

An Activation-dependent Pathway Modulated by Dicer1 Neosynthesis and Down-regulating Platelet Reactivity Is Impaired in Diabetes
Speaker: Elisa Piselli (Italy)

Acquired GPVI Deficiency Is a Biomarker for Early Diagnosis and Prognostic Assessment of Patients with Sepsis
Speaker: Lukas Johannes Weiss (Germany)
Towards the Correlation of Age with Size in Human Platelets under Steady State  
Speaker: Martina Wolff (Germany)

The Iron Uptake Receptor Transferrin Receptor 1 (TfR1) Is Required for Proper Platelet and Megakaryocyte Function in Mice  
Speaker: Timo Vögtle (Germany)

Profiling of COX-dependent Eicosanoids Produced by Blood Cells and the Vasculature  
Speaker: Marilena Crescente (United Kingdom)

Bile Acids Maintain Platelet Homeostasis via p38 and Akt Pathway  
Speaker: Zhipeng Cheng (China)

The Platelet Indices in Patients with Obesity in Najran Area, Saudi Arabia  
Speaker: Osama M Alshehri (Saudi Arabia)

Migraine in Patent Foramen Ovale Patients: Role of Platelet Activation  
Speaker: Paola Canzano (Italy)

The Effect of Ceramic Materials on Platelet Aggregation  
Speaker: Irina P. Antropova (Russian Federation)

The Effect of γ-Irradiation at a Dose of 1 Gy on Calcium Metabolism in Rat Platelets  
Speaker: Volha Bichan (Belarus)

Platelet Alpha-granule Secretion in Total Hip Replacement  
Speaker: Irina P. Antropova (Russian Federation)

Platelet Force-Producing Subpopulations Predicted by a Stochastic Model  
Speaker: David Bark (United States)

Maternal Platelet Function Altered by Cigarette Smoking in Early Pregnancy  
Speaker: Steven Cullen (Ireland)

SHARPIN Restrains αIIbβ3 Activation in Platelets in Three Dimensions  
Speaker: Ana Kasirer-Friede (United States)

Platelet Proteomics and Genomics  
In-Depth Platelet Releasate Proteome Profiling: A Novel Source of Biomarkers for Early-Onset Preeclampsia  
Speaker: Paulina B. Szklanna (Ireland)

Finding the “Switch” in Platelet Activation - Prediction of Key Mediators Involved in the Reversal of Platelet Activation Using a Network Biology Approach  
Speaker: Titus Paul Lemmens (the Netherlands)

Phosphoproteomic Fingerprint of Platelets in Obesity: Insights into Platelet Reactivity  
Speaker: Maria Nuñez Barrachina (Spain)

DOAC Pharmacogenomics: Personalized Therapeutics to Avoid Bleeding and Thrombotic Complications  
Speaker: Caleb Schekel (United States)

Quantitative Phosphoproteomic Profiling and Causal Analysis Reveal Signaling Relations in GPVI/ITAM-Mediated Platelet Activation Programs  
Speaker: Joseph Aslan (United States)
Lipidome Profile in Platelets from Obese Patients: New Assistances of Platelet Dysfunction in Obesity
Speaker: Maria Nuñez Barrachina (Spain)

Towards Complete Assignment of the Full Platelet Proteome and Transcriptome
Speaker: Jingnan Huang (the Netherlands)

Platelet Proteomics to Understand the Pathophysiology of Immune Thrombocytopenia: Studies in Mouse Models
Speaker: Patricia Martínez-Botía (Spain)

High Efficiency Transfection and Preservation of Platelets with Tumor Suppressing Short RNA
Speaker: Amber Lee (United States)

Platelet Receptors

P2Y12 Receptor Gene Polymorphisms and Platelet Aggregation at Patients with Arterial Hypertension in Bukovinian Region
Speaker: Dina Shorikova (Ukraine)

Platelets as Immune Cells: Lateral Mobility Dynamics of FcRIIA on Human Platelets is Directly Linked to Integrity of Platelet Cytoskeleton
Speaker: Raghavendra Palankar (Germany)

An Artificial Lipid Membrane Platform as an Approach to Study CLEC-2 Receptor Clustering
Speaker: Marcin Andrzej Sowa (United Kingdom)

First novel Pathogenic Variant in ITGA2B in a Ecuatorian Patient with Glanzmann Thrombasthenia
Speaker: Nuria Bermejo (Spain)

A Humanised CLEC-2 Mouse Model to Study Anti-Human CLEC-2 Biologics in vivo
Speaker: Helena Brown (Germany)

Heme Activates Platelets and Exacerbates Rhabdomyolysis-Induced Acute Kidney Injury via CLEC-2 and GPVI/FcRy
Speaker: Saori Oishi (Japan)

Targeting of a Conserved Epitope in Mouse and Human GPVI Differently Affects Receptor Function and in vivo Depletion
Speaker: Stefano Navarro (Germany)

Tetraspanin CD9 Regulates GPIIb-IIIa-Mediated Platelet Function: Identification of Unique Protein Interactomes
Speaker: Jayaprakash Kotha (United States)

Differential Regulation of the Platelet GPIb-IX Complex by Anti-GPIbβ Antibodies
Speaker: Renhao Li (United States)

Non-redundant Roles of Platelet Glycoprotein VI and IIb/IIIa via Syk Kinase in Fibrin-dependent Thrombus Shielding under Flow
Speaker: Gina Perrella (the Netherlands)

Role of Receptor for Advanced Glycation End-products (RAGE) in Human Platelets
Speaker: Daniela Recabarren-Leiva (Chile)
Scientific Programme

Prediction of Dynamic Structural Changes in the Complex of Platelet Glycoprotein (GP) Ibα Bound with von Willebrand Factor in the Absence and Presence of Coagulation Factor XI using Molecular Dynamics Simulations
Speaker: Masamitsu Nakayama (Japan)

Physiological Significance of Lysophosphatidylinositol/G Protein-coupled Receptor 55 System in the Regulation of Platelet Function
Speaker: Adam Gadd (United Kingdom)

The Recombinant Disintegrins Jarastatin and Jararacin and their Inhibitory Activity on Platelet and Endothelial Adhesion
Speaker: Russolina Zingali (Brazil)

Platelet Signaling

Role of HIF-2α in Promoting Thrombogenicity through PAI-1 Synthesis & EV-Releae during Adaptive Signalling in Human Platelets
Speaker: Ram Lala Mallick (Nepal)

Reelin Modulates Glycoprotein VI and Integrin Outside-in Signaling of Platelets
Speaker: Irena Krueger (Germany)

Plasma Fibrinogen Interaction with Prion Peptide Mitigates Prion-Mediated Neuronal Cell Toxicity And Human Platelet Activation
Speaker: Deepa Gautam (India)

NAADP/SERCA3-Dependent Ca2+ Stores Pathway Specifically Controls Early Autocrine ADP Secretion Potentiating Platelet Activation
Speaker: Miao Feng (France)

The Inhibitory Mechanism of Adiporon during Platelet Activation
Speaker: Xianghui Zhou (China)

Fibrillar Amyloid Peptides Promote Platelet Aggregation through the Coordinated Action of ITAM- and ROS-Dependent Pathways
Speaker: Ilaria Canobbio (Italy)

Phosphorylation and Activation of Pannexin-1 upon Platelet Activation and Thrombus Formation
Speaker: Lisa Maria Metz (Germany)

Feedback Inhibition of Human Platelet Syk by PKC-caused Syk S297 Phosphorylation
Speaker: Stephanie Makhoul (Germany)

Dysfunctional CLEC-2- and GPVI-mediated Signaling in Syk Y342F Knock-in Mouse Platelets
Speaker: John Kostyak (United States)

Acetyl-CoA Carboxylase Inhibition Alters Tubulin Acetylation and Aggregation in Thrombin-stimulated Platelets
Speaker: Marie Octave (Belgium)

NADPH Oxidase 1 and Protein Disulphide Isomerase Synergize to Modulate Platelet Function
Speaker: Renato Gaspar (United Kingdom)

Role of RXRbeta in Platelet Function and Arterial Thrombosis
Speaker: Tobias Petzold (Germany)
Acetylation of α-Tubulin by Aspirin and Histone Deacetylase 6 in Human Platelets
Speaker: Antonio Moscardo (Spain)

Interplay between the Tyrosine Kinases Chk, Csk and Phosphatase CD148 Is Critical for Regulating Platelets in Mice
Speaker: Zoltan Nagy (United Kingdom)

Influence of Bile Acids on Hemostasis and Arterial Thrombosis
Speaker: Friedrich Reusswig (Germany)

Loss of the Exocyst Complex Component, EXOC3, Accelerates Arterial Thrombosis
Speaker: Tony Walsh (United Kingdom)

Omega-6 DPA and its 12-LOX Oxylipins Regulate Platelet Reactivity in a Non-genomic PPARα-dependent Manner
Speaker: Michael Holinstat (United States)

Important Role for SHARPIN in Supporting Platelet Linear Ubiquitination and Thrombus Formation
Speaker: Ingeborg Hers (United Kingdom)

Role of Hemostatic System in Cancer, Inflammation and Immunity Abstracts
The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Coagulation Proteins Beyond Hemostasis

Cross-Talk of Activated Protein C (aPC) with Integrin and its Effect on T-Cell Signaling
Speaker: Dheerendra Gupta (Germany)

Chronically Elevated Interleukin-6 Levels in Mice Lead to a Disturbance in the Coagulation System
Speaker: Tanja Knopp (Germany)

Human Plasma Kallikrein (PKa) Potentiates ADP-Induced Platelet Activation
Speaker: Maria Luiza Vilela Oliva (Brazil)

The Fc and C1/C2 Domains of Recombinant Factor VIII Fc Fusion Protein Engage Monocytes in an FcgammaRII-Dependent Manner to Reduce Their Differentiation Potential into Osteoclasts
Speaker: Susu Duan (United States)

Coagulation Factor XII Signaling Triggers Inflammasome-associated Renal Damage in Diabetic Nephropathy
Speaker: Ahmed Elwakiel (Germany)

A Validated Model for the Diagnosis of Periprosthetic Joint Infection with Coagulation-related Markers: TGT and NETs
Speaker: Julia Oto (Spain)
Coagulation Markers, Neutrophil Extracellular Traps and Thrombin Generation Test, in the Detection and Risk Stratification of Prostate Cancer
Speaker: Julia Oto (Spain)

Plasma Concentration of Activated Factor VII-antithrombin, But Not Tissue Factor Pathway Inhibitor and Factor VII Levels, Predicts Mortality in Subjects with Liver and Colon Cancer Undergoing Curative Surgical Intervention
Speaker: Domenica De Santis (Italy)

Hemostatic and Thrombotic Profiles in Pre and Post Remission Induction Phase of Acute Leukemia
Speaker: Arshi Naz (Pakistan)

Complement and Hemostatic System

The Role of Antithrombin in Complement Activation: Pilot Data from Patients with Inherited Antithrombin Deficiency
Speaker: Katarzyna Mayger (United Kingdom)

Complement Mannan-Binding-Lectin Is Associated with Activated Platelets during Clot Formation in a Microfluidic Bleeding Model
Speaker: Murielle Golomingi (Switzerland)

Anti-complement Effect of Heparin in Stimulated Whole Blood
Speaker: John Hogwood (United Kingdom)

Activated Factor XI Promotes Complement Activation by Neutralizing Complement Factor H
Speaker: Owen McCarty (United States)

Infection and Hemostatic Factors

Lung Vessels Thrombosis Induced by Severe CAP: 3D Model of Thrombus
Speaker: Maria Krykhtina (Ukraine)

Relationship between HAART treatment and Markers of Coagulation among People Living with HIV/AIDS (PLWHA) in Gombe, Nigeria
Speaker: Sani Adamu (Nigeria)

Coagulation Profile in Patients with Pneumonia Assessed by Thrombin Generation Procedures
Speaker: Erica Scalambrino (Italy)

M1 Protein from Group A Streptococcus Regulates Fibrin Clot Formation, Structure and Fibrinolytic Potential
Speaker: Sophie Cherrington (United Kingdom)

Coagulation Factor XII Binds to the Opportunistic Pathogen, Candida albicans and Promotes Biofilm Formation
Speaker: Maria Louise Williams (United Kingdom)

Platelets and Cancer

Successful Improvement Sexual Dysfunction After Pelvic Irradiation by Platelet Growth Factor
Speaker: Saeed Mohammadi (Iran, Islamic Republic of)

Platelet Function in Primary Myelofibrosis
Speaker: Olga Smirnova (Russian Federation)
ML355 Inhibits Platelets via GC Activation and Blocks Caspase-Dependent Apoptosis in Platelets
Speaker: Valentina Shpakova (Russian Federation)

Modulation of ABT-737 Induced Platelet Apoptosis by Curcumin
Speaker: Valentina Shpakova (Russian Federation)

Anti-Platelet Drug Ticagrelor Has a Direct Anticancer Activity
Speaker: Omar Elaskalani (Australia)

Platelet Function and Coagulation Abnormalities in Polycythemia Vera Patients: Effects of Low-Dose Aspirin
Speaker: Rossella Cacciola (Italy)

Comparison of Platelet Parameters in the Patients with JAK2 V617F Mutated Essential Thrombocytosis and Reactive Thrombocytosis
Speaker: Yifeng Wu (United States)

Tumor Platelet Transcriptome Changes in Hyperthrombotic Mice
Speaker: Carina Santos (Germany)

Generation of 12-HETE in Platelet-Cancer Cell Crosstalk
Speaker: Melania Dovizio (Italy)

Platelet-derived Microparticles Regulate Migration, But Do Not Influence Proliferation of Breast Cancer Cells
Speaker: Mauro Vismara (Italy)

A Potential Role for the FcγRIIa in Vinorelbine Induced Thrombocytopenia and Neutropenia
Speaker: Marian Brennan (Ireland)

Chemotherapy - Induced Thrombocytopenia in Pediatric Acute Lymphoblastic Leukemia: A Single-institution Report
Speaker: Mane Gizhlaryan (Armenia)

The Assessment of Platelet Membrane Alteration in Patients with Chronic Myeloproliferative Neoplasms
Speaker: Viola Maria Popov (Romania)

Platelets and Infection

High-throughput Mechano-Phenotyping of Single Platelet Activation Induced by Bacterial Proteins
Speaker: Raghavendra Palankar (Germany)

Risk Factors, Outcomes, and Score Models of Serious Pulmonary Infection in Non-Splenectomized Immune Thrombocytopenia Adults
Speaker: Yejun Wu (China)

Platelet Activation in Community-acquired Pneumonia Remains Increased Until 30 Days Later
Speaker: Antonio Moscardo (Spain)

Lyophilized Human Platelets Exhibit Adhesive Interactions with Staphylococcus aureus
Speaker: Amber Lee (United States)

Effects of the Bacterial Toxin Cytotoxic Necrotising Factor 1 on Platelet Function
Speaker: Francisco Rivero (United Kingdom)
From the Antiplatelet Drug Ticagrelor to New Antibiotics
Speaker: Nicolas Jacques (Belgium)

Platelets and Inflammation

Effect of cART on Platelet:Lymphocyte Ratio in HIV Patients Initiating Treatment
Speaker: Hannah Omunakwe (Nigeria)

Acute Exacerbations of COPD Induce a Prothrombotic State through Platelet-Monocyte Complexes, Endothelial Activation and Increased Thrombin Generation
Speaker: Lisa N. van der Vorm (the Netherlands)

Role of Formyl Peptide Receptor 2 (FPR2/ALX) and its Anti-Inflammatory Ligand, Lipoxin A4 Analogue (BML-111) in the Modulation of Platelet Function
Speaker: Shatha AlOmar (United Kingdom)

Prognostic Value of Platelet-Derived Parameters in Septic Patients: A Prospective Study
Speaker: Ghada Alharbi (Bahrain)

Platelet and Extracellular Vesicle Mediated Inflammasome Activation Impairs Embryonic Survival by Reducing Placental Thrombomodulin Expression
Speaker: Shrey Kohli (Germany)

Is Platelet Hyper-Reactivity a Modifiable Risk Factor in Inflammatory Arthritis?
Speaker: Dermot Kenny (Ireland)

Role of Platelets in Processes of Myocardial Healing After Myocardial Ischemia and Reperfusion in Mice
Speaker: Meike Klier (Germany)

Toll-Like Receptor 2 Ligands Promote and Enhance Platelet Activation
Speaker: Ivan Parra-Izquierdo (United States)

Platelets Express a Stable and Functional Proteasome System and All Components of the Antigen Processing and Presentation Pathway (APP) Machinery
Speaker: Lisa Colberg (Germany)

Sirolimus Is Effective in Autoimmune Lymphoproliferative Syndrome (ALPS)/ALPS-Like Syndrome: Results of a Single Centre Experience
Speaker: Hao Gu (China)

Cold Storage of Apheresis Platelets Promotes IL-8 Release in Platelet: Leukocyte Co-cultures
Speaker: Kimberly A. Thomas (United States)

Platelets Are Active Players as Inflammatory Cells in Nonalcoholic Fatty Liver Disease
Speaker: Erica De Candia (Italy)

Sarcoidosis and Autoimmune Thrombocytopenic Purpura: Random Association or Hematologic Manifestation of Sarcoidosis?
Speaker: Yosra Cherif (Tunisia)

Immature Platelet Fraction and Platelet Indices in Acute Coronary Syndrome
Speaker: Yetti Hernaningsih (Indonesia)

Platelet β1 and β3 Integrins Cooperate to Stop Cutaneous and Cerebral Bleeding under Inflammatory Conditions in Mice
Speaker: Emily Janus-Bell (France)
Platelets in Resolution of Liver Inflammation and Tissue Regeneration
Speaker: Sylwia Anna Stefańczyk (Germany)

Effect of Human Myeloperoxidase on Ca2+-response, Membrane Conductivity and Phosphatidylserine Exposure on Platelet Surface
Speaker: Ekaterina Shamova (Belarus)

Influence of HOCl-modified Myeloperoxidase on Platelet and Neutrophil Activity
Speaker: Irina Gorudko (Belarus)

Specific Inhibition of MRP4 Affects Several Signaling Pathways and Thrombus Formation in Human Platelets
Speaker: Bernhard H. Rauch (Germany)

Critical Role of Platelets during Pulmonary Fibrosis
Speaker: Raphaël Martos (France)

Critical Role for Platelet Ral GTPases in the Regulation of Venous Thrombosis
Speaker: Yong Li (United Kingdom)

Fat Emulsion for Parental Nutrition as Well as Lipid Emulsion of the Drug Propofol Strongly Enhance Platelet Activation Induced by Human Albumin, Misfolded by Structural Modification with the Granulocyte Defence Weapon HOCl
Speaker: Beate E. Kehrel (Germany)

Platelet Depletion Limits the Severity But Does Not Prevent the Occurrence of Experimental Transfusion-related Acute Lung Injury
Speaker: Fabrice Cognasse (France)

P-selectin (CD62P) Deficiency Is Associated with Increased Coxsackievirus B3 Myocarditis But Not Influenza A Virus Infection in Mice
Speaker: Silvio Antoniak (United States)

Defining the Effects of Storage Lesion on Platelet Autophagic Activity
Speaker: Sebastien Fauteux-Daniel (France)

Platelets Induce Rapid Subset and Phenotypic Switching in Monocytes in Whole Blood
Speaker: Paul Armstrong (United Kingdom)

Evaluation of Analyser Flag ´Abnormal Platelet Distribution´ in Routine Complete Blood Count (CBC)
Speaker: Fatmawati Kamal (Malaysia)

Proteases and Cancer

Hypochlorous Acid Modification to Antithrombin Results in Generation of Neo-epitopes, and a Shift towards Prothrombotic and Proangiogenic State in Cancer Patients
Speaker: Parvez Ahmad (India)

Hepsin Is Involved in the Tumorigenicity and in the Hypercoagulability of Colon and Gastric Cancer Cells
Speaker: Mari Carmen Rodenas (Spain)

Novel Urokinase-derived Peptides Inhibiting the Pro-tumoral Activity of Cancer-associated Fibroblasts
Speaker: Maria Patrizia Stoppelli (Italy)
Scientific Programme

On-Demand Poster Session
14:00 - 15:00
Virtual Meeting Room 6

Thrombotic Microangiopathies Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

**ADAMTS13 and TTP**

**Oligosymptomatic Thrombosis in a Young Girl with Upshaw-Schulman Syndrome (USS) Not Receiving Prophylactic Plasma Infusion**
Speaker: Saori Tanabe (Japan)

**Differential Diagnosis of Thrombotic Thrombocytopenic Purpura at Acute Phase by the Ratio of VWF Activity to VWF Antigen Based on Automatic Immunologic Assays**
Speaker: Ning Tang (China)

**Prognostic Value of A Disintegrin and Metalloprotease with Thrombospondin Motif 13 in Patients with Severe Sepsis and Septic Shock**
Speaker: Syed Shahid Habib (Pakistan)

**Rituximab Prolongs the Time to Relapse in Patients with Immune Thrombotic Thrombocytopenic Purpura: Analysis of Off-Label Use in Japan**
Speaker: Masayuki Kubo (Japan)

**Exploration of Coagulation Disorders, von Willebrand Factor and ADAMTS13 in a Cohort of 45 Patients with Hemophagocytic Lymphohistiocytosis**
Speaker: Bérangère Joly (France)

**Automated Chemiluminescent ADAMTS13 Activity Immunoassay for Thrombotic Thrombocytopenic Purpura Diagnosis and Follow-up**
Speaker: Nicolas Beranger (France)

**Caplacizumab in a Case of Acquired Thrombotic Thrombocytopenic Purpura (TTP) Poor Responsive to Plasma Exchange and Immunosuppressive Therapy**
Speaker: Alfredo Molteni (Italy)

**Current Possibilities of ADAMTS 13 Diagnostics - Advantages and Limitations**
Speaker: Ludek Slavik (Czech Republic)

**Relapsing or Refractory Thrombotic Microangiopathies: The Key Role of ADAMTS13 Activity and Complement Testing**
Speaker: Eleni Gavriilaki (Greece)

**Clinical Analysis of 83 Patients with Thrombotic Thrombocytopenic Purpura**
Speaker: Wang Xiyan (China)

**PLASMIC Score Predicts Outcome of Transplanted Patients with Severe Thrombotic Thrombocytopenic Purpura**
Speaker: Yael Cohen (Israel)

**Pregnancy and Non-Pregnancy Related Acquired Thrombotic Thrombocytopenic Purpura in Women of Reproductive Age: Clinical Course and Outcomes**
Speaker: Amihai Rottenstreich (Israel)

**Retrospective Study of 30 TTP Patients from 2017 to 2019 in a Single Center of Suzhou, China**
Speaker: Jie Yin (China)
Development and Validation of a Prediction Model (AHC) for Early Identification of Refractory Thrombotic Thrombocytopenic Purpura Using Nationally Representative Data  
Speaker: Qiu-Sha Huang (China)

Follow-up Evaluation of Patients with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) from the International Hereditary TTP Registry: Incidence of Acute Disease Episodes with or without Regular Prophylactic Plasma Infusions  
Speaker: Erika Tarasco (Switzerland)

Multicentric Multicountry Evaluation of the Fully Automated Adamts13 Activity Assay  
Speaker: Cristina Pascual (Spain)

Genetic Study of von Willebrand Factor Variants in Congenital Thrombotic Thrombocytopenic Purpura Patients  
Speaker: Chiara Lupo (United Kingdom)

Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP) Should Be Managed in a Critical Care Setting - A UK Single TTP Referral Centre Experience  
Speaker: Rebecca Shaw (United Kingdom)

Performance Evaluation of a New Fully Automated Fluorogenic ADAMTS13 Activity Assay  
Speaker: Marcos Llusa (Austria)

Efficacy of Preemptive Subcutaneous Rituximab in Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Study of 12 Cases  
Speaker: Maxime Delrue (France)

Risk Factors Associated with Severe Neurological Symptoms in Thrombotic Thrombocytopenic Purpura (TTP)  
Speaker: José Thiago Souza Castro (Brazil)

Influence of Personality and Life Conditions on Depression, Anxiety and Cognitive Performance in 104 Patients Having Survived Acute Autoimmune Thrombotic Thrombocytopenic Purpura (iTTP)  
Speaker: Tanja Falter (Germany)

The Effect of Liver Transplantation on ADAMTS13 Activity and Antigen Levels  
Speaker: Tanja Falter (Germany)

Is Therapeutic Plasma Exchange (TPE) Still Necessary for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)?  
Speaker: Paul Knoebl (Austria)

Acquired Thrombotic Thrombocytopenic Purpura: Key Findings of Patients from Southern Italy  
Speaker: Giovanni, Luca Tiscia (Italy)

Lombardy Network for the Study and Treatment of Patients Undergoing Apheresis  
Speaker: Ilaria Mancini (Italy)

Correlation between Phenotype-genotype versus in-silico Prediction of Novel and Known Disease-causing Variants in Upshaw-Schulman Syndrome Patients in a Single Institution of Argentina  
Speaker: Juvenal Paiva (Argentina)

Association of Plasmic Score with Neurological Symptoms in Patients with Thrombotic Thrombocytopenic Purpura (TTP)  
Speaker: José Thiago Souza Castro (Brazil)
The Changing Face of Thrombotic Thrombocytopenic Purpura (TTP) in South Africa in the Human Immunodeficiency Virus (HIV) Era  
Speaker: Susan Louw (South Africa)

Inhibitory Anti Adams13 Antibodies with a New Rapid Fully Automated Clia Assay  
Speaker: Barbara Montaruli (Italy)

Evaluation of a Rapid, Automated Chemiluminescent ADAMTS-13 Activity Assay for the ACL AcuStar  
Speaker: Rebekah Ellen Fretwell (United Kingdom)

Clinical and Economic Impacts of a New Rapid ADAMTS-13 Assay for the Diagnosis of Suspected Thrombotic Thrombocytopenic Purpura  
Speaker: Chiara Novelli (Italy)

Genetic Variants in ADAMTS13 in Patients with Acquired TTP (aTTP)  
Speaker: Juvenal Paiva (Argentina)

Impact of Ultralarge von Willebrand Factor (VWF) Multimers and Platelets in Cultured Endothelial Cells in Acute Immune-mediated Thrombotic Thrombocytopenic Purpura  
Speaker: Chiara Vendramin (United Kingdom)

Treatment of Acquired Thrombotic Thrombocytopenic Purpura in Rituximab Era: A Single Center Experience from India  
Speaker: Nitin Gupta (India)

Varied Presentations of TTP  
Speaker: Anil Arribandi (India)

Antiphospholipid Syndrome  

Obstetric Antiphospholipid Syndrome: ADAMTS-13 Tested at Pregnancy Diagnosis Is Associated with the Occurrence of Early-Onset Pre-Eclampsia Despite Treatment  
Speaker: Jean-Christophe Gris (France)

Role of Anti Phosphatidylserine/Prothrombin Antibodies on Thrombin Generation and Protein C Resistance in Carriers of Antiphospholipid Antibodies  
Speaker: Elena Pontara (Italy)

Tetra Positive Thrombotic Antiphospholipid Syndrome: Major Contribution of Anti Phosphatidyl-Serine/Prothrombin Antibodies to Lupus Anticoagulant Activity  
Speaker: Mariagrazia Cattini (Italy)

Effect of Immune-Purified aβ2-Glycoprotein I (aβ2GPI) and Anti Phosphatidylserine/Prothrombin (aPS/PT) Antibodies on Thrombin Generation  
Speaker: Elisa Bison (Italy)

Lupus Anticoagulant and Antiphospholipid Antibodies: A Real-World Study  
Speaker: Eva Kempers (the Netherlands)

Increased Baseline Platelet Activation and Decreased Platelet Reactivity in Patients with the Antiphospholipid Syndrome  
Speaker: Lena Hell (Austria)

Observational Study of Outcomes in Patients with Antiphospholipid Syndrome Anticoagulated with Rivaroxaban  
Speaker: Thura Win Htut (United Kingdom)
Scientific Programme

Laboratory versus Point-of-Care INR Measurement in Patients with Lupus Anticoagulant - A Retrospective Cohort Analysis
Speaker: Aaron Lubetsky (Israel)

The Prothrombin/MHC II Complexes on Cell-Surface of Monocytes Is the Antigenic Targets in Antiphospholipid Syndrome
Speaker: Yuichiro Fujieda (Japan)

Assessment and Comparison of Acquired Activated Protein C Resistance with Two Thrombin Generation Methods, CAT and ST-Genesia, in APS and SLE Patients
Speaker: Maria Efthymiou (United Kingdom)

Hydroxychloroquine Effect on the Immune System, Coagulation and Lipid Profile in Patients with Thrombotic Primary Antiphospholipid Syndrome
Speaker: Fernanda Orsi (Brazil)

IVF Outcomes in Women with Antiphospholipid Antibodies Circulation
Speaker: Jamilya Khizroeva (Russian Federation)

Monocyte Activation and Acquired Protein S Deficiency Promote Disseminated Intravascular Coagulation in a Patient with Antiphospholipid Antibodies
Speaker: Lennart Beckmann (Germany)

Lupus Anticoagulant-Hypothrombinemia Syndrome (LAHS): A Case Report
Speaker: Karan Mayani (Spain)

Cohort of Patients with Triple Antiphospholipid Antibodies: Differences between Asymptomatic and Symptomatic Individuals
Speaker: Patricia Casais (Argentina)

Does the von Willebrand Factor: ADAMTS-13 Axis Differ between Antiphospholipid Syndrome and Systemic Lupus Erythematosus?
Speaker: My Nhi Dang (United Kingdom)

Antiphospholipid Antibodies "Multi-Positivity" in Women with Thromboembolism
Speaker: Victoria Bitsadze (Russian Federation)

Thrombotic Outcomes in Pregnant Women with Antiphospholipid Antibodies in a Tertiary Referral Centre
Speaker: Amihai Rottenstreich (Israel)

MicroRNAs as Potential Biomarkers in Thrombotic Primary Antiphospholipid Syndrome
Speaker: Camila Oliveira Vaz (Brazil)

Identification of microRNAs Potentially Involved in Primary Antiphospholipid Syndrome Related Thrombosis
Speaker: Camila Oliveira Vaz (Brazil)

Secondary Thromboprophylaxis in Antiphospholipid Syndrome Patients with Arterial Thrombosis: A Systematic Review and Meta-analysis
Speaker: Tanawat Attachaipanich (Thailand)

What to Expect about Antiphospholipid Positivity in Otherwise Healthy Patients: Is There a Real Risk of Thrombosis?
Speaker: Lidia Costa (Portugal)
Treating Antiphospholipid Syndrome Patients with Vitamin K Inhibitors in Real Life; Long Term Outcomes from a Single Centre Retrospective Study of 101 Patients
Speaker: Charalampos Kartsios (United Kingdom)

Anti-β2-Glycoprotein I and Anti-Prothrombin Antibodies Cause Lupus Anticoagulant by Interfering with Factor Xa-Mediated Factor V Activation
Speaker: Tessa Noordermeer (the Netherlands)

Patients with Antiphospholipid Syndrome Display a Marked Resistance to the Profibrinolytic Activity of Anticoagulants
Speaker: Mario Colucci (Italy)

Penile Mondor’s Disease Associated with Anticardiolipid Antibodies: A Very Rare Case of Antiphospholipid Syndrome
Speaker: Emmanouil Papadakis (Greece)

Neutrophil Activity in Patients with Antiphospholipid Syndrome-Related Thrombosis
Speaker: Fernanda Orsi (Brazil)

Catastrophic Antiphospholipid Syndrome, Kikuchi-Fujimoto Disease and Adult-Onset Still Disease: An Unusual Association
Speaker: Silvia Daniela Amanda Peres (Argentina)

Vitamin K Antagonist (VKA) Monitoring Using Point of Care Testing (POCT) in Patients with Antiphospholipid Syndrome (APS)
Speaker: Michael Masucci (United Kingdom)

Complement Regulatory Abnormalities are Frequent in Patients with Catastrophic APS and Refractory Patients Respond Rapidly to Eculizumab Treatment
Speaker: Ilene Weitz (United States)

Direct Oral Anticoagulants versus Vitamin K Antagonists in Antiphospholipid Syndrome: A Meta-analysis
Speaker: Adriana Iriarte Fuster (Spain)

Triple Positive Antiphospholipid Antibodies: A 10-year Retrospective Review of 37 Patients with Triple Positive Antiphospholipid Antibodies and their Thrombotic Outcomes and Mortality in a Single Centre in Singapore
Speaker: Bingwen Eugene Fan (Singapore)

Prevalence of “Cofactor Effect” on Lupus Anticoagulant Mixing Studies: Patients and Laboratory Characteristics
Speaker: Marta M Martinuzzo (Argentina)

FXI Levels as Independent Risk Factor for Antiphospholipid Syndrome: Development of a New Predictive Score, APS-FXI
Speaker: Maria Eugenia de la Morena-Barrio (Spain)

β2-Glycoprotein I (β2GpI) Is a Fibrinogen Binding Protein
Speaker: Vincenzo De Filippis (Italy)

Mixing Studies in Lupus Anticoagulant Tests: A Useful Tool at the Time of Analysis
Speaker: Sergio Felipe Pinzon Mariño (Spain)

CllA Immunoassay: Better Identification of High Thrombotic Risk Triple Positive Antiphospholipid Patients
Speaker: Barbara Montaruli (Italy)
**Scientific Programme**

**Contribution of Beta2 Glycoprotein1 IgA (B2GP1 IgA) Antibodies Research in Diagnosis of Seronegative Antiphospholipid Syndrome in Cerebral Thrombosis: A Case Series of 21 Patients**  
Speaker: Imene Hocine (Algeria)

**Thrombosis and Antiphospholipid Antibodies**  
Speaker: Ivanka Nikoloska (Macedonia, the Former Yugoslav Republic of)

**Lupus Anticoagulant Testing in Patients with Prolonged INR, Mixing Test Results**  
Speaker: Teresa Villalba (Spain)

**Recurrence of Thrombotic Events in Antiphospholipid Syndrome Patients Receiving Prolonged Vitamin K Antagonists Therapy**  
Speaker: Marcos Sousa (Portugal)

**Weakly Positive Lupus Anticoagulants Are also Associated with High Event Rate**  
Speaker: Frances Compton (United States)

**HUS**

**Differential Expression of CD46 in Leukocytes by Flow Cytometry: Methodological Aspects**  
Speaker: Sabrina Rotondo (Argentina)

**Personalized Dosing of Eculizumab Using C5 Functional Activity and Eculizumab Level in Complement-mediated Thrombotic Microangiopathy: A Safe and Cost-saving Approach**  
Speaker: Meera Sridharan (United States)

**Non HUS/TTP Microangiopathies**

**Fulminant Pulmonary Tumor Thrombotic Microangiopathy (PTTM) in a Young Man: Clinical and Immunoistochemical Characterization of a Rare Complication of Gastric Signet Ring Cell Carcinoma**  
Speaker: Raffaella Rossio (Italy)

**Complement Pathway and Endothelial Dysfunction in Severe Preeclampsia**  
Speaker: Marta Palomo (Spain)

**Factor VIII/Protein C and Not ADAMTS13/VWF:Ag Ratio Is a Prognostic Risk Factor for Patients with Cirrhosis and Low MELD Score**  
Speaker: Niccolò Bitto (Italy)

**An Unusual Case of Cerebral Cavernous Malformation Complicated with Consumptive Coagulopathy and Heightened Fibrinolysis**  
Speaker: Ming Ching Shen (Taiwan, Republic of China)

---

**Vascular Biology Abstracts**

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

**Blood Cells and Vessel Wall**
The Red Laser- Mediated Photobiomodulation Therapy, Accompanied by Aspirin Administration, Improve Endothelial Dysfunction after Balloon Angioplasty in the Rabbit Model of Carotid Artery Injury
Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Neointimal Hyperplasia Regression using Lipid- Based Encapsulated Methotrexate Nanoparticles- Mediated Catheter- Based Low- Level Blue Laser Photodynamic Therapy
Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Neutrophils and Neutrophil Extracellular Traps (NETs) Can Promote Clotting and Impact Clot Structure in a Distinctive Manner
Speaker: Yu Shi (United Kingdom)

Morphological and Functional Alterations of Platelets from Transgenic APP23 Mice at Early Alzheimer Disease State
Speaker: Lili Donner (Germany)

CTL-2 is a VWF Receptor Involved in Neutrophil Activation
Speaker: Gaia Zirka (France)

Tripeptides Affected Hemostas in Various Pathologies
Speaker: Maria Golubeva (Russian Federation)

Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes
Speaker: Nicole Ziliotto (Italy)

The Induction Strategies Administered in the Treatment of Multiple Myeloma Exhibit a Deleterious Effect on the Endothelium
Speaker: Julia Martinez-Sanchez (Spain)

Colonization with the Minimal Microbial Consortium Altered Schaedler Flora Hampers the Formation of Neutrophil Extracellular Traps in Acute Mesenteric Ischemia-Reperfusion Injury
Speaker: Franziska Bayer (Germany)

Role of Thrombopoietin in Rescuing Vascular Niche of ITP Patients
Speaker: Jieyu Ye (China)

The Antioxidant and Antiinflammatory Effect of Synbiotic Beverage from Soybean Water Kerfir on Aortic Tissue of Hyperlipidemic Rats Model
Speaker: Mochamad Affifudin (Indonesia)

Vessel-On-A-Chip Model Revealing Rapid Offset and Onset Mechanisms of Collagen- and Thrombin-Induced Platelet Activation
Speaker: Isabella Provenzale (the Netherlands)

Redox Regulation of Neutrophil Mac-1 Function by Protein Disulphide Isomerase
Speaker: Alexander Dupuy (Australia)

Mechanisms and Functional Consequences of Platelet-derived Extracellular Vesicle and Chemokine Internalisation by Endothelial Cells
Speaker: Alexandra. C.A Heinzmann (the Netherlands)

Aortic Ring Angiogenesis Proceeds Normally Despite Minimal Tissue Factor Expression
Speaker: Maureane Hoffman (United States)
Development of a Novel Mouse Model of Abdominal Aortic Aneurysm with Intraluminal Thrombus
Speaker: Katia Yahiaoui (France)

Optimization of Disease- and Patient-specific in vitro Assays for Endothelial Dysfunction Investigation by Using Endothelial Colony-forming Cells
Speaker: Francesca Calcaterra (Italy)

Generation and Isolation of Extracellular Vesicles from Endothelial and Smooth Muscle Cells Grown out of Human Blood
Speaker: Plinio Ferreira (United Kingdom)

The Effects of Hypoxia on Activation of Endothelial Cells
Speaker: Casper Ullsten-Wahlund (Norway)

Differential Expression of Inflammatory Mediators in Venous Tissue and Serum Suggest Natural Killer (NK) Cell-mediated Responses in Chronic Venous Insufficiency
Speaker: Ulka Sachdev (United States)

Endothelial Cell Signaling
Elevated Plasminogen Activator Inhibitor Type-1 and Soluble Thrombomodulin of Type 2 Diabetes Mellitus Subjects with Increasing Loss of Glycemic Control in Calabar, Southern Nigeria
Speaker: Margaret S. Edem (Nigeria)

Speaker: Montamas Suntravat (United States)

Trimethylamine N-oxide (TMAO) Disrupts Haemostasis Balance in Human Vascular Endothelial Cells
Speaker: Saravanan Subramaniam (United States)

The survival of endothelial cells in the conditions of nutrient deficiency
Speaker: Tetiana Nikolaenko (Ukraine)

TRPV4 Channel Activation Induces the Transition of Venous and Arterial Endothelial Cells Toward a Pro-Inflammatory Phenotype
Speaker: Kathia Beddek (France)

MADD Regulates von Willebrand Factor Trafficking in Endothelial Cells via Activation of Weibel-Palade Body-Associated Rab GTPases
Speaker: Marijt Kat (the Netherlands)

Novel Anti-Inflammatory Network: The Phosphatase Domain of Soluble Epoxide Hydrolase Mediates the regulation of β2 Adrenergic Receptor-IL-6 Signaling and Vascular Endothelial Activation
Speaker: Eriko Suzuki (Japan)

Epigenetic Regulation of Endothelial Dysfunction in Venous Thromboembolism
Speaker: Marion Pillard (France)

Endothelial Protein C Receptor Signaling via Protease-activated Receptor 1 Promotes Neovascularization after Ischemia in Mice
Speaker: Magdalena Bochenek (Germany)
Scientific Programme

The R398w Gata-2 Variant Negatively Regulates E-Nos Activity: Possible Role in GATA2 Deficiency-associated Thrombosis
Speaker: Giulio Purgatorio (Italy)

Astrocytes Are Central Contributors in Restoration of the Blood Brain Barrier via Transcriptional Upregulation of Key Gap Junction Proteins between Endothelial Cells
Speaker: Preston Stafford (United States)

Inflammation and Sepsis

The Anti-Inflammatory Effects Of 3´-Hydroxygenkwanin from Aquilaria sinensis in Human Neutrophils
Speaker: Hsiang-Ruei Liao (Taiwan, Republic of China)

The Tissue Factor Surface Expression of Monocyte Subsets during Sepsis
Speaker: Kathryn Mary Musgrave (United Kingdom)

The Tissue Factor Expression of Monocyte Subsets and the Activation of Coagulation during Human Endotoxaemia
Speaker: Kathryn Mary Musgrave (United Kingdom)

Prevalence of Disseminated Microvascular Thrombosis, Unresolved Infection, and Lymphoid Depletion in Autopsies of Pediatric Sepsis-Induced Disseminated Intravascular Coagulation (DIC)
Speaker: Trung Nguyen (United States)

Ca2+ Release from Stores Controlled by Sarco/Endoplasmic Reticulum Ca2+-ATPase 3 (SERCA3) Is Involved in Endothelial Permeability and Inflammatory Response
Speaker: Kathia Beddek (France)

Pro-Inflammatory Cytokines, Tissue Factor Gene Polymorphism (A603G, C1322T, C1812T, G1442C) and Tissue Factor Expression in Patient with Erysipelas
Speaker: Artur Emelyanov (Russian Federation)

Design and Characterization of Novel Activated Protein C (APC) Variants for the Proteolysis of Cytotoxic Extracellular Histone H3
Speaker: Joram Huckriede (the Netherlands)

Inhibitory Effect of Heparin and Modified Heparin on Neutrophil Migration
Speaker: John Hogwood (United Kingdom)

Significance of Macrophage Migration Inhibitory Factor and Toll-Like Receptor 4 as Predictive Factors of Sepsis in Shock Patients
Speaker: Sung-Hyuk Choi (Korea, Republic of)

Significance of Macrophage Migration Inhibitory Factor for Sepsis in Hemorrhagic Shock Patients
Speaker: Sung-Hyuk Choi (Korea, Republic of)

Defibrotide Prevents Sepsis Induced Endothelial Cell Activation
Speaker: Marta Palomo (Spain)

The Role of α1AMP-Activated Protein Kinase (α1AMPK) in Haemostatic Dysfunctions Induced by Sepsis
Speaker: Julien De Poortere (Belgium)

Systemic Inflammation in Sepsis Patients Is Demonstrated by Levels of IL-8, IL-13, and TAFI
Speaker: Emily Bontekoe (United States)
Scientific Programme

Immunization with Recombinant Atherogenic Antigen (AHC) Does Not Enhance Susceptibility to Sepsis
Speaker: Xinjie Lu (United Kingdom)

Cell-free DNA and Citrullinated Histone H3 Plasma Levels Improve the Prediction of Mortality in Septic Patients
Speaker: Mauro Hernán Moiana (Argentina)

Fibrinolytic Activity in Patients with Granulomatosis with Polyangiitis (GPA)
Speaker: Teresa Iwaniec (Poland)

Megakaryocytes Are Reprogrammed by Lipopolysaccharide Exposure during Bacterial Sepsis
Speaker: Krystin Krauel (Germany)

Neutrophilic Extracellular Traps (NETs) Are a Subset of Smudge Cells identifiable by Peripheral Smear Autoanalyzers
Speaker: Morayma Reyes Gil (United States)

Promising Therapeutic Effects of a Novel RNA Aptamer, Apta-1, in a Severe Systemic Inflammation Model on Non-human Primates
Speaker: Luiza Jedlina (Sweden)

Cytokine Network Architecture at the Endothelial Interface
Speaker: A.J. Hoogendijk (the Netherlands)

Biomarkers of Platelet Activation and their Prognostic Value in Patients in Sepsis Associated Coagulopathy
Speaker: Debra Hoppensteadt (United States)

Human Vascular Endothelial Cell Derived Exosomes Contribute to the Excessive Inflammatory Response Observed in Sepsis through a Dysregulated MicroRNA Expression Profile
Speaker: Glenn Fitzpatrick (Ireland)

Candida albicans Expresses an Integrin-like Protein that Is Involved in Yeast Adhesion to Endothelial Cells
Speaker: Danielle Nader (Ireland)

Diabetes Mellitus Increases Thrombin and Activated Protein C Effects on Mast Cell and Macrophages
Speaker: Liubov Gorbacheva (Russian Federation)

Altered Coagulation Parameters and D-Dimer Measurements in Sepsis Are Useful in Scoring the Risk Stratification
Speaker: Divya Joshi (United States)

Innate and Adaptive Immunity

Activation of ERK Signaling Pathway by Plasma IgG in Venous Thromboembolism Patients without Antiphospholipid Antibodies
Speaker: Sylvie Bouvier (France)

Determinants of Neutrophil Extracellular Trap Formation in the General Population: Based on the Rotterdam Study Cohort
Speaker: Samantha Joyce Donkel (the Netherlands)
Ageing Affects Neutrophils - Changes in Activation, DNA Release and Neutrophil Extracellular Formation of Neutrophil Subpopulations with Human Age  
Speaker: Lisa-Marie Mauracher (Austria)

The Gut Microbiota Restricts NETosis in Acute Mesenteric Ischemia-Reperfusion Injury  
Speaker: Christoph Reinhardt (Germany)

Specialized Regulatory T Cells Control Venous Blood Clot Resolution  
Speaker: Fatemeh Shahneh (Germany)

Neutrophil Extracellular Traps (Nets) Increase the Pro-Tumoral Properties of the Human Breast Cancer Cell Line, MCF7  
Speaker: Robson Monteiro (Brazil)

In Vitro Disruption of Endothelial Barrier Integrity by Heme and by Serum from Patients with Sickle Cell Disease  
Speaker: Erich Vinicius de Paula (Brazil)

mir-146a Deficiency Promotes Neutrophil Aging and Increases their Sensitivity to Form Neutrophil Extracellular Traps (NETs) in a Murine Model  
Speaker: Maria Piedad Fernandez Perez (Spain)

Stabilin-2 Promoter Modulates Immune Response in the Liver of Lentiviral Vector Injected Mice  
Speaker: Ester Borroni (Italy)

Antisense Oligonucleotide Targeting of Thrombopoietin Represents A Novel Platelet Depletion Method to Assess the Role of Platelets During Inflammation Resolution  
Speaker: Tessa Barrett (United States)

Non-coding RNAs

Low Levels of Circulating Extracellular Vesicle-Encapsulated HULC Are Associated with Left Ventricular Hypertrophy in Japanese  
Speaker: Satoshi Fujii (Japan)

MiR-146a Regulates Platelet Function and Thrombosis  
Speaker: Ana Belén Arroyo (Spain)

Microrna-365a-3p, a Novel Modulator of Tissue Factor Protein Expression and Function  
Speaker: Jiayin Tian (Australia)

Platelet miRNoma and Variability in the Responsiveness to Low-dose Aspirin in Patients with Type 2 Diabetes mellitus  
Speaker: Sonia Ciotti (Italy)

High Efficiency Unassisted Transfection of Platelets with Naked Double-stranded miRNAs Modulates Signal-activated Translation and Platelet Function  
Speaker: Sophie Lazar (United States)

Protease Activated Receptors

PAR1-Derived and PAR3-Derived Peptides and their Variants Synergistically Inhibit Human Macrophage NLRP3-Dependent Inflammasome Activity  
Speaker: Laura Healy (United States)

Thrombomodulin Makes the Difference - Novel Role of Protease-Activated Receptor 4 as Low-Dose Thrombin Receptor  
Speaker: Dorothea Monika Heuberger (Switzerland)
Scientific Programme

The Protective Effects of PAR1-agonists - Thrombin, Activated Protein C and Peptide 9 in the Model of the Neuroinflammation in vitro
Speaker: Irina Babkina (Russian Federation)

Stem Cells and Vascular Cell Growth

Pituitary Hormones Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Prolactin (PRL) Modulate Endothelial Colony Forming Cells Angiogenic and Thrombotic Properties
Speaker: Gregoire Detriche (France)

Thrombopoietin Rescues Megakaryopoiesis, Reduces Hemorrhage via Protecting Bone Marrow Endothelial Function of Chemotherapy-Treated Hematological Malignancies Patients
Speaker: Jieyu Ye (China)

Investigation of a Significant Factor to Improve an Establishment of Endothelial Colony Forming Cell
Speaker: Shuichi Okamoto (Japan)

Transplantation of Fetal Liver Cells into Newborn Hemophilic Mice for Hemophilia A Cell Therapy
Speaker: Simone Merlin (Italy)

On-Demand Poster Session
14:00 - 15:00
Virtual Meeting Room 6

Venous Thromboembolism Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Artificial Valves

Standard Versus Higher Intensity Anticoagulation for Patients with Mechanical Aortic Valve Replacement and Additional Risk Factors for Thromboembolism: A Multi-center Registry Analysis
Speaker: Sarah Hanigan (United States)

Atrial Fibrillation

Clinical Case: Reversal of Dabigatran Levels in Patients with Renal Insufficiency that Have Required the use of Idarucizumab
Speaker: Albert Tugues Peiró (Spain)

Reduced Bleeding After an Intervention to Limit Excess Aspirin Use Among Patients on Chronic Warfarin
Speaker: Jordan K. Schaefer (United States)

Relationship between TTR and Daily Vitamin K Intake in Patients Taking Warfarin: The Difference among VKORC1 Genotype
Speaker: Takehiko Nagao (Japan)

Persistence to Direct Oral Anticoagulants among Non-Valvular Atrial Fibrillation Patients in the Netherlands: A Nationwide Cohort Study
Speaker: Qingui Chen (the Netherlands)
Non-Valvular Atrial Fibrillation Patients Anticoagulated with Rivaroxaban Compared with Warfarin Exhibit Attenuated Plasma Platelet Activation Markers and Pro-Inflammatory Extracellular Vesicle Proteomic Signatures  
Speaker: Luisa Weiss (Ireland)

Non-Persistence to Direct Oral Anticoagulants and Risk of Thromboembolic Stroke among Patients with Non-Valvular Atrial Fibrillation: A Dutch Nationwide Cohort Study  
Speaker: Myrthe M.A. Toorop (the Netherlands)

Long-term Mortality and Functional Status in Older Adults with Atrial Fibrillation After Stroke  
Speaker: Anna Parks (United States)

Characterization of VKA Control in Patients with Thrombotic and Major Hemorrhagic Events in Anticoagulation Hematology Units: Results from the EVENTHO Study  
Speaker: Olga Gavín (Spain)

Ratio of Inhibited Thrombin Generation Based on Dilute Prothrombin Time May Predict the Major Bleeding or Thrombotic Tendency in NVAF Patients Treated with Anti-Xa DOAC  
Speaker: Kazumasa Ohmura (Japan)

Differences in Treatment and Outcomes in Recently Diagnosed Atrial Fibrillation between the Netherlands and Belgium: Results from the GARFIELD-AF Registry  
Speaker: Jaap Seelig (the Netherlands)

Factor V Leiden Is Associated with Atrial Fibrillation, but Not Ischemic Stroke in Atrial Fibrillation. The Tromsø Study  
Speaker: Erin Mathiesen Hald (Norway)

Predictors of Left Atrial Thrombus before Catheter Ablation or Cardioversion in Patients with Non-Valvular Atrial Fibrillation  
Speaker: Ivan Zaigraev (Russian Federation)

Effect of Patient and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) Study  
Speaker: Kira MacDougall (United States)

Anticoagulation in Non-Valvular Atrial Fibrillation: Old or New Friends?  
Speaker: Mihnea-Alexandru Gaman (Romania)

Management of DOACs in Elective Surgery Procedures: A Measurement Based Approach  
Speaker: Loredana Tomassini (Italy)

Assessment and Predictors of Inappropriate Dose of Direct Oral Anticoagulants  
Speaker: Mosaad Almegren (Saudi Arabia)

Vitamin K Antagonists Dosing According to Pharmacogenetics  
Speaker: Elena Ristovska (Macedonia, the Former Yugoslav Republic of)

Rates, Management and Outcome of Bleeding Complications during Edoxaban Therapy in Daily Care - Results from the Dresden NOAC Registry  
Speaker: Jan Beyer-Westendorf (Germany)

Association of Clinical Risk Factors and Biomarkers with Thromboembolism, Major Bleeding, and All-Cause Death in Patients with Atrial Fibrillation in a Tertiary Care Setting  
Speaker: Daniel Kraemmer (Austria)
The Role of Hemodialysis in Patients with Re-Elevation of Dabigatran Levels After Idarucizumab Treatment: A Case Series
Speaker: Ana Boban (Croatia)

Differential Effect of Direct Oral Anticoagulants (DOACs) on Thrombin Generation and Clot Lysis in Patients with Non Valvular Atrial Fibrillation (AF) and Venous Thromboembolism (VTE)
Speaker: Mario Colucci (Italy)

Plasma from Patients under Direct Oral Anticoagulants (DOACs) Displays a Strong Resistance to Heparin Compared to Patients under Vitamin K Antagonists (VKA)
Speaker: Mario Colucci (Italy)

Clinical Outcomes for Patients of High Body Weight on Apixaban or Rivaroxaban
Speaker: Gurpreet Bahra (United Kingdom)

Fatal Intracerebral Hemorrhage in a Patient on Warfarin: A Case Report
Speaker: Maria Auxiliadora Parreiras Martins (Brazil)

Relationship of Health Literacy and Adherence to Treatment with Oral Anticoagulants in Patients with Atrial Fibrillation in Brazil
Speaker: Maria Auxiliadora Parreiras Martins (Brazil)

Emergency Room Access of Patients on DOACs: A Six Years Single Center Experience
Speaker: Luciano Crippa (Italy)

Anticoagulation Resumption After Intracerebral Hemorrhage in Two Cohorts of Patients Treated with Vitamin K Antagonists and Direct Oral Anticoagulants
Speaker: Daniela Poli (Italy)

More Precise Dosing of Acenocoumarol for Better Control in Patients Aged above 80 Years, a Randomized Controlled Pilot Study
Speaker: Margriet Piersma-Wichers (the Netherlands)

Time in Therapeutic Range During Therapy with Vitamin K Antagonists Is Lower in Women than in Men and Is Not Explained by Differences in Age
Speaker: Ilaria Avarello (Italy)

Towards Individualizing Apixaban Therapy in Elderly Patients Through Thrombin Generation
Speaker: Alejandra Scazziota (Argentina)

Anticoagulant Management Strategies in Cancer Patients with Atrial Fibrillation in Daily Clinical Practice
Speaker: Gordon Chu (the Netherlands)

Heparin Resistance and a Probable Dabigatran Non Response in a Case of AFib and Left Atrial Atrium Clot
Speaker: Ana Coimbra (Portugal)

Single Centre Daily Practice Evaluation of Bleeding and Thromboembolic Complications in Cancer Patients with Atrial Fibrillation
Speaker: Gordon Chu (the Netherlands)

Stroke, Major Bleeding, and Net-clinical Benefit of Anticoagulation in Patients with Atrial Fibrillation on Hemodialysis
Speaker: Oliver Koenigsbruegge (Austria)
Scientific Programme

Study of Real Clinical Practice to Evaluate the Efficacy and Safety of Edoxaban in Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation. Differences between Results by Age and Creatinine Clearance Greater than 95 ml/min
Speaker: Almudena Garcia Ruiz (Spain)

Beyond the Registry: A Nuanced Evaluation of Real World Anticoagulation for Nonvalvular Atrial Fibrillation Patients at a Tertiary Care Center
Speaker: Cali Lunowa (United States)

Association of Body Mass Index (BMI) with Bleeding Events in Patients Taking Oral Anticoagulation for Atrial Fibrillation (AF) or Venous Thromboembolism (VTE)
Speaker: Thane Fieldeisen (United States)

The Association between Neighborhood Socioeconomic Status, Geographical Area and Non-persistence to Using DOACs
Speaker: Nienke van Rein (Denmark)

Inappropriate Dosing of Direct Oral Anticoagulants in Older Patients with Non-Valvular Atrial Fibrillation: Impact on Plasma Drug Levels
Speaker: Anne-Laure Sennesael (Belgium)

The Impact of Soluble Thrombomodulin and Circulating miRNAs on Catheter Ablation in Patients with Atrial Fibrillation
Speaker: Fuminori Namino (Japan)

Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation
Speaker: Michela Giustozzi (Italy)

An observational Study of INR Control and Bleeding Events, According to European Society of Cardiology (ESC) Guidelines, in Non-valvular Atrial Fibrillation (NVAF) Stratified by Male and Female Sex
Speaker: Daniel Harris (United Kingdom)

Intracardiac Levels of Soluble P Selectin Is Associated with Ischemic Stroke Risk in Patients with Atrial Fibrillation
Speaker: Ferenc Sarkady (Hungary)

Atrial Fibrillation Treated with Warfarin at an Academic Medical Center: The Potential Impact of Direct Oral Anticoagulants on Future Management
Speaker: Peter Collins (United States)

Trends in Direct Oral Anticoagulant Use in Renal Failure
Speaker: Scott Kaatz (United States)

Preliminary Results from EGINA Registry: A New Model in the Management of Anticoagulation with DOACs in Southern Italy
Speaker: Nicola Ciavarella (Italy)

Using Baseline Characteristics to Differentiate Atrial Fibrillation Prevalence and Incidence in Pulmonary Embolism
Speaker: Dimpi Patel (United States)

Predictive Value of CBC Indices in Determining Risk of Atrial Fibrillation After Pulmonary Embolism
Speaker: Dimpi Patel (United States)
Profile of Patients Using Oral Anticoagulants in Primary Care: ‘Anticoagula Divinópolis” Project  
Speaker: João Antonio Oliveira (Brazil)

Cancer Associated Thrombosis

Efficacy of Primary Thromboprophylaxis Agents (PTA) in Multiple Myeloma (MM) Treated with Immunomodulators (IMiD): A Network Meta-Analysis  
Speaker: Philip A Haddad (United States)

L-Asparaginase Induced Hyperlipidemia, Pseudohyponatremia and Cerebral Venous Thrombosis during Acute Lymphoblastic Leukemia Remission Induction Therapy  
Speaker: Murat Soker (Turkey)

Amelioration of the Pathologic Changes in the Hepatocyte-Specific BRAFV600E Mutated Mice by Administration of Aspirin  
Speaker: Hiroki Tanaka (Japan)

Use of Direct Oral Anticoagulants (DOACs) as Primary or Secondary Prophylaxis of Venous Thromboembolism in Patients with Multiple Myeloma on Immunomodulatory Drugs  
Speaker: Carlos Aguilar (Spain)

JAK2 Mutation: A Predictor of Thrombotic Events in Myeloproliferative Neoplasia?  
Speaker: Sindhura Lakshmi Koulmane Laxminarayana (India)

Development of Predictive Score for Venous Thromboembolism in Hematologic Malignancies  
Speaker: Agnerys López Sacerio (Cuba)

Risks and Benefits of Antithrombotic Therapy in Polycythemia Vera: A Systematic Review  
Speaker: Marissa Laureano (Canada)

Clinical Outcome of Anticoagulation for Acute Venous Thromboembolism Associated with Different Types of Cancer  
Speaker: Waldemar Wysokinski (United States)

Survival after Cancer-related Venous Thrombosis: The Scandinavian Thrombosis and Cancer Study (STAC)  
Speaker: Rayna Janine Sushmita Anijs (the Netherlands)

Risk of venous Thromboembolism among Subgroups of Cancer Patients Undergoing Chemotherapy: Post-Hoc Analysis of the AVERT Trial  
Speaker: Ameeta Lubina Nayak (Canada)

Thrombosis in Hematologic Malignancies: A Five Year Single-Center Experience in Mexico  
Speaker: María Teresa García-Lee (Mexico)

Risk Factors of Venous Thromboembolism in Patients Undergoing Systemic Cancer Therapy: A Systematic Review and Meta-Analysis  
Speaker: Sandra Lee (Canada)

Elevated Von Willebrand Factor Antigen and Activity Levels Are Risk Factors for Predicting Thrombosis in Cancer  
Speaker: Bin Yan (China)

Incidence and Risk Factors for Venous Thromboembolism (VTE) among Lymphoma Patients in a Southeast Asian Population  
Speaker: Vanessa Cui Lian Chong (Singapore)
**Scientific Programme**

**Increased Coagulation Potential in Patients with Polycythemia Vera and Essential Thrombocythemia with Thrombotic History**  
Speaker: Natalya Korsakova (Russian Federation)

**Non-Randomized Patient Outcomes. ADAM-VTE Registry Analysis**  
Speaker: Ewa Wysokinska (United States)

**Are Patients with an Active Cancer and those with a History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding while on Anticoagulants?**  
Speaker: Corinne Frere (France)

**Effectiveness and Safety of Enoxaparin in Patients with Active Cancer and Venous Thromboembolism (VTE): A Systematic Literature Review**  
Speaker: Jenny Shan (France)

**Long-Term Use of Tinzaparin for the Treatment of Cancer-Associated Thrombosis: A Subgroup Analysis of the Prospective Observational TROPIQUE Study**  
Speaker: Dominique Farge (France)

**Intracranial Hemorrhage with Direct Oral Anticoagulants in Patients with Brain Metastases**  
Speaker: Avi Leader (the Netherlands)

**Use of a Cancer Screening Tool as Part of a Conservative Approach to Screening for Occult Malignancy after Unprovoked DVT: The King’s College Hospital Experience**  
Speaker: Catrin Cox (United Kingdom)

**Increased Potential of Neutrophil Activation and Neutrophil Extracellular Trap Formation in Patients with Lung Cancer**  
Speaker: Lisa-Marie Mauracher (Austria)

**No Impact of Previous Venous Thromboembolism on the Survival of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Refractory Lymphoma**  
Speaker: Joanna Rupa-Matysek (Poland)

**Risk Factors, Mortality and Costs of Cancer-Associated Thrombosis in Hospitalised Patients**  
Speaker: Wei Ying Jen (Singapore)

**Assessment of the Ottawa Score in the Prediction of Recurrent Venous Thromboembolism in Patients Treated for Lymphoma**  
Speaker: Joanna Rupa-Matysek (Poland)

**Massive Life-Threatening Intravascular Tumor Thrombus (ITT) as the Initial Manifestation of Renal Cell Carcinoma Complicated with Heparin-Induced Thrombocytopenia: A Case Study**  
Speaker: Elia Seguí (Spain)

**Bleeding Risk Assessment Model for Older Multiple Myeloma Patients on Immunomodulatory Drugs (IMIDs)**  
Speaker: Ang Li (United States)

**Empowering Cancer Patients for Non-Pharmacological Primary Prevention and Early Recognition of Cancer-Associated Thrombosis (CAT): The EMPATIC-CP Survey**  
Speaker: Marta Merino (Spain)

**Venous Thromboembolism (VTE) Events with Cancer as a Risk Factor in a Teaching Hospital: 2015-2019**  
Speaker: Huw Rowswell (United Kingdom)
Risk of Arterial Thromboembolism in Cancer Patients: A Population-Based Cohort Study  
Speaker: Frits I. Mulder (the Netherlands)

Haemostatic State in Hodgkin Lymphoma Patients  
Speaker: Alexander Poletaev (Russian Federation)

Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Patients with Cancer-Associated Thrombosis. A Pooled Analysis of two Prospective Cohort Studies  
Speaker: Philippe Girard (France)

Biomarkers of Venous Thromboembolism Recurrence After Discontinuation of Anticoagulation for Cancer-Associated Thrombosis (HISPALIS-Study)  
Speaker: Julia Oto (Spain)

Use of Anti-Factor Xa Levels in Cancer Patients Taking Direct Oral Anticoagulants  
Speaker: Anna Weatherill (United Kingdom)

The Downregulation of Mucin1 Initiates Aberrant Calcium Signalling Pathways of Cancer Cells which Are Partly Responsible for the Procoagulant Phenotype  
Speaker: Yunliang Chen (United Kingdom)

Current Status on Non-hematological Cancer Associated Thrombosis at Tertiary Care Hospital in India  
Speaker: Mukul Aggarwal (India)

A Newly Developed Kit for High-Sensitivity Measurement of TF-Dependent Procoagulant Activity on Microvesicles Purified by High-Speed Centrifugation  
Speaker: Tarik Bouriche (France)

Thromboprophylaxis with Rivaroxaban in Patients with Malignancy and Central Venous Lines (TRIM-line): a Multi-centre Open-label Pilot Randomized Controlled Trial  
Speaker: Rick Ikesaka (Canada)

Elevated Plasma Factor VIII Levels Are Associated with Hypercoagulability and Shorter Survival in Patients with Non-Hodgkin Lymphoma  
Speaker: Chatphatai Moonla (Thailand)

Plasma Levels of Procoagulant and Anticoagulant Factors in Patients with Acute Cancer-associated Thrombosis  
Speaker: Elena Campello (Italy)

Apixaban Levels In Cancer-Associated Thrombosis In Low-Weight Individuals  
Speaker: Veronica Bravo-Villa (Mexico)

Venous Thromboembolism in Patients with Cancer in Palliative Care  
Speaker: Gabriela Cesarman-Maus (Mexico)

Catheter-Associated Upper Extremities Deep Vein Thrombosis in Cancer Patients: Does Anticoagulation Time Matter?  
Speaker: Annalisa Dalla Salda (Italy)

Deep Venous Thrombosis and Intraductal Papillary and Mucinous Tumor of the Pancreas: about 3 Cases  
Speaker: Yosra Cherif (Tunisia)

Aspects of Cancer-Related Venous Thrombosis in a cohort of 207 Tunisian Patients  
Speaker: Marwen Mama (Tunisia)
Clinical Outcome of Splanchnic and Usual Site Venous Thrombosis in Patients with Solid Cancer
Speaker: Emanuele Valeriani (Italy)

Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-dimer, CRP, vWF and TNF-α. Interrelationship between Thrombogenesis and Inflammation
Speaker: Fakiha Siddiqui (United States)

Differential Augmentation of Thrombin Generation by Andexanet Alfa in Lymphoma Patients
Speaker: Fakiha Siddiqui (United States)

Pulmonary Embolism as a Presenting Manifestation of Cerebral Glial Tumor
Speaker: Maroua Mrouki (Tunisia)

Uncovering Clinical Gaps in Treatment of Cancer-Associated Thrombosis: A Clinical Practice Assessment
Speaker: Jelena Spyropoulos (United States)

Influence of Tumor Site on Clinical Outcomes in Cancer Patients with Venous Thromboembolism. Insights from the Prospective PREDICARE Cohort Study
Speaker: Philippe Girard (France)

Anticoagulation Therapy as Prevention of Cancer Relapse
Speaker: Alexander Vorobev (Russian Federation)

Dynamics of ADAMTS13 and vWF Activity Change in Ovarian Cancer Patients
Speaker: Alexander Vorobev (Russian Federation)

Impact of Obesity in Pulmonary Embolism among Patients with Solid Malignancies
Speaker: Karol Quelal (United States)

Fondaparinux versus Enoxaparin in the Treatment of Venous Thromboembolism in Cancer Patients: Retrospective Cohort Study - "ONCOTEV"
Speaker: Barbara Abbate (Italy)

Histopathological Features of Cancer-Associated Venous Thromboembolism in Human
Speaker: Toshihiro Gi (Japan)

Anticoagulation Therapy Management in Oncological Patients: Experience in a Center
Speaker: Ana Pimentel Feliciano (Spain)

The Activated Coagulation Factor X (FXa) Directly Stimulates Colorectal Cancer Cell Migration and Proliferation - Characterizing the Underlying Molecular Mechanisms
Speaker: Ulrike Meyer (Germany)

Direct Oral Anticoagulants in Patients with Hematological Malignancies
Speaker: Alessandra Serrao (Italy)

Incidence, Risk Factors and Clinical Outcome of Venous and Arterial Thromboembolic Events in Patients Treated with Immune-checkpoint Inhibitors: A Single-center Cohort Study
Speaker: Florian Moik (Austria)

Cerebral Sinus Venous Thrombosis in Children with Leukemia: Single-institution Report
Speaker: Irina Melnichenko (Armenia)

Patients Experience of Living with Cancer Associated Thrombosis in Singapore (PELICAN)
Speaker: Simon Noble (United Kingdom)
Scientific Programme

Cooperation about the Treatment of the Venous Thromboembolism in Cancer Institute Hospitals and Neighboring Cooperation Acute Hospitals
Speaker: Chikao Yasuda (Japan)

Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Ph-negative Myeloproliferative Neoplasms and Venous Thromboembolism
Speaker: Silvia Betti (Italy)

Differential Expression of Neutrophil Activation Markers in Venous Thromboembolism Patients with and without Association to Cancer
Speaker: Julia Oto (Spain)

Antimetastatic Profile of Bovine Intestinal Heparin and its Low Anticoagulant Activity Derivative
Speaker: Mariana Sá Pereira (Brazil)

Developing an ex vivo Method to Study Thrombosis in Cancer Patients: Cancer-associated Thrombosis-on-a-Chip
Speaker: Araci M R Rondon (the Netherlands)

ThroLy and Khorana Scores Comparison in a Group of Lymphoma Patients
Speaker: Pilar Llamas (Spain)

Effectiveness and Safety of Rivaroxaban in Patients with Cancer-associated Venous Thromboembolism
Speaker: Olivia S. Costa (United States)

Cancer Patients Has Lower Plasmin Generation by Simultaneous Thrombin and Plasmin Assay Evaluation
Speaker: Gabriele da Silva Souza Gois (Brazil)

Venous Thromboembolic Risk in Ambulatory Cancer Patients: Awareness Needed!
Speaker: Sara Lopes (Portugal)

No Agreement among Risk Prediction Scores for Venous Thromboembolism in Cancer Patients: A Prospective Cohort Study
Speaker: Millene Evelyn Alves de Almeida (Brazil)

Clinical Presentation and Outcomes of Cancer-associated Distal Deep Vein Thrombosis: Data from the RIETE Registry
Speaker: Jean-Philippe Galanaud (Canada)

Cancer Site and Distant Metastasis at Diagnosis Predict the Risk of VTE in Cancer
Speaker: Sigrid K. Braekkan (Norway)

Risk of Venous Thromboembolism in the Clinical Course of Osteosarcoma
Speaker: Milou A. M. Stals (the Netherlands)

Cancer Associated Thrombosis: Are DOACs a Treatment Option? Systematic Review and Meta-analysis of Randomised Controlled Trials
Speaker: Raza Alikhan (United Kingdom)

Genetic Risk Factors of Thrombosis

Thrombophilia Gene Screening in Pediatrics Solid Tumors with Thrombosis
Speaker: Osama El Safy (Egypt)
Scientific Programme

Does blood Group Predicts Thrombosis Risk? A Pilot Study Assessing Thrombin Generation
Speaker: María Marcos Jubilar (Spain)

Genetic Study for Idiopathic Venous Thromboembolism in Japanese Using Short-Read and Long Read Sequencers: A Pilot Study of Japanese Group of Idiopathic Thromboembolism
Speaker: Akihiro Tsuji (Japan)

The Sex-Related Risk of Venous Thromboembolism Attributed to Recognized Prothrombotic Genotypes
Speaker: Carl Arne Løchen Arnesen (Norway)

Role of ADAMTS13, VWF and FVIII in Deep Vein Thrombosis
Speaker: Maria Teresa Pagliari (Italy)

Clinical and Laboratory Characteristics of Patients with Hereditary Thrombophilias in the North-Western Region of Russia
Speaker: Olga Soldatenkova (Russian Federation)

Characterisation of a Novel F5 Gene Mutation (Ala2114Asp, Factor V Besançon) Associated with Factor V Deficiency and Recurrent Venous Thrombosis
Speaker: Elisabetta Castoldi (the Netherlands)

Assessment of Fibrinolysis Markers in Patients with Lower Limb Deep Venous Thrombosis: A Prospective Case-control Study
Speaker: Saniya Sharma (India)

Afibrinogenemia and Leiden FV Within the Same Family
Speaker: Soraya Hadjali - Saichi (Algeria)

“Gene-gene Interaction” between FXIII-A VAL34LEU and PAI-1 - 675 4G/5G Polymorphisms Can Modify the Risk of Pulmonary Embolism in Young VTE Patients
Speaker: Anna Chechulova (Russian Federation)

Homozygous State of Leiden Mutation in Factor V Associated with Other Genetic and Biochemical Risk Factors and Late Onset of Thrombotic Episodes in Five Clinical Cases
Speaker: Marija Vukovic (Bosnia and Herzegovina)

“Gene-gene Interaction” between PAI-1 - 675 4G/5G and TNF-A -308 G/A Polymorphisms Can Modulate the Risk of Pulmonary Embolism in Young Patients with Venous Thromboembolism
Speaker: Sergei Kapustin (Russian Federation)

Carrier Frequencies of Antithrombin-, Protein C-, or Protein S-deficient Variants Estimated Using a Public Database and Expression Experiments
Speaker: Koichi Kokame (Japan)

De Novo Variants in Antithrombin Deficiency: Incidence and Heterogeneous Mechanisms
Speaker: Maria Eugenia de la Morena-Barrio (Spain)

Structural Basis of the Pro-coagulant Phenotype of Prothrombin Variant Arg553Trp (p.Arg596Trp - Padua 2)
Speaker: Vincenzo De Filippis (Italy)

Pulmonary Embolism and Thrombophilia Gene Mutations: Georgian Population Study
Speaker: Tea Mukhuradze (Georgia)

Decreased Expression of Annexin A2 Is Associated with Reduced Cell Surface Fibrinolysis and Venous Thromboembolism
Speaker: Katherine Hajjar (United States)
Effects of Body Mass Index on the Human Plasma Proteome - Potential Drivers of Obesity-related Cardiovascular Disease?
Speaker: Lucy Goudswaard (United Kingdom)

Post-thrombotic Syndrome

Exploring Alternative Approaches of Using the Villalta Scale to Capture the Post-Thrombotic Syndrome: A Sub-analysis of the ATTRACT Trial
Speaker: Susan R Kahn (Canada)

Leukocyte Gene Expression in Post-Thrombotic Syndrome
Speaker: Aaron Frans Jacob Iding (the Netherlands)

Measuring Functional Limitations after Venous Thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale
Speaker: Frederikus A. Klok (the Netherlands)

VTE and its complications: A Real World View Daryl Pollock, RN, MN CNS Thrombosis/Haemostasis
Speaker: Daryl Pollock (New Zealand)

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome (The TILE Pilot Study): Rationale and Study Protocol
Speaker: Jean-Philippe Galanaud (Canada)

The Impact of Successful Ultrasound-Accelerated Catheter-Directed Thrombolysis on the Prevention of Post-Thrombotic Syndrome: A Post-Hoc Analysis of the CAVA-Trial
Speaker: Pascale Notten (the Netherlands)

Hokusai Post-DVT Study: A Follow-up Study on Long-term Outcomes of Deep Vein Thrombosis in Patients Treated with Edoxaban vs Warfarin
Speaker: Ingrid Bistervels (the Netherlands)

Recanalization of Venous Thrombosis by Robotic Assisted High Frequency Pulsed Cavitational Ultrasound Therapy: 2 Weeks Follow-up in a Swine Model
Speaker: Lina Khider (France)

Study of Plasma miRNAs and Microparticle miRNAs in Severe Forms of Pulmonary Hypertension
Speaker: Julia Oto (Spain)

Post-Thrombotic Syndrome in Patients with Venous Thromboembolism Treated with Dabigatran or Warfarin - a Long-Term Cross-Sectional Follow-up of RE-COVER Study Patients
Speaker: Hilde Skuterud Wik (Norway)

Effectiveness and Safety of Pulmonary Rehabilitation to Reduce Functional Impairment Based on the Post-PE Syndrome
Speaker: Duliëtte Boon (the Netherlands)

Endovascular Management with Iliofemoral Stenting in a Patient with Chronic Venous Occlusive Disease and Antiphospholipid Antibodies
Speaker: Franco Piovella (Italy)

Results of a Dedicated Diagnostic Work-up of Patients with Post-PE Syndrome
Speaker: Duliëtte Boon (the Netherlands)
Assessment of Radiological Signs of Chronic Thromboembolic Pulmonary Hypertension on CTPAs Performed for Acute Pulmonary Embolism Leads to Earlier Diagnosis of CTEPH
Speaker: Duliëtte Boon (the Netherlands)

Prevention of Post-thrombotic Syndrome with Elastic Compressive Stockings
Speaker: Rumjana Apostolovska (Macedonia, the Former Yugoslav Republic of)

Patency and Clinical Outcomes of Venous Recanalization in the Treatment of Postthrombotic Syndrome
Speaker: Lina Khider (France)

Quality of Life (QOL) Assessment Using VEINES/QOL Score for Deep Vein Thrombosis (DVT) Patients in Uruguay
Speaker: Maria Victoria Matosas (Uruguay)

Quality of Life Outcomes after Iliac Vein Stenting for Chronic Deep Venous Obstruction: A Tertiary Centre Experience Using the VEINES-QoL/Sym
Speaker: Rachael Morris (United Kingdom)

Thrombophilia

Are We Choosing Wisely? Heritable Thrombophilia (HT) Testing in a District General Hospital in the UK
Speaker: Leila Khalil (United Kingdom)

Evaluation of Platelet Indices in Patients with Splanchnic Vein Thrombosis
Speaker: Narender Kumar (India)

What Kind of Thrombophilia in Reunion Island?
Speaker: Sabine Mustun (Reunion)

High Prevalence of the Hereditary Anticoagulant Deficiency in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Speaker: TianYu Lian (China)

Use of Direct Oral Anticoagulants in Congenital Thrombophilias
Speaker: Natalie Montanez (United States)

Positive Thrombophilia Study in the Context of Starting Hormonal Treatment in the Gender Dysphory: Experience in a Single Center
Speaker: Bianca Díaz Roldán (Spain)

Increased Levels of Procoagulant Factors and the Risk of Venous Thromboembolism
Speaker: Luca Spiezia (Italy)

Primary Aortic Thrombus with Multiple Visceral Embolisation: A Presenting Manifestation of Chronic Myelomonocytic Leukemia
Speaker: Veerendra Chadachen (Singapore)

Thrombophilia Testing in Patients with Arterial Thrombosis in Routine Clinical Practice
Speaker: Gala Aglaia Méndez Navarro (Spain)

A New Global Assay for Detection of Protein C Pathway-Associated Thrombophilia Using Thrombomodulin-Mediated Clot Waveform Analysis
Speaker: Naoki Hashimoto (Japan)

Thrombophilia Testing in Algerian Pediatric Patients
Speaker: Imene Hocine (Algeria)
The Prothrombin Belgrade Mutation Causing Antithrombin Resistance Does Not Affect Fibrin Clot Formation  
Speaker: Sofija Dunjic (Serbia)

Is May-Thurner Syndrome a Forgotten Cause of Deep Vein Thrombosis?  
Speaker: Sara Lopes (Portugal)

Relevance of Thrombophilia Screening in Adult Renal Transplant Recipients  
Speaker: Dhouha Bahri (Tunisia)

Homozygous Antithrombin Budapest 3 Deficiency Causes Inferior Vena Cava System Agenesis  
Speaker: Carlos Bravo-Perez (Spain)

Inherited Deficiency of Antithrombin, Protein C or Protein S Is Associated with an Increased Risk of Cancer at a Younger Age  
Speaker: Daniela Tormene (Italy)

Mandor’s Disease: A Manifestation of Rare Conditions  
Speaker: Yosra Cherif (Tunisia)

Deep Vein Thrombosis Associated with Protein S Deficiency  
Speaker: Pradana Romadhon (Indonesia)

Relation between the von Willebrand Factor and ADAMTS13 with Venous Thrombosis Risk. Results from the Retrove Project  
Speaker: Dolors Llobet (Spain)

Characterisation of Antithrombin p.Thr147Ala, the First Common Founder Variant from African Origin Responsible for Inherited Antithrombin Deficiency  
Speaker: Belén de la Morena-Barrio (Spain)

Thrombophilia and Thrombotic Complications in Armenia  
Speaker: Heghine Khachatryan (Armenia)

Venous Thrombosis-dominant Congenital Dysfibrinogenemia Presenting with Cerebral Venous Sinus Thrombosis  
Speaker: Hana Iris Lim (United States)

The Presence of Paraproteinaemia in Patients with Antiphospholipid Syndrome - A Single Centre Case Series  
Speaker: Andrew Doyle (United Kingdom)

Risk of Recurrence after a First-lifetime Venous Thrombosis: Impact of Inherited Thrombophilia  
Speaker: Maroua Belhadj (Tunisia)

Thrombophilic Abnormalities Screening in Elderly Women Patients with Venous Thrombosis  
Speaker: Loredana Liliana Hurjui (Romania)

Hypoplasminogenemia - A Forgotten Diagnosis: A Case Series of Genotype and Phenotype Correlation  
Speaker: Rosa Sonja Alesci (Germany)

Efficacy and Safety Profile of Direct Oral Anticoagulants in Consecutive Patients with Severe Hereditary Thrombophilia: A Single-centre Cohort Study  
Speaker: Elena Campello (Italy)
Thrombophilic Mutations in Macedonian Women with Adverse Pregnancy Outcome  
Speaker: Elena Petkovikj (Macedonia, the Former Yugoslav Republic of)

Upregulation of Factor XI in End Stage Renal Disease Is Associated with Increased Thrombin Generation and D-dimer  
Speaker: Debra Hoppensteadt (United States)

Visceral Vein Thrombosis  
Epidemiology and Clinicopathology of Latent versus Active JAK2-Myeloproliferative Neoplasms (MPN) in Splanchnic Venous Thrombosis  
Speaker: Philip A Haddad (United States)

Association of Portal Vein Thrombosis and Clinical Outcomes in Cirrhotic Patients: A Nested Case-Control Study  
Speaker: Pipu Tavornshevin (Thailand)

Case report: Renal Vein Thrombosis Associated with Oral Contraceptive Use and Posterior Nutcracker Syndrome  
Speaker: Abdulaziz AlHumaidi (Saudi Arabia)

Anticoagulant Therapy for Splanchnic Vein Thrombosis: A Systematic Review and Meta-Analysis  
Speaker: Emanuele Valeriani (Italy)

A Retrospective Cohort Study on Splanchnic Vein Thrombosis  
Speaker: Eri Kawata (Iida) (Canada)

Portal Vein Thrombosis Revealing Paroxysmal Nocturnal Hemoglobinuria  
Speaker: Melek Kechida (Tunisia)

Essential Thrombocythemia Complicated with Portal Vein Thrombosis and Liver Cirrhosis - A Case Report  
Speaker: Nina Petkova (Bulgaria)

Budd Chiari Syndrome: Beyond 5 Years of Follow up  
Speaker: Daniela Mezzarobba (Argentina)

VTE Diagnosis  
Dynamic Upper Limb Ultrasound in Idiopathic Upper Extremity Deep Vein Thrombosis  
Speaker: Hiu Lam Agnes Yuen (Australia)

D-Dimer is Useful in the Assessment of Suspected Recurrent Venous Thromboembolism in Patients on Rivaroxaban or Apixaban  
Speaker: Hiu Lam Agnes Yuen (Australia)

Serial Ultrasounds in Deep Vein Thrombosis Diagnosis, a Single Centre Retrospective Review  
Speaker: Ronald Yan (Canada)

Ten Years of Venous Thromboembolism Events in a Large Teaching Hospital: Changing Patterns of Disease  
Speaker: Huw Rowswell (United Kingdom)

Elevated von Willebrand Factor Antigen Levels and Ristocetin Cofactor Activity are Risk Factors in Predicting Deep Vein Thrombosis  
Speaker: Yiming Zhao (China)
Is There a Predictive Value of High Mean Platelet Volume in Early Diagnosis of Venous Thromboembolism in the Emergency Department?  
Speaker: Andrei Braester (Israel)

Optimizing Magnetic Resonance Direct Thrombus Imaging for Differentiating Acute from Chronic Splanchnic Vein Thrombosis  
Speaker: Lisette F. van Dam (the Netherlands)

Diagnosing Deep Vein Thrombosis in Patients with Suspected Symptoms and a Concurrent Malignancy: An Individual Participant Data Meta-Analysis  
Speaker: Toshihiko Takada (the Netherlands)

Comparative Study between Thromboelastography and Conventional Coagulation Tests in Deep Vein Thrombosis  
Speaker: Bin Yan (China)

A Systematic Review and Meta-Analysis on Diagnostic Delay in Pulmonary Embolism  
Speaker: Geert-Jan Geersing (the Netherlands)

An Assessment of the Cost-Effectiveness of Whole-Leg Ultrasound Scans Compared to Proximal Leg Vein Ultrasound Scans in the Diagnosis of Acute Deep Vein Thrombosis  
Speaker: Gianluca Bertone (United Kingdom)

Predictive Accuracy of Computed Tomography Pulmonary Perfusion Imaging for Adverse Outcome in Patients with Acute Pulmonary Embolism  
Speaker: Lisette F. van Dam (the Netherlands)

The Use of ADJUST (age-adjusted) D-Dimer Cut-off in the Assessment of Individuals Over 50 Years Old with Suspected Deep Vein Thromboses Can Decrease the Need for Compression Ultrasonography: Initial Results of a Prospective Primary Care Study  
Speaker: Andy Hughes (United Kingdom)

A Practical Comparison of a PE Diagnostic Approach: Is All Wells in the World?  
Speaker: Lindsey Gerstein (Canada)

Outcome of the Symptomatic Subsegmental Isolated Pulmonary Embolism: The SSPE Padua Study  
Speaker: Davide Ceccato (Italy)

Prospective Study of a Screening Protocol for Venous Thromboembolic Complications in Patients Operated on for Pelvic Ring Fractures  
Speaker: Stéphanie Bonhomme (France)

D-Dimer Plasma Levels and the Anatomical Extension of Acute Symptomatic Deep Vein Thrombosis of the Lower Limbs  
Speaker: Benilde Cosmi (Italy)

Identification of Somatic Mutations Associated with Clonal Hematopoiesis in Unprovoked Venous Thromboembolism  
Speaker: Ana Marín-Quilez (Spain)

Venous Thromboembolism (VTE) Events in Elective and Emergency Orthopaedic Surgery in a Large Teaching Hospital 2011 to 2019  
Speaker: Huw Rowswell (United Kingdom)

Safety of Using the Wells Rule and D-Dimer Test for Excluding Acute Recurrent Ipsilateral Deep Vein Thrombosis  
Speaker: Lisette F. van Dam (the Netherlands)
Immuno-Magnetic Separation (IMS) Allows Efficient and Selective Extraction of Microvesicles Bearing Tissue Factor Activity from Various Liquid Biopsies
Speaker: Corentin Franco (France)

A Combination of Age Adjusted Cut-Off and Preanalytical Conditions Monitoring for Increased DDIM Assay Specificity
Speaker: Ludek Slavik (Czech Republic)

Cost-Effectiveness of Magnetic Resonance Direct Thrombus Imaging for Diagnosing Recurrent Ipsilateral Deep Vein Thrombosis
Speaker: Lisette F. van Dam (the Netherlands)

A Simplified Management Strategy for Suspected Pulmonary Embolism: External Validation of the YEARS Diagnostic Algorithm
Speaker: Helia Robert-Ebadi (Switzerland)

Radiological Parameters on Computed Tomography Pulmonary Angiography Correlate Poorly with Early Mortality from Acute Pulmonary Embolism
Speaker: Ian Wu (Singapore)

D-dimer Diagnostics: An International Assessment of the Quality of Laboratory Testing
Speaker: Carolyne Elbaz (Canada)

Vein Thrombosis after an Osteopathy Session
Speaker: Valentina Kieffer (France)

Impact of Beta-Blockers on the Clinical Diagnosis of Patients with Pulmonary Embolism
Speaker: Farès Moustafa (France)

Determining Predictive Factors of Venous Thromboembolism Using Design of Experiments
Speaker: Gabriel Yoshiaki Ottaiano (Brazil)

High Thrombus Burden and its Correlation with In-hospital Mortality or Right Ventricular Dysfunction in Patients with Acute Pulmonary Embolism and Low-risk Simplified-PESI Score
Speaker: Nicolas Torres (Argentina)

Detection of MicroRNA-126 as a Plasma Biomarker for Diagnosis of DVT
Speaker: Xia Bai (China)

The Significance of Haemostatic System’s Changes in the Assessing of Unfavorable Prognosis in Patients with Burn Injury
Speaker: Elena Klychnikova (Russian Federation)

The Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Venous Thromboembolism and Related Mortality
Speaker: Muhamad Fajri Adda’i (Indonesia)

Acquired Type II (IIb) Protein S Deficiency, Case Report
Speaker: Tereza Fenclova (Czech Republic)

Venous Involvement in Behcet Disease: Clinical Spectrum and Predictive Factors
Speaker: Melek Kechida (Tunisia)

Incidental Pulmonary Embolism in an Internal Medicine Department
Speaker: Ines Naceur (Tunisia)
Scientific Programme

Developing Fluidic Models that Replicate Cephalic Arch Geometry and Flow Conditions of Dialysis Patients to Understand and Predict Access Thrombosis
Speaker: Andres Moya Rodriguez (United States)

Analysis of Hemodynamic and Hemocoagulation Changes in Mortality Structure in Polytrauma Patients
Speaker: Nadezhda Baranova (Ukraine)

A Non-invasive Diagnostic Work-up Is Safe and Efficient to Exclude Pulmonary Embolism in Low Risk Pregnant Women with Suspected Pulmonary Embolism: A Systematic Review and Meta-analysis
Speaker: Milou A. M. Stals (the Netherlands)

Right Ventricular to Left Ventricular Diameter Ratio Assessment with Non-ECG GatedComputed Tomography Scans and its Correlation with Right Ventricular Dysfunction in Acute Pulmonary Embolism
Speaker: Jorge Bilbao (Argentina)

Particularities of Venous Thromboembolism in Systemic Vasculitides
Speaker: Tayssir Ben Achour (Tunisia)

Deep Venous Thrombosis with Atypical Location: About 22 Cases
Speaker: Yosra Cherif (Tunisia)

Photoshop-GSM versus Customized-GSM Software to Analysis of Echogenicity of Residual Venous Obstruction
Speaker: Arlindo Lemos (Brazil)

VTE Epidemiology

Risk Factors and Hemostatic Aspects of Aseptic Cerebral Venous Sinus Thrombosis
Speaker: Kostiantyn Stepanchenko (Ukraine)

Epidemiologic Study of Patients with Thrombotic Events Referred to Tertiary Hospital in Southern Iran
Speaker: Mehran Karimi (Iran, Islamic Republic of)

Management Strategies and Clinical Outcomes in Patients with Inferior Vena Cava Thrombosis: Data from the GARFIELD-VTE Registry
Speaker: Omri Cohen (Italy)

The Influence of Anemia on Clinical Outcomes in Venous Thromboembolism: Results from GARFIELD-VTE
Speaker: Shinya Goto (Japan)

Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE
Speaker: Pantep Angchaisuksiri (Thailand)

Influence of Body Mass Index on Outcomes in Patients with Venous Thromboembolism: Insights from GARFIELD-VTE
Speaker: Jeffrey I. Weitz (Canada)

Risk Factors of Thrombotic Complications in Thai Thalassemia Patients
Speaker: Nonthakorn Hantrakun (Thailand)

The Association of BMI and Waist Circumference Improves the Prediction of VTE Risk as Compared to BMI Alone
Speaker: Lucia Maria Caiano (Italy)
Multidisciplinary Approach of Deep Venous Thrombosis (DVT) in Vall d’Hebron University Hospital: Two Years’ Experience
Speaker: Milagros Aurora Suito Alcántara (Spain)

A Retrospective Study of Incidence of Venous Thromboembolism (VTE) and Prevalence of Risk Factors Associated with VTE in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience
Speaker: Bharath Ram S (India)

Risk Factors and Patterns of Lower Limb Deep Venous Thrombosis in Gombe, North-Eastern Nigeria
Speaker: Saleh Yuguda (Nigeria)

Clinical Spectrum and Prothrombotic Risk Factors of Cerebral Venous Sinus Thrombosis in Children
Speaker: Özcan Bör (Turkey)

Saddle Pulmonary Embolism: Demographics, Clinical Presentation, and Outcomes
Speaker: Kevin Wong (United States)

Risk of Receiving a Permanent Work-Related Disability Pension After Incident Venous Thromboembolism
Speaker: Helle Jorgensen (Norway)

A Single-Centre Case Series of Venous Thromboembolic Disease
Speaker: José Portillo Sánchez (Spain)

Impact of Socioeconomic Status on the Risk of Receiving a Permanent Work-Related Disability Pension After Incident Venous Thromboembolism
Speaker: Helle Jorgensen (Norway)

High Levels of Uric Acid Are Associated with Increased Risk of Recurrent Venous Thromboembolism
Speaker: Lara De Lucchi (Italy)

Impact of Clostridium Difficile Infections on In-Hospital Outcomes of Venous Thromboembolism (DVT or PE) Hospitalizations
Speaker: Khushali Jhaveri (United States)

Plasma Levels of Complement Factor D and Future Risk of Incident Venous Thromboembolism
Speaker: Tobias Frischmuth (Norway)

Correlation between Intrinsic D-Dimer Levels and D-Dimer Measured at First Venous Thromboembolism (VTE)
Speaker: Fridtjof B. Rinde (Norway)

Impact of Competing Risk of Death on the Cumulative Incidence of Venous Thromboembolism in a Nationwide Danish Cohort of Men and Women
Speaker: Carl Arne Lachen Arnesen (Norway)

Recovery from Acute Kidney Injury in Patients with Pulmonary Embolism: A Monocenter Study
Speaker: Laurent Bertoletti (France)

Tissue Factor Pathway Inhibitor, Activated Protein C Resistance and Risk of Venous Thrombosis Associated with Menopausal Hormone Therapy
Speaker: Deeksha Khialani (the Netherlands)
**Scientific Programme**

**Incidence of Chronic Thromboembolic Pulmonary Hypertension: Results from a Longitudinal Prospective Cohort (Osiris Study)**
Speaker: Remedios Otero-Candelera (Spain)

**The Characteristics of Patients with Isolated Superficial Vein Thrombosis of the Legs, their Follow-up and Outcomes**
Speaker: Jana Hirmerova (Czech Republic)

**Retinal Vein Thrombosis and the Association with Inherited Thrombophilia, Cardiovascular Risk Factors and the Risk of Occult Cancer. a Prospective Study**
Speaker: Daniela Tormene (Italy)

**Association of Surgical and Medical Hospitalizations with Venous Thromboembolism (VTE) in a Primary Care Population**
Speaker: Ximena Jordan Bruno (United States)

**Prevalence of Bilateral DVT in Ghanaian Patients**
Speaker: Dela Fiawoo (Ghana)

**A Decade of Experience in Peripherally Inserted Central Catheter (PICC) Related Thrombosis in Hematological Malignancies of a Single Spanish Center**
Speaker: Marta Fonseca (Spain)

**Seasonality in Hospitalizations for Pulmonary Embolism between 2006 - 2016**
Speaker: Andrea Torres (United States)

**Relevance of Immobility as Deep Vein Thrombosis Risk Factor for Medically Ill Patients**
Speaker: Michelangelo Sartori (Italy)

**Risk of Venous Thrombosis in the Elderly: Lifestyle and its Joint Effect with Factor V Leiden and Prothrombin 20210A**
Speaker: Huijie Wang (the Netherlands)

**Characterising the Burden of Hospital-acquired Venous Thromboembolism Arising during Admission and Following Discharge in an Irish Hospital Group Serving a Population of over One Million Individuals**
Speaker: Karl Ewins (Ireland)

**The Season Role in the Occurrence of Thromboembolic Disease**
Speaker: Wafa Skouri (Tunisia)

**Catheter-associated Thrombosis at the Hematology Center: Analysis of 2212 Medical Records from a Developing Country**
Speaker: Liana Hambardzumyan (Armenia)

**Prevalence of Pulmonary Embolism in Patients Accessing the Emergency Department, Reported by Country of Study: A Systematic Review and Meta-analysis**
Speaker: Federico Germini (Canada)

**The Impact of Body Mass Index (BMI) Dynamics on the Risk of Venous Thromboembolism Recurrence (VTE)**
Speaker: Leslie Padrnos (United States)

**The Review of the Data from the National Registry of Thrombophilic States in the Slovak Republic**
Speaker: Lucia Stanciakova (Slovakia)
Apo(a) Polymorphisms rs3798220 and rs10455872 in a Brazilian Population of Deep Venous Thrombosis Patients
Speaker: Isabella Macedo Toni (Brazil)

Epidemiology and Risk Factors for Thrombosis in Pregnancy and Puerperium. Experience in One Reference Center in Mexico
Speaker: Eunice Rojas-Zaldivar (Mexico)

VTE Prophylaxis
Factors Associated with Major Bleeding Risk in Medical and Surgical Patients: Findings from a Multi-Center, Cross-Sectional Study (DissolVE-2)
Speaker: Zhu Zhang (China)

Post-Discharge Hospital-Associated Venous Thromboembolism
Speaker: Hiu Lam Agnes Yuen (Australia)

Risk Factors and Frequency of Recurrent Long-Term Venous Thromboembolism After Superficial Vein Thrombosis of The Lower Limbs
Speaker: Konstantinos M. Nikolakopoulos (Greece)

Clinical Indications and Efficacy of Low Molecular Weight Heparin (LMWH) in Pregnancy
Speaker: Romana Akbar (Pakistan)

VTE Prophylaxis Performance in a Tertiary and Secondary Level Hospital in Ireland
Speaker: Alice Talbot (Ireland)

Prevention of Thrombogenesis in the Development of Metabolic Syndrome
Speaker: Ludmila Lyapina (Russian Federation)

Is Low Molecular Weight Heparin-Calibrated Chromogenic Anti-Xa Assay Suitable for Assessing Anticoagulant Effect of Apixaban in Adolescents?
Speaker: Ivana Ćelap (Croatia)

Thromboprophylaxis to International Conferences and Number of Thromboses (PINOT) study
Speaker: Hannah Stevens (Australia)

A Prospective Observational Multicentre Study to Assess the Incidence of and Risk Factors for (T) Thrombosis (I) in Patients with (L) Lower (L) Limb (I) Injuries (R) Requiring (I) Immobilisation in Ireland (TILLIRI)
Speaker: Denis O’Keeffe (Ireland)

The Application of the Lymphoma International Prognostic Index (IPI) to Predict Venous Thromboembolic Events (VTE) in Patients with Diffuse Large B-Cell Lymphoma (DLBL)
Speaker: Hikmat Abdel-Razeq (Jordan)

Can an Effective anticoagulation Clinic Reduce Bleeding Risks?
Speaker: Ahmed Al-Hassani (United Kingdom)

Weight-Adjusted versus Fixed Dose Heparin Thromboprophylaxis in Hospitalized Obese Patients: A Systematic Review and Meta-Analysis
Speaker: Davide Ceccato (Italy)

Efficacy and Safety of Pre-Operative Insertion of Inferior Vena Cava Filter in Patients Undergoing Bariatric Surgery: A Systematic Review
Speaker: Rick Ikesaka (Canada)
Incidence and Risk Factors of Venous Thromboembolism in Patients Undergoing Bariatric Surgery  
Speaker: Valentina Baez (United States)

The Added Benefit of Mechanical Compression to Prevent VTE after Hip or Knee Arthroplasty: Post-Hoc Analysis of the EPCATII Study  
Speaker: Christopher J.M. Green (Canada)

Weight-Adjusted Tinzaparin for Venous Thromboembolism Prophylaxis in Bariatric Surgery Patients Weighing 160kg or More  
Speaker: Allen Li (Canada)

The Application of the Original and a Modified Version of the ThroLy Risk Assessment Model (RAM) to Predict Venous Thromboembolic Events (VTE) in Patients with Diffuse Large B-Cell Lymphoma (DLBL)  
Speaker: Hikmat Abdel-Razeq (Jordan)

Antithrombotic Offices of the Arkhangelsk Region Russia  
Speaker: Nadezda Vorobyeva (Russian Federation)

Lysophosphatidic Acid Promotes Thrombus Stability by Inducing Rapid Formation of Neutrophil Extracellular Traps via a Peptidylarginine Deiminase 4-Dependent Pathway: A New Mechanism of Thrombosis  
Speaker: Rui Peng (China)

Prevalence and Predictors of Thromboembolic Events in Patients with Gastric Cancer  
Speaker: Razan Mansour (Jordan)

Real Life Experience of an Antithrombotic Stewardship Program for Thrombosis Prophylaxis during Hospitalisation in a Large Teaching Hospital  
Speaker: Mehmet Taskopru (the Netherlands)

Venous Thromboembolism in Patients with Renal Transplantation  
Speaker: Daniela Poli (Italy)

Is the Caprini Score a Reliable Tool to Predict the Risk of Venous Thrombosis in Orthopedic Patients?  
Speaker: Roberto Zambelli (Brazil)

Visualization of Thrombin Formation on Activated Platelets and Fibrin Formation in Venous Flow Condition  
Speaker: Naoko Sugita (Japan)

Prevalence and Predictors of Venous Thromboembolic Events (VTE) in Patients Undergoing Salvage Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Lymphomas  
Speaker: Mohammad Ma'koseh (Jordan)

Dilemma in Initiating Thromboprophylaxis in Critically Ill Patients  
Speaker: Pearla Lasut (Indonesia)

Predictors of Venous Thromboembolic Events (VTE) in Patients with Testicular Cancer  
Speaker: Rashid Abdel-razeq (Jordan)

Efficacy and Safety of Apixaban for the Primary Prevention of VTE among Patients with Gastrointestinal Cancers: A Post-hoc Analysis of the AVERT Trial  
Speaker: Danyal Ladha (Canada)
Scientific Programme

An Audit Examining Information Provided to Patients Regarding Venous Thromboembolism (VTE) at Discharge
Speaker: Kishan Karia (United Kingdom)

Preventing Maternal Death and Morbidity from Venous Thromboembolism (VTE): Results from a VTE Risk Score Trial during Hospitalization
Speaker: Venina Barros (Brazil)

The Incidence of Venous Thromboembolism along with Adherence to Guideline in Major Orthopedic Surgery
Speaker: Hun-Gyu Hwang (Korea, Republic of)

Effectiveness of Implementing a Prophylaxis Protocol for Thromboembolic Events in Patients Admitted to a Tertiary Hospital
Speaker: Monica Amorim de Oliveira (Brazil)

Prevention of Catheter Complications in Patients with Cystic Fibrosis: Enoxaparin vs. a Direct Oral Anticoagulant
Speaker: Paul Dobesh (United States)

Effectiveness of Thromboprophylaxis in the Prevention of Peripherally Inserted Central Catheter (PICC) Associated Venous Thromboembolism in Pediatric Patients: A Case-control Study
Speaker: Matthew Speckert (Canada)

Point-of-Care Monitoring of Unfractionated Heparin Treatment in the Intensive Care Unit: Preliminary Results of a Comparative Study with Laboratory-based APTT and Anti-Xa Activity
Speaker: Benjamin Lardinois (Belgium)

Thromboprophylaxis Audit in a Public Hospital - The Impact of Protocol Implementation
Speaker: Pedro Henrique Fernandes do Carmo Las Casas (Brazil)

VTE Treatment

Two Weeks of Low Molecular Weight Heparin for Isolated Symptomatic Distal Vein Thrombosis (TWISTER Study): Final Analysis of 242 Patients
Speaker: Eileen Merriman (New Zealand)

Fixed Dose Rivaroxaban Can Be Prescribed in Extremes of Bodyweight, Results of a Population Pharmacokinetic Analysis
Speaker: Victoria Speed (United Kingdom)

Management and Outcomes of Idiopathic Axillosubclavian Vein Thrombosis: Impact of the Treating Specialty
Speaker: Hiu Lam Agnes Yuen (Australia)

Rivaroxaban for Extended Thromboprophylaxis in Acutely Ill Medical Patients 75 Years of Age or Older
Speaker: Walter Ageno (Italy)

Variability of Management of Peripheral Catheter-Related Upper Extremity Superficial Vein Thrombosis
Speaker: Hiu Lam Agnes Yuen (Australia)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the Mariner Trial
Speaker: Alex Spyropoulos (United States)
**Scientific Programme**

**Reasons and Associated Outcomes in Delayed Anticoagulation in Venous Thromboembolism**  
Speaker: Nichole E Brunton (United States)

**Effect of Antiplatelet Therapy on Clinical Outcome of Patients Treated with Anticoagulation for Acute Venous Thromboembolism**  
Speaker: Ana I Casanegra (United States)

**Preliminary Investigation of Venous Thromboembolism Risk Assessment and Prophylaxis for Medical In-patients: A Multicenter Study in Nigeria**  
Speaker: Angela Ogechukwu Ugwu (Nigeria)

**Direct Oral anti-Xa Inhibitors for Treatment of Venous Thromboembolism after Gastrectomy: Report on 3 Cases**  
Speaker: Lisbeth Eischer (Austria)

**Apixaban versus Heparin/Warfarin Treatment in Pulmonary Embolism: Results from the UK Apixaban Length-of-Stay Pulmonary Embolism - Hospital Admissions Study (ALPHA-PE)**  
Speaker: Steven Lister (United Kingdom)

**Demographics and Clinical Outcomes of Patients Younger than 40 Years Treated for Acute Venous Thromboembolism**  
Speaker: Danielle T Vlazny (United States)

**Pre-Treatment with Heparinoids Does Not Impact Clinical Outcome of Apixaban and Rivaroxaban in Patients Treated for Venous Thromboembolism**  
Speaker: Danielle T Vlazny (United States)

**Demographics and Clinical Outcomes of Older Adults Treated for Acute Venous Thromboembolism**  
Speaker: Rahul Chaudhary (United States)

**Management of Intermediate-High Risk Pulmonary Embolism Utilizing a PE Response Team**  
Speaker: Yuri Matusov (United States)

**Inferior Vena Cava Filter (IVCF) Utilization: Quality Assurance at a Quaternary Care Medical Center**  
Speaker: June Choe (United States)

**Management and Outcomes Following Subsegmental Pulmonary Embolism: Single Centre Experience at King’s College Hospital**  
Speaker: Rita Pardal (United Kingdom)

**Edoxaban for the Long-Term Therapy of Venous Thromboembolism in Real-Life RIETE Registry**  
Speaker: Giuseppe Camporese (Italy)

**Management of Acute Venous Thromboembolism in Patients Taking Antiplatelet Therapy: A Bi-Center Analysis**  
Speaker: Marie Giraud (France)

**Edoxaban Treatment of Venous Thromboembolism in Routine Clinical Practice in the Non-Interventional Global ETNA-VTE Program: A Sub-Analysis by Age Groups**  
Speaker: Giancarlo Agnelli (Italy)

**The Use of Fondaparinux for Recurrent Thrombotic Events**  
Speaker: Zara Sayar (United Kingdom)
Role of Residual Pulmonary Vascular Obstruction on the Risk of Long-Term Recurrence of Venous Thromboembolism After Pulmonary Embolism: A Cohort Study
Speaker: Marco Paolo Donadini (Italy)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in a Large Daily Practice Cohort
Speaker: Stephan V. Hendriks (the Netherlands)

Home Treatment Compared to Initial Hospitalization in Patients with Acute Pulmonary Embolism in the Netherlands: A Cost Analysis
Speaker: Stephan V. Hendriks (the Netherlands)

Direct Oral Anticoagulants and Vitamin K Antagonists for Treatment of Cerebral Vein Thrombosis
Speaker: Marco Capecchi (Italy)

Risk of Bleeding of Concomitant Antiplatelet and Anticoagulation Therapy in Patient Treated for a Venous Thromboembolic Event
Speaker: Antoine Fayol (France)

Long-Term Management of Anticoagulants in Patients with Cancer-Associated Thrombosis (CAT) Beyond 6 Months: A 432-Patient Retrospective Non-Interventional Study
Speaker: Ludovic Plaisance (France)

Sodium Valproate-induced Drug Interactions with DOAC Anticoagulant Activity: A Case Report
Speaker: Ivanka Paskaleva (Bulgaria)

Hypermenorrhea and Menometrorrhagia during Rivaroxaban Therapy
Speaker: Olga Dzhenina (Russian Federation)

Rivaroxaban versus Warfarin for Treatment and Prevention of Recurrent Venous Thromboembolism in Obese Patients
Speaker: Olivia S. Costa (United States)

Venous Thromboembolism Profile and Management Differences between Sexes in a RIETE’s Hospital in Brazil
Speaker: Ana Rocha (Brazil)

The Impact of an Educational Intervention in Patients with Atrial Fibrillation Treated with Warfarin
Speaker: Maria Auxiliadora Parreiras Martins (Brazil)

90-Day Follow up in Patients with Suspected Deep Vein Thromboses (DVT) who Have Had a DVT Excluded: Should this Be Routine Clinical Practice?
Speaker: Andy Hughes (United Kingdom)

Hokusai Post-PE Study: A Follow-up Study on Long-Term Outcomes of Pulmonary Embolism in Patients Treated with Edoxaban vs Warfarin
Speaker: Roisin Bavalia (the Netherlands)

Development of Cyclic Peptide Inhibitors of Coagulation Factor Xla for Safer Anticoagulation
Speaker: Vanessa Carle (Switzerland)

Risk Factors of Hemorrhagic Complications on the Anticoagulant Therapy
Speaker: Nadezda Vorobyeva (Russian Federation)
EmpoderACO: Elaboration and Validation of a Protocol for Behavioral Change in Patients on Warfarin
Speaker: Maria Auxiliadora Parreiras Martins (Brazil)

Evaluation of Thrombin and Fibrin Generation in Venous Thromboembolism (VTE) Patients Receiving Anticoagulation
Speaker: Julie Wang (Australia)

Variability in Exposure to Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in Hospitalised Patients
Speaker: Emmanouela Kampouraki (United Kingdom)

Heparin Induced Thrombocytopenia in an Obese Pregnant Woman with Venous Thrombosis
Speaker: Matija Kozak (Slovenia)

ETNA-VTE Europe: The Effect of Body Mass Index on 12-Month Outcomes in VTE Patients with Edoxaban
Speaker: Marc Schindewolf (Switzerland)

Predicting Recurrence and Bleeding in Patients with Venous Thromboembolism: A Systematic Review and Critical Appraisal of Prediction Models
Speaker: Maria Adriana de Winter (the Netherlands)

ETNA VTE Europe: A Contemporary Snapshot of VTE Patients Treated with Edoxaban in Clinical Practice across Eight European Countries
Speaker: Alexander Cohen (United Kingdom)

Upper Extremities Deep Vein Thrombosis and DOAC Treatment: a Prospective Cohort Study
Speaker: Maria Cristina Vedovati (Italy)

Saddle Pulmonary Embolism in the Era of Incidental Events: Incidence, Clinical Findings and Outcomes in a Single Center Cohort
Speaker: Mario Aramberri (Spain)

Early Physiotherapy Intervention Reduces the Long Term Effects of Venous Thromboembolism and Promotes an Improved Quality of Life: Results from a Pilot Study
Speaker: Regitse Lewis (United Kingdom)

Retrospective Study of Patients with Upper Extremity Clots Presenting to Emergency Departments in Tertiary Care Hospitals in a Major Canadian City in the Last Five Years
Speaker: Tania Pannu (Canada)

How Often Measurements of Direct Oral Anticoagulant Levels Have Consequences in Anticoagulation Management
Speaker: Roisin Bavalia (the Netherlands)

Survey on the Prescription and Biological Monitoring of Direct Oral Anticoagulants in Algeria
Speaker: Sarra Bounaas (Algeria)

Outcomes of the First Australian Pulmonary Embolism Response Team (PERT) Model of Care for Intermediate to High Risk Pulmonary Embolism
Speaker: Jennifer Curnow (Australia)

Anticoagulant Therapy for Splanchnic Vein Thrombosis in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis
Speaker: Emanuele Valeriani (Italy)
Analysis of Outcomes Following Inferior Vena Cava (IVC) Filter Placement in a Single Center Population
Speaker: Claudio Enciso (Argentina)

Single Centre Experience of DOAC Use in Patients with Antiphospholipid Syndrome (APS) with Venous Thromboembolism
Speaker: Karen A Breen (United Kingdom)

Anticoagulation in Cirrhosis: Thrombin Generation Assay vs Anti FXa Activity
Speaker: Silvina Pons (Argentina)

Investigation of the Optimal Dose of aPCC in Reversing the Effect of Factor Xa Inhibitors Rivaroxaban and Apixaban- an in vitro Study
Speaker: Nina Haagenrud Schultz (Norway)

Time in Therapeutic Range in Venous Thromboembolic Diseases in a North African Geriatric Population
Speaker: Maroua Mrouki (Tunisia)

Clinical Characteristics and Outcomes of Non-cancer, Non-CVC Associated upper Extremity DVT
Speaker: Omri Cohen (Italy)

Venous Recanalization after a Thromboembolic Event in a North Africanan Population
Speaker: Maroua Mrouki (Tunisia)

Antithrombin III Levels Immediately Following Acute Venous Thromboembolism
Speaker: Christopher Kabrhel (United States)

Concentration Levels of Direct Oral Anticoagulants and Clinical Relevance in a Tertiary Hospital
Speaker: Filipa Martins Pereira (Portugal)

Antithrombotic Stewardship: A Novel Approach to Appropriate Anticoagulant Prescription
Speaker: Maral Koolian (Canada)

Management Strategy of Venous Thrombosis in a Dialysis Patient with History of Heparin Induced Thrombocytopenia
Speaker: Putu Amrita (Indonesia)

A Case Report of Deep Vein Thrombosis after Kidney Transplantation
Speaker: Ira Puspitawati (Indonesia)

Extended Treatment in Unprovoked Venous Thromboembolism: What Is Important to Patients?
Speaker: Anouk van de Brug (the Netherlands)

The Increasing Bleeding Risk from Drug-drug Interactions in Patients with Direct Oral Anticoagulants
Speaker: Ji Yun Lee (Korea, Republic of)

Improvements in Short- and Long-term Outcomes in Patients with Pulmonary Embolism after Outpatient Pulmonary Rehabilitation
Speaker: Stephan Nopp (Austria)

Efficacy of Reversible Factor Xa Inhibitors is Related to the Level of Factor VIII: Best Practice is Adjustment of the Dose for Factor VIII Level?
Speaker: Cornelis Kluft (the Netherlands)
Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: A Systematic Review  
Speaker: Marta Bellesini (Italy)

Anticoagulation Control with the Point-of-Care INR: A Retrospective Pre-/Post-analysis  
Speaker: Nicoletta Riva (Malta)

Association Between Index VTE Event and 12-Months Outcomes for Patients in Routine Clinical Practice Enrolled in the ETNA-VTE-Europe Registry  
Speaker: Michiel Coppens (the Netherlands)

Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Patient Characteristics, Treatment Trends and Patterns  
Speaker: Waleed Ghanima (Norway)

Major Bleeding Complications from Direct Oral Anticoagulants in Thai Adult Patients  
Speaker: Pitiphong Kijrattanakul (Thailand)

Long-term Anticoagulant Treatment of Splanchnic Venous Thrombosis in High Risk Patients: Direct Oral Anticoagulants vs Vitamin K Antagonists  
Speaker: Alessandra Serrao (Italy)

Direct Oral Anticoagulants in Comparison with Vitamin K Antagonists and Antiplatelet Agents on Timing and Outcomes in Hip Fracture Surgery Patients Older than 75: The ORTHO-GER-DOAC Study  
Speaker: Benilde Cosmi (Italy)

The Effect of rs4148738 Polymorphism of ABCB1 on the Plasma Concentrations of Direct Oral Anticoagulants and Bleeding and Thromboembolic Complications  
Speaker: Benilde Cosmi (Italy)

Direct Oral Anticoagulants in Patients with Severe Familial Thrombophilia  
Speaker: Daniela Tormene (Italy)

Cerebral Vein Thrombosis Treatment with Direct Oral Anticoagulants: A Case Series  
Speaker: Sofia Barbar (Italy)

An Evaluation of the Basis for Anti-Xa Testing in Patients on Low Molecular Weight Heparin and its Impact on Subsequent Management  
Speaker: Shu Hui Yeang (Singapore)

May Thurner Syndrome, Experience on Argentinean Hospital  
Speaker: Daniela Mezzarobba (Argentina)

Systematic Review of the Risk of Bleeding in Patients with Chronic Kidney Disease Treated with Tinzaparin  
Speaker: Esteve Colomé (Spain)

The Psychosocial Impact of Venous Thromboembolism: An Exploratory Systematic Review and Narrative Synthesis  
Speaker: Gabrielle Saul (United Kingdom)

Correlation of Reperfusion Therapy and In-hospital Mortality in Patients with Intermediate Risk Acute Pulmonary Embolism and Right Ventricular Dysfunction  
Speaker: Jose Bonorino (Argentina)
Risk of Intracranial Bleeding in Patients with Primary Brain Cancer Receiving Therapeutic Anticoagulation for Venous Thromboembolism: A Meta-analysis  
Speaker: Marzia Giordano (Italy)

Correlation between Anti-Xa Activity and Plasmatic Levels of Apixaban  
Speaker: Diego Velasco (Spain)

The Effect of Postoperative Analgesia on the Hemostatic System in Gerontological Patients with Multiple Trauma  
Speaker: Yuliya Volkova (Ukraine)

VTE Treatment in Routine Clinical Practice: A Pre-specified Combined Evaluation of XALIA and XALIA-LEA with Additional Analyses of Special Patient Populations  
Speaker: Sylvia Haas (Germany)

ETNA-VTE Global: Evaluation of Bleeding Risk Based on VTE-BLEED Score on 12-month Outcomes in a Population Treated with Edoxaban  
Speaker: Alexander Cohen (United Kingdom)

DOACs in Real Clinical Practice  
Speaker: Maria Hulikova (Slovakia)

Predicting Factors for Pulmonary Embolism Response Team (PERT) Activation in a General Pulmonary Embolism Population  
Speaker: Christian Schmidt Mortensen (Denmark)

A Single Centre Experience on the Use of Direct Oral Anticoagulants in People with Human Immunodeficiency Virus (HIV)  
Speaker: Sheena Patel (United Kingdom)

The Use of Thrombolytic Therapy in a Multidisciplinary Pulmonary Embolism Response Team  
Speaker: Anders Kramer (United States)

Impact Analysis of Prognostic Stratification for Pulmonary Embolism (iAPP): A Randomized Controlled Trial  
Speaker: Alessandra Grittini (Italy)

Direct Oral Anticoagulants vs. Warfarin for the Treatment of Venous Thromboembolism in Patients with Thrombophilia. A Single Center Experience  
Speaker: Maha Elsebaie (United States)

Appropriateness of Direct Oral Anticoagulant Prescriptions in Emergency Department Outpatients with Acute Deep Vein Thrombosis  
Speaker: Justin Tabah (Canada)

E-selectin Inhibitor Is Superior to LMWH for Treatment of Experimental Venous Thrombosis  
Speaker: Daniel Myers, Jr (United States)

Heparinox, a Generic Version of Low Molecular Weight Heparin Enoxaparin, Is Bioequivalent to the Branded Version  
Speaker: Dalia Qneibi (United States)

Implementation of a Text-message Intervention to Warfarin Users in a Brazilian Primary Care Setting  
Speaker: Maira Viana Rego Souza e Silva (Brazil)
**Scientific Programme**

Optimal Duration and Dose Intensity of the Anticoagulation Therapy with Doacs in Venous Thromboembolism: Retrospective, Cohort Study “Real Choice”
Speaker: Angelo Ghirarduzzi (Italy)

National Survey about Management of Venous Thromboembolism (VTE) Associated with Pregnancy / Puerperium or Oral Contraceptives in Uruguay
Speaker: Valentina Mérola (Uruguay)

Biological and Pharmacological Profiling of Pentosan Polysulfate (PPS) in Comparison to Heparin and its Relative Neutralization by Protamine Sulfate
Speaker: Vishnu Venkitasubramony (United States)

Direct Oral Anticoagulants and Antiepileptic Drugs: Is There Room for Concurrent Treatment?
Speaker: Sofia Barbar (Italy)

---

**On-Demand Poster Session**

**Women’s Health Abstracts**

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

**Estrogens and Progestinics**

Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk
Speaker: Jonathan Douxfils (Belgium)

Hematologic Alterations in Patients Undergoing Controlled Ovarian Stimulation for in vitro Fertilization: A Prospective Observational Study
Speaker: Maria T. DeSancho (United States)

Development and External Validation of a Risk Assessment Model for First Venous Thromboembolism in Women Starting Combined Oral Contraceptives
Speaker: Deeksha Khialani (the Netherlands)

Speaker: Deeksha Khialani (the Netherlands)

Knowledge vs Actual Thrombotic Risks Associated with Hormonal Contraception in Young Women
Speaker: Yan Deng (Canada)

Low Dose Warfarin (LDW) for the Prevention of Hypercoagulation of Blood and Venous Thromboembolism (VTE) in Women Receiving Hormone Replacement Therapy (HRT)
Speaker: Vladimir Sukhanov (Russian Federation)

Use of Oral Contraceptives (OCs) and Thrombin Generation: Cross-sectional Analysis of the Longitudinal Study of Adult Health (ELSA-Brazil)
Speaker: Thaís Batista (Brazil)

Levonorgestrel Releasing Intrauterine System (LNG-IUS) in a Patient with Deep Endometriosis, Adenomyosis and Behcet’s Disease: Case Report
Speaker: Rayana Valéria Cruz (Brazil)
Lack of Association between the Use of Female Hormones and Platelet Volume Indexes: Evidence from the Longitudinal Study of Adult Health (ELSA-Brasil)
Speaker: Thaís Resende (Brazil)

Pregnancy and Pregnancy Complications

Management of a Pregnancy in a Woman with Hypodysfibrinogenemia: An Experiment in Strasbourg
Speaker: Dominique Desprez (France)

Study of the State of the Hemostatic System in Women with Various Pregnancy Complications
Speaker: Irina Gribkova (Russian Federation)

Analysis of Population Values in Pregnant Women
Speaker: María Luisa Iglesias Varela (Argentina)

Comparative Study of the Clinical Application of Two Bleeding Grading Systems for Pregnant Women with Immune Thrombocytopenia (ITP)
Speaker: Mei Juan Huang (China)

Maternal Thrombocytopenia in Women Initiating Antenatal Care: A Hospital-Based Study
Speaker: Hannah Omunakwe (Nigeria)

Pregnancy Complications among Filipino Women
Speaker: Cherry Ann Durante (Philippines)

Haematologic and Haemorheologic Parameters of Pre-Eclamptic Patients in a Nigerian Tertiary Hospital
Speaker: Patience Akpan (Nigeria)

Systematic Review of Viscoelastic Testing (TEG/ROTEM) in Obstetrics and Recommendations for Future Studies
Speaker: Ariunzaya Amgalan (United States)

Reassessment of Venous Thromboembolism Risk and Prophylaxis in Post-Delivery Period of Healthy Women
Speaker: Andrei Braester (Israel)

Safety of Withholding Antithrombotic Treatment in Pregnanacies after Antiphospholipid Antibodies Disappearance in Women with Obstetric Antiphospholipid Syndrome, a Cohort Study
Speaker: Maria Manuela Clavijo (Argentina)

Microvesicles, Fibrinolytic and Coagulation Biomarkers in Blood from Pregnant Women
Speaker: Sylvie Bouvier (France)

D-Dimer Variability in the Postpartum Period
Speaker: Tanja Malinova (Macedonia, the Former Yugoslav Republic of)

Anticoagulation for Women with Mechanical Heart Valves during Pregnancy: A Survey
Speaker: Isabelle Malhame (Canada)

Multidisciplinary Care of Pregnancies with VWD Improves Rates of Primary Postpartum Hemorrhage
Speaker: Sajida Kazi (Canada)
Systemic Evaluation of Neuroserpin, Interleukin-17 and Hemostatic Factors in Association with Clinical Parameters in Preeclamptic Women: A Principal Component Analysis Approach
Speaker: Luiza Oliveira Perucci (Brazil)

Efficacy and Safety of Low-Molecular-Weight Heparin for the Prevention of Pregnancy-Related Recurrent Venous Thromboembolism and Obstetrical Complications
Speaker: Maria Abbattista (Italy)

Investigation of Risk Factors of Deep Vein Thrombosis during Pregnancy Using a CFD Model
Speaker: Qudus Jimoh-Taiwo (South Africa)

Low Molecular Weight Heparins in the Prevention of Placenta-Mediated Complications in Carriers of the Prothrombin G20210A Mutation
Speaker: Mariya Nikolaeva (Russian Federation)

Approach to Venous Thromboembolism Risk in Women with Physical Disability in Pregnancy - Multidisciplinary Survey
Speaker: Sajida Kazi (Canada)

Thromboprophylaxis during Pregnancy - 10-year Review of Women Seen in the Haematology Clinic at King's College Hospital (KCH)
Speaker: Jignesh Patel (United Kingdom)

The Role of Antithrombotic Therapy in the Prevention of Adverse Pregnancy Outcomes
Speaker: Alexander Makatsariya (Russian Federation)

Efficiency of Inhibition of Thrombin Generation and Stimulation of Fibrinolysis in vitro Fertilization Programs
Speaker: Mariya Nikolaeva (Russian Federation)

Peculiarities of the Hemostasis System in Pregnant Women with Severe Preeclampsia
Speaker: Bakhodir Kurbanov (Uzbekistan)

Histone H4 Plasma Levels in Women with Pregnancy Complications
Speaker: Luca Spiezia (Italy)

Lack of Disease Modification of HbF on Pregnant Women with Sickle Cell Disease
Speaker: Charles Kenworthy (United States)

Pregnancy Complications and Outcomes in Women with Moderate and Severe von Willebrand Disease (VWD)
Speaker: Ozlem Turan (United Kingdom)

Alternative Complement Pathway Activation in the Severe Hypertensive Disorders of Pregnancy
Speaker: Reiko Neki (Japan)

Mean Platelet Volume from Adolescent to Adult and during Pregnancy
Speaker: Yue Xu (China)

Deviations in Red Blood Cell Gas Transport Function in Pregnant State
Speaker: Ekaterina lastrebova (Russian Federation)

Antithrombotic Therapy for Pregnant Woman with Bland-White-Garland Syndrome and Prosthetic Mitral Valves
Speaker: Madina Arslanbekova (Russian Federation)
Scientific Programme

Early Plasma Transfusion and Maternal Outcomes in Women with Persistent Postpartum Haemorrhage: Does the Amount of Resuscitation Fluids Matter?
Speaker: C Caram-Deelder (the Netherlands)

Rotational Thromboelastometry (ROTEM) in Obstetric Population
Speaker: Beatriz Grand (Argentina)

Pregnancy Outcomes in Women with Budd Chiari Syndrome or Portal Hypertension
Speaker: Eva Nicole Hamulyá (the Netherlands)

Risk Factors for Severe Preeclampsia in Obstetric Antiphospholipid Syndrome (OAPS) with Conventional Treatment
Speaker: Gabriela de Larrañaga (Argentina)

F1+2 in Preeclampsia: Is it a Good Hemostatic Marker?
Speaker: Luci Dusse (Brazil)

Maternal Carriage of the Annexin A5 M2 Haplotype Combined with Inherited or Acquired Thrombophilia Would Synergistically Increase the Risk of Suffering Intra Uterine Growth Restriction
Speaker: Federico Aranda (Argentina)

The Impact of Hydroxychloroquine on the Prevention of Severe Preeclampsia in Patients with Obstetric Anti-Phospholipid Syndrome
Speaker: Federico Aranda (Argentina)

Antithrombotic Therapy (Nadroparin Calcium) in the Prevention of Pregnancy Loss in aPL-Positive Women
Speaker: Victoria Bitsadze (Russian Federation)

Impaired Platelet Contractility in Women with a History of Miscarriage
Speaker: Svetlana I. Safiullina (Russian Federation)

Assessment of Endocan as a Marker for Preeclampsia and Its Clinical Forms
Speaker: Luci Dusse (Brazil)

Personalized Control of Anticoagulant and Antiplatelet Therapy for Pregnant Women with a Complicated Obstetric Anamnesis Is Pathogenetically Justified for the Purpose of Prevention of Placenta-associated Complications
Speaker: Svetlana I. Safiullina (Russian Federation)

Disorders in the Fibrinolytic System as a Possible Factor in the Failure of Assisted Reproductive Technologies
Speaker: Svetlana I. Safiullina (Russian Federation)

Reduction of Thromboembolic Disorders in Pregnancy and Postpartum Period: Role of National Pregnancy Heart Team
Speaker: Iuliia Davydova (Ukraine)

Prevalence and Management of Post Partum Hemorrhage in Latin America: An Overview of Systematic Reviews
Speaker: Patricia Casais (Argentina)

Long-term Incidence of Venous Thromboembolic Recurrence After a First Venous Thrombotic Episode During Pregnancy
Speaker: Manal Ibrahim-Kosta (France)
Outcomes in Women with Mechanical Heart Valves Anticoagulated with Low Molecular Weight Heparin During Pregnancy
Speaker: Nadine Shehata (Canada)

Hemostasis Disorders in Tunisian Women with Severe Post Partum Hemorrhage: A Case Control Pilot Study
Speaker: Ons Kaabia (Tunisia)

First Direct Evidence in Humans of a Severe Antithrombin Defect Causing Embryonic Lethality
Speaker: Carlos Bravo-Perez (Spain)

Pregnancy Associated Bleeding in Women with Inherited Bleeding Disorders
Speaker: Ons Kaabia (Tunisia)

Women’s Experience of Bleeding and Adverse Events Associated with Postpartum Pharmacological Thromboprophylaxis: A Prospective Cohort Study
Speaker: Margaret Donnelly (Ireland)

Fertility Issues in Women with Inherited Bleeding Disorders
Speaker: Ons Kaabia (Tunisia)

The Attitudes of Haemophilia Carriers towards Prenatal Diagnosis and Mode of Delivery
Speaker: Ozlem Turan (United Kingdom)

ABO Blood Groups and Inherited Thrombophilia in Women with Abortion
Speaker: Luca Spiezia (Italy)

Hold Your Breath for 498 (Alternative) Diagnoses in Pregnant Women Suspected of Pulmonary Embolism
Speaker: Ingrid Bistervels (the Netherlands)

Assessment of Post-partum Haemorrhage Risk among Women with Thrombocytopenia: A Cohort Study
Speaker: Sara Arcudi (Italy)

Impact of 399C/T Polymorphism of Tissue Factor Pathway Inhibitor on Risk of Recurrent Pregnancy Loss in India
Speaker: Kamal Kishor (India)

Rituximab before Pregnancy in Refractory Obstetrical Antiphospholipid Syndrome
Speaker: Alessandro Ciavarella (Italy)

Utility of Fibrinogen Levels and Rotational Thrombo Elastometry (ROTEM) in Predicting Post Partum Hemorrhage
Speaker: Jyoti Kotwal (India)

Successful Pregnancy Outcomes in Patients with Protein S Deficiency Treated with Daily Fondaparinux Regimen
Speaker: Aghnia Permatasari (Indonesia)

Five Years of Evaluation of Postpartum Haemorrhage in a Tertiary Portuguese Hospital
Speaker: Sara Ferreira (Portugal)

Family History of Preeclampsia and Hypertension: A Predictor of Preeclampsia in a Resource Limited Country
Speaker: Feriha Fatima Khidri (Pakistan)
Reference Ranges for Hemostasis Parameters during Pregnancy and Puerperium  
Speaker: Pierre Toulon (France)

Management of Thrombocytopenia in Obstetric Patients: A Retrospective Teaching Hospital Experience  
Speaker: Marta Moreno Carbonell (Spain)

Hemophagocytic Lymphohistiocytosis in Pregnancy Evolving towards Fulminant Hepatitis: A Case Report and Complete Literature Review  
Speaker: Camille Simard (Canada)

Management of Pregnancy in Severe Factor V Deficiency in Women with Varying Phenotypes  
Speaker: Bella Madan (United Kingdom)

Optimizing Tranexamic Acid Dosing for Hemorrhage Prevention in Pregnant Women  
Speaker: Homa Ahmadzia (United States)

Role of Thrombin Generation Potential (TGP) in Cesarean Sections and Vaginal Deliveries Puerperium to Guide Thromboprophylaxis. Preliminary Results  
Speaker: Paola Turcatti (Uruguay)

Late-Breaking and COVID-19 Abstracts

COVID-19

Dipyridamole Added to Anticoagulant Prophylaxis: Decline in Poor Outcome of Clinically Severe Ill COVID-2019 Patients  
Speaker: Sevgi Kalayoglu Besisik (Turkey)

Clinical and Computed Tomography Characteristics of COVID-19 Associated Acute Pulmonary Embolism: A Different Phenotype of Thrombotic Disease?  
Speaker: Lisette F. van Dam (the Netherlands)

The prothrombotic imbalance between VWF and ADAMTS13 in COVID-19  
Speaker: Ilaria Mancini (Italy)

Identification of a COVID-19 Subpopulation Responsive to Hydroxychloroquine Using Machine Learning: The IDENTIFY Trial  
Speaker: Anna Lynn-Palevsky (United States)

A Low Dose Heparin Protocol Is Associated with Improved Duration of Arterial Line Patency in Critically Ill COVID-19 Patients  
Speaker: Lydia Maurer (United States)

Disantangling the Mechanisms behind the Thrombotic Complications of COVID-19 Patients: Insights into Platelet and Endothelial Activation  
Speaker: Marina Camera (Italy)

Venous Thrombotic Complications in Cancer Patients with SARS-CoV-2 Infection: Report from the COVID-19 and Cancer Consortium (CCC19) Registry Analysis  
Speaker: Rachel Rosovsky (United States)
Neutrophil Extracellular Traps Infiltrate Lung Vascular, Interstitial and Airway Compartments in Severe Covid-19  
Speaker: Cécile Oury (Belgium)

Prevalence of Pulmonary Embolism in Patients at the Time of Hospital Admission for COVID-19  
Speaker: Mitja Jevnikar (France)

Biomarkers of COVID-19 Coagulopathy and D-dimer in a Biracial Cohort Study  
Speaker: Debora Kamin Mukaz (United States)

Platelet Activation is Associated with Thrombosis or Death in Patients with COVID-19  
Speaker: Tessa Barrett (United States)

Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-wide Sample of Hospitalized COVID-19 Positive Compared to Negative Patients  
Speaker: Damon Houghton (United States)

The Acquired Coagulopathy of COVID-19  
Speaker: Flora Peyvandi (Italy)

Increased Doses of Low-molecular-weight Heparin in Hospitalized Patients with Covid-19  
Speaker: Ida Martinelli (Italy)

The Effect of Anticoagulation on Mortality in COVID-19 Patients: The Drug, the Dose, and the D-Dimer  
Speaker: Henny Billett (United States)

Thrombin Generation in Severe COVID-19 Patients Hospitalized in the ICU  
Speaker: Maxime G. Zermatten (Switzerland)

Reduction of Venous Thromboembolic Events in Hospitalized Patients with Coronavirus Disease 2019 after Intensification of Thromboprophylaxis  
Speaker: Paraskevas Filippidis (Switzerland)

Elevated D-dimers Useful Prediction of Pulmonary Artery Thrombosis in COVID-19 Patients at Initial Presentation to Hospital  
Speaker: Adrian Perera (United Kingdom)

Monitoring Unfractionated Heparin Using PTT Versus Anti-Xa in Veno-venous Extracorporeal Membrane Oxygenation Patients with COVID-19 Infection  
Speaker: Brandi Thoma (United States)

COVID-19 Pandemic: Dissecting Coagulation apart from Inflammation  
Speaker: Jesus Gonzalez-Lugo (United States)

Late-breaking  
Elevated BAFF Promote B Cell Survival and Autoantibody Production through Upregulating let-7b in Immune Thrombocytopenia  
Speaker: Yang He (China)

Low 1-Year Venous Thromboembolic Recurrence Rates in Patients with and without Thrombotic Risk Factors in Routine Clinical Practice Treated with Edoxaban: The Global ETNA-VTE Study  
Speaker: Alexander Cohen (United Kingdom)
Scientific Programme

Differences in Outcomes between Real-World vs Clinical Trial in Atrial Fibrillation and Chronic Kidney Disease
Speaker: Wern Yew Ding (United Kingdom)

The eTHINK Study: Cognitive and Behavioral Outcomes in Children with Hemophilia
Speaker: Christine Mrakotsky (United States)

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia
Speaker: Adrian C Newland (United Kingdom)

Oral Anticoagulation in Elderly Patients with Atrial Fibrillation: The Murcia AF Project Phase II
Speaker: José Miguel Rivera Caravaca (Spain)
ISTH 2020 Virtual Congress, July 12, - 14, 2020

Scientific Programme

Monday, 13. July 2020

Plenary Session
07:40 - 08:30
Virtual Meeting Room 1

**PL 03, Plenary Session**

Chair: Giancarlo Agnelli (Italy)
Chair: Walter Ageno (Italy)

ISTH 2020 Virtual Congress Welcome 07:40
Speaker: Claire McLintock (New Zealand)

Unmet Clinical Needs and Future Advances in VTE 08:10
Speaker: Alexander Cohen (United Kingdom)

Virtual Exhibition
08:00 - 14:00
Virtual Meeting Room 8

Virtual Exhibition

State-of-the-Art Session
08:45 - 10:00
Virtual Meeting Room 1

**SOA 07, State-of-the-Art on Diagnostics and OMICs**

Illustrated SOA Capsules: [https://www.isth.org/page/soair](https://www.isth.org/page/soair)

Chair: Stefano Duga (Italy)

Genome-Wide Polygenic Scores for Common Diseases 08:45
Speaker: Heribert Schunkert (Germany)

Q&A 09:05

High-Throughput Sequencing Approaches and Database Mining for Profiling the Mutational Landscape and Diagnosing Hereditary Bleeding Disorders 09:10
Speaker: Rosanna Asselta (Italy)

Q&A 09:30

Genomics on Venous Thromboembolism 09:35
Speaker: Nicholas L. Smith (United States)

Q&A 09:55
Scientific Programme

State-of-the-Art Session
08:45 - 10:00
Virtual Meeting Room 2

SOA 08, State-of-the-Art on Platelet Disorders and von Willebrand Disease
Illustrated SOA Capsules: https://www.isth.org/page/soair
Chair: Augusto B. Federici (Italy)

Clinical Versus Genetic Approach to the Diagnosis of Platelet Function Disorders
Speaker: Michele Lambert (United States)

Q&A

Impact of Genotyping on VWD Diagnosis
Speaker: Jeroen Eikenboom (the Netherlands)

Q&A

VWF Self Association Role in Hemostasis and Thrombosis
Speaker: José Aron López (United States)

Q&A

State-of-the-Art Session
08:45 - 10:00
Virtual Meeting Room 3

SOA 09, State-of-the-Art on Pediatrics
Illustrated SOA Capsules: https://www.isth.org/page/soair
Chair: Samantha Gouw (the Netherlands)

Risk Factors for First Stroke at Onset and Recurrence in Pediatric Patients
Speaker: Ulrike Nowak-Göttl (Germany)

Q&A

How to Manage Children with Hemophilia: Replacement and Non-Replacement Therapy
Speaker: Guy Young (United States)

Q&A

Immune Eradication of Anti-FVIII Inhibitor: What a Clinician Should Know in the Era of Non-Replacement Therapies
Speaker: Steven W. Pipe (United States)

Q&A
State-of-the-Art Session
08:45 - 10:00

SOA 10, State-of-the-Art on Women's Health

Illustrated SOA Capsules: https://www.isth.org/page/soair

Chair: Ida Martinelli (Italy)

- **Thrombo-Inflammatory Mechanisms at the Maternal-Fetal Interface**
  Speaker: Berend Isermann (Germany)
  08:45

- **Q&A**
  09:05

- **Obstetric Antiphospholipid Syndrome**
  Speaker: Lai Heng Lee (Singapore)
  09:10

- **Q&A**
  09:30

- **Reproductive Issues in Women on DOACs**
  Speaker: Jan Beyer-Westendorf (Germany)
  09:35

- **Q&A**
  09:55

State-of-the-Art Session
08:45 - 10:00

SOA 11, State-of-the-Art on Coagulation and Natural Anticoagulants

Illustrated SOA Capsules: https://www.isth.org/page/soair

Chair: Coen Maas (the Netherlands)

- **Factor X Clearance and Amyloid Disease**
  Speaker: Olivier D. Christophe (France)
  08:45

- **Q&A**
  09:05

- **Contact Activation in Alzheimer's Disease**
  Speaker: Sidney Strickland (United States)
  09:10

- **Q&A**
  09:30

- **Factor XII as a Modulator of Hemostasis and Wound Healing**
  Speaker: Evi X. Stavrou (United States)
  09:35

- **Q&A**
  09:55

State-of-the-Art Session
08:45 - 10:00

SOA 12, State-of-the-Art on Vascular Biology

Illustrated SOA Capsules: https://www.isth.org/page/soair

Chair: Cecile Denis (France)
Scientific Programme

Endothelial Cell Transitions
Speaker: Peetra Magnusson (Sweden)
08:45

Q&A
09:05

Cell Therapy Targeting Endothelium
Speaker: Florence Sabatier (France)
09:10

Q&A
09:30

Sepsis: Vascular Endothelial Cell Dysfunction During Sepsis
Speaker: Steve Kerrigan (Ireland)
09:35

Q&A
09:55

State-of-the-Art Session
08:45 - 10:00
Virtual Meeting Room 7

SOA 13, State-of-the-Art on Venous Thromboembolism
Illustrated SOA Capsules: https://www.isth.org/page/soair
Chair: James Douketis (Canada)

Managing DOACs in Emergencies
Speaker: Cecilia Becattini (Italy)
08:45

Q&A
09:05

New Antithrombotics and New Interventions for VTE Beyond Anti-IIa and Anti-Xa
Speaker: Stavros Konstantinides (Germany)
09:10

Q&A
09:30

DOACs for Unusual Site Venous Thromboembolism
Speaker: Nicoletta Riva (Malta)
09:35

Q&A
09:55

Oral Communication Session
10:15 - 11:30
Virtual Meeting Room 1

OC 08, Diagnostics and OMICs Oral Communication Session
Chair: Mirko Pinotti (Italy)

Ultra High-throughput Screening Assay to Identify New Antiplatelet Drugs with Discriminative Mode of Receptor-dependent Action
Speaker: Delia Irene Fernández (the Netherlands)
10:15

Features of Hematopoietic Stem and Progenitor Cells Identified through Single-Cell RNA Sequencing in Immune Thrombocytopenia
Speaker: Anli Liu (China)
10:27
**Scientific Programme**

**Genetic Dissection of Structural Variants in the Largest Cohort of Patients with Antithrombin Deficiency and Characterisation of the First Complex Structural Variant in SERPINC1 by Long-read Whole Genome Sequencing**

Speaker: Belén de la Morena-Barrio (Spain)

10:39

**Platelet-targeted Magnetic Nanoparticles Enhance the Efficacy of Thrombolysis through Induction of Magnetic Hyperthermia**

Speaker: Alan Harper (United Kingdom)

10:51

**Characterization of the Protein Profile in Thrombi of Patients with Ischemic Stroke and Identification of Potential Biomarkers as Predictors of Negative Clinical Evolution**

Speaker: Chary Lopez-Pedrera (Spain)

11:03

**Q&A**

11:15

---

**Oral Communication Session**

10:15 - 11:30

Virtual Meeting Room 2

**OC 09, Hemophilia and Rare Bleeding Disorders Oral Communication Session 2**

Chair: Michael Makris (United Kingdom)

- **Maternal Microchimerism Protects Hemophilia A Patient from Inhibitor Development**
  
  Speaker: Yeling Lu (China)
  
  10:15

- **An International Multicenter Study of Bevacizumab for Bleeding in Hereditary Hemorrhagic Telangiectasia (The INHIBIT-Bleed Study)**
  
  Speaker: Hanny Al-Samkari (United States)
  
  10:27

- **An Insight into Clinical Outcomes in Mild, Moderate, and Severe Hemophilia A (HA): A Preliminary Analysis of the CHESS II Study**
  
  Speaker: Francis Nissen (Switzerland)
  
  10:39

- **First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A: Safety and FVIII Activity Results**
  
  Speaker: Steven W. Pipe (United States)
  
  10:51

- **HAT and HAT RI: Novel Factor VIII Molecules Addressing Patients' Needs**
  
  Speaker: Peter Herbener (Germany)
  
  11:03

- **Q&A**
  
  11:15

---

**OC 10, Venous Thromboembolism and Cardioembolism Oral Communication Session**

Chair: Cecilia Becattini (Italy)

- **Association between Initial and Residual Pulmonary Vascular Obstruction and Venous Thromboembolism Recurrence, a Pooled Analysis**
  
  Speaker: Robin Chaux (France)
  
  10:15
The ALK Rearrangement is a Major Risk Factor for Venous and Arterial Thrombosis in Non-Small Cell Lung Cancer  
Speaker: Hanny Al-Samkari (United States)  

Accurate and Efficient Non-Invasive Strategy for Early Identification of Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism (InShape II Study)  
Speaker: Duliëtte Boon (the Netherlands)  

High throughput Proteomic Profiling in Cancer-Associated VTE and Link to the Clinical Outcome  
Speaker: Marina Panova-Noeva (Germany)  

Plasma Protein Disulfide Isomerase Levels Predict Thrombosis in Myeloproliferative Neoplasms: A Prospective Cohort Study  
Speaker: Anish Sharda (United States)  

Q&A  

Oral Communication Session  
10:15 - 11:30  
Virtual Meeting Room 4  

OC 11, Women's Health Oral Communication Session  
Chair: Maha Othman (Canada)  

Outcome of DOAC Exposure during Pregnancy (...and the Problem of Event Reporting...)  
Speaker: Jan Beyer-Westendorf (Germany)  

Comparison of Recommended Postpartum Thromboprophylaxis and of Absolute Risk Thresholds According to the RCOG, ACCP and ACOG Guidelines  
Speaker: Natacha Gassmann (Switzerland)  

Planned Induction versus Spontaneous Delivery among Women Using Prophylactic Anticoagulation Therapy  
Speaker: Amihai Rottenstreich (Israel)  

Evaluation of Platelets Activation and Fibrin Clotting in Post-Menopausal Women with Takotsubo Syndrome  
Speaker: Patrizia Amadio (Italy)  

NETosis in Pregnancy: Role of Different Histones Subtypes  
Speaker: Sylvie Bouvier (France)  

Q&A  

Oral Communication Session  
11:45 - 13:00  
Virtual Meeting Room 1  

OC 12, Pediatrics Oral Communication Session  
Chair: Maria Elisa Mancuso (Italy)
Scientific Programme

Efficacy and Safety of Dabigatran Etexilate for Treatment of Venous Thromboembolism in Paediatric Patients Aged from Birth to &LT; 2 Years - Results of the DIVERSITY Trial
Speaker: Jaqueline Halton (Canada)

Safety and Efficacy of Anticoagulant Therapy in Pediatric Catheter-related Venous Thrombosis (EINSTEIN-Jr. CVC-VTE): A Pre-specified Substudy
Speaker: Christoph Male (Austria)

Impact of SERPINC1 Mutation on Thrombotic Phenotype in Children with Congenital Antithrombin Deficiency - First Analysis of the International Society on Thrombosis and Hemostasis (ISTH) Pediatric AT Database and Biorepository
Speaker: Riten Kumar (United States)

Risk Factors for Venous and Arterial Thrombosis in the Neonatal Intensive Care Unit (NICU)-A Multicenter Case Control Analysis
Speaker: Rukhmi Bhat (United States)

Treatment of Heavy Menstrual Bleeding in a Multidisciplinary Young Women's Bleeding Clinic for Adolescents: An Institutional 2-year Experience
Speaker: Megan C Brown (United States)

Q&A

OC 13, Platelet Disorders and von Willebrand Disease Oral Communication Session
Chair: Giancarlo Castaman (Italy)

Force-induced Unfolding of the Autoinhibitory Module Activates VWF
Speaker: Nicholas Arce (United States)

Genetic Analyses in 391 VWD Patients: Novel VWF Gene Variations, and Important Differences in the Phenotype of Type 1 VWD Patients with and without a VWF Gene Mutation
Speaker: Ferdows Atiq (the Netherlands)

Combination of New Homozygous MPlG6B and SH2B3 Variants Leads to Early Onset Myelofibrosis, Thrombocytopenia and Abnormal Platelet Function
Speaker: Marie-Christine Morel-Kopp (Australia)

The Association between Platelet Count and Perioperative Bleeding Complication in a Cohort of Cirrhotic Patients Undergoing Surgical Excision of Hepatocellular Carcinoma
Speaker: Gianmarco Podda (Italy)

Platelet Desialylation Affects Bleeding Tendency in Immune Thrombocytopenic Patients
Speaker: Irene Marini (Germany)

Q&A
OC 14, Vascular Biology Oral Communication Session

Chair: Françoise Dignat-George (France)

A Novel Neutrophil Extracellular Traps (NETs) Assay Predicts DIC and Stratifies Patients with Sepsis for Anti-IL-8 Therapy
Speaker: Simon Abrams (United Kingdom)  11:45

PAD4-Dependent Assembly of NLRP3 Inflammasome Promotes NET Formation Resulting in Venous Thrombus Progression
Speaker: Patrick Münzer (United States)  11:57

The Proline-Rich Tyrosine Kinase Pyk2 Contributes to Venous Thrombosis
Speaker: Ilaria Canobbio (Italy)  12:09

Induction of Innate Immune Memory in Macrophages Profoundly Enhances their Procoagulant and Antifibrinolytic Activity
Speaker: Seán McCluskey (Ireland)  12:21

Thrombin-PAR1/2 Signaling Axis Modulates TLR3-Mediated Procoagulant, Proinflammatory, and Proadhesive Responses in Vascular Endothelial Cells
Speaker: Saravanan Subramaniam (United States)  12:33

Q&A  12:45

Late-Breaking and COVID-19 Oral Communication Session

Chair: Flora Peyvandi (Italy)

A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)
Speaker: Pratima Chowdary (United Kingdom)  11:45

Thrombosis, Bleeding, and the Effect of Anticoagulation on Survival in Critically Ill Patients with COVID-19 in the United States
Speaker: Hanny Al-Samkari (United States)  12:00

Incidence of Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalisation
Speaker: Matthias M. Engelen (Belgium)  12:15

Higher Incidence of Thrombotic Complications in Hospitalized Patients with SARS-COV-2 Virus versus Influenza Virus Infections
Speaker: Milou A. M. Stals (the Netherlands)  12:30

Q&A  12:45
PL 04, Plenary Session

Chair: Armando D'Angelo (Italy)
Chair: Anna Falanga (Italy)

Guidance or Organ Specific Vascular Patterning
Speaker: Anne Eichmann (United States)
Scientific Programme

Tuesday, 14. July 2020

Special Session
07:30 - 08:30
Virtual Meeting Room 1

COVID19, COVID-19 and Thrombosis
Chair: Nicola Mutch (United Kingdom)

Coronavirus Mouse Models and Coagulation 07:30
Speaker: Lisa Gralinski (United States)

The Domino Effect of Inflammation in COVID-19 Microthrombosis 07:50
Speaker: Roberta Gualtierotti (Italy)

Thromboprophylaxis and COVID-19: The Pandemic Dilemma of Managing Patients Without Any Grade 1A Evidence 08:10
Speaker: Beverley Hunt (United Kingdom)

Virtual Exhibition
08:00 - 14:00
Virtual Meeting Room 14

Supported Symposium
08:45 - 10:00
Virtual Meeting Room 1

Bayer AG Supported Symposium
Title: New Insights for Addressing Challenges in the Management of Patients with Cancer-Associated Thrombosis This session is supported by: Bayer AG

Welcome and Introductions 08:45
Speaker: Ajay Kakkar (United Kingdom)

Addressing Unmet Needs in Cancer-Associated Thrombosis: Insights from the CALLISTO Programme 08:50
Speaker: Alok A. Khorana (United States)

NOACs for the Treatment of Cancer-Associated Thrombosis: Totality of Data in Perspective 09:05
Speaker: Jeffrey I. Weitz (Canada)

Changing to Rivaroxaban for the Treatment of Cancer-Associated Thrombosis: Patient-reported Outcomes from the COSIMO Study 09:25
Speaker: Jan Beyer-Westendorf (Germany)

Live Q&A on Cancer-Associated Thrombosis 09:45
Speaker: Jeffrey I. Weitz (Canada)
Speaker: Ajay Kakkar (United Kingdom)
Scientific Programme

Closing Remarks 09:55
Speaker: Ajay Kakkar (United Kingdom)

Supported Symposium 08:45 - 10:00
Virtual Meeting Room 2

Octapharma Supported Symposium
Title: The evolution of FVIII to meet life-long patient needs: New data and future studies with Nuwiq This session is supported by: Octapharma

Welcome And Introduction 08:45
Speaker: Jan Astermark (Sweden)

Making Informed Treatment Decisions In PUPs: Insights From The NuProtect Study 08:50
Speaker: Ri Liesner (United Kingdom)

Inhibitor Management In Haemophilia A - Real-life Experience And Future Studies 09:05
Speaker: Robert F. Sidonio Jr. (United States)

Personalised Approaches To Meet The Life-long Needs Of Patients For Effective Bleed Protection 09:20
Speaker: Linda Sun (Canada)

Elucidating The Role of FVIII In Long-term Joint And Bone Health In People With Haemophilia A 09:35
Speaker: Jess Snedeker (Switzerland)

Concluding Remarks 09:50
Speaker: Jan Astermark (Sweden)
Speaker: Jess Snedeker (Switzerland)
Speaker: Robert F. Sidonio Jr. (United States)
Speaker: Linda Sun (Canada)
Speaker: Ri Liesner (United Kingdom)

Supported Symposium 08:45 - 10:00
Virtual Meeting Room 3

Novo Nordisk Healthcare AG Supported Symposium
Title: Shaping haemophilia care through real-word data: Stepping closer to reality This session is supported by: Novo Nordisk Healthcare AG

Driving clinical care forward: The Canadian Bleeding Disorders Registry (CBDR) 08:45
Speaker: Alfonso Iorio (Canada)

Real-world insights on EHLs in haemophilia B from the CBDR 09:00
Speaker: Man-Chiu Poon (Canada)

Clinical experience of EHL FVIII in haemophilia A in Germany 09:15
Speaker: Robert Klamroth (Germany)
**Scientific Programme**

**Digging deep: Mining trial data for a greater understanding**
Speaker: Pratima Chowdary (United Kingdom)

**Pfizer Supported Symposium**
Title: From Science Fiction to Reality: a Journey of Evolving Scientific Innovation in Hemophilia B
This session is supported by: Pfizer

- **Welcome and Introduction**  
  Speaker: Giovanni Di Minno (Italy)  
  Time: 08:45

- **Back to Basics: The Importance of Continued Research Into the Science of Hemophilia B**  
  Speaker: Stacy E Croteau (United States)  
  Time: 08:50

- **Factoring the Future: Managing the Coagulation “Balancing act”**  
  Speaker: Andreas Tiede (Germany)  
  Time: 09:05

- **Deep space FIX: Exploring the Hidden Depths of Gene Therapy**  
  Speaker: John Rasco (Australia)  
  Time: 09:20

- **Panel Discussion**  
  Speaker: Giovanni Di Minno (Italy)  
  Speaker: Stacy E Croteau (United States)  
  Speaker: Andreas Tiede (Germany)  
  Speaker: John Rasco (Australia)  
  Speaker: Ian Winburn (United Kingdom)  
  Time: 09:40

- **Meeting Summary and Close**  
  Speaker: Ian Winburn (United Kingdom)  
  Time: 10:00

**Grifols Supported Symposium**
Title: Update on immune thrombocytopenia: clinical perspectives
This session is supported by: Grifols

- **Welcome & Introduction**  
  Speaker: Francesco Zaja (Italy)  
  Time: 08:45

- **New insights in ITP: What new guidelines say**  
  Speaker: Adrian C Newland (United Kingdom)  
  Time: 08:50

- **Clinical approaches to the ITP patient treatment**  
  Speaker: Francesco Zaja (Italy)  
  Time: 09:10

- **Practical experience with Fostamatinib**  
  Speaker: Nichola Cooper (United Kingdom)  
  Time: 09:30
**Q&A and Closing Remarks**
Speaker: Francesco Zaja (Italy) 09:50

**Supported Symposium**
08:45 - 10:00

**Daiichi Sankyo Europe GmbH Supported Symposium**
Title: Challenges in the Management of VTE: New Evidence in the COVID-19 Era
This session is supported by: Daiichi Sankyo Europe GmbH

**Introduction**
Speaker: Jeffrey I. Weitz (Canada) 08:45

**Cancer-Associated VTE: Are NOACs the Answer?**
Speaker: Marcello di Nisio (Italy) 08:50

**Insights From Real World Evidence: ETNA-VTE Registry**
Speaker: Ander Cohen (United Kingdom) 09:05

**Translating Data Into Clinical Practice in the COVID-19 Era**
Speaker: Cihan Ay (Austria) 09:20

**Discussion and Q&A Session**
Speaker: Jeffrey I. Weitz (Canada) 09:35

**Summary and Conclusions**
Speaker: Jeffrey I. Weitz (Canada)
Speaker: Marcello di Nisio (Italy) 09:55

**COR2ED Independent Accredited Supported Symposium**
Title: Current Perspectives on the Treatment of Primary Chronic ITP in Adults
This session is supported by: COR2ED.
This scientific medical education symposium is hosted by COR2ED based on an independent medical educational grant from Sobi.

**Welcome and Introduction**
Speaker: Jerzy Windyga (Poland) 08:45

**Evolution of Treatment in Chronic Primary ITP in Adults**
Speaker: Pål Andrè Holme (Norway) 08:50

**Clinical Experience With TPO-RAs**
Speaker: David J. Kuter (United States)
Speaker: Vickie McDonald (United Kingdom) 09:08

**Current Challenges and Novel Treatment Options in ITP**
Speaker: Jerzy Windyga (Poland)
Speaker: Vickie McDonald (United Kingdom)
Speaker: David J. Kuter (United States)
Speaker: Pål Andrè Holme (Norway) 09:28
### Scientific Programme

#### Questions and Conclusions 09:46
Speaker: Jerzy Windyga (Poland)
Speaker: Vickie McDonald (United Kingdom)
Speaker: David J. Kuter (United States)
Speaker: Pål André Holme (Norway)

#### Supported Symposium
10:15 - 11:30  Virtual Meeting Room 1

**F. Hoffmann-La Roche Ltd Supported Symposium**
Title: The Evolution of Safety in Haemophilia A: Adapting to an Ageing Population
This session is supported by: F. Hoffmann-La Roche Ltd.

- **Opening Video and Chair’s Welcome** 10:15
  Speaker: Guy Young (United States)

  Speaker: Guy Young (United States)

- **Interview-style panel discussion** 10:26
  Speaker: Guy Young (United States)
  Speaker: Charles R.M Hay (United Kingdom)

  Speaker: Charles R.M Hay (United Kingdom)

- **Interview-style panel discussion** 10:47
  Speaker: Charles R.M Hay (United Kingdom)
  Speaker: Claude Négrier (France)

- **The Safety Question: Challenges and Considerations** 10:53
  Speaker: Claude Négrier (France)

- **Interview-style panel discussion** 11:08
  Speaker: Claude Négrier (France)
  Speaker: Guy Young (United States)

- **Closing remarks and meeting close** 11:14
  Speaker: Guy Young (United States)

- **Panel Q&A via Simulive** 11:15

#### CSL Behring Supported Symposium
10:15 - 11:30  Virtual Meeting Room 2

**CSL Behring Supported Symposium**
Title: New Standards of Care: Treatment Across the Spectrum of Hemophilia B
This session is supported by: CSL Behring

- **Welcome** 10:15
  Speaker: Maria Elisa Mancuso (Italy)
Scientific Programme

Raising Standards, Raising Troughs  
Speaker: Maria Elisa Mancuso (Italy)  
10:20

Broadening the Spectrum  
Speaker: Cedric Hermans (Belgium)  
10:35

The Evidence for rIX-FP  
Speaker: Michael Wang (United States)  
10:50

Beyond the Trial Data  
Speaker: Johannes Oldenburg (Germany)  
11:05

Close  
Speaker: Maria Elisa Mancuso (Italy)  
11:20

Supported Symposium  
10:15 - 11:30  
Virtual Meeting Room 3

Octapharma Supported Symposium

Title: Managing the complexities of VWD - Clinical experiences with wilate®  
This session is supported by: Octapharma

Welcome and introduction  
Speaker: Fernando F. Corrales-Medina (United States)  
10:15

VWD and surgery - Balancing the need for bleed management with the risk of thrombosis  
Speaker: Mario von Depka (Germany)  
10:25

VWF prophylaxis in VWD - Are we protecting our patients enough?  
Speaker: K. John Pasi (United Kingdom)  
10:40

Spotlight on women’s issues in VWD  
Speaker: Jill Johnsen (United States)  
10:55

Towards a better diagnosis of VWD  
Speaker: Fernando F. Corrales-Medina (United States)  
11:10

Concluding Remarks  
11:25

Supported Symposium  
10:15 - 11:30  
Virtual Meeting Room 4

Springer Healthcare IME CME accredited Supported Symposium

Title: New Hopes and Opportunities for Hemophilia and other Bleeding Disorders  
This CME-accredited session is organized by Springer Healthcare IME. This program is made possible thanks to an independent educational grant from Novo Nordisk A/S and Pfizer.

Welcome and Introduction  
Speaker: Steven W. Pipe (United States)  
10:15
**Scientific Programme**

**10:20**
**How has our Current Understanding of Hemophilia Driven New Treatment Options**
Speaker: Stacy E Croteau (United States)

**10:30**
**What are these New Treatment Options?**
Speaker: David Lillicrap (Canada)

**10:45**
**What do we know about Anti-TFPI Inhibitors?**
Speaker: Johnny Mahlangu (South Africa)

**11:15**
**Faculty Discussion and Audience Questions**

---

**Supported Symposium**
**10:15 - 11:30**
**Virtual Meeting Room 5**

**Sobi Supported Symposium**
**Title: Certainty Versus Myths: Increasing Certainty Around Individual Protection Needs**
This session is supported by: Sobi

**10:15**
**Holistic and Personalised Management of People With Haemophilia**
Speaker: Steven W. Pipe (United States)

**10:25**
**New Decade, New Tools Supporting Personalised Treatment**
Speaker: Carmen Escuriola-Ettingshausen (Germany)

**10:50**
**Personalised and Intense Protection for People With Haemophilia**
Speaker: Claude Négrier (France)

**11:15**
**Panel Discussion**
Speaker: Steven W. Pipe (United States)
Speaker: Carmen Escuriola-Ettingshausen (Germany)
Speaker: Claude Négrier (France)

---

**Supported Symposium**
**10:15 - 11:30**
**Virtual Meeting Room 6**

**LFB Supported Symposium**
**Title: From Protection to Bypass of Factor VIII in Inherited Bleeding Disorders: Insights and Therapeutic Options**
This session is supported by: LFB

**10:15**
**Bringing Novel Therapies to Manage Hemophilia A/B Patients with Inhibitors and Bleedings**
Speaker: Steven W. Pipe (United States)

**10:40**
**Treatment Strategies in von Willebrand Disease – With or Without Factor VIII?**
Speaker: Cedric Hermans (Belgium)

**11:05**
**Revisiting Plasmatic vs. Recombinant Human von Willebrand Factors in the Management of von Willebrand Disease**
Speaker: Sophie Susen (France)
Boehringer Ingelheim Supported Symposium

Title: Building on a Decade of DOACs: Supporting Safety with Reversal

This session is supported by: Boehringer Ingelheim


10:15
Strong Foundations: Dabigatran’s Safety Profile in AF and VTE
Speaker: John Eikelboom (Canada)

10:35
New Developments With DOACs in Pediatric Patients
Speaker: Leonardo Brandão (Canada)

10:50
Anticoagulation Reversal: is it Needed?
Speaker: Peter Verhamme (Belgium)

11:05
Case-based Guidance for Reversal in Practice
Speaker: Richard Whitlock (Canada)

11:20
Panel Discussion and Audience Q&A
Speaker: Richard Whitlock (Canada)
Speaker: Peter Verhamme (Belgium)
Speaker: John Eikelboom (Canada)
Speaker: Leonardo Brandão (Canada)

Roche Supported Symposium

Title: Partnering for Progress: Driving Shared Decision Making in Haemophilia A Care

This session is supported by: Roche

11:45
Opening video and Chair’s welcome
Speaker: Giancarlo Castaman (Italy)

11:46
Defining a New Normal - Reflecting on Treatment Options for Haemophilia A
Speaker: Giancarlo Castaman (Italy)

11:57
Partnering for Progress 1
Speaker: Giancarlo Castaman (Italy)
Speaker: Rebecca Kruse-Jarres (United States)

12:02
Redefining our Aspirations for Patients - Part 1
Speaker: Gerard Dolan (United Kingdom)

12:12
Redefining our Aspirations for Patients - Part 2
Speaker: Gerard Dolan (United Kingdom)

12:23
Partnering for Progress 2
Speaker: Gerard Dolan (United Kingdom)
Speaker: Bruno Steiner (United States)
Scientific Programme

Facilitating Holistic Haemophilia A Care 12:28
Speaker: Bruno Steiner (United States)
Speaker: Rebecca Kruse-Jarres (United States)

Partnering for Progress 3 12:39
Speaker: Giancarlo Castaman (Italy)
Speaker: Rebecca Kruse-Jarres (United States)
Speaker: Bruno Steiner (United States)

Closing Remarks 12:45
Speaker: Giancarlo Castaman (Italy)

Simulive questions 12:46
Speaker: Giancarlo Castaman (Italy)
Speaker: Gerard Dolan (United Kingdom)
Speaker: Rebecca Kruse-Jarres (United States)
Speaker: Bruno Steiner (United States)

Supported Symposium
11:45 - 13:00
Virtual Meeting Room 2

CSL Behring Supported Symposium
Title: Beyond Clinical Trials: Hemophilia A Care in the Real World This session is supported by: CSL Behring

Welcome 11:45
Speaker: Maria Elisa Mancuso (Italy)

Advances in Hemophilia A Care 11:50
Speaker: Maria Elisa Mancuso (Italy)

The Evidence for rVIII-SingleChain 12:10
Speaker: Vinod Balasa (United States)

Use of rVIII-SingleChain in the Real World 12:30
Speaker: Martin Olivieri (Germany)

Close 12:50
Speaker: Maria Elisa Mancuso (Italy)

Supported Symposium
11:45 - 13:00
Virtual Meeting Room 4

Sanofi Genzyme Supported Symposium
Title: The Future of Haemophilia Treatment: Disrupting Expectations This session is supported by: Sanofi Genzyme

Welcome and Introductions 11:45
Speaker: Dan Hart (United Kingdom)

Health Equity: An Achievable Goal 11:50
Speaker: Mark Skinner (United States)
Scientific Programme

Factor FVIII Reimagined  
Speaker: Dan Hart (United Kingdom)
12:05

Advancing Possibilities With New Technologies  
Speaker: Johnny Mahlangu (South Africa)
12:20

Translating Innovation  
Speaker: Joe Salas (United States)
12:35

Panel Discussion  
Speaker: Dan Hart (United Kingdom)
12:50

BioMarin Supported Symposium

Title: Investigational AAV Gene Therapy for Hemophilia: Considerations for Potential Clinical Practice  
This session is supported by: Biomarin
11:45 - 13:00

Welcome and Introductions  
Speaker: Maria Elisa Mancuso (Italy)
11:45

Variability and Durability of Response to AAV Gene Therapies  
Speaker: Glenn F. Pierce (United States)
11:50

Towards Clinical Practice: AAV Gene Therapy Dosing and Patient Monitoring  
Speaker: Maria Elisa Mancuso (Italy)
12:10

Q&A  
Speaker: Maria Elisa Mancuso (Italy)
12:30

Grifols Supported Symposium

Title: Key questions in the new hemophilia era. Update on concomitant use of FVIII and emicizumab  
This session is supported by: Grifols
11:45 - 13:00

Welcome and introduction - The changing face of immune tolerance induction in hemophilia A with the advent of emicizumab  
Speaker: Manuel Carcao (Canada)
11:45

Concomitant Studies: What about during ITI?  
Speaker: Maria Elisa Mancuso (Italy)
12:00

Concomitant Studies: What about after ITI?  
Speaker: Guy Young (United States)
12:15

Concomitant use in the clinical real practice  
Speaker: Victor Jimenez-Yuste (Spain)
12:30
Scientific Programme

Q&A 12:40

Product Theater
13:15 - 14:00  Virtual Meeting Room 1

Bayer AG Product Theater
Title: Optimizing the Management of VTE with Rivaroxaban in Challenging Clinical Scenarios This session is supported by: Bayer AG

Rivaroxaban for the Patient with VTE and Renal Impairment: Clinical Case 13:15
Speaker: Rupert Bauersachs (Germany)

Rivaroxaban for the Patient with Cancer-Associated Thrombosis: Clinical Case 13:25
Speaker: Mari Thomas (United Kingdom)

When to Extend Anticoagulation Beyond Six Months: Clinical Case 13:40
Speaker: Philip Wells (Canada)

Product Theater
13:15 - 14:00  Virtual Meeting Room 2

Bayer AG Product Theater
Title: Optimizing Hemophilia A Treatment in the Time of COVID-19 and Beyond This session is supported by: Bayer AG

Welcome and Introduction 13:15
Speaker: Snejana Krassova (Switzerland)

Speaker: Cedric Hermans (Belgium)

Optimizing hemophilia A treatment: Individualized prophylaxis with BAY 94-9027 and the importance of a favorable PK profile 13:35
Speaker: Mark Reding (United States)

Q+A 13:50

Product Theater
13:15 - 14:00  Virtual Meeting Room 3

CSL Behring Product Theater
Title: Advancing Standards of Care in VWD: Challenges, Diagnosis and Treatment This session is supported by: CSL Behring

Welcome 13:15
Speaker: Carmen Escuriola-Ettingshausen (Germany)

Diagnosis and Disease Awareness 13:20
Speaker: Karen van Galen (the Netherlands)
Scientific Programme

Factor Concentrates: Matching Phenotype to Treatment Decisions 13:35
Speaker: Carmen Escuriola-Ettingshausen (Germany)

Q&A and Close 13:50
Speaker: Carmen Escuriola-Ettingshausen (Germany)

Product Theater
13:15 - 14:00
Virtual Meeting Room 4

Sobi and Sanofi Genzyme Product Theater
Title: Empowering People With Haemophilia A Throughout Their Life This session is supported by: Sobi and Sanofi Genzyme

Introduction
Speaker: Elena Santagostino (Italy) 13:15

One Size Doesn’t Fit All in Haemophilia A
Speaker: Elena Santagostino (Italy)

Achieve Intense Protection With Personalisation… From Childhood to Adulthood
Speaker: Christoph Königs (Germany) 13:25

Achieve Intense Protection With Personalisation… To Manage Surgery
Speaker: Luigi Piero Solimeno (Italy) 13:40

Q&A and Conclusions
Speaker: Elena Santagostino (Italy) 13:50
Speaker: Luigi Piero Solimeno (Italy)
Speaker: Christoph Königs (Germany)

Product Theater
13:15 - 14:00
Virtual Meeting Room 5

Sobi and Sanofi Genzyme Product Theater
Title: Overcoming Uncertainty in Managing Haemophilia B This session is supported by: Sobi and Sanofi Genzyme

What Makes Haemophilia B Different?
Speaker: Giancarlo Castaman (Italy) 13:15

Extravascular Distribution of FIX: Scientific Perspective
Speaker: Joe Salas (United States) 13:20

Treatment Goals in Haemophilia B: Real World Experience
Speaker: K. John Pasi (United Kingdom) 13:35

Q&A and Conclusions
Speaker: Giancarlo Castaman (Italy) 13:50
Speaker: Joe Salas (United States)
Speaker: K. John Pasi (United Kingdom)
ISTH 2020 Virtual Congress, July 12, - 14, 2020

**Scientific Programme**

**Product Theater**
13:15 - 14:00

**Instrumentation Laboratory Product Theater**

Title: COVID-19 Conundrums: Coagulopathy and Critical Care Implications for ROTEM(R) Testing This session is supported by: Instrumentation Laboratory

- **Introduction**
  - Speaker: Annie Winkler (United States)
  - 13:15

- **COVID-19 Conundrums: Coagulopathy and Critical Care Implications for ROTEM(R) Testing**
  - Speaker: Daniel Katz (United States)
  - 13:20

- **Q&A**
  - Speaker: Annie Winkler (United States)
  - 13:50

**Technoclone GmbH Product Theater**

Title: Ceveron s100 – a Solution for Challenging Times in Haemostasis! This session is supported by: Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH

- **Welcome and Introduction**
  - Speaker: Nikolaus B. Binder (Austria)
  - 13:15

- **Ceveron s100 – the analyzer**
  - Speaker: Marco Wolf (Austria)
  - 13:20

- **TECHNOFLUOR ADAMTS13 Activity A Rapid Quantitative FRET ADAMTS13 Activity Assay**
  - Speaker: Gary Moore (Austria)
  - 13:30

- **TECHNOFLUOR FXIII Activity – Fast, Accurate and Precise**
  - Speaker: Gary Moore (Austria)
  - 13:40

- **Single Platform Monitoring of Concentrates, EHLs and Non-Replacement Haemophilia Therapies with Clotting, Chromogenic and Thrombin Generation Assays**
  - Speaker: Gary Moore (Austria)
  - 13:50

**Supported Symposium On-Demand**
14:15 - 15:30

**On-Demand Takeda Pharmaceutical Company Limited Supported Symposium**

Title: Fit for Purpose: Personalized Prophylaxis for Joint Health and Beyond This session is supported by: Takeda Pharmaceutical Company Limited

- **Opening Remarks**
  - Speaker: Giovanni Di Minno (Italy)
  - 14:15
Scientific Programme

**Personalized Prophylaxis – Preserving Joint Health and Beyond**  
Speaker: Giovanni Di Minno (Italy)  
14:20

**Trends in Physical Activity and QOL for Patients with Haemophilia**  
Speaker: Angela Forsythe (United States)  
14:35

**Analysis of Ideal Factor Levels for Participation in Physical Activity**  
Speaker: Leonard A. Valentino (United States)  
14:50

**The Application of Personalized Care in Haemophilia: Today and in the Future**  
Speaker: Peter L Turecek (Austria)  
15:05

**Panel Discussion**  
15:20

---

**Supported Symposium On-Demand**  
14:15 - 15:30  
Virtual Meeting Room 2

**On-Demand Takeda Supported Symposium**

Title: Protein C Deficiencies and Their Impact in Critical Care  
This session is supported by: Takeda

**Introduction**  
Speaker: Leonardo Brandão (Canada)  
14:15

**Developmental Haemostasis: A Focus on Protein C**  
Speaker: Vera Ignjatovic (Australia)  
14:20

**Q&A**  
14:35

**Congenital vs Acquired Protein C Deficiencies: Commonalities and Differences**  
Speaker: Paul Knoebl (Austria)  
14:40

**Q&A**  
14:55

**Current Standard of Care for Protein C Deficiencies**  
Speaker: Leonardo Brandão (Canada)  
15:00

**Q&A**  
15:15

---

**Supported Symposium On-Demand**  
14:15 - 15:30  
Virtual Meeting Room 3

**On-Demand Haemonetics S.A Supported Symposium**

Title: COVID-19 patients and viscoelastic testing: what we know so far?  
This session is supported by: Haemonetics S.A

**COVID-19 patients and viscoelastic testing: what we know so far?**  
Speaker: Hunter Moore (United States)  
14:15
Supported Symposium On-Demand
14:15 - 15:30
Virtual Meeting Room 4

On-Demand Novo Nordisk Healthcare AG Supported Symposium
Title: Spotlight on Women with Rare Bleeding Disorders
This session is supported by: Novo Nordisk Healthcare AG

Welcome and Introduction 14:15
Speaker: Ahmad Tarawah (Saudi Arabia)

FVII deficiency in women: Pregnancy management and outcome 14:20
Speaker: Rezan Abdul-Kadir (United Kingdom)

Management of female patients with Glanzmann’s Thrombasthenia: clinical case and expert recommendations from gulf cooperation council countries 14:40
Speaker: Ahmad Tarawah (Saudi Arabia)

Pregnancy-related Acquired Hemophilia - remaining alert for rare events 15:00
Speaker: Dan Hart (United Kingdom)

Panel Discussion 15:20

Supported Symposium On-Demand
14:15 - 15:30
Virtual Meeting Room 5

On-Demand Sanofi Supported Symposium
Title: State of the art and science in prevention of VTE in medical patients
This session is supported by: Sanofi

Welcome & Introduction 14:15
Speaker: Ajay Kakkar (United Kingdom)

Thromboprophylaxis in acute medically illness: news and controversies 14:20
Speaker: Grégoire Le Gal (Canada)

Risk-stratified thromboprophylaxis in special patient groups 14:40
Speaker: Ismail Elalamy (France)

Thrombosis management in critical ill patients: learning from COVID-19 pandemic 14:55
Speaker: Ana Rocha (Brazil)

Panel discussion 15:10

Conclusion and take-home message 15:25
Speaker: Ajay Kakkar (United Kingdom)

Supported Symposium On-Demand
14:15 - 15:30
Virtual Meeting Room 6

On-Demand uniQure Supported Symposium
Title: The Immune System and AAV Gene Therapy: What Every Clinician Should Know
This session is supported by: uniQure
**Scientific Programme**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>Chair’s Introduction&lt;br&gt;Speaker: Annette von Drygalski (United States)</td>
</tr>
<tr>
<td>14:20</td>
<td>Reviewing the Immune Response to AAV Gene Therapy&lt;br&gt;Speaker: Valder R. Arruda (United States)</td>
</tr>
<tr>
<td>14:40</td>
<td>Liver-Directed AAV Gene Therapy: Lessons from a Hepatologist&lt;br&gt;Speaker: Graham Foster (United Kingdom)</td>
</tr>
<tr>
<td>15:00</td>
<td>A Physician’s Perspective on the Immunological Response from Haemophilia Clinical Trials: A Pragmatic Approach&lt;br&gt;Speaker: Dan Hart (United Kingdom)</td>
</tr>
<tr>
<td>15:15</td>
<td>Close&lt;br&gt;Speaker: Annette von Drygalski (United States)</td>
</tr>
</tbody>
</table>

---

**Supported Symposium On-Demand**<br>14:15 - 15:30<br>Virtual Meeting Room 7

**On-Demand Kedrion Biopharma Supported Symposium**

Title: Optimizing Patient Care in Hemophilia A: A Critical Appraisal This session is supported by: Kedrion Biopharma

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>Welcome and Introduction&lt;br&gt;Speaker: Pier Mannuccio Mannucci (Italy)</td>
</tr>
<tr>
<td>14:20</td>
<td>Inhibitor Patients and Inhibitor Eradication&lt;br&gt;Speaker: Jerzy Windyga (Poland)&lt;br&gt;Speaker: Guy Young (United States)</td>
</tr>
<tr>
<td>14:40</td>
<td>Prevention of Bleeds, Joints Protection, Personalization of Treatment&lt;br&gt;Speaker: Jerzy Windyga (Poland)&lt;br&gt;Speaker: Guy Young (United States)</td>
</tr>
<tr>
<td>15:00</td>
<td>Safety Considerations about Replacement and non-Replacement Factors&lt;br&gt;Speaker: Jerzy Windyga (Poland)&lt;br&gt;Speaker: Guy Young (United States)&lt;br&gt;Speaker: Michael Makris (United Kingdom)</td>
</tr>
<tr>
<td>15:20</td>
<td>Wrap up and conclusions&lt;br&gt;Speaker: Pier Mannuccio Mannucci (Italy)</td>
</tr>
</tbody>
</table>

---

**Supported Symposium On-Demand**<br>14:15 - 15:30<br>Virtual Meeting Room 8

**On-Demand Takeda Supported Symposium**

Title: VWD and TTP in Women: Taking a Patient-centered Approach to Care This session is supported by: Takeda:

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15</td>
<td>Opening Remarks&lt;br&gt;Speaker: Michael Laffan (United Kingdom)</td>
</tr>
<tr>
<td>14:16</td>
<td>The Science of ADAMTS13 and VWF in Women&lt;br&gt;Speaker: Michael Laffan (United Kingdom)</td>
</tr>
</tbody>
</table>
ISTH 2020 Virtual Congress, July 12, - 14, 2020

Scientific Programme

**cTTP in Women: Short-and Long-term Complications in Pregnancy and Throughout Reproductive Life**
Speaker: Marie Scully (United Kingdom) 14:21

**Panel Discussion - Addressing Women-specific Issues in TTP** 14:31

**Advances in Care for Heavy Menstrual Bleeding and Pregnancy in VWD**
Speaker: Eugenia Biguzzi (Italy) 14:46

**Panel Discussion - Addressing Women-specific Issues in VWD** 14:56

---

**On-Demand CSL Behring Product Theater**

Title: Urgent Warfarin Reversal for Fast and Sustained Action: A Case-Based Presentation This session is supported by: CSL Behring

**Urgent Warfarin Reversal for Fast and Sustained Action: A Case-Based Presentation**
Speaker: Ayreh Shander (United States) 14:15

---

**On-Demand Takeda Product Theater**

Title: The Management of Severe Congenital Protein C Deficiency This session is supported by: Takeda

**Management of Patients with SCPCD in Turkey**
Speaker: Selin Aytac (Turkey) 14:15

**Practical Aspects of Therapy with Protein C Concentrate**
Speaker: Adrian Minford (United Kingdom) 14:30

**Q&A and Discussion** 14:45

---

**On-Demand Sysmex Product Theater**

Title: Nearing 360° in Haemostasis Testing: Latest Developments From Sysmex This session is supported by: Sysmex

**Opening**
Speaker: Ian Mackie (United Kingdom) 14:15

In case of any questions about the session, please contact: segcoagsupport@sysmex-europe.com
Scientific Programme

Speaker: Steve Kitchen (United Kingdom)

14:17

Introduction to the next talk
Speaker: Ian Mackie (United Kingdom)

14:37

Speaker: Chris Gardiner (United Kingdom)

14:38

Closing
Speaker: Ian Mackie (United Kingdom)

14:53

On-Demand HYPHEN BioMed Product Theater

Title: Laboratory Updates on Specialized Hemostasis Testing This session is supported by: HYPHEN BioMed

A FVIII Chromogenic Assay System for Measuring EMICIZUMAB and Titrating FVIII Inhibitors in Plasma
Speaker: Jean Amiral (France)

14:15

Measurement of Edoxaban and its Metabolites with Anti-FXa Assays Comparatively to LC:MS/MS
Speaker: Claire Dunois (France)

14:30

Optimized LA Clotting Assays Presenting Low Interference with DOACs
Speaker: Marie Peyrafitte (France)

14:45

On-Demand Instrumentation Laboratory Product Theater

Title: COVID-19 & Hemostasis: Laboratory and Clinical updates This session is supported by: Instrumentation Laboratory

Introduction of Armando Tripodi
Speaker: Annie Winkler (United States)

14:15

COVID-19 & Hemostasis: Laboratory and Clinical updates
Speaker: Armando Tripodi (Italy)

14:17

Introduction of Benilde Cosmi
Speaker: Annie Winkler (United States)

14:37

COVID-19 & Hemostasis: Laboratory and Clinical updates
Speaker: Benilde Cosmi (Italy)

14:39

Closing
Speaker: Annie Winkler (United States)

14:59